final program - International Society for Infectious Diseases

Transcription

14th International Congress
on Infectious Diseases (ICID)
MIAMI, FLORIDA • USA • MARCH 9-12, 2010
FINAL PROGRAM
Organized by the International Society
for Infectious Diseases
With the
4th Regional Conference of the International Society of Travel Medicine
SLA MVI
Sociedad Latinoamericana
de Medicina del Viajero
II Congreso Latinoamericano de Medicina del Viajero
In collaboration with the
Infectious Diseases Society of America (IDSA)
Pan American Association for Infectious Diseases (API)
Latin American Society of Pediatric Infectious Disease (SLIPE)
2010
THURSDAYMARCH THE GLOBAL IMPACT
OF HPV INFECTION
AND RELATED DISEASES
CONSEQUENCESAND STRATEGIES
FOR PREVENTION
HYATTREGENCYMIAMI
SOUTHHALLRIVERFRONTHALLLOBBYLEVEL
MIAMIFLORIDA
PM–PM
REGISTRATIONANDLUNCH
PM–PM
SYMPOSIUM
ACTIVITYCHAIRPERSON
Mark A. Kane, MD, MPH
Retired Director, Children’s Vaccine Program
Program for Appropriate Technology in Health (PATH)
Founding President, Global Fund for Children’s Vaccines
Consultant in Vaccinology
Mercer Island, Washington
FACULTY
WILL BE
Maura L. Gillison, MD, PhD
Professor of Medicine
Jeg Coughlin Chair of Cancer Research
The Ohio State University
James Cancer Hospital and Solove Research Institute
Columbus, Ohio
Joel M. Palefsky, MD
LUNCH
PROVIDED
ONSITE
REGISTRATION
IS AVAILABLE
Professor of Medicine
Associate Dean for Clinical and Translational Research
Co-Director, UCSF Clinical and Translational Sciences Institute
University of California, San Francisco
San Francisco, California
Accreditation Statement
SciMed is accredited by the Accreditation Council for
Continuing Medical Education (ACCME) to provide
continuing medical education for physicians.
Sponsored by
FOR MORE INFORMATION,
PLEASE VISIT
Supported by an educational grant from
14th International Congress
on Infectious Diseases (ICID)
MIAMI, FLORIDA • USA • MARCH 9-12, 2010
FINAL PROGRAM
14th International Congress on Infectious Diseases
Time Schedule
Congress Registration & Information
13:00 – 17:00
Monday
March 8, 2010
8:00 – 18:30
Tuesday
March 9, 2010
8:00 – 18:00
Wednesday March 10, 2010
8:00 – 18:00
Thursday March 11, 2010
8:00 – 18:00
Friday
March 12, 2010
ISTM Certificate in Travel Health
Examination (CTH)
13:00 – 18:00
Monday
March 8, 2010
Opening Ceremony
18:30 – 20:00
Tuesday
March 9, 2010
Welcome Reception
20:00
Tuesday
March 9, 2010
9:00 – 17:45
Tuesday
March 9, 2010
through
Friday Poster Sessions
Scientific Sessions
13:30 – 14:30
March 12, 2010
through
Friday Meet-the-Expert Sessions
7:45 – 8:45
Tuesday
through
Friday
March 12, 2010
Business Meeting (lunch provided)
Friday
March 12, 2010
Commercial Exhibition
12:45 – 13:45
9:00 – 17:30
March 9, 2010
through
Friday
ii ~ Final Program
March 12, 2010
March 12, 2010
ii ~ Final Program
Final Program ~ 1
Introduction by ISID
Dear Colleagues,
Welcome to Miami and the 14th International Congress on Infectious Diseases!
It is an honor this year to hold the 14th ICID in conjunction with the 4th Regional Conference of the
International Society of Travel Medicine and the II Congreso Latinoamericano de Medicina del Viajero.
This assembly highlights the truly global scope of both the presentations and the participants, one of the
unique features of the ICID.
Our Program Committee has once again put together an exceptional scientific program with a blend of
pure science, epidemiology, clinical medicine and microbiology. You will learn about new strategies to
manage challenging public health and clinical infectious diseases issues and gain insight into the biological
mechanisms of disease and health. The ICID is distinguished by a strong regional focus and this year has
a particularly robust travel medicine track. The breadth of infectious diseases will be highlighted in the
plenary lectures, which will cover topics ranging from historical infectious diseases discoveries to global public
health policies.
Over 1,500 abstracts were submitted to the 14th ICID Program Committee for consideration. Just over 1,050
were accepted for poster presentation with an additional 50 accepted for oral presentation. Fifteen individuals
will be recognized with awards for their outstanding research thanks to support from Novartis, Sanofi Pasteur,
the US CDC and the ISID. In addition, twelve promising young women researchers from Latin America and
the Caribbean are here thanks to a travel grant provided by Sanofi Pasteur.
Our coming together at the ICID will most certainly create excellent possibilities for exchange of ideas,
opinions, and the initiation or continuation of collaborative research partnerships. Please make the most of
new and old opportunities for friendship and enjoy your visit to Miami.
Raúl Istúriz MD
President, International Society for Infectious Diseases (ISID)
Final Program ~ 3
Introduction by ISTM
Dear Colleagues,
Bienvenidos a Miami!
The International Society of Travel Medicine (ISTM) welcomes you to RCISTM4, the 4th Regional Conference
of the ISTM on March 9–12, 2010, in Miami, Florida, USA. We are delighted to be co-sponsors with the Sociedad
Latinoamericana de Medicina del Viajero (SLAMVI) for their 2nd Congress. This travel medicine program
is planned in parallel with the 14th International Congress on Infectious Diseases (ICID) organized by the
International Society of Infectious Diseases (ISID).
You will be joining your friends and colleagues from around the world at this years meeting. The program
committees have organized a state of the art educational experience with multiple tracks guaranteed to
offer something of interest for all attendees. There will be engaging plenary sessions, symposia, meet the
expert, primary research and workshops for all levels of background training and expertise. Please refer to
www.istm.org for updates to the program and additional information to enhance your participation in this
important meeting on travel medicine and infectious diseases.
Miami in March promises to be a delightful destination with warm weather, bright sun, and the famous Miami
beaches close by. It is a very international city with a Latin American flavor.
We wish you a productive, educational, and pleasurable stay in Miami. We also hope to see you at our next
biennial worldwide meeting CISTM12 in Boston in May 2011.
With best regards,
Alan J. Magill MD, FACP, FIDSA
President, International Society for Travel Medicine (ISTM)
2009-2011
David O. Freedman, MD, FIDSA
Secretary-Treasurer, ISTM
4 ~ Final Program
Introduction by SLAMVI
Dear Colleagues and Friends:
Welcome to the II Congreso Latinoamericano de Medicina del Viajero by SLAMVI, the Sociedad Latinoamericana
de Medicina del Viajero.
SLAMVI is honored to co-chair this year’s congress with the 4th Regional Conference of the International
Society of Travel Medicine (RCISTM4). The travel medicine track is included in the 14th International Congress
of Infectious Diseases.
SLAMVI is immensely grateful to both the ISTM and the ISID for this unique opportunity to help us promote
the growth of Travel Medicine as a prominent specialty in our region as well as the membership of our
young society.
The scientific program of the 14th ICID includes a comprehensive Travel Medicine track with sessions
that focus on almost all aspects of our rapidly developing discipline. There is particular emphasis on the major
topics of concern in Latin America. We especially invite our colleagues to join the sessions on March 9th,
which in recognition to our languages will be held, in part, in Spanish and Portuguese.
We hope this conference presents to all attendees the opportunity of meeting colleagues and friends, enhancing
their knowledge of Travel Medicine and enjoying the complete update in Infectious Diseases that the
14th ICID presents to us all.
Welcome to Miami, Bienvenidos a Miami, Bem-vindos a Miami!
Mario Masana Wilson, MD
President, Sociedad Latinoamericana de Medicina del Viajero (SLAMVI)
SLA MVI
Sociedad Latinoamericana
de Medicina del Viajero
Final Program ~ 5
Table of Contents
Time Schedule. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ii
Welcome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Congress Committees and Organization. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Congress Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Members of the ISID Council. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Membership in the ISID. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
International Journal of Infectious Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Awards. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Acknowledgements. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
ISID Business Meeting. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Speakers Center and Lounge. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Poster Presentations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Plenary Lectures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Meet-the-Expert . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
CME Accreditation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
Commercial Exhibition. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Schedule-at-a-Glance. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
Floorplans. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
Opening Ceremony. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Scientific Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Tuesday, March 9, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Wednesday, March 10, 2010. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
Thursday, March 11, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
Friday, March 12, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
Disclosures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210
Index of Authors and Co-Authors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212
6 ~ Final Program
Congress Committees
International Organizing Committee
Timothy Brewer (Canada)
Keryn Christiansen (Australia)
Jonathan Cohen (UK)
Raúl Istúriz (Venezuela), President
Keith Klugman (USA)
Daniel Lew (Switzerland)
Carla Odio (Costa Rica)
Heikki Peltola (Finland)
Didier Raoult (France)
Eric Summers (USA)
Richard Wenzel (USA)
Program Advisory Committee
Guillermo Acuña (Chile)
Deshratn Asthana (USA)
NC Bodonaik (Jamaica)
Lina Bofill (USA)
Pedro Cahn (Argentina)
Gordon Dickinson (USA)
Gustavo Kouri (Cuba)
Samuel Ponce de Leon (Mexico)
Frederick Southwick (USA)
Jaime Torres (Venezuela)
Sergio Wey (Brazil)
RCISTM4/SLAMVI Travel Medicine
Program Committee
Arlene Calvo (Panamá), Associate Chair
Jessé Reis Alves (Brazil), Chair
Cristián Biscayart (Argentina), Co-Chair
Susana Lloveras (Argentina), Associate Chair
Members
Suni Boraston (Canada)
Marcos Boulos (Brasil)
Jeanette Dabanch Peña (Chile)
Carlos Franco-Paredes (USA/Mexico)
David Freedman (USA)
Eduardo Gotuzzo (Peru)
Sylvia Lemos Hinrichsen (Brasil)
Alejandro Lepetic (Argentina)
Alejandra Macchi (Argentina)
Alan Magill (USA)
Melissa Mascheretti (Brasil)
Mario Masana Wilson (Argentina)
Tomás Orduna (Argentina)
Alejando Ortiz (Mexico)
Cecilia Perret (Chile)
Franklin Simões de Santana Filho (Brasil)
Nestor Sosa (Panamá)
Tânia Souza Chaves (Brasil)
Collaborating Organizations
Cooperating Organizations
Infectious Diseases Society of America (IDSA)
International Society of Travel Medicine (ISTM)
Latin American Society of Pediatric
Infectious Diseases (SLIPE)
Pan American Association for
Infectious Diseases (API)
Sociedad Latinoamericana de Medicina
del Viajero (SLAMVI)
American Society for Microbiology (ASM)
Argentinian Society of Infectious Diseases (SADI)
Asociación Colombiana de Infectología (ACIN)
Brazilian Society of Infectious Diseases (BSID)
Costa Rican Society of Infectious Diseases
European Society of Clinical Microbiology and
Infectious Diseases (ESCMID)
International Society for Anaerobic Bacteria (ISAB)
Panamanian Society of Infectious Diseases
Pan American Health Organization (PAHO)
Paraguayan Society for Infections Diseases
Venezuelan Society of Infectious Diseases (SVI)
Final Program ~ 7
Congress Information
Congress Site
14th ICID Congress Secretariat
James L Knight International Center &
Hyatt Regency Miami
Miami, FL, USA
Registration
B.P. SERVIMED, S.A. DE C.V.
Barranca del Muerto No. 520, Col. Alpes,
01010 México, D.F.
Phone: +52 (55) 9171 9570
Fax:
+52 (55) 5660 1903
E-mail: isid@servimed.com.mx
Official Language
The official language of the Congress is English.
Some Spanish language sessions will be
available on Tuesday, March 9, 2010 during
the SLAMVI/ISTM program.
International Society for
Infectious Diseases (ISID)
Norman R. Stein, Executive Director
Eric Summers, Program Director
International Society for Infectious Diseases
1330 Beacon Street, Suite 228
Brookline, MA 02446, USA
Phone: (617) 277-0551
Fax:
(617) 278-9113
E-mail: info@isid.org
web site: http://www.isid.org
Official Travel Agency
Stewart International Travel is delighted to have
been selected as the Official Travel Agent for the
14th International Congress on Infectious Diseases.
As such, we would be happy to assist with your
air transportation to Miami.
For further information please contact:
Stewart International Travel
50 Boylston Street
Brookline, MA 02445
Phone: (617) 738-1575
(800) 738-1575
E-mail: pilar@stewartintltravel.com
web site: www.stewartintltravel.com
8 ~ Final Program
Housing
Greater Miami Convention & Visitors Bureau
701 Brickell Ave., Ste. 2700
Miami, FL 33131, USA
Phone: (305) 539 2928
(800) 476 9969
Fax:
(305) 539 3106
E-mail: housing@gmcvb.com
Exhibition Management
Media Plan
Ms. Bettina Kreiner
Freyung 6
1010 Vienna, Austria
Phone: (+43 1) 536 63 0
Fax: (+43 1) 535 60 16
E-mail: maw@media.co.at
International Society for Infectious Diseases (ISID)
Members of the ISID Council
John Bartlett (USA)
Mohammed Benbachir (Morocco)
Zulfiqar Bhutta (Pakistan)
N.C. Bodonaik (Jamaica)
Pedro Cahn (Argentina)
Jun Cheng (China)
Ron Dagan (Israel)
Adriano Duse (South Africa)
Le Dang Ha (Vietnam)
Javier Ena (Spain)
Barry Gilbert (Australia)
Bart Gordts (Belgium)
Nii Hanson-Nortey (Ghana)
Waleria Hryniewicz (Poland)
Abeeda Kamarulzaman (Malaysia)
Moses Kamya (Kenya)
Gustavo Kourí (Cuba)
Vladimir Krčméry (Slovak Republic)
Hsieh-Shong Leu (Taiwan)
Chewe Luo (Zambia)
Cristina Marino (Colombia)
Ziad Memish (Saudi Arabia)
Alaine Nyaruhirira (Ewanda))
Emanuele Nicastri (Italy)
Nobuhiko Okabe (Japan)
Franco Paradisi (Italy)
Samuel Ponce de Leon (Mexico)
Mahbubur Rahman (Bangladesh)
RK Ratho (India)
Marie-Christine Roy (Canada)
Sally Roberts (New Zealand)
Roberto Salvino (The Philippines)
Atef Shibl (Egypt)
Yupin Suputtamongkol (Thailand)
Constanze Wendt (Germany)
Sergio Wey (Brazil)
Membership in the ISID
Any individual interested in infectious diseases may become a Regular Member of the Society.
Benefits include:
•1-year online subscription to the International Journal of Infectious Diseases
•Discounts at the International Congress on Infecious Diseases (ICID)
• Subscription to the Society’s newsletter (ISID News)
• Subscription to ProMED-mail, an email network providing up-to-date, reliable reports
on infectious diseases outbreaks around the world.
Individuals who pay the full registration fee for the ICID become Regular Members and are entitled to all of the
benefits of membership for a two-year term.
You may also become a Regular Member by paying the membership fee of US$150. The term of membership
is one year. Membership is available for individuals who work and reside in low-resource countries, or for
students, for US$50 per year.
Corresponding Membership in the Society is available without charge through application to the Society.
This type of membership includes all of the benefits of Regular Membership, except for the Journal and the
discounts at the ICID.
For additional information or to apply for membership, please contact the ISID headquarters or visit the Society
website at http://www.isid.org.
International Journal of Infectious Diseases
The International Journal of Infectious Diseases (IJID) is an English-language publication of the International
Society for Infectious Diseases available in an on-line format. Because the Society is the only international organization dealing specifically with infectious diseases, its journal has a unique mission: to communicate and
disseminate information to infectious disease researchers and clinicians throughout the world. The IJID is cited
and indexed in MEDLINE.
Final Program ~ 9
Awards
More than 1,000 abstracts were considered for the Awards Program. The award-winning scientists
were selected by the Program Committee and representatives from Sanofi Pasteur and Novartis
Vaccines according to the criteria described in the preliminary program.
Winners of the Novartis Vaccines Awards for Epidemiology of Infectious Diseases
Phabiola M. Herrera Aldana ~ Peru is a medical research scientist working with The Johns Hopkins School of
Public Health overseas research site in Lima, Peru. Her research focuses on gastrointestinal infectious diseases,
specifically the Helicobacter pylori infection. Her training from Johns Hopkins was crucial in developing and
coordinating epidemiologic projects in shantytowns and other underserved Peruvian communities. This work
with diverse communities in Peru led to international collaboration with colleagues at Johns Hopkins, Washington
University St Louis, Center for Disease Control (CDC) and Universidad Federal de Minais Gerais in Brazil.
The National Institutes of Health (NIH) funded Helicobacter pylori infection research focused on three areas:
Intrafamiliar transmission in Lima’s shantytowns, genetic characterization in Peruvian jungle villages, and
genotypes of strains related to gastric cancer in hospital settings.
The Novartis Vaccines
Awards will be officially
presented during the
Opening Ceremony on
March 9 at 18:30hrs
In addition to several publications, Dr. Herrera has supervised foreign students, interacted with young US and
developing country researchers and received the Fogarty/Ellison Global Overseas Fellowship from the NIH.
Dr. Herrera has also been involved in other areas of infectious disease research including first episode of
schizophrenia and childhood diarrheal and neglected mucosal enteric infection. In social research, her work
has examined the link between drug and alcohol consumption with sexual behavior in young adults with a grant
funded by Belgium Technical Cooperation.
Currently, Dr. Herrera is focusing on improving her understanding of clinical environments to enhance and
continue her gastroenterology infectious disease research. Mussaret Zaidi ~ Mexico is an investigator at the Hospital General O’Horan and the Hospital Regional de
Alta Especialidad in Yucatan, Mexico. She is currently a member of the World Health Organization Advisory
Group for Integrated Surveillance of Antimicrobial Resistance. Over the last decade, her research has focused on
the epidemiology of antimicrobial resistance in foodborne and nosocomial pathogens and the transmission of
foodborne pathogens from animals to humans. More recently, her studies have centered on the immune response
to foodborne pathogens in highly endemic settings.
With the support of a generous grant from the United States Food and Drug Administration, Dr. Zaidi coordinated
the first multistate study on antimicrobial resistance in foodborne pathogens in Mexico. This study integrated
active surveillance data from food-animals, raw retail meat and human fecal specimens to study transmission
through the food chain. This integrated approach was subsequently used in a community-based cohort study to
determine the frequency of transmission of antimicrobial resistant foodborne pathogens from food-animals to
humans and its impact on human health. These studies provided the first data on antimicrobial-resistant foodborne
pathogens throughout the food chain in Mexico. Using data from active epidemiological surveillance and pulsedfield gel electrophoresis analysis, public health risks were determined for the different foodborne pathogens and
Salmonella serotypes. Multilocus sequence typing was used to identify recently emerging multidrug-resistant
clones that are associated with specific resistance determinants and geographic distributions within Mexico.
The Society gratefully acknowledges the support of
NOVARTIS VACCINES, which made these awards possible.
Winner of the ISID New Investigator Award
Juan Carlos Quintero Vélez ~ Colombia is an investigator of the Veterinary Science “Centauro” group and DMV
at the Universtiy of Antioquia and Animal Productions at the National University of Colombia. Msc Candidate
of Animal Science at the University of Antioquia. His current research is on Rickettsial Disease and zoonoses in
the Urabá area of Antioquia, Colombia. This research is carried out in collaboration with the National Institute of
Health, Colombia; Gorgas Institute, Panama; University of Sao Paulo, Brazil; and the University of Texas, USA.
The ISID New Investigator Award will be officially presented
during the Opening Ceremony on March 9 at 18:30hrs
10 ~ Final Program
Awards
Winners of the Sanofi Pasteur Awards
Beate Sander, RN, MBA, MEcDev ~ Canada is a PhD candidate in the Department of Health Policy, Management and Evaluation at the University of Toronto, Canada, a collaborator with THETA, the Toronto Health Economics and Technology Assessment Collaborative, and a research fellow in decision-analytic modeling in the
Division of Clinical Decision Making at the University Health Network Research Institute. Her research interests
include the use of advanced modeling techniques to evaluate new health technologies within the larger context
of comprehensive health care programs to support health policy decision-making. Her doctoral research extends
current modeling techniques used in economic evaluation to incorporate individual human behavior, important
for simulating infectious disease transmission. She is interested in answering public health policy questions by
using models to assess the impacts of vaccination and other control measures. Recent projects include an economic evaluation of Ontario’s Universal Influenza Immunization program and economic evaluations of influenza
pandemic mitigation strategies in Canada and the US. Beate Sander works extensively with mathematicians,
epidemiologists, and public health researchers on various interdisciplinary collaborations.
Akira Suzuki, MD, PhD, MPH ~ Japan is an assistant professor in Department of Virology at Tohoku University
Graduate School of Medicine, Japan. After eight years of practice as pediatrician in Japan, he earned his Master’s
Degree in Public Health at University of Michigan on the Fulbright Scholarship. His main research topic is
the epidemiology of respiratory viruses among children. Currently, Tohoku University and Research Institute
for Tropical Medicine, the Philippines, have been conducting a series of collaborating studies on emerging and
re-emerging infections, supported by Ministry of Education, Culture, Sports, Science, and Technology-Japan. The
study covers not only respiratory viruses (influenza virus, human metapneumovirus, RS virus, and rhinovirus) but
also enteric viruses (norovirus, rotavirus), polio-related viruses (enteroviruses), and zoonosis (ebola and rabies).
The Sanofi Pasteur Awards will be officially presented during the Opening Ceremony on March 9 at 18:30hrs
The Society gratefully acknowledges the support of
SANOFI PASTEUR, which made these awards possible.
Sanofi Pasteur Travel Grants for Latin American Women Physicians and Scientists
Carmen Sarah Mota
Mayra Ligia Raciny
Carina Ramos
Silvina Ruvinsky
Yagahira Castro Sesquen
Kelly Salomão
DOMINICAN REPUBLIC
COLOMBIA
BRAZIL
ARGENTINA
PERU
BRAZIL
Carmona Sandoval
Virgina Verdaguer
Gabriela Vidiella
Cecilia Vizcaya
Maria Laura Yantorno
CHILE
ARGENTINA
ARGENTINA
CHILE
ARGENTINA
Final Program ~ 11
Awards
CDC Awards for Epidemiology, Surveillance and Communications in Travelers’ Health
José Roberto P.
De Andrade-Lima
Pablo Elmassian
Cristiano Gregis
Cristiane Lamas
Maria Ester Lázaro
ARGENTINA
BRAZIL
BRAZIL
ARGENTINA
Susana Lloveras
Manuel Loayza
Alejandra Macchi
Melissa Mascheretti
Tomas Orduña
ARGENTINA
PERU
ARGENTINA
BRAZIL
ARGENTINA
BRAZIL
12 ~ Final Program
Acknowledgements
The International Organizing Committee would like to take this opportunity
to acknowledge the following sponsors:
PREMIER SPONSORS
Pfizer
Sanofi Pasteur
SPONSORS
ASM (American Society for Microbiology)
API (Associacion Panamericana de Infectiologia)
Astellas Pharma Global Development Inc.
Baxter
CDC (U.S. Centers for Disease Control and Prevention)
ESCMID (European Society of Clinical Microbiology and Infectious Diseases)
GMCVB (Greater Miami Convention & Visitors Bureau)
ISC (International Society of Chemotherapy)
Merck
Novartis Vaccines
PAHO (Pan American Health Organization)
Salix Pharmaceuticals, Inc.
Final Program ~ 13
General Information
Badges
All registrants have been issued badges, which must be worn to gain admission to the convention
facilities and social program. Badges are color-coded as follows:
Participants – blue
Staff – red
Accompanying Persons – orange
Exhibitors – yellow
Press – grey
A fee of USD 150 will be charged for the replacement of lost or forgotten badges.
Only participants with blue and grey badges will be admitted to the scientific sessions.
Congress Venue
The 14th ICID takes place at the Hyatt Regency Miami. No smoking is allowed. Mobile phones must be switched
off in the meeting rooms. Your cooperation will be appreciated. Unauthorized recording (video and/or audio) and
photography are not allowed.
Congress Language
The official language of the Congress is English. Some Spanish language sessions will be available on Tuesday,
March 9, 2010 during the SLAMVI / ISTM program.
Lunch/Snack Bar and Restaurant
A lunch and snack bar area will be available to Congress participants. This area is located in the Exhibit area in
Riverfront Hall on the Lobby Level. Lunch is also available at the Riverwalk Cafe on the Lobby Level.
Message & Info Center
A message center for collection and distribution of messages is available on the Terrace Level near the meeting
rooms.
Internet Corner
Congress participants are invited to the internet corner which is located in the exhibit area in Riverfront Hall on
the Lobby Level.
Dining
Miami’s dining scene is truly exciting, one of varying tastes that can satisfy the most complete palate or craving.
With so many different cultures migrating to Miami, local flavors tend to be much more exotic. The influence of
flavors and culture here is almost overwhelming and has many positive effects on menu and recipe design.
Entertainment
Miami offers exciting nightlife. Besides local and international theatre shows and symphony orchestras, there
is a wide variety of entertainment including live bands, jazz bands, strollers, dinner shows, cabaret, disco
and karaoke lounges. Nightlife in the city also thrives with the many pubs, street cafés and bistros that offer
visitors a guaranteed exciting night.
Tipping
Tipping is customary in Miami (15%–20%).
14 ~ Final Program
General Information
Credit Cards
Major credit cards are accepted in most hotels, shops and restaurants. Travelers checks and currency can be
changed at hotels or at a bank. Banking hours vary, but most banks are open weekdays from 9am to 3pm. Several
stay open until 5pm or so at least 1 day during the week.
Currency
The US Dollar is the United States’ unit of currency. The dollar is divided into 100 cents (100¢) with coins of
one cent (penny), five cents (nickel), 10 cents (dime), 25 cents (quarter) and relatively rare 50 cents (half dollar).
Shopping
As a general rule, shop hours are Monday through Saturday from 10am to 6pm, and Sunday from noon to 5pm.
Many stores stay open late (until 9pm or so) 1 night of the week, usually Thursday. Shops in Coconut Grove are
open until 9pm Sunday through Thursday, and even later on Friday and Saturday. South Beach’s stores also stay
open later—as late as midnight. Department stores and shopping malls keep longer hours as well, with most staying open from 10am to 9 or 10pm Monday through Saturday, noon to 6pm on Sunday.
Sales Tax
A 7% state sales tax is added on at the register for all goods and services purchased in Florida.
Electrical Current
Type A & B sockets with 110 volts AC at 15A are used.
Official Carrier
American Airlines was appointed official carrier for the 14th International Congress on Infectious Diseases.
Taxis and Public Transportation
Taxis are always available and required to use meters when ferrying passengers. Fares do not include a tip, plan
to give around 15%. Public transportation (‘People Mover’) is very convenient and free.
Tours
Tours can be booked through the Tours Counter in the registration area on the Lobby Level.
Safety Precautions
As in most places, it is advisable to take the following precautions while in Miami:
•. Do not leave luggage or valuables unattended.
•. Use the safety deposit boxes provided by most hotels.
•. Carry only the cash, credit cards, and identification that you need.
Insurance
The Organizing Committee, ISID and Servimed accept no liability for personal injuries sustained by or for loss
or damage to property belonging to Congress participants, either during or as a result of the Congress or during
tours.It is therefore recommended that delegates and accompanying persons arrange for appropriate travel and
health insurance before traveling.
Emergencies
For emergencies, dial tel. 911 from any phone. No coins are needed for this call. For other police matters, call
tel. 305/595-6263.
Final Program ~ 15
ISID Business Meeting
The ICID, held every 2 years, is the only opportunity for the Society’s membership to come together. It is only
then that members can actively exchange ideas concerning the ISID and its activities with representatives of the
Executive Committee and Council. Your input is important and your contributions are appreciated. We would like
to invite all members to participate in the Business Meeting, which will take place on Friday, March 12, 2010,
at 12:30hrs in Room Orchid B/C/D on Terrace Level. During this meeting, Regular Members will vote on the
composition of the Executive Committee and Council for the period 2010–2012. You will hear reports from various officers concerning the ongoing activities of the Society, and you will be able to voice your suggestions and
concerns. A light lunch will be provided. We hope you will attend this important meeting.
Speakers Center and Lounge
An LCD projector and laptop for MS Powerpoint presentations are provided in all meeting rooms. All speakers
are requested to take their presentations on CD/USB stick to the speakers center in Room Orchid A on Terrace
Level at the Hyatt Regency Miami. All presentations must be received as early as possible but no later than two
hours before the presentation. Please use the meeting room laptop computer rather than your personal computer
for your presentation.
A technician will be available to assist the speakers. Any questions regarding presentations should be directed to
the speakers center located in room Orchid A on Terrace Level at the Hyatt Regency Miami.
Poster Presentations
Riverfront Hall
Exhibition Area
Lobby Level
9.45 – 10:15hrs
12:30 – 14:30hrs
15:15 – 15:45hrs
Posters are displayed in the exhibition area in Riverfront Hall on the Lobby Level of the Hyatt Regency Miami.
Each poster board is marked with the number assigned to each abstract, which can be found in the abstract and/
or program book. Authors are requested to affix their posters at the number assigned to them (as listed in the
program) on the morning of their designated date of presentation between 8:00 and 9:30hrs. At least one author
of each poster should be present for discussion and questions during the official poster sessions each day from
12:30 to 13:30hrs and, if possible, during the coffee breaks.
All posters must be removed at the end of the day of the poster session, but no later than 17:45hrs. Posters not
removed by this time will be dismantled by the Congress staff and may be claimed from the poster attendant. The
Congress assumes no responsibilities for the condition of posters not removed by the presenter. All posters not
collected by 17:45hrs on Friday, March 12, will be disposed of.
Abstracts of poster presentations are published on the abstract CD-rom which is a supplement to the International
Journal of Infectious Diseases (IJID). Abstracts accepted for “International Scientific Exchange” are not presented
but published on a separate “International Scientific Exchange” CD-rom.
16 ~ Final Program
Riverfront Hall
Exhibition Area
Lobby Level
9.45 – 10:15hrs
12:30 – 14:30hrs
15:15 – 15:45hrs
Wednesday, March 10, 2010
Riverfront Hall
Sessions 23–34
Thursday, March 11, 2010
Riverfront Hall
Sessions 48–59
Friday, March 12, 2010
Riverfront Hall
Sessions 73–84
23
Antibiotic Resistance: Gram-Negative
24
Arboviruses
25
Clinical Bacterial Infections
26
Foodborne Diseases and Outbreaks
27
HIV: Epidemiology and Prevention
28
Influenza
29
Malaria & Blood-borne Parasites
30
Mycology, Fungal Infections and Antifungal Drugs
31
Non-tuberculous Mycobacteria
32
Travel Medicine and Travel Health
33
Tuberculosis: Epidemiology, Prevention & Control
34
Zoonoses and Infections in Animals
48
Antibiotics: Mechanisms and Spectrum
49
Antibiotics: Pharmacology and Clinical Studies
50
Antibiotics: Usage and Stewardship
51
Epidemiology of Pathogens
52
Gram-negative Bacterial Infections
53
Hepatitis
54
HIV: Pathogenesis
55
HIV: Therapeutics
56
Infection Control, Nosocomial Infections and Critical Care
57
Infectious Diseases Surveillance
58
Parasites
59
Tuberculosis: Diagnosis, Treatment & Drug Resistance
73
Animal Models, Pathogenesis & Host Defenses
74
Antibiotic Resistance: Gram-Positive
75
Diagnostics
76
Emerging Infectious Diseases
77
Gram-positives & Miscellaneous Pathogens
78
HIV: Opportunistic Infections & Malignancies
79
Obstetrical-Gynecological, Surgical and Sexually Transmitted Infections
80
Pediatric and Perinatal Infections
81
Mycobacterial Pathogenesis, Immunology and Vaccines
82
Trypanosomiasis, Leishmaniasis & Schistosomiasis
83
Vaccines and Vaccine Development
84
Virology and Viral Infections (Non-HIV)
Final Program ~ 17
Plenary Lectures
Jarbas Barbosa da Silva, BRAZIL
Emerging Infectious Diseases in Latin America
Dr. Jarbas Barbosa da Silva Jr. has been Manager of the Health Surveillance, Disease Prevention and Control
Area of the Pan American Health Organization (PAHO) since 10 January 2007. The HSD area is responsible
for coordinating regional activities on surveillance, prevention and control of communicable and noncommunicable diseases; health information and analysis; and veterinarian public health.
Dr. Barbosa received his degree in medicine from the Federal University of Pernambuco. He later received
specialized credentials in public health and epidemiology from the National School of Public Health at the
Oswaldo Cruz Foundation (FIOCRUZ), Brazil. He received a Master’s degree and later a Doctoral degree in
public health from the State University of Campinas (Unicamp) in São Paulo state, Brazil.
Dr. Barbosa began his professional career in the public health sector in 1982, working for the Secretariat of
Health for the state of Pernambuco, Brazil. In 1987, he became Coordinator for the Program on Sexually
Transmitted Diseases and HIV/AIDS in this state. In 1993, he was appointed Secretary of Health of the
municipality of Olinda, and in 1995 Secretary of Health for the State of Pernambuco. In these positions he
was the coordinator of the entire municipality health system and the state health system, respectively.
From 1997 to 2003, Dr. Barbosa da Silva worked as Director of the National Center for Epidemiology
(CENEPI) in Brasilia, Brazil, in the Ministry of Health. In this position he was the national coordinator of
the epidemiological surveillance system. In 2003 he was nominated as the first Secretary of Public Health
Surveillance, a new branch created in the Brazilian MoH that joined the areas of epidemiological surveillance
and the prevention and control of diseases programmes. In the second semester of 2007 he was appointed
as Executive Secretary (Vice Minister) of the Ministry of Health.
Dr. Barbosa is author and co-author of articles, books and chapters on several public health and
epidemiological matters.
Edward H. Kass Lecture
Françoise Barré-Sinoussi, FRANCE
The Discovery of HIV: An Example of Translational Research on Response to an Emerging Epidemic
Françoise Barre-Sinoussi, PhD, is the acting Director of the “Regulation of Retroviral Infections” Unit at the
Institut Pasteur in Paris. She has been involved in retrovirology research since the early 1970’s and is recognized for her contributions to HIV/AIDS research, in particular as the first author of the publication that
reported in 1983 the discovery of a retrovirus, later named HIV, in a patient at risk for AIDS. In 1988, she
became responsible for her own laboratory at the Institut Pasteur and initiated research programs on viral and
host determinants of HIV/AIDS pathogenesis.
Between 1988 and 1998, Dr. Barré-Sinoussi has been involved in collaborative programs on HIV vaccine
research using primate models. Today, the research programs of her team are focused on regulations of HIV/
SIV infection (intracellular restrictions of HIV-1infection and innate immunity, in particular regulations of
T cell activation resulting from the NK-dendritic cell interplay).
Dr. Barré-Sinoussi is author and co-author of more than 220 original publications and more than 120 articles
and book reviews. She has been invited to speak at more than 250 International meetings and/or conferences. She has been (and is still) a member of a number of scientific committees in France and elsewhere,
including scientific committees of several International AIDS Conferences. She has received 10 awards, both
nationally and internationally for her contributions to HIV/AIDS research. Dr. Barré-Sinoussi shared the 2008
Nobel Prize in Medicine with Dr. Luc Montagnier for their discovery of HIV.
Along with her research activities, since the early 80’s Dr. Barré-Sinoussi has been strongly involved in
promoting integration between HIV/AIDS research and actions in resource-limited countries, in particular
through the Institut Pasteur International Network and the coordination of the ANRS research programs in
Cambodia and Vietnam, in accordance with her strong commitment to building capacity, training and technology transfers on site in Africa and Asia.
18 ~ Final Program
Plenary Lectures
Martin Cetron, USA (SLAMVI/ISTM Plenary Speaker)
The Changing Patterns of Global Migration and the Impact on Infectious Diseases
Dr. Martin Cetron is the Director for the Division of Global Migration and Quarantine (DGMQ) at the
U.S. Centers for Disease Control and Prevention (CDC). The DGMQ mission is to prevent introduction of
infectious diseases in the U.S. and to prevent morbidity among immigrants, refugees, migrant workers, and
international travelers.
Dr. Cetron received his M.D. from Tufts University and trained in Infectious Diseases at the University of
Washington before joining the CDC’s Epidemic Intelligence Service in 1992.
His primary research interests are international health and global migration with a focus on emerging
infections, tropical diseases, and vaccine-preventable diseases in mobile populations. He has been in this
current leadership role at CDC during responses to the key emerging infectious disease outbreaks of the 21st
century including the anthrax bio-terrorism incident, the smallpox threat, the global SARS epidemic, and the
U.S. Monkeypox outbreak. He is part of the CDC Pandemic Influenza Planning and Preparedness Team and
the WHO Influenza Pandemic Task Force.
Richard K. Root Memorial Lecture
Myron S. Cohen, USA
Transmission and Prevention of Transmission of HIV: Clues from the Early 21st Century
Myron S. Cohen is the J. Herbert Bate Distinguished Professor of Medicine, Microbiology and Immunology
and Public Health at the University of North Carolina at Chapel Hill. He is Associate Vice Chancellor for
Medical Affairs-Global Health. Dr. Cohen received his BS degree (Magna Cum Laude) from the University of
Illinois, Champaign-Urbana, an MD degree from Rush Medical College, Chicago Illinois and he completed
an Infectious Disease Fellowship at Yale University.
Dr. Cohen serves as the Director of the UNC Division of Infectious Disease and the UNC Institute for Global
Health and Infectious Disease, and he is Associate Director of the UNC Center for AIDS Research. Dr. Cohen
serves on the Senior Leadership Group of the NIH Center for HIV Vaccine Immunology (CHAVI), and serves
as part of the leadership group of the NIH HIV Prevention Trials Network (HPTN). Dr. Cohen serves as an
Associate Editor of the journal, Sexually Transmitted Diseases, and the comprehensive textbook, Sexually
Transmitted Diseases.
Dr. Cohen received the Distinguished Alumnus Award from Rush Medical College in 2000. He received
the Thomas Parran Award (2005) for lifetime achievement in STD research from the American Sexually
Transmitted Diseases Association. In 2008 Dr. Cohen received the O. Max Gardner Award for “contributions
to mankind,” the greatest honor in the University of North Carolina 16-campus system. Dr. Cohen has been
repeatedly recognized as one of America’s “Top Doctors” and “Best Doctors.”
Dr. Cohen’s research work focuses on the transmission and prevention of transmission of HIV, with emphasis
on the role played by STD co-infections. He has conducted landmark studies related to the biology of HIV
transmission and use of antiretroviral agents for prevention. In 2005, Dr. Cohen received an NIH MERIT
Award for ongoing support of this work. Dr. Cohen is the author of more than 400 publications. Much of Dr.
Cohen’s research has been conducted internationally, especially in the African country of Malawi and in the
People’s Republic of China.
Final Program ~ 19
Plenary Lectures
Keith Klugman, USA
Pneumococcal Infections in Children and their Impact on Adults
Keith Klugman is the William H. Foege Chair of Global Health in the Hubert Department of Global Health at
the Rollins School of Public Health, Emory University, in Atlanta, Georgia. He is a Professor of Medicine in
the Division of Infectious Diseases of the School of Medicine at Emory University and a Visiting Researcher in
the Respiratory Diseases Branch of the Centers for Disease Control and Prevention (CDC). He is also the CoDirector of the Respiratory and Meningeal Pathogens Research Unit of the University of the Witwatersrand, the
Medical Research Council and the National Institute for Communicable Diseases in Johannesburg, South Africa.
Professor Klugman is the Treasurer of the Executive Committee of the International Society for Infectious
Diseases, and Chair of the International Board of the American Society for Microbiology. He has chaired expert
committees for the World Health Organization in Geneva and the Wellcome Trust in London, and currently
serves as an editor or member of the editorial board of 8 international journals on medicine, infectious diseases
and antimicrobials.
Professor Klugman’s research interests are in antibiotics, antimicrobial resistance and vaccines for bacterial
pathogens—particularly the pneumococcus. He has published more than 375 papers on these subjects to date.
Roberto Kolter, USA
Microbial Chemical Ecology and the Future of Antibiotics
Roberto Kolter has been a highly influential microbiologist for a period that spans four decades. Early in his
career he made enduring advances in our understanding of the regulation of DNA replication as well as
practical advances in the development of the most widely used “suicide delivery vectors” of today.
Since establishing his own laboratory at Harvard Medical School in 1983, Dr. Kolter has made contributions
in diverse areas of microbiology. Initially, he worked on peptide antibiotic synthesis and secretion, providing
some of the earliest knowledge on “ABC exporters.” This was followed by an exploration of the starvation
physiology of E. coli at a time when virtually no one else thought of investigating stationary phase cultures. In
part as a result of those efforts, the control of gene expression in non-growing cells became an area of intense
investigation by others that continues to this day. Dr. Kolter’s work on the population dynamics of stationary
phase cultures, the so-called “GASP” (growth advantage in stationary phase) phenomenon, established such
cultures as excellent model systems for experimental evolution studies. Since the mid-1990’s he has applied
genetic approaches to study bacterial biofilms; Dr. Kolter’s laboratory developed the most widely used highthroughput assay for detection of biofilm development. His studies with Bacillus subtilis as a model system
to understand biofilms continue to be at the leading edge of the field. Most recently, Dr. Kolter is investigating the chemistry of interspecies communication in bacteria. In this area he discovered that a bacterium’s
quorum sensing signal can also act as a fungal morphogen. In addition, he has developed screens that have
led to the discovery of novel secondary metabolites produced by one species that profoundly affect the
developmental patterns of other species.
Since 2002, Dr. Kolter has played a key role in the organizing and launching of the Microbial Sciences
Initiative at Harvard (MSI) and is currently its co-director. The MSI (www.msi.harvard.edu) is an innovative
University-wide interdisciplinary science program aimed at developing new approaches to explore the
microbial world. MSI is playing a leadership role in microbial sciences worldwide by bringing together
scientists from diverse backgrounds to think about and discuss key issues in microbiology.
Dr. Kolter is the current President of the American Society for Microbiology.
20 ~ Final Program
Plenary Lectures
Louis Loutan, Switzerland
The Challenges of Travel Medicine in the 21st Century
Louis Loutan, MD, MPH is the head of the Division of International and Humanitarian Medicine since its
creation in the Department of Community Medicine and Primary Care at the Geneva University Hospitals
(HUG) in Geneva, Switzerland. He is also Associate Professor in International and Humanitarian Medicine
at the University of Geneva. Dr. Loutan is a specialist in internal medicine and tropical medicine and has a
Master’s in Public Health from Harvard SPH.
Dr. Loutan has extensive field experience in international health projects in Africa, the Balkans, Nepal and
Central Asia conducting research projects and organizing training programs. He has spent five years in
the Republic of Niger running epidemiological surveys in nutrition and tropical medicine, and organizing
programs in community health for nomadic populations. He spent two years in the Department of Community
Health at Tufts University School of Medicine (Boston) organizing training courses in international health. He
also served as technical advisor and coordinator of training and research programs in the family medicine
reform in Bosnia & Herzegovina.
Dr. Loutan has been the founder and head of the Geneva travel and migration medicine unit since 1991.
He has conducted research in various aspects of travel medicine including immunogenicity and tolerance of
vaccines, security and the health of humanitarian expatriates.
His appointments included: president of the Swiss Society of Tropical Medicine and Parasitology; president
of the International Society of Travel Medicine; board member of the Federation of European Societies for
Tropical Medicine and International Health; chair of the organizing committee of the 5th International
Conference on Travel Medicine (Geneva 1997); president of the HUG Committee of Humanitarian and
International Cooperation Activities; president of the Geneva Forum: Towards Global Access to Health, held
in Geneva in 2006, 2008 and in preparation for 2010.
Christopher Plowe, USA
Malaria Eradication
Christopher Plowe is a Howard Hughes Medical Institute Investigator and Professor of Medicine, of
Microbiology and Immunology, and of Epidemiology and Preventive Medicine at the University of Maryland
School of Medicine, where he is Chief of the Malaria Section of the University’s Center for Vaccine
Development. Plowe received his B.A. in Philosophy from Cornell University, an M.D. from Cornell University
Medical College, and an M.P.H. in Tropical Medicine from Columbia University School of Public Health.
He completed fellowships in Malaria Research at the National Institutes of Health, USA and in Infectious
Diseases at Johns Hopkins University. He has received a Doris Duke Distinguished Clinical Scientist Award
and the Bailey K. Ashford Medal for distinguished work in tropical medicine from the American Society of
Tropical Medicine and Hygiene.
Dr. Plowe leads a multidisciplinary clinical translational malaria research program with field sites in Mali,
West Africa and Malawi, Central Africa. He is best known for his work on the molecular epidemiology of
drug resistant malaria. Working with African colleagues, his group at the University of Maryland developed
rapid molecular assays to detect drug resistant malaria using dried blood spots on paper. These tests have
been used to understand the population genetics of malaria and to control malaria outbreaks and inform
treatment policy decisions. Dr. Plowe’s work encompasses malaria drug resistance, molecular epidemiology,
molecular evolution, rapid diagnostics, pathogenesis, immunology, international research ethics, interactions
between HIV and malaria, and clinical trials of drugs and vaccines. His group is currently concentrating on
understanding and mitigating the impact of genetic diversity on malaria vaccine efficacy and on developing
strategies to deter the emergence and spread of drug resistant malaria. Dr. Plowe directs the Molecular
Module of the Worldwide Antimalarial Resistance Network (WWARN).
Dr. Plowe provides expert advice on malaria research and control to national and international agencies and
has testified before Congress on tropical medicine research priorities and before a Presidential commission
on international research ethics.
Final Program ~ 21
Meet-the-Expert
Meet-the-Expert Sessions are scheduled from Tuesday, March 9, to Friday, March 12, from 07:45
to 08:45hrs. Delegates are invited to meet informally with leading scientists. Meet-the-Expert
Sessions will be held at the Miami Hyatt Regency in rooms Jasmine and Orchid B/C/D on Terrace Level.
Continental breakfast will be provided for participants in the Meet-the-Expert sessions.
Tuesday, March 9, 2010
Revisions of Yellow Fever Risk Mapping: Rationale and Recent Updates
Emily Jentes, USA
Travel Medicine Resources
Gilles Poumerol, Switzerland
Family Travel: Andes and Amazonia
Eduardo Gotuzzo, Peru
Issues of Antibiotic Usage in Pediatrics
Carla Odio, Costa Rica
Corporate Travel: A Returning Executive
Gordon Dickinson, USA
Room Orchid B/C/D
Room Jasmine
Room Orchid B/C/D
Room Jasmine
Room Orchid B/C/D
Choosing Between Second Line ARVs
Pedro Cahn, Argentina
Integration of Informal Information into Disease Surveillance
Marjorie Pollack, USA
Antiviral Prophylaxis in Transplant Recipients
Sherif Mossad, USA
Room Jasmine
Room Orchid B/C/D
Room Jasmine
CME Accreditation
The scientific program of 14th International Congress on Infectious Diseases has been reviewed by the
American Medical Association and approved for a maximum of 22 AMA PRA Category 1 Credits™.
Physicians should only claim credit commensurate with the extent of their participation in the activity.
One credit may be claimed for each hour of participation in approved sessions.
All sessions approved for CME credit are designated CME . AMA PRA Category 1 Credit™ Claim
Forms and information for US participants are available in the congress bags and at the CME counter
in the registration area on the Lobby Level. Completed AMA PRA Category 1 Credit™ Claim Forms
must be returned to the AMA CME counter by Friday, March 12, 2010 at 18:00hrs or submitted via fax
to (312) 464-5830 by May 11, 2010.
The American Medical Association (AMA) has an agreement of mutual recognition of continuing
medical education (CME) with the European Union of Medical Spcialities (UEMS). International
physicians interested in converting AMA PRA Category 1 Credits™ to EACCME credit should contact
the UEMS.
Opening hours / AMA Desk: Tuesday, March 9 to Thursday, March 11, 2010: 12:00–14:30hrs and
Friday, March 12, 2010: 12:15–13:15hrs and 15:15–18:00hrs
22 ~ Final Program
Commercial Exhibition
The exhibits and coffee break areas are located on the Lobby Level in Riverfront Hall.
All delegates are encouraged to visit the exhibits.
09:00 – 17:30 hrs
09:00 – 17:30 hrs
09:00 – 17:30 hrs
Exhibitors
(as per printing date)
Abbott Molecular, United States
American Society for Microbiology, United States
Ani Labsystems, Finland
Applied Maths, United States
Bioquell, United States
Bridge PTS, United States
CDC Travelers’ Health Branch, United States
Elsevier, United States
International Society for Infectious Diseases (ISID), United States
International Society of Travel Medicine (ISTM), United States
Inverness Medical, United Kingdom
Merck & Co., United States
National Institute of Allergy and Infectious Diseases, United States
Novartis, United States
Oxford Immunotec, United States
Pfizer, United States
QBC Diagnostics, United States
Royal Society Publishing, United Kingdom
Sage Products, United States
Sanofi Pasteur, France
Travis Medical Software, United States
Exhibition Management
Media Plan
International Exhibitions and Advertising
Helferstorferstr. 2
1010 Vienna, Austria
Phone: (43 1) 536 63-37
Fax:
(43 1) 535 60 16
E-mail: mp@media.co.at
Final Program ~ 23
Hyatt Regency Miami & James L. Knight Center
General
James L. Knight Center
Ballroom 1 (Brickell)
Ballroom 2 (Flagler & Monroe)
Ballroom 3 (Tuttle)
09:00–09:45hrs
TUESDAY
•
March 9
09:45–10:15hrs
10:15–12:15hrs
12:15–14:30hrs
12:30–14:15hrs
14:30–15:15hrs
15:15–15:45hrs
15:45–17:45hrs
18:30–20:00hrs
Registration & Info ~ 08:00 – 18:30
On Tuesday only: Some sessions will be in Spanish
as marked, no translation into English provided.
07:45–08:45hrs
01 ~ PLENARY ~ Challenges of TM in the
21st Century ~ L. Loutan (Switzerland)
BREAK
02 ~ Travel Medicine Symposium
ABCs of Travel Medicine I (Spanish)
Epicenters of Major Diseases
The Ill Returned Traveler (Spanish)
LUNCH BREAK (Optional)
Lunch Satellite Symposium
Meningococcal Disease in Travelers
05 ~ PLENARY Lecture ~ Emerging ID in
Latin America ~ J. Barbosa (Brazil)
BREAK
ABCs of Travel Medicine II (Spanish)
TM & Influenza Pandemic (Spanish)
Rabies, Bites & Envenomations
OPENING CEREMONY
WELCOME RECEPTION — Terrace Level (Hyatt Regency Miami)
20:00–21:30hrs
09:45–10:15hrs
10:15–12:15hrs
WEDNESDAY
12:15–14:30hrs
12:30–14:15hrs
14:30–15:15hrs
15:15–15:45hrs
09:00–09:45hrs
•
March 10
07:45–08:45hrs
09 ~ PLENARY Lecture ~ The Discovery of HIV: An Example of Translational Research
in Response to an Emerging Epidemic ~ F. Barre-Sinoussi (France)
BREAK [Coffee Break— Exhibition & Poster Area (Riverfront Hall/Lobby Level]
10 ~ Symposium
MRSA: Mechanisms and Control
12 ~ Travel Medicine Symp.
Traveler’s Diarrhea & Enteric Dis.
LUNCH BREAK (Optional) — Exhibition & Poster Sessions 23–34 (12:30–13:30)
16 ~ PLENARY Lecture
The Changing Patterns of Global Migration and the Impact on Infectious Diseases ~ Martin Cetron (USA)
17 ~ Symposium
15:45–17:45hrs
11 ~ Symposium
Seasonal Influenza Vaccines
Will the Next Generation End AIDS?
18 ~ Symposium
H1N1 Influenza Pandemic
Malaria in the Americas
09:00–09:45hrs
09:45–10:15hrs
10:15–12:15hrs
12:15–14:30hrs
12:30–14:15hrs
14:30–15:15hrs
15:15–15:45hrs
THURSDAY
•
March 11
07:45–08:45hrs
Transmission and Prevention of Transmission of HIV: Clues from the Early 21st Century ~ M. Cohen (USA)
36 ~ Symposium
37 ~ Symposium
Dengue and Pertussis
ID and Vaccines Updates
Malaria Eradication ~ C. Plowe (USA)
43 ~ Symposium
15:45–17:45hrs
The Ill Returnee from Latin America
44 ~ Symposium
Neonatal Sepsis
Bacterial Infections Following Influenza
Travelers to Latin America
07:45–08:45hrs
09:45–10:15hrs
10:15–12:15hrs
12:15–14:30hrs
12:45–13:45hrs
14:30–15:15hrs
15:15–15:45hrs
15:45–17:45hrs
FRIDAY
•
March 12
09:00–09:45hrs
Pneumococcal Infections in Children and their Impact on Adults ~ K. Klugman (USA)
61 ~ Symposium
Antimictobial Stewardship
63 ~ Symposium
Biomarkers in Infectious Diseases
Microbial Chemical Ecology and the Future of Antibiotics ~ R. Kolter (USA)
68 ~ Symposium
Tuberculosis: Tools for the Future
n ICID Scientific Sessions
24 ~ Final Program
62 ~ Symposium
Current Challenges in HIV Care
69 ~ Symposium
Infections in Tranplant Patients
n Travel Medicine Sessions
70 ~ Symposium ~ International
Perspectives on Infection Control
n Satellite Symposia
14th International Congress on Infectious Diseases ~ Schedule at-a-Glance
General
Room Jasmine
Room Orchid B/C/D
Meet-the-Expert
Meet-the-Expert
On Tuesday only: Some sessions will be in Spanish
as marked, no translation into English provided.
Travel Medicine Resources
BREAK
LUNCH BREAK (Optional)
12:15–14:30hrs
15:15–15:45hrs
BREAK
March 9
14:30–15:15hrs
•
12:30–14:15hrs
TUESDAY
15:45–17:45hrs
18:30–20:00hrs
WELCOME RECEPTION — Terrace Level (Hyatt Regency Miami)
20:00–21:30hrs
Meet-the-Expert
07:45–08:45hrs
Family Travel: Andes and Amazonia
09:00–09:45hrs
13 ~ Symposium
14 ~ Symposium
Viral Hepatitis
15 ~ Symposium
ID Following Catastrophes
Update on Fungal Infections
12:15–14:30hrs
12:30–14:15hrs
14:30–15:15hrs
20 ~ Symposium
21 ~ Oral Presentations
Multi Drug-Resistant Gram-Negatives
Pathogens in Population
Meet-the-Expert
Meet-the-Expert
Choosing Between Second Line ARVs
22 ~ Symposium
Short Course Rx for Childhood Pneumonia
15:15–15:45hrs
15:45–17:45hrs
07:45–08:45hrs
Neglected Tropical Diseases
Viral Diseases
41 ~ Symposium
Carbapenemase-Producing Bacteria
12:15–14:30hrs
12:30–14:15hrs
14:30–15:15hrs
46 ~ Symposium
ID Surveillance Systems in Practice
Meet-the-Expert
15:45–17:45hrs
Advances from the Laboratory
Meet-the-Expert
Antiviral Prophylaxis
15:15–15:45hrs
March 11
HPV Infection & Prevention
10:15–12:15hrs
•
09:45–10:15hrs
THURSDAY
09:00–09:45hrs
39 ~ Symposium
March 10
A Decade of Experience with PCV7
10:15–12:15hrs
•
09:45–10:15hrs
WEDNESDAY
09:45–10:15hrs
10:15–12:15hrs
Antibiotic Usage in Pediatrics
07:45–08:45hrs
Yellow Fever Risk Mapping
09:00–09:45hrs
Meet-the-Expert
07:45–08:45hrs
Disease Surveillance
09:00–09:45hrs
64 ~ Symposium
P.vivax Malaria in Latin America
Influenza
66 ~ Symposium
MRSA: The Clinical Challenge
ISID Business Meeting
12:15–14:30hrs
12:45–13:45hrs
14:30–15:15hrs
71 ~ Symposium
Bacterial Meningitis: Prevention and Cure
n ICID Scientific Sessions
Parasitology
n Travel Medicine Sessions
March 12
Death of Enrico Caruso
10:15–12:15hrs
•
Cultural Lecture
09:45–10:15hrs
FRIDAY
South Hall
15:15–15:45hrs
15:45–17:45hrs
n Satellite Symposia
Final Program ~ 25
Floorplans
Terrace Level
Hyatt Regency Miami
Azalea
Elevators
Ba
(Tullro
ttl om
e) 3
Jasmine
(F
la Ba
gl ll
er ro
& om
M 2
on
ro
e)
Hibiscus B
Gardenia A
ISID Office
Gardenia B
Gardenia C
UN
CT
IO
N
PROMENADE LOWER
EF
PROMENADE UPPER
PR
B
(B allr
ric oo
ke m
ll) 1
Hibiscus A
WC WC
RIVERWALK
Or
ch
id
B/
C/
D
MIAMI RIVER
Info Counter and Message Center
Speakers Center
Orchid A
TERRACE LEVEL (HYATT REGENCY MIAMI)
Ballroom 1 (Brickell)
Ballroom 2 (Flagler & Monroe)
Ballroom 3 (Tuttle)
Speakers Center (Orchid A)
ISID Office (Gardenia B)
Info Counter & Message Center
LOBBY LEVEL (JAMES L. KNIGHT CENTER)
South Hall
Riverfront Hall (Exhibition, Coffee, Posters, Snack Bar)
Registration Area
Congress Bag Counter (Cloak Room, Lost & Found)
THIRD LEVEL (JAMES L. KNIGHT CENTER)
Opening Ceremony
26 ~ Final Program
Lobby Level
o
rfr
e
Riv
all
H
nt
Registration Area &
Congress Bags
Exhibition
Internet Corner
Snack Bar
Coffee
Posters
uth
So
ll
Ha
Third Level
Opening
Ceremony
Final Program ~ 27
Save-the-Date
JULY 8–10, 2011
Over 1 billion of the world’s poorest people suffer from one or more
NTDs that profoundly affect their lives. These diseases are termed
“neglected” because, in spite of the great suffering they cause, only
limited resources have been available to prevent and treat them even
though some of the most common NTDs can be treated effectively at
very low cost.
Awareness about the problem of NTDs has grown over recent years.
Governments, foundations and nonprofit organizations are increasingly taking notice and taking action. ISID aims to bring this community of providers and investigators together by organizing the first
ISID-NTD meeting to encourage cross-discipline sharing of information related to combating NTDs as well as provide an opportunity to
raise public awareness of the importance of NTDs around the world.
Partial List of NTDs:
• Schistosomiasis
• Lymphatic Filariasis
• African Trypanosomiasis
• Chagas Disease
• Soil Transmitted
Helminthiasis
• Trachoma
• Onchocerciasis
• Leishmaniasis
Boston, Massachusetts • USA
Planned Topics Include:
•Documenting the global NTD burden
•Development of diagnostics and drugs for NTDs
•Current NTD treatment and control programs:
Successes and challenges
•Program integration: Sharing of infrastructure and operations
•Achieving sustained control and elimination of NTDs
•Improving access to clean water and sanitation to prevent NTDs
•The role of human and animal health integration in the
control of NTDs
ISID-NTD Program Committee
Alan Fenwick, Imperial College
Christy Hanson, USAID
Peter Hotez, Sabin Vaccine Institute
Adrian Hopkins, Task Force for Global Health
Julie Jacobson, Bill and Melinda Gates Foundation
Daniel Lew, Geneva University Hospital and
Adel Mahmoud, Princeton University
David Molyneux, Liverpool School of Tropical Medicine
Mary Moran, George Institute
Mirta Roses Periago, Pan American Health Organization
Lorenzo Savioli, World Health Organization
Eric Summers, International Society for Infectious Diseases
International Society for Infectious Diseases • 1330 Beacon Street, Suite 228 • Brookline, MA 02446 USA
Phone: (617) 277-0551 • Fax: (617) 278-9113 • Email: info@isid.org • Web site: http://isid.org
Meet-the-Expert
07:45–08:45
Travel Medicine Track
TUESDAY
Room Jasmine ~ Terrace Level
Hyatt Regency Miami
MEET-THE-EXPERT
•
Travel medicine resources
G. Poumerol
Geneva (Switzerland)
March 9, 2010
Meet-the-Expert
Room Orchid B/C/D ~ Terrace Level Tuesday, March 9, 2010
Hyatt Regency Miami
07:45–08:45
MEET-THE-EXPERT
Revisions of yellow fever risk mapping: Rationale and recent updates
E. Jentes
Atlanta, GA (USA)
Final Program ~ 29
CME
Ballroom 2: Flagler/Monroe
Terrace Level ~ Hyatt Regency Miami
09:00–09:45
Plenary
PLENARY LECTURE I
Chair:
David FREEDMAN, USA
01.001
The Challenges of travel medicine in the 21st century
L. Loutan
TUESDAY
•
March 9, 2010
Session 1
30 ~ Final Program
Session 2
Symposium
(In Spanish)
Mario MASANA WILSON, Argentina
Sergio SOSA-ESTANI, Argentina
02.001
Development of travel medicine in Latin America
A. Lepetic
Buenos Aires (Argentina)
02.002
Approach to pre-travel consultation
G. Acuña
Santiago (Chile)
02.003
Traveling with kids
C. Perret
Santiago (Chile)
02.004
The elderly traveler
S. Lemos Hinrichsen
São Paulo (Brazil)
March 9, 2010
Co-Chairs:
•
ABCS OF TRAVEL MEDICINE (I)
TUESDAY
Balloom 1: Brickell ~ Terrace Level
Hyatt Regency Miami
10:15–12:15
Final Program ~ 31
CME
10:15–12:15
Symposium
EPICENTERS OF MAJOR DISEASES (I)
TUESDAY
•
March 9, 2010
Session 3
32 ~ Final Program
Co-Chairs:
Jesse ALVES, Brazil
Edward RYAN, USA
03.001
Central America and the Caribbean: Dengue and P.Vivax malaria
J. Torres
Caracas (Venezuela)
03.002
Hantavirus and bartonellosis
E. Gotuzzo
Lima (Peru)
03.003
Yellow fever transmission in Brazil
M. Mascheretti
São Paulo (Brazil)
03.004
The Amazon II: Leishmaniasis and Chagas disease
S. Sosa-Estani
Session 4
Symposium
(In Spanish)
Tania CHAVES, Brazil
Cristian BISCAYART, Argentina
04.001
Assessment in travelers coming from Latin America
J. Dabanch Pena
Santiago (Chile)
04.002
Fever and their etiologies
T. Orduna
04.003
After a trip: The souvenirs in the skin
S. Lloveras
04.004
Ten most common imported diseases in Florida
J. Murillo
Miami, FL (USA)
March 9, 2010
Co-Chairs: •
THE ILL-RETURNED TRAVELER
TUESDAY
Ballroom 3: Tuttle ~ Terrace Level
Hyatt Regency Miami
10:15–12:15
Final Program ~ 33
CME
14:30–15:15
PLENARY LECTURE II
Chair:
Gilles POUMEROL, Switzerland
05.001
Emerging infectious diseases in Latin America
J. Barbosa da Silva Jr
Washington, DC (USA)
TUESDAY
•
March 9, 2010
Session 5
34 ~ Final Program
Plenary
Session 6
Symposium
(In Spanish)
Susana LLOVERAS, Argentina
Sylvia LEMOS HINRICHSEN, Brazil
06.001
Customizing immunization to travelers
A. Macchi
06.002
Routine immunization
A. Rísquez Parra
Caracas (Venezuela)
06.003
Vaccines recommended for global travelers
T. S. Chaves
São Paulo (Brazil)
06.004
Yellow fever vaccine
C. Biscayart
March 9, 2010
Co-Chairs:
•
ABCS OF TRAVEL MEDICINE (II)
TUESDAY
Ballroom 1: Brickell ~ Terrace Level Tuesday, March 9, 2010
Hyatt Regency Miami
15:45–17:45
Final Program ~ 35
Terrace Level ~ Hyatt Regency Miami 15:45–17:45
TRAVEL MEDICINE AND THE INFLUENZA PANDEMIC
TUESDAY
•
March 9, 2010
Session 7
36 ~ Final Program
Co-Chairs:
Cecilia PERRET, Chile
Tomas ORDUNA, Argentina
07.001
From the Americas to the world
J. Sotelo Morales
Mexico City (Mexico)
07.002
Clinical spectrum of disease. Influenza AH1N1 2009
J. Dabanch Peña
Santiago (Chile)
07.003
Interim lessons from 2009
J. Alves
São Paulo (Brazil)
07.004
Prospects on influenza vaccines
G. Baracco
Miami, FL (USA)
Symposium
(In Spanish)
Session 8
CME
15:45–17:45
Symposium
RABIES, BITES AND ENVENOMATIONS
08.001
Rabies, the emerging challenge
D. Warrell
Oxford (United Kingdom)
08.002
Envenomation by Latin American arthropods
C. Malaque
São Paulo (Brazil)
08.003
Diagnostic and treatment of snake bites
F. Franca
São Paulo (Brazil)
08.004
Immunobiologicals in South America
J. Murillo
Miami, FL (USA)
March 9, 2010
Marcos BOULOS, Brazil
Miguel CABADA, Peru
•
Co-Chairs:
TUESDAY
Hyatt Regency Miami
Final Program ~ 37
James L. Knight Center / 3rd Floor
TUESDAY
•
March 9, 2010
Opening Ceremony
18:30–20:00
18:15hrs
All guests to be seated
18:30hrs
Welcome Remarks
Raúl Istúriz
President
Alan J. Magill
President
International Society for Travel Medicine (ISTM)
2009–2011
Mario Masana Wilson
President
Sociedad Latinoamericana de Medicina del Viajero (SLAMVI)
Mirta Roses Periago
Director
Award Presentation
– Presentation of the Novartis Vaccines Awards for
Epidemiology of Infectious Diseases
– Presentation of the Sanofi Pasteur Awards for
Communicable Disease Epidemiology
38 ~ Final Program
– Presentation of the ISID New Investigator Award
20:00hrs
Welcome Reception at the Hyatt Regency Miami (Terrace Level)
For all participants and registered accompanying persons
Dress code: Business Attire
Meet-the-Expert
Hyatt Regency Miami
07:45–08:45
MEET-THE-EXPERT
Issues of antibiotic usage in pediatrics
C. Odio
San Jose (Costa Rica)
Meet-the-Expert
Family travel: Andes and Amazonia
E. Gotuzzo
Lima (Peru)
March 10, 2010
•
MEET-THE-EXPERT
WEDNESDAY
Room Orchid B/C/D ~ Terrace Level Wednesday, March 10, 2010 Travel Medicine Track
Hyatt Regency Miami
07:45–08:45
Final Program ~ 39
Session 9
CME
Ballroom 1/2/3 ~ Terrace Level
Hyatt Regency Miami
09:00–09:45
Plenary
PLENARY LECTURE III
Chair:
Daniel LEW, Switzerland
EDWARD H. KASS LECTURE
09.001
The discovery of HIV
F. Barre-Sinoussi
Paris (France)
WEDNESDAY
•
March 10, 2010
Final Program ~ 41
Session 10
CME
Ballroom 1: Brickell ~ Terrace Level
Hyatt Regency Miami
10:15–12:15
WEDNESDAY
•
March 10, 2010
MRSA: DISEASE MECHANISMS AND CONTROL
42 ~ Final Program
Co-Chairs:
Keryn CHRISTIANSEN, Australia
Gonzalo BEARMAN, USA
10.001
Inducible dormant MRSA
G. Bearman
Richmond, VA (USA)
10.002
The role of PVL in severe disease—What is the evidence?
K. Christiansen
Perth (Australia)
10.003
MRSA control programs in the UK: Impact on quality of care,
nosocomial infection, and public perception
I. Gould
Aberdeen (Saudi Arabia)
10.004
MRSA epidemiology and control in developing countries
V. Rosenthal
Symposium
Session 11
CME
Ballroom 2: Flagler/Monroe ~ Terrace Level
Hyatt Regency Miami
10:15–12:15
Symposium
SEASONAL INFLUENZA VACCINES: CURRENT STATUS AND FUTURE DIRECTIONS
Introduction
G.A. Poland
Rochester, MN (USA)
11.001
Influenza vaccination: Where do we stand?
A. E. Fiore
Atlanta, GA (USA)
11.002
Overcoming limitations of seasonal vaccines
A. S. Monto
Ann Arbor, MI (USA)
11.003
Emerging Trends: Vaccines in late development
R. L. Atmar
Houston, TX (USA)
Conclusion and Question-and-Answer Session
March 10, 2010
•
Gregory POLAND, USA
WEDNESDAY
Chair:
This CME program is sponsored by Albert Einstein College of Medicine
and supported by an educational grant from Sanofi Pasteur
Final Program ~ 43
Session 12
CME
Ballroom 3: Tuttle ~ Terrace Level Wednesday, March 10, 2010
Hyatt Regency Miami
10:15–12:15
Symposium
WEDNESDAY
•
March 10, 2010
TRAVELER’S DIARRHEA AND ENTERIC DISEASES OF LATIN AMERICA
Co-Chairs:
Frank VON SONNENBURG, Germany
Robert STEFFEN, Switzerland
12.001
Epidemiology of traveler’s diarrhea
A. McCarthy
Ottawa, ON (Canada)
12.002
Traveler’s diarrhea: Prevention and treatment
R. Steffen
Zurich (Switzerland)
12.003
Helminths of Latin America
C. Coyle
Bronx, NY (USA)
12.004
Food-borne toxins
V. Ansdell
Honolulu, HI (USA)
Supported in part by an educational grant from
Salix Pharmaceuticals Inc.
44 ~ Final Program
Session 13
CME
Hyatt Regency Miami
10:15–12:15
Symposium
VIRAL HEPATITIS
Epidemiology of chronic viral Hepatitis in Latin America
D. Diament
São Paulo (Brazil)
13.002
Update on Hepatits B therapy
E. Savio
Montevideo (Uruguay)
13.003
Hepatitis C treatment today and the future
R. Sarmento e Castro
Porto (Portugal)
13.004
Management of HIV and Hepatitis C co-infection
M. Brito
Chicago, IL (USA)
March 10, 2010
13.001
•
Sergio CIMERMAN, Brazil
Jun CHENG, China
WEDNESDAY
Co-Chairs:
Organized in collaboration with the
Pan American Association for Infectious Diseases (API)
Final Program ~ 45
Session 14
CME
Room Orchid B/C/D ~ Terrace Level
Hyatt Regency Miami
10:15–12:15
Symposium
WEDNESDAY
•
March 10, 2010
INFECTIOUS DISEASES FOLLOWING CATASTROPHES
46 ~ Final Program
Co-Chairs:
Vladimir KRČMÉRY, Slovak Republic
Nabin BODONAIK, Jamaica
14.001
Infectious diseases and infection control after natural disasters.
J. Ambrosioni
14.002
Infectious diseases and war conflicts in the Middle East
A. Shibl
Ryadh (Saudi Arabia)
14.003
Infectious diseases and earthquakes in Peru
E. Gotuzzo
Lima (Peru)
14.004
Disaster relief in Haiti
V. Krčméry
Bratislava (Slovak Republic)
Session 15
South Hall ~ Lobby Level
Hyatt Regency Miami
CME
10:15–12:15
Symposium
UPDATE ON FUNGAL INFECTIONS
Treating resistant filamentous fungi infections
R. Graybill
San Antonio, TX (USA)
15.002
The endemic systemic fungal infections in Latin America
A. Restrepo
Medellin (Colombia)
15.003
Fungal skin infections in the tropics
R. Hay
London (United Kingdom)
15.004
Prevention and treatment of nosocomial Candidiasis
M. Nucci
Rio de Janeiro (Brazil)
March 10, 2010
15.001
•
Thomas PATTERSON, USA
Jorge GABINO, Switzerland
WEDNESDAY
Co-Chairs:
Final Program ~ 47
Session 16
CME
Hyatt Regency Miami
14:30–15:15
WEDNESDAY
•
March 10, 2010
PLENARY LECTURE IV
48 ~ Final Program
Chair:
Alan MAGILL, USA
16.001
The changing patterns of global migration and the
impact on infectious diseases
M. Cetron
Atlanta, GA (USA)
Plenary
Session 17
CME
Hyatt Regency Miami
15:45–17:15
Symposium
WILL THE NEXT GENERATION END AIDS?
Margaret JOHNSTON, USA
Akichi IWAMOTO, Japan
17.001
Role of innate immunity in the control of HIV infection
G. Alter
Boston, MA (USA)
17.002
The role of T-cell immunity in the control of HIV infection
N. Goonetilleke
17.003
Understanding anti-HIV antibody targets
P. Moore
Johannesburg (South Africa)
17.004
The hope and progress in microbicides and pre-exposure prophylaxis
to prevent HIV
P. Ndase
Kampala (Uganda)
WEDNESDAY
Co-Chairs:
•
March 10, 2010
Final Program ~ 49
Session 18
CME
Hyatt Regency Miami
Wednesday, March 10, 2010 Symposium
15:45–17:45
WEDNESDAY
•
March 10, 2010
THE H1N1 INFLUENZA PANDEMIC
50 ~ Final Program
Co-Chairs:
Richard WENZEL, USA
Samuel PONCE DE LEON, Mexico
18.001
Historical perspective: Lessons learned from past pandemics
D. Morens
Bethesda, MD (USA)
18.002
The H1N1 outbreak in Mexico
S. Ponce de Leon
Mexico (Mexico)
18.003
Global surveillance of the H1N1 pandemic
A. W. Mounts
18.004
International response to the H1N1 pandemic
A. S. Monto
Ann Arbor, MI (USA)
Session 19
CME
Ballroom 3: Tuttle ~ Terrace Level Wednesday, March 10, 2010 Symposium
Hyatt Regency Miami
15:45–17:45
MALARIA IN THE AMERICAS
Epidemiology and intensity of transmission
K. Carter
19.002
Need for chemoprophylaxis for travelers to the Americas: Yes
P. Arguin
Atlanta, GA (USA)
19.003
Need for continuous prophylaxis for travelers to the Americas: No
M. Boulos
São Paulo (Brazil)
19.004
Choice of drugs for the prophylaxis of malaria in the Americas
A. Magill
Silver Spring, MD (USA)
Final Program ~ 51
March 10, 2010
19.001
•
Melissa MASCHERETTI, Brazil
Gary BRUNETTE, USA
WEDNESDAY
Co-Chairs:
Session 20
CME
Hyatt Regency Miami
15:45–17:45
Symposium
CURRENT ISSUES IN MULTI DRUG-RESISTANT GRAM-NEGATIVES
Escherichia coli
M.-I. Morosini
Madrid (Spain)
20.002
Multidrug-resistance in Klebsiella pneumoniae
P. Nordmann
Paris (France)
20.003
Pseudomonas aeruginosa
G. Cornaglia
Siena (Italy)
20.004
Evolution of antimicrobial resistance in Acinetobacter baumannii:
Factors affecting multiresistance
J. Vila
Barcelona (Spain)
March 10, 2010
20.001
•
Giuseppe CORNAGLIA, Italy
Manuel GUZMAN-BLANCO, Venezuela
WEDNESDAY
Co-Chairs:
European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
Final Program ~ 53
Session 21
Room Orchid B/C/D ~ Terrace Level Wednesday, March 10, 2010
Hyatt Regency Miami
15:45–17:45
Oral Presentations
WEDNESDAY
•
March 10, 2010
PATHOGENS IN POPULATIONS
54 ~ Final Program
Co-Chairs:
Tam GARLAND, USA
Stuart HANDYSIDES, United Kingdom
21.001
Incidence and trends of imported malaria in the Netherlands: 2000–2007
G. Van Rijckevorsel1, G. J. B. Sonder1, R. B. Geskus1, P. J. J. Van Genderen2,
M. Keuter3, R. J. Ligthelm2, L. G. Visser4, J. C. F. M. Wetsteyn1,
J. A. R. Van Den Hoek1
1
Amsterdam (Netherlands), 2Rotterdam (Netherlands), 3Nijmegen (Netherlands),
4
Leiden (Netherlands)
21.002
Predictors of primary multiple drug resistant tuberculosis (MDR-TB) transmission
in Lima, Peru
L. Shah1, H. Choi2, F. Krapp3, C. Zamudio3, C. Seas3, A. Ciampi1, T. Brewer1,
E. Gotuzzo3
1
Montreal, QC (Canada), 2Baltimore, MD (USA), 3Lima (Peru)
21.003
Foodborne Campylobacter infections have a low impact on human health:
A community-based cohort study in Yucatan, Mexico
M. B. Zaidi1, F. D. Campos1, F. Martinez1, F. Gutierrez1, A. Polanco1, M. Leon1,
S. Patzi-Vargas2, T. Estrada-Garcia2, J. J. Calva2
1
Merida (Mexico), 2Mexico City (Mexico)
21.004
DNA-Level diversity and relatedness of Helicobacter pylori strains in Shantytown
families in Peru and transmission in a developing-country setting
P. Herrera Aldana1, M. Mendez1, B. Velapatiño1, L. Santivañez1, J. Balqui1,
S. A. Finger2, J. Sherman1, M. Zimic1, L. Cabrera1, J. Watanabe1, C. Rodriguez1,
R. H. Gilman3, D. E. Berg2
1
Lima (Peru), 2St Louis, MO (USA), 3Baltimore, MD (USA)
21.005
Etiology of childhood pneumonia in Tacloban, the Philippines
A. Suzuki1, S. Lupisan2, N. Fuji1, A. Ohno1, Y. Furuse1, R. Tamaki2, M. Saito2,
H. Oreste2, M. Mondoy2, L. Sombrero2, A. De Leon3, R. Olveda2, H. Oshitani1
1
Sendai (Japan), 2Manila (Philippines), 3Tacloban (Philippines)
Session 21
Room Orchid B/C/D ~ Terrace Level Wednesday, March 10, 2010
Hyatt Regency Miami
15:45–17:45
Oral Presentations
PATHOGENS IN POPULATIONS
Controlling persistent cholera outbreaks in Africa: Lessons from the recent
Cholera Outbreak, West District Unguja Zanzibar, Tanzania, 2009
S. Masauni1, M. Mohammed1, G. H. Leyna1, F. Mosha1, J. Mghamba1,
K. Omar2, H. Ali2, F. Abdallah2, O. Oleribe1, P. Mmbuji1
1
Dar Es Salaam (United Republic of Tanzania),
2
Zanzibar (United Republic of Tanzania)
21.008
High-risk travelers in the Boston Area Travel Medicine Network:
Demographics, trip plans and vaccinations
N. S. Hochberg1, M. M. Sosa1, J. B. Trivedi1, M. Pfaff1, W. B. Macleod1,
C. Benoit1, L. H. Chen2, L. Kogelman1, W. W. Ooi3, A. W. Karchmer1,
M. E. Wilson2, D. H. Hamer1, E. D. Barnett1
1
Boston, MA (USA), 2Cambridge, MA (USA), 3Burlington, MA (USA)
21.009
cancelled
Factors determining performance of integrated disease surveillance strategy
in Kenya, 2008
C. Njuguna, J. K. Onsongo, C. M. Nzioka, D. Mutonga
Nairobi (Kenya)
21.010
Molecular analysis of excised valves in the diagnosis of blood culture
negative infective endocarditis (BCNE) in a Cardiac Surgery Referral Center
in Rio de Janeiro, Brazil: 1998 to 2009
C. Lamas1, R. G. Ramos1, G. Q. Lopes2, W. Golebiovski1, M. D. S. Santos1,
C. Weksler1, G. D. Ferrauioli1, H. Lepidi3, P.-E. Fournier3, D. Raoult3
1
Rio de Janeiro (Brazil), 2Duque de Caxias (Brazil), 3Marseilles (France)
Final Program ~ 55
March 10, 2010
21.007
•
Population-based surveillance for pneumonia, sepsis and meningitis in all ages
in The Gambia: Implications for pneumococcal vaccine introduction and
surveillance in Africa
G. Mackenzie1, E. Usuf1, M. Jasseh1, D. Nsekpong2, N. Ikumapayi1, H. Badji1,
D. Saha1, D. Ameh1, U. Uchendu1, T. Corrah1, P. Hill3, S. Howie1,
B. Greenwood4, R. A. Adegbola5
1
Fajara (Gambia), 2Banjul (Gambia), 3Dunedin (New Zealand),
4
London (United Kingdom), 5Seattle, WA (USA)
WEDNESDAY
21.006
Session 22
Hyatt Regency Miami
CME
15:45–17:45
Symposium
WEDNESDAY
•
March 10, 2010
SUCCESSFUL SHORT ANTIBIOTIC TREATMENT OF CHILDHOOD PNEUMONIA—
MYTH OR REALITY?
Co-Chairs:
Ron DAGAN, Israel;
Zulfiqar BHUTTA, Pakistan
22.001
Determinants of Bacteriologic Eradication in Respiratory Tract Infections
M. Jacobs
Cleveland, OH (USA)
22.002
What Are the Benefits of Short Antibiotic Treatment?
H. Goossens
Edegem-Antwerp (Belgium)
22.003
Short Treatment and the WHO Pneumonia—What are We Treating?
Z. Bhutta
Karachi (Pakistan)
22.004
Can Short Antibiotic Treatment be Widely Used in Developed Countries
R. Dagan
Beer-Sheva (Israel)
Pfizer
56 ~ Final Program
Session 23
Riverfront Hall ~ Lobby Level
Hyatt Regency Miami
12:30–13:30
ANTIBIOTIC RESISTANCE: GRAM-NEGATIVE
The resistance patterns of Pseudomonas aeruginosa in hospitals from Greece and
Romania and its importance for the therapy of nosocomial infections and
infection control practices
L. M. Junie1, S. KASTANAKIS2, M. Petrascu1, C. Boboş1, A. Tsouri2, P. Karagianni2,
E. Papadomanolaki2, G. Aleuraki2, M. Gatzima2, I. Varthalitis2
1
Cluj Napoca (Romania), 2Chania (Greece)
23.003
Extended spectrum β-lactamase production at the Komfo Anokye Teaching
Hospital, Kumasi, Ghana
Y. Adu-Sarkodie
Kumasi (Ghana)
23.004
Antimicrobial susceptibility profile of Pseudomonas aeruginosa strains isolated at
a tertiary-care University Hospital (S. Orsola Hospital, Bologna, Italy)
R. Manfredi
Bologna (Italy)
23.005
Characterization of ertapenem resistance in Klebsiella pneumoniae from Croatia
B. Bedenic, J. Vranes, Z. Bosnjak, A. Budimir, S. Kalenic
Zagreb (Croatia)
23.006
Changing trends in antimicrobial resistance among salmonella serotypes in
Southern India
S. Rao1, B. Kabir2
1
Karnataka (India), 2Madhav Nagar, Manipal (India)
23.007
Molecular epidemiology of aminoglycosides resistance in Acinetobacter spp.
with emergence of multidrug-resistant strains in hospitalized patients in Iran
R. Moniri, R. Kheltabadi Farahani
Kashan (Islamic Republic of Iran)
23.008
Incidence of Carbapanemase Resistance Gene (KPC) among Klebsiella
pneumoniae isolates and its Clinical Implications
B. Yegneswaran, W. Numsuwan, D. Alcid
New Brunswick, NJ (USA)
Final Program ~ 57
March 10, 2010
23.002
•
Clinico epidemiologic and molecular characterization of metallo
beta lactamases (MBLs) producing nosocomial Pseudomonas aeruginosa (PSA)
S. Chatterjee1, A. Kumar2, K. N. prasad3, D. Mathai1, A. Manoharan1
1
Vellore, Tamil Nadu (India), 2Kochi (India), 3Lucknow (India)
WEDNESDAY
23.001
Session 23
Hyatt Regency Miami
12:30–13:30
WEDNESDAY
•
March 10, 2010
58 ~ Final Program
23.009
In vitro activity of Tigecycline against molecularly defined Carbapenemase
producing Acinetobacter baumannii
M. Hackel1, P. Higgins2, H. Seifert2, S. Bouchillon1, B. Johnson1, R. Badal1,
J. johnson1, D. Hoban1, S. Hawser3, M. Dowzicky4
1
Schaumburg, IL (USA), 2Cologne (Germany), 3Epalinges (Switzerland),
4
Collegeville, PA (USA)
23.010
Molecular typing of multi-drug resistant Acinetobacter baumannii from
London hospitals
D. Wareham, D. Bean
23.011
Emerging multi drug-resistant Acinetobacter in Iran: Study of 800 cases
F. Abbasi, D. Yadegarynia, M. Mardani, B. Frasinejad, T. Yaghubi, S. Gholamin
Tehran (Islamic Republic of Iran)
23.012
The prevalence of extended spectrum beta-lactamases at a tertiary hospital
in South Africa
N. Mbelle
23.013
First characterization of blaIMP and blaVIM cassette-containing Novel Integron
in metallo-β-lactamase producing Pseudomonas aeruginosa in Malaysia
Y. Khosravi, S. T. Tay, V. Jamuna
Kuala Lumpur (Malaysia)
23.014
Carbapenem hydrolyzing multidrug resistant Acinetobacter baumannii
J. Koirala1, I. Tyagi1, V. Sundareshan1, S. Bergman2, J. Lawhorn1, C. Drake1,
C. Speil1
1
Springfield, IL (USA), 2Edwardsville, IL (USA)
23.015
Antimicrobial resistance in non-typhoidal Salmonellae
B. Harish1, M. Khan2, J. Hays2, G. Menezes1
1
Pondicherry (India), 3Rotterdam (Netherlands)
23.016
First description of CTX-M extended-spectrum β-lactamase-producing clinical
Escherichia coli strains from Macao, China
Q. H. Ye, Y. Lau
Macao (China)
Session 23
Hyatt Regency Miami
12:30–13:30
A Comparative study on gram-negative bacterial infections in Mansoura University
Hospitals, Egypt
W. El-Naggar, R. Ibrahim, E. Habib, S. Gerorge, E. Abd-Elmagid
Mansoura (Egypt)
23.019
Extended spectrum beta-lactamases in Escherichia coli and Klebsiella spp. from
Eastern Romania
E. Miftode1,, O. Dorneanu, D. Leca, A. Teodor, A. Badescu, G. Juganariu,
A. Vita, C. Dorobat
Iasi (Romania)
23.020
Can we rely on automated VITEK2 system the detection of KPC and other class A
carbapenemase producers enterobacteriaceae?
F. Pasteran, C. Lucero, R. Soloaga, A. Corso
23.021
Emergence of multi-drug-resistant gram-negative bacilli and enterococci from
rectal swabs of newborn and their mothers from Central India
S. Chitnis, V. Chitnis, D. Chitnis
Indore (India)
23.022
Patients with hematological malignancies who are prescribed quinolone
prophylaxis post-chemotherapy in a hospital with high gram-negative quinolone
resistance are at a higher risk for febrile neutropenia
E. Ng, Y. X. Liew, Y. Ding, L. P. Koh, J. Jin, L. Y. Hsu
Singapore (Singapore)
23.023
Multidrug resistant and sensitive strains of Pseudomonas aeruginosa:
Establishing clonal relationship by Pulsed Field Gel Electrophoresis and in vitro
antibiotic synergy testing by E test
S. F. A. Mohd Nawi1, R. Karunakaran2, K.-L. Thong2, M. Y. Yusof2, J. Vadivelu2
1
Shah Alam, Selangor (Malaysia), 2Kuala Lumpur (Malaysia)
Final Program ~ 59
March 10, 2010
23.018
•
Utilizing hospital generated antibiograms to examine state trends in
antibiotic resistance
S. Onofrey, M. Morrison, M.-Y. Lin, B. Bolstorff, A. DeMaria
Jamaica Plain, MA (USA)
WEDNESDAY
23.017
Session 23
Hyatt Regency Miami
12:30–13:30
WEDNESDAY
•
March 10, 2010
60 ~ Final Program
23.024
KPC Antibiogram in a large teaching Brazilian Hospital
J. Almeida, A. P. Cury, M. Maffucci, H. Caiaffa, J. A. Duarte, F. Rossi
São Paulo (Brazil)
23.025
Decreased susceptibility to polymyxins emerging during treatment for
carbapenem-resistant Enterobacter aerogenes infection
J. Almeida, H. Caiaffa, A. P. Cury, G. D. Almeida, D. O. Garcia,
M. N. Burattini, F. Rossi
São Paulo (Brazil)
23.026
Outbreak of (OXA-66 carbapenemase) multidrug-resistant
Acinetobacter baumannii in a Spanish tertiary-care hospital:
Epidemiology and study of patient movements
F. Gonzalez, E. Culebras, J. Head, M. Gomez, G. Morales, J. Picazo
Madrid (Spain)
23.027
Online games teaching children hygiene and antibiotic resistance:
Evaluation of the e-Bug games
D. Farrell1, P. Kostkova1, J. Weinberg1, D. Lecky2, C. McNulty2
1
London (United Kingdom), 2Gloucester (United Kingdom)
23.028
Antimicrobial utilization and susceptibility patterns of a sentinel group of
bacterial isolates prior and subsequent to the introduction of Ertapenem to
the hospital formulary
J. Araujo1, C. Rodriguez-Osorio1, E. Criollo-Mora1, A. Ramos-Hinojosa1,
A. Macías Hernandez2, A. Ponce-de-Leon1, J. Sifuentes-Osornio1
1
Tlalpan (Mexico), 2Mexico City (Mexico)
23.029
Clinical characterization of patients with carbapenem-resistant versus
carbapenem-susceptible Acinetobacter baumannii infections
I. Tyagi, J. Koirala
Springfield, IL (USA)
Session 24
Hyatt Regency Miami
12:30–13:30
ARBOVIRUSES
Field hospital for fluid intake: The solution for the decrease mortality in
dengue fever
D. Borghi, M. D. Canetti, W. Braz, L. Cortes, R. C. Vasconcellos
24.003
Utility of dengue antigen-capture ELISA in the diagnosis of dengue fever
in the real world
S. Kalimuddin, H. N. Leong, X. L. Bai, S. H. Lim, K. P. Chan
24.004
Specific point mutations in the envelope protein of Tick-borne encephalitis
virus enhance non-viraemic transmission efficiency in a tick vector.
M. Khasnatinov1, K. Ustanikova2, T. V. Frolova3, V. V. Pogodina3,
N. G. Bochkova3, L. S. Levina3, M. Slovak2, M. Kazimirova2, M. Labuda2,
B. Klempa2, E. Eleckova2, E. A. Gould4, T. S. Gritsun5
1
Irkutsk (Russian Federation), 2Bratislava (Slovak Republic),
3
Moscow (Russian Federation), 4Oxford (United Kingdom),
5
Reading (United Kingdom)
24.005
A pre-exposure prophylactic for arenaviral hemorrhagic fever in the
pirital virus—Syrian golden hamster model
E. Vela, R. Stammen, J. Garver, S. Sarrazine
Columbus, OH (USA)
24.006
Characterization of a novel neutralizing monoclonal antibody that recognizes
the fusion loop of Flavivirus envelope protein
Y. Deng1, G. Ji2, Y. Kang2, T. Jiang1, J. Dai2, E. Qin1, Y. Guo2, C. Qin1
1
Beijing (China), 2Shanghai (China)
24.007
Gene optimization for expression of Crimean-Congo haemorrhagic fever
viral nucleoprotein
R. Samudzi, F. J. Burt
Bloemfontein (South Africa)
24.008
Preparation of antigenically active recombinant yellow fever viral envelope
domain III protein
S. Smouse, F. J. Burt
Final Program ~ 61
March 10, 2010
24.002
•
Doxycycline modify the cytokine storm in patients with dengue and dengue
hemorrhagic fever
J. Zavala Castro1, T. Fredeking2
1
Merida, Yucatán (Mexico), 2Hurst, TX (USA)
WEDNESDAY
24.001
Session 24
Hyatt Regency Miami
12:30–13:30
WEDNESDAY
•
March 10, 2010
ARBOVIRUSES
62 ~ Final Program
24.009
Development of a recombinant antigen and multiplex PCR for differentiation of
tick-borne and mosquito-borne flaviviruses.
L. Mathengtheng, F. J. Burt
24.010
A novel cell encapsulation mode for delivery of therapeutic antibodies against
West Nile Virus infections that maintains steady plasma antibody levels
throughout therapy
A. J. S. Chua, E. M. Brandtner, J. A. Dangerfield, B. Salmons,
W. H. Gunzburg, M. L. Ng
24.011
Association of tumor necrosis factor-alpha gene promoter regions polymorphism
in Japanese encephalitis patients
S. K. Pujhari, R. K. Ratho, S. Prabhakar, B. Mishra, M. Sharma, M. Modi
Chandigarh (India)
24.012
A novel antagonistic relationship between human Sec3 exocyst and flavivirus
capsid protein
B. Raghavan, K. L. Yeo, M. L. Ng
24.013
Effect of dengue virus infection on the host signal transduction pathways
M. K. Chong, A. J. S. Chua, M. L. M. Ng
24.014
Jumping over the sharp edge of dengue shock syndrome
V. Pinto
Kandy (Sri Lanka)
24.015
Japanese encephalitis virus and neuronal cell interaction: a study on cellular
receptor and gene expression profile
S. Das, R. Vasanthapuram
Chandigarh (India)
24.016
Chikungunya virus (CHIKV) infection: Analytical performance of real-time
NASBA assay
G. Rossini, F. Cavrini, P. Gaibani, A. Pierro, M. P. Landini, V. Sambri
Bologna (Italy)
24.017
Wild yellow fever cases in São Paulo state, Brazil, 2009
M. Mascheretti1, A. Ribeiro1, C. Tengan1, H. K. Sato1, P. Opromolla1, A. Suzuki1,
R. Brasil1, C. Fortaleza2, F. Chudk1, M. S. Carli1, R. Albernaz1, R. Souza1
1
São Paulo (Brazil), 2Botucatu (Brazil)
Session 25
Hyatt Regency Miami
12:30–13:30
CLINICAL BACTERIAL INFECTIONS
Infective endocarditis after dental surgery
V. Krčméry, A. Demitrovicova, E. Kalavsky, P. Kisac, M. Karvaj, F. Bauer,
R. Kovac, P. Mlkvy
25.003
Efficacy of serum semi-quantitative procalcitonin measurement kit PCT-Q®
for bacteremia
T. Kodama, H. Wakatake, M. Yanai, S. Fujitani
Kawasaki-City (Japan)
25.004
Salivary IgA responses in newborn against pathogen of oral cavity. Influence of
prematurity in this response
R. D. Nogueira, M. L. T. Sesso, M. C. L. Borges, L. R. Roberti, V. P. L. Ferriani
Ribeirao Preto, SP (Brazil)
25.005
Infectious complications of venomous snakebite: 2 cases from Eastern Nepal
S. K. Sharma, S. Shrestha, B. Badhu, C. S. Agrawal, B. Khanal
Dharan (Nepal)
25.006
Clinicomicrobiological profile of infective endocarditis in a tertiary care centre
of Nepal
M. Ghimire
Dharan (Nepal)
25.007
The relation of the contraction period and the bacteria of the otorrhea of
chronic otitis media
M. Shinogami, H. Iwamura, W. Nakanishi, C. Yamada
Tokyo (Japan)
25.008
Bone and joint infections in elderly and young adults patients:
Comparison of clinical features and outcomes (1991–2007)
F. Nacinovich, C. A. Pensotti, C. Vizzotti, P. Fernandez Oses, A. Ferraris,
P. Luchetti, M. Marin,
A. Sucari, J. Thierer, C. Di Stéfano, D. Stamboulian
Final Program ~ 63
March 10, 2010
25.002
•
Clinical significance of polymicrobial bacteremial as determined by the pattern
of gram stain
M. Norizuki, S. Yamamoto, N. Hosokawa
Kamogawa (Japan)
WEDNESDAY
25.001
Session 25
Hyatt Regency Miami
12:30–13:30
WEDNESDAY
•
March 10, 2010
64 ~ Final Program
25.009
Prosthetic joint infections: A multidisciplinary approach (1992–2008)
C. A. Pensotti, F. Nacinovich, P. Fernandez Oses, J. Thierer, A. Ferraris,
C. Vizzotti, C. Di Stéfano, D. Stamboulian
25.010
Cerebrospinal meningitis outbreak in Kano state, Nigeria
O. Biya, O. Alabi, G. Tolough
Abuja (Nigeria)
25.011
A comparison of infective endocarditis related Sequelae incidence among
population-based, multicenter, and hospital-based cohorts: Data trom a
systematic review for the global burden of disease project
A. Bin Abdulhak1, M. George2, L. M. Baddour3, E. Patricia3, V. Chu4,
M. Ezzati5, B. Hoen6, I. M. Tleyjeh1
1
Riyadh (Saudi Arabia), 2Georgia, GA (USA), 3Rochester, MN (USA),
4
North Carolina, NC (USA), 5Boston, MA (USA), 6Paris (France)
25.012
The impact of a microbial sealant to reduce surgical site infection reduction in
cardiac surgery
P. Dohmen, T. Christ, J. Linneweber, W. Konertz
Berlin (Germany)
25.013
The global burden of infective endocarditis: Methodology for a systematic review
to assess disease burden and trends in 21 world regions for 1990–2005
I. M. Tleyjeh1, M. George2, A. Bin Abdulhak1, E. Patricia3, V. Chu4, M. Ezzati5,
B. Hoen6, L. M. BADDOUR3
1
Riyadh (Saudi Arabia), 2Georgia, GA (USA), 3Rochester, MN (USA),
4
North Carolina, NC (USA), 5Boston, MA (USA), 6Paris, Paris (France)
25.014
Psoas abscess in Korea: Etiology, clinical features, treatment and outcome
M. W. Kang, Y. J. Kim, K.-W. Hong, S. I. Kim, Y. R. Kim
Seoul (Republic of Korea)
25.015
Mortality and ICU-admission in community-acquired pneumonia: CURB-65
score validation in Uruguay
H. Albornoz1, D. Goleniuk2
1
Montevideo (Uruguay), 2Rivera (Uruguay)
Session 25
Hyatt Regency Miami
12:30–13:30
Distant infection and the risk of Prosthetic Joint Infection (PJI):
A case control study
G. Tsaras, D. R. Osmon, A. D. Hanssen, L. M. Baddour, D. G. Greene,
W. S. Harmsen, J. N. Mandrekar, J. M. Steckelberg, W. R. Wilson, E. F. Berbari
Rochester, MN (USA)
25.018
Infective endocarditis in children: Analysis of cases admitted to a cardiac surgery
referral hospital from January 2006 to July 2009
L. A. Pereira1, G. Q. Lopes2, M. R. G. Vasques1, P. R. Travancas1, W. Paiva1,
L. C. Simões1, G. I. D. Ferraiuoli1, M. D. S. Santos1, C. Lamas1
1
Rio de Janeiro (Brazil), 2Duque de Caxias (Brazil)
25.019
Anaerobic bacteria as etiological agents of intraabdominal infections from a
Costa Rican hospital
C. Quesada-Gómez, E. Rodríguez-Cavallini, M. D. M. Gamboa-Coronado
San José (Costa Rica)
25.020
Blood culture negative infective endocarditis (IE). Clinical features, long-term
outcome and comparison with positive blood culture IE
F. Nacinovich, E. Perez Carrega, M. Trivi, J. Thierer, D. Navia, F. Piccinini,
M. Marin, A. Sucari, P. Fernandez Oses, D. Stamboulian
25.021
Treatment of Chronic Osteomyelitis (COM): Rwanda experience of in situ sterile
Plaster Of Paris (POP) pellets containing antibiotics
I. Nyaruhirira, E. Nsengiyumva
Kigali (Rwanda)
Final Program ~ 65
March 10, 2010
25.017
•
Encrusted Pyelitis: A kidney stone disease of infectious origin
M. Lodigiani, C. Ottone, V. Bellesi, D. Cera, S. Rojas, A. Celentano, S. Ripoll
Rosario (Argentina)
WEDNESDAY
25.016
Session 26
Hyatt Regency Miami
12:30–13:30
WEDNESDAY
•
March 10, 2010
FOODBORNE DISEASES AND OUTBREAKS
66 ~ Final Program
26.001
Shiga-toxin producing Escherichia coli in fresh milk from small-holder dairy
farms in Kaduna, Nigeria
N. E. Waziri1, J. U. Umoh2, H. M. Kazeem2, I. Ajogi2
1
Plateau (Nigeria), 2Zaria (Nigeria)
26.002
Investigation and control of a meningitis outbreak in Birbhum-Murshidabad
border of West Bengal, India, March 2009
G. Roy
Kolkata (India)
26.003
Burden of illness for food-borne Salmonella: a cohort study in an agricultural
community in Yucatan, Mexico
M. B. Zaidi1, F. D. Campos1, F. Martinez1, F. Gutierrez1, M. Leon1, A. Polanco1,
T. Estrada-Garcia2, J. J. Calva2
1
Merida (Mexico), 2Mexico City (Mexico)
26.004
Laboratory investigation for clonality of a foodborne outbreak due to Vibrio
parahaemolyticus in Singapore, 2009
M.-V. La, S. Zulaina, R. Jureen, R. Lin
26.005
Detection waterborne diseases associated viruses in the river water Metro Manila
and Bulacan, the Philippines
T. Imagawa1, A. Suzuki1, M. Saito2, Y. Masago1, C. Okumura1, S. Lupisan2,
R. Olveda2, T. Omura1, H. Oshitani1
1
Sendai (Japan), 2Manila (Philippines)
26.006
Detection of human enteric viruses in shellfish, vegetables, waters and
environmental samples: A preliminary study
V. Cannella1, G. Purpari1, A. Ferrari2, A. Migliazzo1, P. Di Marco1, A. Guercio1
1
Palermo (Italy), 2Genoa (Italy)
26.007
Gastroenteritis outbreak investigation in Adamawa State Nigeria, 2009
M. Adamu Kida1, S. A. Idris2
1
Abuja (Nigeria), 2Zaria (Nigeria)
Session 26
Hyatt Regency Miami
12:30–13:30
FOODBORNE DISEASES AND OUTBREAKS
An outbreak of Cerebrospinal meningitis in Jigawa state Nigeria 2009.
M. O. Akhimien, H. Akpan H.
Abuja (Nigeria)
26.010
Risk factors for repeated cholera outbreak in Arua municipal council,
north-western Uganda
M. Andrawa1, P. Anguzu2, A. Anguaku2, C. Nalwadda1, O. Namusisi1,
R. Tweheyo1
1
Kampala (Uganda), 2Arua (Uganda)
26.011
Top health concerns in rural Honduras following the introduction of
clay water filters
R. Hemrajani, B. Morehouse, K. Elam, D. Markley, L. F. Stevens,
G. Bearman, M. P. Stevens
Richmond, Va (USA)
26.012
E.coli infectious complicated with HUS in Georgia
E. Vashakidze, T. Megrelishvili, E. Pachkoria, P. Imnadze, S. Canava,
L. Tevzadze, M. Lashkarashvili
Tbilisi (Georgia)
26.013
Epidemiology of alimentary toxiinfection in western Romania
S.-M. Draghici, C. Laslau, A. Jarca
Oradea (Romania)
Final Program ~ 67
March 10, 2010
26.009
•
Phenotypical profile against antibiotics of Lactobacillus sp isolated
from artisanal cheeses
G. Rozos1, A. Vatopoulos2, X. Voidarou3, D. Vassos3, A. Alexopoulos4,
S. Plessas4, E. Bezirtzoglou4
1
Syros (Greece), 2Athens (Greece), 3Arta (Greece), 4Orestiada (Greece)
WEDNESDAY
26.008
Session 27
Hyatt Regency Miami
12:30–13:30
27.001
The vertical transmission of the HIV/AIDS. 22 years of experience in Cuba
I. González Nuñez
Ciudad De La Habana (Cuba)
27.002
Community involvement in HIV/AIDS prevention
C. Okonkwoh
Lagos (Nigeria)
27.003
Community awareness including male involvement in prevention of
mother-to-child transmission of HIV infection is crucial
K. A. Myint
Yangon (Myanmar)
27.004
Frequency of isolated antibody to hepatitis B core antigen in HIV-HCV
coinfected individuals
A. Ramezani, A. Aghakhani, A. Eslamifar, M. Mohraz, M. Banifazl
27.005
HIV voluntary counseling and testing (VCT) in three sites in Nigeria
M. L. Alkan1, O. A. Akinwande2, U. I. Gebi2, R. Owolabi2, P. S. Dakum2
1
Beer Sheva (Israel), 2Abuja, FCT (Nigeria)
27.006
Does knowing someone who has died of AIDS affect condom use?
An analysis from Ivory Coast
A. Ngui Ngamini
Montreal, QC (Canada)
27.007
The features of HIV-infected patients at A. Wahab Sjahranie General Hospital
Samarinda, Indonesia
C. Gunawan
Samarinda (Indonesia)
27.008
Bile salt stimulated lipase genotype distribution in Ghanaian couples discordant
for HIV-1 infection
Y. Affram
Accra (Ghana)
27.009
Safety and immunogenicity of measles vaccine in HIV-infected children:
Systematic review and meta-analysis
P. Scott1, W. J. Moss2, Z. Gilani2, N. Low1
1
Berne (Switzerland), 2Baltimore, MD (USA)
WEDNESDAY
•
March 10, 2010
HIV: EPIDEMIOLOGY AND PREVENTION
68 ~ Final Program
Session 27
Hyatt Regency Miami
12:30–13:30
27.011
Body composition measurements and fat redistribution in HIV-infected children
and adolescents from São Paulo city, Brazil
C. Zanin Palchetti, R. Vega Patin, D. M. Machado, S. Vasconcelos Beltrão,
E. R. Paulino, V. L. Szejnfeld, R. C. de Menezes Succi, F. L. Ceragioli Oliveira
São Paulo (Brazil)
27.012
Antioxidant nutritional status and superoxide dismutase (SOD) levels in
school–aged children infected with human immunodeficiency virus
R. Vega Patin, F. L. Ceragioli Oliveira, R. C. de Menezes Succi,
O. M. Silvério Amâncio, A. D. F. Thomé Barbosa Gouvea, C. Zanin Palchetti,
D. M. Machado, F. Ancona Lopez
São Paulo (Brazil)
27.013
Lipodystrophy and antioxidants in school-aged children infected with
human immunodeficiency virus
R. Vega Patin, F. L. Ceragioli Oliveira, R. C. de Menezes Succi, D. M. Machado,
C. Zanin Palchetti, S. Pessoa, O. M. Silvério Amâncio, F. Ancona Lopez
São Paulo (Brazil)
27.014
Factors influencing pregnancy among HIV positive women receiving
anti-retroviral therapy in Tororo district, Uganda
M. Busuulwa
Kampala (Uganda)
27.015
Epidemiologic characteristics and transmitted drug resistance mutation patterns
among newly diagnosed HIV infected individuals in a large tertiary care hospital
in Detroit
M. Huaman, J. Aguilar, N. Markowitz, D. Baxa, A. Golembieski, I. Brar
Detroit, MI (USA)
27.016
Occupational risk of HIV infection among Nigerian dentists
C. Azodo
Benin City (Nigeria)
27.017
Outbreak investigation of HIV/AIDS in Jalalpur Jattan (JPJ), Pakistan—2008
J. Ansari1, M. Salman1, R. M. Safdar1, N. Ikram1, T. Mahmood1, H. A. Zaheer1,
B. M. Kazi1, H. Walke2, R. J. Asghar1
1
Islamabad (Pakistan), 2Atlanta, GA (USA)
•
Metabolic changes in HIV-infected children and adolescents from
São Paulo city, Brazil
C. Zanin Palchetti, R. Vega Patin, A. D. F. Thomé Barbosa Gouvea,
F. Bononi do Carmo, A. M. Rufino, V. L. Szejnfeld, R. C. de Menezes Succi,
F. L. Ceragioli Oliveira
São Paulo (Brazil)
WEDNESDAY
27.010
March 10, 2010
Final Program ~ 69
Session 27
Hyatt Regency Miami
12:30–13:30
WEDNESDAY
•
March 10, 2010
70 ~ Final Program
27.018
A randomized controlled field trial of HIV-STI risk reduction program among
undergraduate students at a University in Northern Nigeria
A. Saad1, L. Rampal1, K. Sabitu2, H. AbdulRahman1, B. AbuSamah1,
A. Y. Ibrahim3, A. Awaisu4
1
Serdang (Malaysia), 2Zaria (Nigeria), 3Kano (Nigeria), 4Penang (Malaysia)
27.019
Qualitative analysis of a new web-based system for monitoring and evaluation
of HIV/AIDS, El Salvador 2009
M. Mengel1, J. Armero2, F. Job1
1
Madrid (Spain), 2San Salvador (El Salvador)
27.020
HIV infection in elderly (patients over 65 years)
F. Almasi Nokiani
Courbevoie (France)
27.021
Primary human immunodeficiency virus-1 infection: Clinical, virological and
immunological characteristics of a braziliam cohort
D. Pellegrino, E. Boccardo, M. Eira, R. Silva, I. Moreira, M. Bocoli Rossi
São Paulo (Brazil)
27.022
Prevalence of metabolic syndrome and estimated Framingham risk score among
Brazilian HIV-infected patients
E. Margareth, E. L. Dorea, I. M. Bensenor, I. R. S. Oliveira, G. A. Pinto,
A. L. Sassaki, P. A. Lotufo
São Paulo (Brazil)
27.023
Factors affecting acceptance of HIV testing among antenatal care attendees in
Ethiopia: With emphasis on role of male partners
T. Zewde
Hawassa (Ethiopia)
27.024
Attitudes towards neonatal male circumcision among Hispanic men and women
in Miami, Florida
J. G. Castro, D. Jones, I. Barradas, M. Lopez, S. Weiss
Miami, FL (USA)
27.025
Patients with newly-diagnosed HIV in 2004 versus 2008:
No apparent difference in progression
A. Brown, C. Ní Bhuachalla, C. de Gascun, R. Hagan, C. Bergin
Dublin (Ireland)
27.026
Effectiveness of “positive prevention”among people living with HIV/AIDS in
Yunnan Province, China
L. Li, Y. Guo
Beijing (China
Session 27
Hyatt Regency Miami
12:30–13:30
The role of HIV Viral Load and CD4+ Cell Count in the prolongation of the QT
interval in patients from an HIV outpatient clinic
H. Shaaban, A. Qaqa, J. Slim, G. Perez
Newark, NJ (USA)
27.029
Modelling the between-host evolution of set-point viral load in HIV infection
G. Shirreff, T. D. Hollingsworth, W. P. Hanage, C. Fraser
27.030
Large scale HIV survey in Cameroon by mass HIV testing mobile units: Evidence
of HIV epidemic hot spot areas and high HIV vulnerability of women over time
F.-X. Mbopi-Keou1, G. C. M. Kalla1, R. Guiadem1, H. Tchouamani1, R. Mbele1,
C. Nkada1, E. Voundi1, G. Ondobo Andze1, I. Takoungang1, L. Bélec2,
P. Ndumbe3, F. Angwafo III1
1
Yaounde (Cameroon), 2Paris (France), 3Buea (Cameroon)
27.031
Potential impact of a customized peer-facilitators training program on sexual
health intervention
A. Saad1, L. Rampal1, K. Sabitu2, H. AbdulRahman1, B. AbuSamah1,
A. Awaisu3, A. Y. Ibrahim4
1
Serdang (Malaysia), 2Zaria (Nigeria), 3Penang (Malaysia), 4Kano (Nigeria)
27.032
Molecular epidemiology of HIV-1 in newly-diagnosed treatment-naïve patients
in Singapore
Y.-J. Sun, P. Kaur, Y. S. Leo
27.033
Factors influencing access to HIV care services by clients referred from a district
home-based HIV counseling and testing program in eastern Uganda, 2009
D. Lubogo, H. Wamani, J. Ddamulira, R. Tweheyo
Kampala (Uganda)
27.034
Adherence to infant feeding practices among HIV positive women with infants
aged less than six months in Rakai district, South-western Uganda
V. Kawooya, B. T. Kirunda, W. G. Maina, R. Tweheyo
Kampala (Uganda)
Final Program ~ 71
March 10, 2010
27.028
•
Demographic and psychosocial factors associated with appointment attendance
among HIV-positive outpatients
L. Bofill
Miami, FL (USA)
WEDNESDAY
27.027
Session 28
Hyatt Regency Miami
12:30–13:30
WEDNESDAY
•
March 10, 2010
INFLUENZA
72 ~ Final Program
28.001
The new North American strain of influenza A virus (H1N1) may not be a novel
variant of H1 subtype
Y.-H. Lu, L.-W. Ju, C.-Y. Jiang, Y.-J. Zheng, Q.-W. Jiang
Shanghai (China)
28.002
NS1 protein of avian influenza A virus prevents activation of NF-κB through
binding to IKKα and IKKβ
S. Gao, H. Peng, W. Jiang, L. Song
Beijing (China)
28.003
H5N1 NS1 change the cell cytoskeleton and interferes with host cell motility
through the GTPase
W. Jiang, Q. Wang, S. Gao, L. Song, W. Huang
Beijing (China)
28.004
Novel influenza A H1N1 infection among healthcare workers
M. Querci, F. Herrera, E. Temporiti, W. Alcala, L. Figueras, F. Barberis,
G. Carballal, M. Echavarria, M. Stryjewski, P. Bonvehi
28.005
Demographic and epidemiological characteristics of influenza in HIMA,
San Pablo Caguas Hospital, Puerto Rico
M. Collado, L. Collado, C. Cortes
Caguas, PR (USA)
28.006
Influenza disease burden study on 2 sentinel sites of Mongolia, 2008/09 season
N. Nukiwa1, A. Burmaa2, T. Naranzul2, T. Kamigaki1, B. Darmaa2, B. Gantsooj2,
H. Oshitani1, P. Nymadawa2
1
Sendai (Japan), 2Ulaanbaatar (Mongolia)
28.007
Clinical profile and outcome in 100 patients admitted with pandemic influenza
in four intensive care units in Uruguay during the winter of 2009
H. Bagnulo, A. Soca, M. Buroni, G. Limongi, E. Echavarria, S. Noveri, M. Godino
28.008
Intravenous peramivir for treatment of influenza A and B infection in
high-risk patients
S. Kohno1, H. Kida2, M. Mizuguchi3, N. Hirotsu4, T. Ishida5, J. Kadota6,
J. Shimada4
1
Nagasaki (Japan), 2Sapporo (Japan), 3Tokyo (Japan), 4Kawasaki (Japan),
5
Kurashiki (Japan), 6Yufu (Japan)
Session 28
Hyatt Regency Miami
12:30–13:30
INFLUENZA
Influenza in the tropics—Epidemiology and burden
L. Da Silva, M. H. Kyaw
Cambridge, MA (USA)
28.011
Novel influenza A H1N1 (NIA) infection in Argentinean Children—Experience at
Hospital de Niños “Ricardo Gutiérrez”
E. L. Lopez, A. FALLO, M. M. Contrini, A. Mistchenko, C. Molise, S. Neyro,
N. Gonzalez, D. Lazzarini, G. Manonelles, J. Grichener, M. Dastugue,
A. Teper, N. Study Group
28.012
Assessing the risk of Influenza virus strains isolated from birds and
mammals to humans
G. Vdovichenko, A. Sergeev, O. K. Demina, A. Kabanov, A. S. Kudriavcev,
A. V. Palcev, U. E. Narov, L. N. Shishkina, I. G. Drozdov
Novosibirsk (Russian Federation)
28.013
In vitro inactivation of avian influenza virus by Capryilic acids and its derivatives
N. I. Hariastuti, S. Babapoor, Y. Huang, M. I. Khan
Storrs, CT (USA)
28.014
Development of new effective antiinfluenza drugs based on extracts
of basidiomycetes
A. Kabanov, A. O. Sementsova, M. O. Skarnovich, T. V. Teplyakova,
L. N. Shishkina, A. N. Sergeev
28.015
Multifocal cerebral hemorrhages in H1N1 SOIV influenza patients:
Report of 2 cases
E. Carvalho Siqueira, L. M. Carvalho valle, A. D. F. Borges,
P. S. Gonçalves da Costa
Juiz de Fora (Brazil)
Final Program ~ 73
March 10, 2010
28.010
•
Neuraminidase sub typing and drug resistance among influenza A viruses
circulating in western India
V. Potdar, M. Dakhave, M. Chadha, A. Mishra
Pune (India)
WEDNESDAY
28.009
Session 28
Hyatt Regency Miami
12:30–13:30
WEDNESDAY
•
March 10, 2010
INFLUENZA
74 ~ Final Program
28.016
Development of a consensus microarray method for identification of different
influenza A viruses
D. Barlic-Maganja1, A. Fratnik Steyer2, N. Toplak2, A. Zrimec2, O. Zorman Rojs2
1
Izola (Slovenia), 2Ljubljana (Slovenia)
28.017
Clinic-epidemiologic identification of the first wave of AH1N1 in adults in Albania
N. Como, D. Kraja, P. Pipero, S. Bino, E. Meta, N. Gjermeni, E. Muco, A. Kica,
E. Erindi, V. Ostreni, R. Petrela, S. Cibuku
Tirana, AL (Albania)
28.018
Analysis of first cluster outbreak of the pandemic influenza (H1N1) in Georgia
K. Zakhashvili, P. Imnadze, O. Tarkhan-Mouravi
Tbilisi (Georgia)
28.019
2009 Influenza A (H1N1) first outbreak in a Spanish military training center
E. Ballester, E. Mayo-Montero, P. Santa Olalla, M. J. Sierra-Moros, A. Fe Marques
Madrid (Spain)
28.020
Investigation of pandemic influenza A (H1N1) 2009 virus:
Isolation and genetic analysis of brazilian strains
T. Paiva
São Paulo (Brazil)
28.021
An analysis of critically ill patients with the novel influenza A (H1N1)
virus in Japan
K. Wada1, H. Nishiura2, A. Kawana2
1
Sagamihara (Japan), 2Saitama (Japan)
28.022
Clinical, radiological features and outcome in children with confirmed infection
by 2009 influenza A H1N1, admitted to a reference hospital of Curitiba,
Brazillian South region
H. Giamberardino1, L. F. Bricks2, V. H. Costa Jr.1, P. F. A. Boze1, F. A. Motta1,
A. P. P. Oliveira1, M. Guedes1
1
Curitiba (Brazil), 2São Paulo (Brazil)
28.023
Novel influenza A 2009—A comparison of intensive care unit vs non-intensive
care unit patients
C. Boehringer
Fresno, CA (USA)
Session 28
Hyatt Regency Miami
12:30–13:30
INFLUENZA
How was the telephone consultation service perceived by the officers who
provided it in Japan during swine-origin influenza A (H1N1) outbreak?
A qualitative study
K. Iwata, C. Shirai
Kobe (Japan)
28.026
Epidemiological profile of the A (H1N1) pandemic influenza in the state of
São Paulo, Brazil, for the April–September 2009 timeframe
T. R. M. P. Carvalhanas, A. L. F. Yu, G. D. Freitas, A. C. G. Pellini,
A. F. Ribeiro, B. L. Liphaus
São Paulo, SP (Brazil)
28.027
H1N1 Pandemic: From imported cases in July 2009 to sustained transmission
in school clusters in September, Uganda, 2009
L. Lukwago1, J. Wamala1, B. Erima1, C. Okot1, B. Bakamutumaho1,
I. Nabukenya1, J. J. Lutwama2
1
Kampala (Uganda), 2Entebbe (Uganda)
28.028
Factors associated to death in patients with confirmed diagnosis for
influenza A/H1N1. State of São Paulo, Brazil, April to October, 2009
A. Ribeiro, A. C. G. Pellini, T. R. M. P. Carvalhanas, B. D. L. Liphaus,
A. L. F. L. F. Yu, G. D. Freitas, M. D. C. S. T. Timenetsky
28.029
H1N1 Epidemic: Our experience at PGIMER Delhi, India
A. Yadav, T. Samra, M. Pawar
New Delhi (India)
28.030
Deaths in women during fertile years and pregnant women as confirmed for
pandemic influenza A (H1N1) in the state of São Paulo
A. Ribeiro, G. D. Freitas, A. C. G. Pellini, T. R. M. P. Carvalhanas,
A. L. F. Yu, B. D. L. Liphaus, M. D. C. S. T. Timenetsky
Final Program ~ 75
March 10, 2010
28.025
•
Impact of educational measures about influenza A (H1N1) directed to
healthcare workers and patients
C. Freuler, C. Ezcurra, M. Mayer-Wolf, V. Rodríguez, R. Durlach
WEDNESDAY
28.024
Session 28
Hyatt Regency Miami
12:30–13:30
WEDNESDAY
•
March 10, 2010
INFLUENZA
76 ~ Final Program
28.031
The impact of the “novel” influenza A (N1H1) pandemic in Norway, as
monitored by recorded fatal cases—end of October 2009
V. Hasseltvedt
Lillehammer (Norway)
28.032
A survey in Taiwan 2009 for the public perception and the willingness to be
vaccinated of pandemic influenza A (H1N1)
W.-S. Jhao, T.-H. Wang, L.-L. Ho, H.-P. Huang, C.-M. Chen, Y.-P. Chou,
M.-C. Peng
Taipei (Taiwan, R.O.C.)
28.033
The outcomes of H1N1 09 screening at the 17th World Transplant Games
G. Thompson1, M. Schmittmann2, C. Hahne2
1
Campbelltown, NSW (Australia), 2Deakin, NSW (Australia)
28.034
Epidemiology of severe pediatric patients with novel influenza A (H1N1) in Korea
S. Soo Youn, J. H. Kim, H. S. Kim, Y. A. Kang, H. G. Lee, J. S. Kim, W. K. Kim
28.035
Epidemiologic characteristics of deaths associated with 2009 pandemic
influenza A (H1N1) virus infection in Korea
H. S. Kim, J. H. Kim, S. Y. Shin, Y. A. Kang, H. G. Lee, J. S. Kim, B. Cho
28.036
The effect of influenza-like illness symptoms and laboratory confirmed influenza A
on hand hygiene and other health habits among US University students
V. Perez, S. Galea, J. Kalbfleisch, A. S. Monto, A. E. Aiello
Ann Arbor, MI (USA)
28.037
The progressive expansion of the Novel A (H1N1) v epidemic in the EpiSouth
region (Mediterranean and Balkans)
F. Ait Belghiti1, N. El Omeiri1, J. Gueguen1, A. Rachas1, M. Gastellu-Etchegorry1,
S. Declich2, M.-G. Dente2, P. Barboza1
1
Saint Maurice (France), 2Rome (Italy)
28.038
An outbreak of influenza A pandemic (H1N1) 2009 in a residential home
for the disabled in Hong Kong and detection of the first local case of
oseltamivir-resistant infection
W. H. A. Leung, L. T. T. LOH
Hong Kong (China)
Session 28
Hyatt Regency Miami
12:30–13:30
INFLUENZA
Evaluation of direct immunofluorescent assay (DFA) and rapid antigen test (RAT)
for diagnosis of new pandemic influenza A H1N1 2009 (FLU AH1N1) during
first wave in Santiago, Chile
C. Vizcaya, M. Ferrés, C. Perret, C. Martinez, P. Godoy, A. M. Contreras,
P. Ferrer, T. Azocar
Santiago (Chile)
28.040
Influenza A (H1N1) pandemic in Argentina. Experience in two private general
hospitals during the outbreak (June 2009)
G. Vidiella, P. Titanti, V. Cruzat, E. Parino, H. Quinteros, G. Diaz Colodrero,
M. Curone, I. Moine, G. Kohan, J. C. Gallo, A. Moreno, P. Gallego
WEDNESDAY
28.041
Epidemiologic and clinical finding of A H1N1 2009 pandemic influenza in the
Dominican Republic
M. Thormann, R. Pimentel, C. Then, C. Perez
Santo Domingo (Dominican Republic)
March 10, 2010
28.042
Prolonged prophylaxis for A H1N1 Influenza pandemic in Oncohematologic
patients—Adherence, security and efficiency.
S. J. Ramirez Borga1 2, A. S. Firpo1, L. Lopez2, J. J. Napal2, M. V. Prates2,
S. Yantorno2, A. Enrico2, J. Milone2
1
Buenos Aires (Argentina), 2La Plata (Argentina)
28.043
Homologous and heterologous immune responses to naturally-acquired
influenza virus infection
L. Lau, V. J. Fang, K. H. Chan, E. Ma, G. M. Leung, M. Peiris, B. J. Cowling
Hong Kong (China)
28.044
The role of schools as social networks in transmission of Influenza A (H1N1 2009):
The Mbulu District, Northern Tanzania, November 2009 experience
E. Mwakapeje, J. Mghamba, E. Nyale, M. A. Mohamed, V. Makundi,
O. Oleribe, P. Mmbuji
Dar Es Salaam (United Republic of Tanzania)
28.045
Co-infection between the pandemic influenza virus A H1N1 and seasonal
influenza A virus in a patient presenting severe acute respiratory disease
A. Feltrin, K. Augusto, V. Isper, J. Delamain, B. Kemp, A. R. R. Freitas,
M. Pacola, R. Angerami
Campinas, SP (Brazil)
Final Program ~ 77
•
28.039
Session 28
Hyatt Regency Miami
12:30–13:30
28.046
Response to pandemic influenza in the English and Dutch Caribbean
E. Boisson, B. Irons
Port of Spain (Trinidad and Tobago)
28.047
Enhanced influenza survey: Khartoum state survey in selected paediatric hospitals
S. Mustafa, M. S. Karsani, A. A. Badri, M. Mangory, R. Elagib, A. S. Abd Elfadeel
Khartoum (Sudan)
28.048
Assessing H1N1 (2009) mitigation strategies under epidemiologic and
programmatic uncertainty
M. Zivkovic Gojovic1, B. Sander1, D. Fisman1, M. Krahn1, C. Bauch2
1
Toronto, ON (Canada), 2Guelph, ON (Canada)
28.049
Providing guidance during the swine flu outbreak in 2009:
An evaluation study of the National Resource for Infection Control (NRIC)
S. Wiseman, P. Kostkova, E. de Quincey, G. Jawaheer
28.050
Severe acute respiratory disease caused by pandemic influenza A H1N1 virus.
A case series of hospitalized patients in Southeastern Brazil during the
2009 epidemic
A. Feltrin1, K. Augusto1, J. Carvalho2, J. Vitone2, A. Silva1, J. Morelli3, F. Toniatti2,
M. Reis3, C. Silva2, B. Kemp1, A. R. R. Freitas1, M. Pacola1,
R. Angerami1
1
Campinas, SP (Brazil), 2Valinhos, SP (Brazil), 3Vinhedo, SP (Brazil)
28.051
Is the 2009 influenza A (H1N1) virus uncovering health disparities in Miami?
F. Leguen, A. LLau, G. Zhang, E. O’Connell
Miami, FL (USA)
28.052
Comparative evaluation of ARDS patients with and without H1N1 infection at
a tertiary care referral center
T. Samra, M. Pawar, A. Yadav
New Delhi (India)
28.053
Comparison between three not pharmacological strategies aimed to prevent the
dissemination of the A/H1N1 influenza virus in Colombia
C. Alvarez, J. A. Cortes, M. Sossa, G. Aristizabal, C. Rodriguez
Bogotá (Colombia)
WEDNESDAY
•
March 10, 2010
INFLUENZA
78 ~ Final Program
Session 29
Hyatt Regency Miami
12:30–13:30
MALARIA & BLOOD-BORNE PARASITES
Severe malaria in East Kalimantan, Indonesia
C. Gunawan, P. D. Nasution, A. R. Magdaleni
Samarinda (Indonesia)
29.003
Performance of four rapid diagnostic tests for diagnosis of falciparum and
non-falciparum malaria in endemic areas of Gondar region, Northern Ethiopia
A. K. Gelaglie
Addis Ababa (Ethiopia)
29.004
Clinical presentation and outcome of severe falciparum malaria in Eastern Nepal
S. K. Sharma1, B. Khanal1, D. Manandhar2, S. Rijal1
1
Dharan (Nepal), 2Kathmandu (Nepal)
29.005
APACHE III score as a prognostic marker in severe malaria in a tertiary care
hospital from south India
K. Nataraj1, M. Prabhu2, M. Sangar2, B. Ramachandran2
1
Kolkata (India), 2Manipal (India)
29.006
Poor impact of the primary health care (PHC) on malaria control in rural
communities of Southeast Nigeria
O. Odikamnoro
Abakaliki (Nigeria)
29.007
Malaria parasitemia in surgical patients in University of Calabar
Teaching Hospital, Nigeria
N. Usoro, E. E. Anwan, I. O. Uchejuru, O. J. Bam
Calabar (Nigeria)
29.008
Improving estimates of malaria intervention coverage from household surveys
using GPS data
C. Burgert1, S. E. Bradley2, F. Arnold2, E. Eckert2
1
Arlington, VA (USA), 2Calverton, MD (USA)
29.009
Assessment of chloroquine resistance of Plasmodium in patients attending
malaria clinic in a government general hospital, Kurnool; Strategies to prevent
chloroquine resistance
N. Mullaguri
Kurnool (India)
Final Program ~ 79
March 10, 2010
29.002
•
A study of acute myocardial infarction in a hospital cohort of malaria:
4 years retrospective analysis
K. Jain1, D. C. M.2
1
Mysore (India), 2Mangalore (India)
WEDNESDAY
29.001
Session 29
Hyatt Regency Miami
12:30–13:30
WEDNESDAY
•
March 10, 2010
MALARIA & BLOOD-BORNE PARASITES
80 ~ Final Program
29.010
Blood microfilarial-stage specific gene expression profile of Brugia malayi
S. Nuchprayoon1, S. Sungpradit1, A. E. Jedlicka2, J. Bailey2, A. L. Scott2
1
Bangkok (Thailand), 2Baltimore, MD (USA)
29.011
Nitric oxide synthase immunity in the malaria non-vector Anopheles culicifacies
species B: a putative transmission blocking Plasmodium vivax immune
responsive mechanism for refractoriness
A. Sharma, S. Vijay, M. Rawat, K. Raghavendra
New Delhi (India)
29.012
Malaria vector studies in the Republic of Korea: Vector parasite rates and
habitat distribution
T. Klein1, H.-C. Kim1, L. M. Rueda2, D. H. Foley2, C. Li2, R. C. Wilkerson2
1
Seoul (Republic of Korea), 2Suitland, MD (USA)
29.013
Cardiac function and haemodynamics in African children with severe malaria
S. Yacoub1, H.-J. Lang1, M. Shebbe2, M. Twimba2, E. Ohuma2, R. Tulloh3,
K. Maitland2
1
London (United Kingdom), 2Kilifi (Kenya), 3Bristol (United Kingdom)
29.014
Transfusion-associated Babesia infections: Reports received by the
FDA 1997 to 2008
D. Gubernot, K. C. Lee, G. B. Conley, L. G. Holness, S. O’Callaghan,
S. Cannon, E. Cowan, H. Nakhasi, R. P. Wise
Rockville, MD (USA)
29.015
Clinical and epidemiological study of patients with malaria treated at the
hospital central de Las Fuerzas Armadas in Dominican Republic
C. Rodriguez-Taveras, L. C. Socias, C. Blanco, J. R. Reyes, J. M. Puello
29.016
Artemisinin combination therapies: Public and private market and policy surveys
in Burundi and Sierra Leone
J. Amuasi1, Y. Karikari1, I. Boakye1, S. Blay1, L. Nsabiyumva2, A. Jambai3, G. Diap4
1
Kumasi (Ghana), 2Bujumbura (Burundi), 3Freetown (Sierra Leone),
4
29.017
Role of ultrasonography in malaria pregnancy
M. Brock, F. E. M. Espinosa, J. R. D. T. Leao
Manaus (Brazil)
29.018
Treatment failure of Artemether-lumefantrine in Falciparum Malaria in
Brazilian Amazon area
M. Quiroga1, A. Lara1, M. Mascheretti2, P. Abati1, M. Boulos3
1
Santarem (Brazil), 2São Paulo (Brazil)
Session 30
Hyatt Regency Miami
12:30–13:30
MYCOLOGY, FUNGAL INFECTIONS AND ANTIFUNGAL DRUGS
Candida species in the lower respiratory tract of healthy individuals
H. J. Salzer, R. B. Raggam, I. Zollner-Schwetz, M. Hoenigl, T. Valentin, R. Krause
Graz (Austria)
30.002
Influence of gender, age, previous hospitalization and hospital stay on
Candida-colonization of patients in a non-surgical ICU
A. Gloeckner, P. Abel
Greifswald (Germany)
30.003
Mixed fungal colonization in non-surgical intensive care patients
A. Gloeckner, P. Abel, K. Zimmermann
Greifswald (Germany)
30.004
Recent trends of Candida epidemiology in cancer and non-cancer patients
M. Karthaus1, R. Biedenkopf1, M. Hentrich1, X. Schiel1, I. Schuth2,
G. Schwarzkopf-Steinhauser1
1
Munich (Germany), 2Coblenz (Germany)
30.005
Anti-Saccharomyces cerevisiae (ASCA) antibody levels in a subgroup of patients
with ulcerative colitis, Crohn’s disease, GI Behcet, and GI tuberculosis:
Correlations with disease duration, activity, and extension
M. Aslan, B. Kocazeybek, A. Celik, Y. Erzin, I. Hatemi, G. Hatemi, H. Yazici
Istanbul (Turkey)
30.006
Clinical utility of perinuclear antineutrophil cytoplasmic antibodies and
anti-Saccharomyces Cerevisiae antibodies for discriminating specific
intestinal inflammations
B. Kocazeybek, M. Aslan, Y. Erzin, A. Celik, I. Hatemi, G. Hatemi, H. Yazici
Istanbul (Turkey)
30.007
Comparative studies on the in-vitro activity of pentamycin against non-albicans
Candida species and Saccharomyces cerevisiae in 161 clinical isolates
C. Winnips1, W. Buzina2, B. Dupont3
1
Basel (Switzerland), 2Graz (Austria), 3Paris (France)
30.008
Mycotic keratitis in Mashhad, Iran: Predisposing factors, etiologic agents and
clinical manifestation
S. Fata1, A. Derakhshan1, A. Boloorian1, M. Sedaghat1, H. Khakshoor1, F. Berenji1,
M. J. Najafzadeh2, M. Afzal Aghee1, M. Meshkat1, A. Fata1
1
Mashhad (Islamic Republic of Iran), 2Amsterdam (Netherlands)
30.009
Assessment of a novel region of the 28S rRNA operon for identification of
clinically significant Mucormycota
U. Kesavachandran, S. Hurst, L. Gade, A. Balajee
Atlanta, GA (USA)
WEDNESDAY
30.001
•
March 10, 2010
Final Program ~ 81
Session 30
Hyatt Regency Miami
12:30–13:30
30.010
Recurrent/resistant fungal infections in females
N. Como, D. Kraja, N. Gjermeni, M. Qato, A. Kica, K. Duraku
Tirana (Albania)
30.011
Recurrent vulvovaginal candidiasis—where does Candida albicans persist?
F. Beikert, M. T. Le, A. Clad
Freiburg (Germany)
30.012
Delayed diagnosis of disseminated Histoplasmosis capsulatum var. capsulatum
infection in AIDS patients in a tuberculosis high endemic country
P. Soentjens1, I. Eshun-Wilson2, J. Taljaard2
1
Brussels (Belgium), 2CapeTown (South Africa)
30.013
Breakthrough Rhizopus spp. in an immunocompromised patient receiving
caspofungin. Case report and review
N. Dunkel, J. Ambrosioni, Y. Chalandon, J. Passweg, J. Garbino
30.014
Granulomatous lesions in experimental Paracoccidioides brasiliensis infection
E. Burger, R. F. S. Molina, J. V. Alves, C. R. P. Pizzo, A. S. Nishikaku
São Paulo (Brazil)
30.015
Fibrosis treatment in experimental Paracoccidioides brasiliensis infection
E. Burger, A. S. Nishikaku, J. V. Alves, C. R. P. Pizzo, R. F. S. Molina
São Paulo (Brazil)
30.016
Cost-effectiveness analysis of the therapy for the invasive Candidiasis
in Colombia
F. J. Molina1, J. A. Cortes2, H. A. Caceres2, R. Soto3, E. V. Lemos Luengas2
1
Medellin (Colombia), 2Bogotá (Colombia), 3Cali (Colombia)
30.017
Myocardial infarction caused by aspergillus embolization in a patient
with cirrhosis
A. Shahzad1, B. Nseir2
1
Kenner, LA (USA), 2New Orleans, LA (USA)
30.018
Correlation between HIV-1 viral load and cryptococcal capsular polysaccharide
concentration: Evaluation in a clinical setting
D. Cecchini, A. M. Cañizal, H. ROJAS, A. Arechavala, R. Negroni,
M. B. Bouzas, J. Benetucci
WEDNESDAY
•
March 10, 2010
82 ~ Final Program
Session 30
Hyatt Regency Miami
12:30–13:30
Analysis of candidemia epidemiological data and antifungigram by distinct
methodologies in a large Brazilian teaching hospital
A. Motta, G. D. Almeida, J. N. Almeida Jr., M. I. Pinto, M. N. Burattini, F. Rossi
São Paulo (Brazil)
30.021
Prevalence of cryptococcal meningitis among HIV seropositive patients
in Georgia
L. Gatserelia, L. Sharvadze, M. Karchava, L. Dzigua, N. Dvali, N. Badridze,
T. Tsertsvadze
Tbilisi (Georgia)
30.022
Clinical analysis of 92 patients with Fungaemia—data from national survey
in Slovak Republic
L. Drgona, J. Trupl, H. Hupkova
30.023
Cryptococcus: Species distribution and susceptibility profile of isolates in a
teaching hospital from São Paulo, Brazil
A. Motta, G. D. Almeida, J. Almeida, M. I. Pinto, S. Onorio, F. Rossi
São Paulo (Brazil)
30.024
Saccharomyces fungemia associated with esophageal disease identified
by D1/D2 Ribosomal RNA gene sequence
A. Cheema, J. Farrell, C. Kurtzman
Peoria, IL (USA)
30.025
Determination of antifungal susceptibility in immunocompromised patients
L. Siegfried, V. Hrabovsky, M. Sabol
Kosice (Slovak Republic)
30.026
Candidemia in third level hospitals in Bogotá, Colombia
J. Cortes, P. Reyes, C. H. Gomez, S. I. Cuervo, P. Rivas, R. Sanchez
Bogotá (Colombia)
Final Program ~ 83
March 10, 2010
30.020
•
Risk factors for candidemia-related mortality in a
Neonatal Intensive Care Unit (NICU)
C. I. Echave, M. L. PRAINO, M. L. Vozza, C. Manso, M. Russman,
C. Enfedaque, A. Martinez Burkett, A. Procopio, N. Rivas, E. L. Lopez
WEDNESDAY
30.019
Session 31
Hyatt Regency Miami
12:30–13:30
WEDNESDAY
•
March 10, 2010
NON-TUBERCULOUS MYCOBACTERIA
84 ~ Final Program
31.001
AIDS-associated atypical mycobacteriosis other than Mycobacterium aviumintracellulare: A 16-year survey of Mycobacterium xenopi, Mycobacterium
kansasii, and Mycobacterium fortuitum infections in the setting of HIV disease
R. Manfredi
Bologna (Italy)
31.002
FOXO3a Transcription Factor mediates Apoptosis of Mycobacterium bovis
BCG-Infected Macrophages
M. Essafi1, M. Houas1, A. Mallavialle2, N. Laabidi1, M. Deckert2,
M. R. Barbouche1
1
Tunis (Tunisia), 2Nice (France)
31.003
Hansen’s disease in Northeast Brazil
F. Pucci, C. R. Teófilo, T. S. Feitosa, S. G. A. Aragão, L. F. Távora
Fortaleza (Brazil)
31.004
Identification of immunogenic proteins of Mycobacterium avium with
diagnostic potential
E. Amador, L. Lloret, A. I. Castillo, Y. López
31.005
Characterization of nontuberculous mycobacteria isolated of potable water
distribution system and wastewater of Mexico City Metropolitan Area
L. Lloret-Sanchez, A. I. Castillo, M. Mazari-Hiriart, M. Vargas, Y. López-Vidal
Session 32
Hyatt Regency Miami
12:30–13:30
TRAVEL MEDICINE AND TRAVEL HEALTH
A. Nguyen1, N. Cohen2, H. Lipman1, C. Brown1, D. Fishbein1
1
Atlanta, GA (USA), 2Chicago, IL (USA)
32.002
Characteristics of travelers to developing countries: Findings from the 2008
consumer styles survey
X. Davis, E. Jentes, P. Han, W. Pollard, C. Marano
Atlanta, GA (USA)
32.003
Attitudes towards Avian influenza and sources of media information in travelers
to developing countries
P. Han, E. Yanni, E. Jentes, X. Davis, W. Pollard, C. Marano
Atlanta, GA (USA)
32.004
Demographics, medical conditions, and use of immunizations and
chemoprophylaxis among international travelers within the Global TravEpiNet
U.S. National Clinic Network
LaRocque1, S. Rao1, E. Yanni2, N. Marano2, N. Gallagher2, C. Marano2,
G. Brunette2, J. Lee3, V. Ansdell4, B. S. Schwartz5, M. Knouse6, J. Cahill7,
S. Hagmann8, J. Vinetz9, R. Hoffman10, S. Alvarez11, J. Goad10,
C. Franco-Paredes2, P. Kozarsky2, D. Schoenfeld1, E. Ryan1
1
Boston, MA (USA), 2Atlanta, GA (USA), 3Chicago, IL (USA),
4
Honolulu, HI (USA), 5San Francisco, CA (USA), 6Allenton, PA (USA),
7
New York, NY (USA), 8Bronx, NY (USA), 9La Jolla, CA (USA),
10
Los Angeles, CA (USA), 11Jacksonville, FL (USA)
32.005
Use and sources of medical information among departing international
travelers to low and middle income countries at Logan International Airport,
Boston, MA, 2009
R. LaRocque1, S. Rao1, T. Lawton1, A. Tsibris1, D. Schoenfeld1, A. Barry1,
E. Yanni2, N. Marano2, N. Gallagher2, C. Marano2, G. Brunette2, E. Ryan1
1
Boston, MA (USA), 2Atlanta, GA (USA)
32.006
Transporting a critically ill patient from the Canadian north—lessons learned
from almost a decade of SkyService Medevac experience
G. Samoukovic1, E. Farias2, T. Malas2, H. Petrie2, M. Churchill Smith2
1
H3A 1A1, QC (Canada), 2Montreal, QC (Canada)
Final Program ~ 85
March 10, 2010
•
Mass screening for fever: A comparison of three infrared thermal dectection
systems and self-reported fever
WEDNESDAY
32.001
Session 32
Hyatt Regency Miami
12:30–13:30
WEDNESDAY
•
March 10, 2010
86 ~ Final Program
32.007
Incidence and impact of travelers diarrhea among foreign backpackers in
Southeast Asia
W. Piyaphanee, T. Kusolsuk, C. Kittitrakul, W. Suttithum, T. Ponam, P. Wilairatana
Bangkok (Thailand)
32.008
The health surveillance stations at points of entry in Brazil under the revised
International Health Regulations—IHR/2005
C. Gregis, F. V. Pascalicchio
Brasilia, DF (Brazil)
32.009
Varicella (Chickenpox) outbreak in Bhutanese refugee camps in Eastern Nepal
A. K. MISHRA, O. Gorbacheva, M. M. T. Hasan, N. Rimal
Jhapa (Nepal)
32.010
Foreign travel associated with increased sexual risk: A cohort study
R. Vivancos1, P. R. Hunter2, I. Abubakar2
1
Liverpool (United Kingdom), 2Norwich (United Kingdom)
32.011
Management of an international outbreak of norovirus on board a cruise ship
R. Vivancos1, A. Keenan1, W. Sopwith2, C. Quigley1, K. Mutton2, G. Nichols4,
J. Harris4, Q. Syed1, J. Reid1
1
Liverpool (United Kingdom), 2Wirral (United Kingdom),
3
Manchester (United Kingdom), 4London (United Kingdom)
32.012
Medical tourism research: A systematic review
V. Balaban, C. Marano
Atlanta, GA (USA)
32.013
Preventing enteric fevers in London VFR travellers
Y. Knight, E. Dapaah, B. Walsh
32.014
International traveler and prevention of diarrheal diseases characterization of
the international traveller to whom has been prescribed cholera vaccine at the
international vaccination center of Oporto during the years 2007 and 2008
G. Saldanha
Porto (Portugal)
32.015
Travelers’ diarrhea (TD) incidence in argentine travelers to high-risk destinations.
A telephonic survey at a private ambulatory center for infectious diseases (ID)
and travel medicine (TM) in Buenos Aires
M.A. Botas, C. Biscayart, P. Elmassian, D. Stamboulian
Session 32
Hyatt Regency Miami
12:30–13:30
Trends in fatal snakebites in Venezuela, 2003–2007
L. Parra, J. Peña, A. Rísquez Parra, L. Echezuria, A. Rodriguez-Morales
Caracas (Venezuela)
32.018
Epidemiology of drowning deaths in Venezuela, 1996–2007
C. Madrid, M. H. Maldonado, A. Rísquez Parra, A. Rodriguez-Morales
Caracas (Venezuela)
32.019
Travellers´ Hantavirus Pulmonary Syndrome in Andean Patagonia. Argentina
M. E. Lazaro1, G. Cantoni1, L. Calanni2, A. J. Resa3, E. Herrero1, M. Iacono2,
L. de Wouters 4
1
Bariloche, Rio Negro (Argentina), 2Neuquen, Neuquen (Argentina),
3
El Bolsón, Rio Negro (Argentina), 4Mar del Plata, Buenos Aires (Argentina)
32.020
Characterization of pre-travel consults at a travel medicine clinic in Buenos Aires
in 2008: Experience with 1,439 Travelers
P. Elmassian, A. Macchi, C. Biscayart, V. Verdaguer, M. P. Della Latta,
D. Stamboulian
32.021
Risk assessment of potential anthropozoonotic pathogen transmission from
ecotourists to wildlife populations in Borneo
M. Muehlenbein1, L. A. Martinez1, A. Lemke2, L. Ambu3, S. Nathan3,
S. Alsisto3, R. Sakong4
1
Bloomington, IN (USA), 2Milwaukee, WI (USA), 3Kota Kinabalu (Malaysia),
4
Sandakan (Malaysia)
32.022
Malaria in a community hospital
O. Mascaro, C. Socolich, A. Pedragosa, E. Reynaga, G. Lucchetti, X. Gimeno,
J. Brugues
Vic (Spain)
Final Program ~ 87
March 10, 2010
32.017
•
First tavel medicine center in a public hospital from Buenos Aires province,
Argentina. The first 18 months of experience
M. L. Yantorno, G. de la Parra, M. Lares, K. Aguilera, D. Lizaso,
M. Correa, A. Esposto
La Plata (Argentina)
WEDNESDAY
32.016
Session 32
Hyatt Regency Miami
12:30–13:30
WEDNESDAY
•
March 10, 2010
88 ~ Final Program
32.023
Meningococcal disease in travelers: A problem more than a 100 years old
L. De Tora, L. Da Silva
Cambridge, MA (USA)
32.024
Free living amoebae encephalitis infection in a child who travelled to Peru
C. A. Mora, N. Orellana, A. Schteinschnaider, N. Arakaki, M. Del Castillo
32.025
New world cutaneous Leishmaniasis in travelers (1994–2008) experience
in Argentina
T. Orduna, S. Lloveras, G. D. Gonzalez, C. C. Falcone, S. L. Garro,
S. E. Echazarreta
32.026
Imported malaria in travelers assisted in Buenos Aires
S. Lloveras1, S. E. Echazarreta2, S. L. Garro2, C. C. Falcone2, G. D. Gonzalez2,
T. Orduna1
1
Corunna (Argentina), 2Buenos Aires (Argentina)
32.027
Travel medicine working group
A. Macchi1, A. Lepetic2, C. Biscayart1, P. Elmassian1, V. Verdaguer1,
M. P. Della Latta1, C. Torroija1, E. Sturba1, M. Arrestia1, D. Stamboulian1
1
Buenos Aires (Argentina), 2Corunna (Argentina)
32.028
Profile of imported malaria in travelers from the north of Portugal
A. Silva, A. R. Silva, T. Teixeira, H. Coelho, R. Sarmento e Castro
Porto (Portugal)
32.029
Demographics and travel patterns of travelers to Central America, South America
and the Caribbean seen in the Boston Area Travel Medicine Network (BATMN)
J. B. Trivedi1, N. S. Hochberg1, W. B. Macleod1, M. Pfaff1, M. M. Sosa1,
C. Benoit1, L. H. Chen2, M. E. Wilson2, L. Kogelman1, W. W. Ooi3,
A. W. Karchmer1, E. D. Barnett1, D. H. Hamer1
1
Boston, MA (USA), 2Cambridge, MA (USA), 3Burlington, MA (USA)
Session 32
Hyatt Regency Miami
12:30–13:30
Immunocompromised travellers in the pre-travel appointment:
A report from Portugal
R. Coelho, C. Abreu, F. Danina, J. Nuak, C. Caldas, E. Quintas, N. Darwich,
A. Sarmento
Porto (Portugal)
32.032
Triquinellosis in domestic travelers in Argentina: Which is the advice for
intenational travelers?
S. E. Echazarreta1, S. Lloveras2, T. Orduna2, S. L. Garro1, C. C. Falcone1,
G. D. Gonzalez1
1
32.033
Health surveillance of Brazilian military peacekeepers deployed in the
United Nations Stabilization Mission in Haiti (MINUSTAH), 2007–2009
J. R. P. De Andrade-Lima1, R. B. Batista2
1
Salvador, Bahia (Brazil), 2Curtiba, Paraná (Brazil)
32.034
Immunizations in travelers attending a private center for infectious diseases
and travel medicine in Buenos Aires, Argentina, 2005–2008
C. Biscayart, P. Elmassian, A. Macchi, V. Verdaguer, M. P. Della Latta,
C. Torroija, D. Stamboulian
Final Program ~ 89
March 10, 2010
32.031
•
Hookworm-related cutaneous Larva Migrans: An annoying souvenir of some trips
S. Lloveras1, S. E. Echazarreta2, T. Orduna1
1
Corunna (Argentina), 2Buenos Aires (Argentina)
WEDNESDAY
32.030
Session 33
Hyatt Regency Miami
12:30–13:30
WEDNESDAY
•
March 10, 2010
TUBERCULOSIS: EPIDEMIOLOGY, PREVENTION & CONTROL
90 ~ Final Program
33.001
Clinical manifestations of tuberculosis among pediatric household contacts with
active culture confirmed disease
A. Ackerman1, C. Whalen2, S. Zalwango3, J. I. Shwartz4
1
Worcester, MA (USA), 2Athens, GA (USA), 3Kampala (Uganda),
4
New Haven, CT (USA)
33.002
A validated clinical practice guideline for community health nurses working in
tuberculosis Out-patient Clinics
A. Ahmed, S. Soliman, L. A. Awad
Dakahlia (Egypt)
33.003
Genetic diversity of Mycobacterium tuberculosis population in Bulgaria
V. Valcheva
Sofia (Bulgaria)
33.004
Transmission of drug resistant tuberculosis and its implication for TB control
in rural China
Y. Hu, W. Jiang, W. Wang, B. Xu
Shanghai (China)
33.005
Evaluation of cost and methods for detecting latent tuberculosis infection among
target individual groups in Trinidad & Tobago
P. E. Akpaka1, S. Baboolal2, D. Ramoutar3
1
Champ Fleurs (Trinidad and Tobago), 2St. Augustine (Trinidad and Tobago),
3
Caura (Trinidad and Tobago)
33.006
HIV prevalence and MDR TB among DOTS attendees in a rural area
of Haryana, India
R. Kumar, S. Rai, S. Kant, K. Anand, L. Dar, U. Singh
New Delhi (India)
33.007
The social representation of DOT-related tuberculosis by patients of Guarulhos
at the metropolitan area of São Paulo, Brazil
V. Souza Pinto, V. M. N. Galesi, M. I. P. S. Braz
33.008
Prevalence of bacteriologically confirmed pulmonary tuberculosis in the
Bhutanese refugees in Nepal. Results of active case finding
O. Gorbacheva, A. K. Mishra, D. Shapovalov, S. Sudtasay
Jhapa (Nepal)
Session 33
Hyatt Regency Miami
12:30–13:30
TUBERCULOSIS: EPIDEMIOLOGY, PREVENTION & CONTROL
Frequency of tuberculosis in the biggest island of the Persian Gulf
K. Hamdi1, A. Shoae Hassani2, A. Akhavan Sepahi1
1
Tehran (Islamic Republic of Iran), 2Fars (Islamic Republic of Iran)
33.011
The clinical and epidemiological characteristics of Mycobacterium tuberculosis
Beijing/W family strains in a major immigrant-receiving province of Canada
D. Langlois-Klassen, D. Kunimoto, D. Saunders, J. Boffa, L. Chui, R. Long
Edmonton, AB (Canada)
33.012
Evaluation of the performance of TB Control in Apac District in 2008 using
Direct Observed Therapy (DOTS)
S. M. Nakaggwa
Kampala (Uganda)
33.013
Analysis of the decentralization of tuberculosis control program in the sanitary
district of Cabula-Beirú (SDCB) Salvador-Bahia-Brazil, 2008
S. Cerqueira, L. G. Almeida, B. A. Santos
Salvador, Bahia (Brazil)
33.014
A community based tuberculosis control project in children in urban and rural
settings: A public-private mix approach
B. Cabrera1, J. Aldaba2, R. Buzon2, A. Fernandez2, B. J. Sablan2, F. Valdes3
1
Pasay City (Philippines), 2Manila (Philippines), 3Pasig City (Philippines)
33.015
Patterns of tuberculosis health problem in India: A gender perspective
S. Gupta
Mumbai (India)
33.016
Tuberculosis in health-care workers: Results of a surveillance program
in Mexico City
P. Leal Moran1, M. Huertas Jimenez2, C. Romero2, A. Chavez RIos2,
A. Haro Osnaya, R. De Paz Garcia, A. De la Torre, A. Macías Hernandez,
S. Ponce de León Rosales
Final Program ~ 91
March 10, 2010
33.010
•
Newly diagnosed tuberculosis patients and tobacco use in North Malaysia:
The prevalence of tobacco use, knowledge, and attitudes
A. Awaisu1, M. H. Nik Mohamed2, N. Mohamad Noordin3, A. R. Muttalif1,
A. Ahmad Mahayiddin3, A. Saad4, S. Muhammadu Gobir5
1
Penang (Malaysia), 2Kuantan (Malaysia), 3Kuala Lumpur, (Malaysia),
4
Serdang (Malaysia), 5Kubang Kerian (Malaysia)
WEDNESDAY
33.009
Session 34
Hyatt Regency Miami
12:30–13:30
34.001
Prevalence and associated risk factors of mastitis in lactating dairy cows
N. Sharma, V. Pandey, J. S. Joodan
Jammu (India)
34.002
The clinico-pathological features associated with experimental concurrent PPR
virus and Mannheimia hemolytica A: 2 infections in the West African dwarf goats
B. O. Emikpe
Ibadan (Nigeria)
34.003
Ancylostoma spp. in sand of beaches of Navolato, Sinaloa, México
M. C. Rubio Robles, S. M. Gaxiola C., N. Castro C.
Culiacan, Sinaloa (Mexico)
34.004
Arconobacterium pyogenes associated with pulmonary and submandibular
lymph node abscessation in white tailed deer (Odocoileus virginiaus)
R. Afifi1, J. M. Sleeman2, G.K. Saunders3, T. Kaur3
1
Ismilia (Egypt), 2Madison, WI (USA), 3Blacksburg, VA (USA)
34.005
Phylogenetic analysis of sporadic hepatitis E virus in Eastern China
Y.-G. Xia1, Y.-T. Li1, Y.-H. Lu1, H. Ren1, F.-D. Wang2, J.-H. Yao2,
Q.-W. Jiang1, Y.-J. Zheng1
1
Shanghai (China), 2Deqing County, Zhejiang (China)
34.006
Molecular characterization of VP1-3 and NSP1-3 genes of porcine group A
rotavirus G12 strain RU172: Evidence for porcine origin of human G12 strains
S. Ghosh1, N. Kobayashi1, M. Ishino1, T. Naik2
1
Sapporo, Hokkaido (Japan), 2Bhubaneshwar, Orissa (India)
34.007
Veterinary practitioners and the spread of infectious diseases
S. T. Olodo-Atitebi
34.008
Trypanosome infections in dogs from Chagas disease endemic regions in
Panama, Central America
V. J. Pineda Segundo1, I. Monfante2, N. L. Gottdenker2, A. Saldaña1,
A. M. Santamaria1, S. Puga1, J. E. Calzada L.1
1
Panama City, PAN (Panama), 2Atlanta, US (USA)
34.009
Molecular evidence of genetic diversity of Borrelia burgdorferi sensu lato
detected in Ixodes granulatus ticks removed from rodents in Taiwan
L.-L. Chao, C.-M. Shih
WEDNESDAY
•
March 10, 2010
ZOONOSES AND INFECTIONS IN ANIMALS
92 ~ Final Program
Session 34
Hyatt Regency Miami
12:30–13:30
34.011
One health: Collaboration, recent research and developments in the
global effort to eliminate Rabies
R. Dedmon1, D. Briggs2, T. Lembo3, S. Cleaveland3
1
Milwaukee, WI (USA), 2Manhattan, KS (USA), 3Glasgow (United Kingdom)
34.012
Epizootiology of foot and mouth disease in Nepal
R. Giri, P. Parshin
Moscow (Russian Federation)
34.013
The micro-adenomatous lesions associated with Lawsonia intracellularis
in the pig intestine
M. Sueyoshi, R. Uemura, H. Nagatomo
Miyazaki (Japan)
34.014
Emerging and zoonotic disease risk mitigation: Rabies prevention as a template
for best practices
C. Hanlon1, S. Moore1, R. J. Rudd2, S. J. Wong2
1
Manhattan, KS (USA), 2Albany, NY (USA)
34.015
Identification and characterization of Shiga toxin-producing Escherichia coli
(STEC) isolated from cattle, sheep and meat samples in Tehran Province, Iran
F. Jafari1, M. Tajbakhsh1, S. Morabito2, M. Azimi Rad1, P. Torabi1,
M. Arabshahi1, M. R. Zali1
1
Tehran (Islamic Republic of Iran), 2Rome (Italy)
34.016
Brucellosis—Emerging zoonosis in Bosnia and Herzegovina
S. Krkic Dautovic1, M. Hadzovic Cengic1, S. Mehanic1, S. Ahmetagic2,
N. Ibrahimpasic3, E. Hadzic4, I. Curic5, N. Derviskadic5, J. Bajic6, J. Bojanic6
1
Sarajevo (Bosnia and Herzegovina), 2Tuzla (Bosnia and Herzegovina),
3
Bihac (Bosnia and Herzegovina), 4Zenica (Bosnia and Herzegovina),
5
Mostar (Bosnia and Herzegovina), 6Banja Luka (Bosnia and Herzegovina)
34.017
Prevalence ectoparasites in dogs of beaches and fields fishing of
Navolato, Sinaloa, Mèxico
M. C. Rubio Robles, S. M. Gaxiola Camacho, N. Castro del C., J. Gaxiola M.
Culiacan (Mexico)
•
Occurrence of Ureaplasma diversum in cows with various
reproductive disorders
P. Chandra, Y. Singh, D. Nand Garg
Hisar (India)
WEDNESDAY
34.010
March 10, 2010
Final Program ~ 93
Session 34
Hyatt Regency Miami
12:30–13:30
WEDNESDAY
•
March 10, 2010
94 ~ Final Program
34.018
Phenotypical and genotypical traits of Listeria monocytogens strains isolated
from tonsils of wild boars hunted in Switzerland
S. Wacheck1, N. Giezendanner2, M. König3, M. Fredriksson-Ahomaa1,
R. Stephan2
1
Oberschleißheim (Germany), 2Zurich (Switzerland), 3Geneva (Switzerland)
34.019
The “One Health” Initiative: Using open source data for disease surveillance
M. Greene
McLean, VA (USA)
34.020
Assessment of Brucella melitensis disease burden in lactating goats
in Mizque, Bolivia
J. A. Zambriski1, M. Saito2, D. V. Nydam1, H. A. Reyes-Garay2, R. Castillo2,
D. Cepeda2, M. J. Cespedes-Zambrano2, P. Garcia-Vara2, R. C. Maves2,
M. Solano3, F. Torrico3, R. H. Gilman4
1
Ithaca, NY (USA), 2Lima (Peru), 3Cochabamba (Bolivia), 4Baltimore, MD (USA)
34.021
Analysis of circulation influenza virus A on the Chany Lake (Novosibirsk region,
Russia) in 2008
M. Sivay, S. Sayfutdinova, M. Kulak
Koltsovo (Russian Federation)
34.022
Epidemiological study on infectious bovine rhinotracheitis in cattle
Y. Alomar, Y. AlYasino
Hama (Syrian Arab Republic)
34.023
Clinical manifestations of leptospirosis
M. Fabri, I. fabri
Novi Sad (Serbia)
34.024
Epidemiology of avian influenza viruses in wild birds in Mongolia
E.-O. Tseren-Ochir1, B. Damdinjav1, T. Sharkhuu1, H. M. Kang2, Y. Sakoda3,
B. Purevsuren1, S. Ruuragchaa1, Y. J. Lee2, H. Kida3, B. Khishgee1, S. Sengee1
1
Ulaanbaatar (Mongolia), 2Anyang-city (Republic of Korea), 3Sapporo (Japan)
34.025
Virological studies on migratory penguins captured in Brazilian southeast coast
L. A. Fornells Arentz1, I. BIANCHI2, C. E. P. F. Travassos2, M. H. T. Liberal3,
C. D. M. Andrade1, J. N. S. S. Couceiro1
1
Cidade Universitária (Brazil), 2Campos dos Goytacazes (Brazil),
3
Niteroi (Brazil)
Session 34
Hyatt Regency Miami
12:30–13:30
Cluster of MRSA in cats and staff of a veterinary clinic:
Follow-up and possible implications for control
A. M. Tjon-A-Tsien1, M. C. Vos1, E. V. Duijkeren2, W. J. Wannet3, H. M. Gotz1,
W. Schop1, J. H. Richardus1
1
Rotterdam (Netherlands), 2Utrecht (Netherlands), 3Bilthoven (Netherlands)
34.028
An exploration of the knowledge, attitudes and perceptions of the local, adult,
non-medically trained Grenadian population about certain zoonotic diseases
S. Bidaisee
St. George’s (Grenada)
34.029
Leishmaniasis in Albania
S. Bino
Tirana (Albania)
34.030
Prevalence of HPAI in live-bird markets in the Jabodatabek region of west Java,
Indonesia in 2009
C. Lockhart, E. Wuryaninggsih, E. Brum, P. R. Barrios
Jakarta (Indonesia)
34.031
Ancylostoma spp. on beaches of Elota, Sinaloa, México
M. C. Rubio Robles, S. M. Gaxiola Camacho, N. Castro del Campo
Culiacan (Mexico)
34.032
Characterization of Venezuelan field strains of EEEV by RT-PCR and SSCP
V. M. Bermudez G., M. C. Gonzalez, J. M. Ruíz, J. Rivero, F. Herrera
Maracay (Venezuela)
34.033
Discovery of reverse zoonotic transmission of pandemic H1N1 influenza virus
infection in cats following the initiation of a real time sero-molecular
epidemiological study
J. Trujillo1, B. Sponseller1, A. Jergens1, T. Pearce1, E. Strait1, K. Harmon1,
S. Ramamoorthy1, C. Prior2, A. West3, P. Nara1
1
Ames, IA (USA), 2Park City, UT (USA), 3Park City, Ut (USA)
Final Program ~ 95
March 10, 2010
34.027
•
Poultry farmers’ response to AI outbreak and its control in Indonesia
E. Basuno, Y. Yusdja, N. Ilham
West Java (Indonesia)
WEDNESDAY
34.026
Meet-the-Expert
Hyatt Regency Miami
07:45–08:45
MEET-THE-EXPERT
Choosing between second line ARVs
P. Cahn
Meet-the-Expert
Hyatt Regency Miami
Thursday, March 11, 2010 Travel Medicine Track
07:45–08:45
MEET-THE-EXPERT
G. Dickinson
Miami, FL (USA)
THURSDAY
•
March 11, 2010
Final Program ~ 97
Session 35
CME
Hyatt Regency Miami
09:00–09:45
THURSDAY
•
March 11, 2010
PLENARY LECTURE V
98 ~ Final Program
Chair:
Raúl ISTÚRIZ, Venezuela
RICHARD K. ROOT MEMORIAL LECTURE
35.001
Transmission and prevention of transmission of HIV:
Clues from the early 21st century
M. Cohen
Chapel Hill, NC (USA)
Plenary
Session 36
Hyatt Regency Miami
10:15–12:15
Symposium
STRATEGIES FOR EXPANDING GLOBAL IMPACT OF IMMUNIZATION PROGRAMS
Roberto DEBBAG, Argentina
Dengue sub-symposium:
Dengue: The next vaccine preventable disease
36.001
Growing burden of dengue in Latin America: A new public health challenge
J. Mendez-Galvan
36.002
Clinical development of a tetravalent dengue vaccine for endemic areas
M. Saville
Marcy L’Etoile (France)
Pertussis sub-symposium:
Measuring and preventing Pertussis: How good are your programs?
36.003
Pertussis surveillance and testing: Recommendations from the GPI
C. H. Wirsing von König
Krefeld (Germany)
36.004
Adolescent and adult Pertussis vaccination programs:
Are they having an impact?
T. Tan
Chicago, IL (USA)
THURSDAY
Chair:
•
March 11, 2010
Sanofi Pasteur
Final Program ~ 99
Session 37
Hyatt Regency Miami
10:15–12:15
INFECTIOUS DISEASE AND VACCINES DEVELOPMENT
Chair:
Stanley PLOTKIN, USA
37.001
Meningococcal epidemiology in Latin America
E. Berezin
São Paulo (Brazil)
37.002
Tick-borne encephalitis: Clinical development of vaccines
for children and adults
E. M. Pöllabauer
Vienna (Austria)
37.003
Strategies for the development of new vaccines
S. Plotkin
Doylestown, PA (USA)
37.004
New technology update: Cell culture derived seasonal and
pandemic fluvaccine
H. Ehrlich
Vienna (Austria)
THURSDAY
•
March 11, 2010
Baxter
100 ~ Final Program
Symposium
Session 38
CME
Hyatt Regency Miami
10:15–12:15
Symposium
THE ILL RETURNEE FROM LATIN AMERICA
Co-Chairs:
Jeannette DABANCH PENA, Chile
Patricia WALKER, USA
38.001
Febrile illnesses
I. Tellez
Atlanta, GA (USA)
38.002
Cutaneous diseases in returnee travelers from Latin America
C. Perret
Santiago (Chile)
38.003
Non-enteric helminths including cysticercosis
R. Istúriz
Caracas (Venezuela)
38.004
Risks of getting HIV infections and STIs when traveling to Latin America
G. Lopardo
THURSDAY
•
March 11, 2010
Final Program ~ 101
Session 39
CME
Hyatt Regency Miami
10:15–12:15
Symposium
NEGLECTED TROPICAL DISEASES: PRESENT NEED AND PRESENT ACTION
Co-Chairs:
Mirta ROSES PERIAGO, USA
Raúl ISTURIZ, Venezuela
39.001
The WHO global plan to map and combat neglected tropical diseases
L. Savioli
39.002
Neglected tropical diseases in Latin America and the Caribbean:
Prospects for control and elimination
S. Ault
39.003
Chagas disease research: Advances and needs
Z. Yadon
Washington DC, DC (USA)
39.004
Integrated control of neglected tropical diseases in Africa
M. J. Bockarie
Liverpool (United Kingdom)
THURSDAY
•
March 11, 2010
102 ~ Final Program
Session 40
Hyatt Regency Miami
10:15–12:15
Oral Presentations
VIRAL DISEASES
Unusual clinical profile of Dengue infection in patients attending a
tertiary care teaching hospital in north India
J. Agarwal, G. Kapoor, S. Srivastava, K. P. Singh, R. Kumar, A. Jain
Lucknow (India)
40.002
An outbreak of pneumonia associated with emergent human adenovirus
serotype 14—Southeast Alaska, 2008
D. Esposito1, T. J. Gardner2, E. Schneider1, L. J. Stockman1, J. Tate1,
C. A. Panozzo1, C. L. Robbins1, S. A. Jenkerson2, L. Thomas3, C. M. Watson4,
A. Curns1, D. D. Erdman1, X. Lu1, T. Cromeans1, M. Westcott5, C. Humphries5,
J. Ballantyne5, G. E. Fischer1, J. B. McLaughlin2, G. Armstrong1, L. J. Anderson1
1
Atlanta, GA (USA), 2Anchorage, AK (USA), 3Klawock, AK (USA),
4
Craig, AK (USA), 5Fairbanks, AK (USA)
40.003
Uptake and impact of Rotavirus vaccines in US Children
J. Cortes, D. Esposito, M. Cortese, D. Bartlett, J. Tate, D. Payne, M. Patel,
A. Curns, J. Gentsch, U. Parashar
Atlanta, GA (USA)
40.004
The epidemiology of rotavirus disease among children <5 years of age—
Santa Rosa, Guatemala, 2007–2009
J. Cortes1, W. Arvelo1, B. lopez2, L. Reyes2, B. Gordillo2, U. Parashar1,
K. Lindblade1
1
Atlanta, GA (USA), 2Guatemala City (Guatemala)
40.005
Surveillance for epidemic of enterovirus infections in Taiwan in 2008
S.-K. Lai, C.-C. Huang, C.-H. Jiang, Y. T. Tsai, H.-L. Chang, J.-H. Chuang
Taipei City (Taiwan, R.O.C.)
40.006
Epidemiology of varicella among passengers and crew on international
conveyances, United States, 2005–2008
P. Szymanowski, H. Lipman, D. Fishbein, C. Chandra
Atlanta, GA (USA)
40.007
Dengue fever outbreak in Lima, Peru 2009: Epidemiological changes
in urban areas
M. Loayza, G. A. Cisneros, L. Loro, G. Yale
Lima (Peru)
Final Program ~ 103
March 11, 2010
40.001
•
Thomas YUILL, USA
Radha Kanta RATHO, India
THURSDAY
Co-Chairs:
Session 40
Hyatt Regency Miami
10:15–12:15
Oral Presentations
THURSDAY
•
March 11, 2010
VIRAL DISEASES
104 ~ Final Program
40.008
Risk of being seropositive for multiple HPV types among Finnish
and Ugandan women
P. B. Namujju1, H.-M. Surcel1, P. Koskela1, E. K. Mbidde2, M. Muwanga2,
R. Byaruhanga3, C. Banura3, M. Kaasila1, R. Kirnbauer4, M. Lehtinen5
1
Oulu (Finland), 2Entebbe (Uganda), 3Kampala (Uganda), 4Vienna (Austria),
5
Tampere (Finland)
40.009
A phase 3 study of a short, two dose regimen of an investigational
Hepatitis B vaccine
J. Martin1, S. Halperin2, F. Diaz-Mitoma3
1
Berkeley, CA (USA), 2Halifax, NS (Canada), 3Ottowa, ON (Canada)
Session 41
Hyatt Regency Miami
CME
10:15–12:15
Symposium
CARBAPENEMASE-PRODUCING BACTERIA: THE THREAT OF ‘PANRESISTANCE’
Co-Chairs: Daniel LEW, Switzerland
Po-Ren HSUEH, Taiwan
41.001
Detecting carbapenemase producers in the clinic
C. Giske
Stockholm (Sweden)
41.002
Clinical impact and current epidemiology of carbapenemase producers
K. Thomson
Omaha, NE (USA)
41.003
Controlling the spread of carbapenemase-producing bacteria
M. Schwaber
Tel Aviv (Israel)
41.004
Treatment options for carbapenenam-resistant infections
G. Daikos
Athens (Greece)
International Society of Chemotherapy (ISC)
THURSDAY
•
March 11, 2010
Final Program ~ 105
Session 42
CME
Hyatt Regency Miami
14:30–15:15
THURSDAY
•
March 11, 2010
PLENARY LECTURE VI
106 ~ Final Program
Chair:
Keryn CHRISTIANSEN, Austalia
42.001
Malaria eradication
C. V. Plowe
Baltimore, MD (USA)
Plenary
Session 43
CME
Hyatt Regency Miami
15:45–17:45
Symposium
A RATIONAL APPROACH FOR THE TREATMENT AND PREVENTION OF NEONATAL SEPSIS
Co-Chairs:
Carla ODIO, Costa Rica
Pablo SANCHEZ, USA
43.001
Understanding the immune system of the neonate
M. de la Morena
Dallas, TX (USA)
43.002
Global burden of neonatal sepsis
E. K. Mulholland
43.003
Rational use of antibiotics in the critically ill neonate and the premature infant
C. Odio
San Jose (Costa Rica)
43.004
Strategies to limit infections in the neonate and to reduce
infection-related mortality
P. Sanchez
Dallas, TX (USA)
THURSDAY
Latin American Society of Pediatric Infectious Diseases (SLIPE)
•
March 11, 2010
Final Program ~ 107
Session 44
CME
Hyatt Regency Miami
15:45–17:45
Symposium
BACTERIAL INFECTIONS FOLLOWING INFLUENZA
Co-Chairs:
Keith KLUGMAN, USA
Tracy HUSSELL, United Kingdom
44.001
Secondary bacterial infections—The other side of influenza pathogenesis
J. McCullers
Memphis, TN (USA)
44.002
The role of mucosal antiviral immunity in bacterial secondary lung infections
D. Metzger
Albany, NY (USA)
44.003
Alteration of the innate immune rheostat and susceptibility to secondary
bacterial super-infections
T. Hussell
44.004
Lessons from 1918 and the current H1N1 pandemic on the role of
bacterial infections during pandemic influenza
K. Klugman
Atlanta, GA (USA)
THURSDAY
•
March 11, 2010
108 ~ Final Program
Session 45
CME
Hyatt Regency Miami
15:45–17:45
Symposium
TRAVELERS TO LATIN AMERICA WITH SPECIAL RISKS
Co-Chairs:
Jaime TORRES, Venezuela
Phyllis KOZARSKY, USA
45.001
High altitude itineraries
M. Cabada
Lima (Peru)
45.002
Risks on common cruise itineraries
A. Rísquez Parra
Caracas (Venezuela)
45.003
Immunocompromised travelers
E. Jong
Seattle, WA (USA)
45.004
Pregnant travelers
D. Carroll
Spring Lake, MI (USA)
THURSDAY
•
March 11, 2010
Final Program ~ 109
Session 46
CME
Hyatt Regency Miami
15:45–17:45
Symposium
THURSDAY
•
March 11, 2010
INFECTIOUS DISEASES SURVEILLANCE SYSTEMS IN PRACTICE
110 ~ Final Program
Co-Chairs:
Larry MADOFF, USA
Arnon SHIMSHONY, Israel
46.001
ProMED and HealthMap: Collaboration to improve
emerging disease surveillance
L. Madoff, J. Brownstein
Boston, MA (USA)
46.002
Google flu trends: Mapping influenza in near real time
C. Conrad
San Francisco (USA)
46.003
CaribVET: A model for surveillance of zoonotic diseases
T. Lefrancois
Petit Bourg (Guadeloupe)
46.004
GeoSentinel: Provider-based Surveillance of International Travelers
D. Freedman
Birmingham, AL (USA)
Session 47
Hyatt Regency Miami
15:45–17:45
Oral Presentations
Co-Chairs:
Eric SUMMERS, USA
Larry LUTWICK, USA
47.001
Epidemiological description of infection with agents of the Rickettsia genus in
rodents, ectoparasites and humans in the northern coast of Antioquia, Colombia
J. C. Quintero Vélez1, A. Londoño1, V. Quiroz1, F. Díaz1, P. Agudelo2,
M. Arboleda2, J. Rodas1
1
Medellin (Colombia), 1Sabaneta (Colombia)
47.002
Distinct pathological signatures after lethal avian H5N1 and swine H1N1
influenza infections suggest variable pathogenesis
M.-M. Garigliany1, A. Habyarimana2, B. Lambrecht2, E. Van de Paar1,
A. Cornet1, T. Van den Berg2, D. Desmecht1
1
Liege (Belgium), 2Brussels (Belgium)
47.003
A novel nervous-to-immune signalling mechanism mediating innate
responses to infections
M. Bakhiet1, S. Taha2
1
Bahrain (Bahrain), 2Manama (Bahrain)
47.004
Variable expression of alpha haemolysin and Panton Valentine leucocidin in
clinical isolates of Staphylococcus aureus are linked to agr-dependent
quorum sensing
T. Sloan, R. O. Jensen, A. Cockayne, L. G. Durrant, P. Williams, R. James
Nottingham (United Kingdom)
47.005
HBs mutations related with YMDD mutation induced the expression
of hfgl2 gene
M. Han1, W. Li1, Y. Li1, D. Chen1, W. Yan1, X. Wang1, X. Luo1, Q. Ning2
1
Wuhan (China), 2Wuhan, Hubei (China)
THURSDAY
•
March 11, 2010
ADVANCES FROM THE LABORATORY
112 ~ Final Program
Session 47
Hyatt Regency Miami
15:45–17:45
Oral Presentations
ADVANCES FROM THE LABORATORY
Gene expression profilling of mouse host response to
Candida tropicalis infection
P. P. Chong1, V.-C. P. Yong1, H. F. Seow2, R. Rosli1
1
Selangor (Malaysia), 2Melbourne (Australia)
47.008
Cytokines in experimental leptospirosis: Association with severe disease and
postimmunization immune response
A. Chagas-Junior, D. Athanazio, J. Macedo, M. Menezes, M. Reis,
F. McBride, A. McBride
Salvador (Brazil)
47.009
Prevalence of genes responsible for resistance to antimicrobials in
surface water Escherichia coli isolates
G. Singh, P. Vajpayee, R. Shanker
Lucknow (India)
47.010
E-gene variation with reference to neurovirulence in the Indian clinical
isolates of Japanese encephalitis virus
S. K. Pujhari, S. Prabhakar, R. K. Ratho, M. Modi, M. Sharma, B. Mishra
Chandigarh (India)
Final Program ~ 113
March 11, 2010
47.007
•
Enteric virus detection and identification with a universal virus discovery assay
C. Uhlenhaut, S. D. McClenahan, S. Sosnovtsev, K. Bok, A. Z. Kapikian,
K. Y. Green, P. R. Krause
Bethesda, MD (USA)
THURSDAY
47.006
Session 48
Hyatt Regency Miami
12:30–13:30
THURSDAY
•
March 11, 2010
ANTIBIOTICS: MECHANISMS AND SPECTRUM
114 ~ Final Program
48.001
Antimycobacterial activity of pyrimido[4,5-b]diazepine derivatives
J. G. Bueno Sánchez1, A. Garcia2, B. Insuasty2, J. Quiroga2
1
Bogotá (Colombia), 2Cali (Colombia)
48.002
Five-year trend of antimicrobial susceptibility rates and daptomycin activity
among Staphylococcus aureus isolates collected in Latin American medical
centers (2005–2009)
D. J. Biedenbach, R. N. Jones, H. Sader
North Liberty, IA (USA)
48.003
In vitro activity of new compound YF-13-1 against gram-postive and
gram-negative bacteria strains of clinical isolates in chain
S. Zhang, Y. Liu
Chengdu (China)
48.004
10-hydroxy-2-decenoic acid induce dispersion of
Streptococcus mutans biofilms
A. Shoae Hassani, N. Ordouzadeh
Fars (Islamic Republic of Iran)
48.005
In vitro activity of biapenem against Burkholderia pseudomallei
V. Thamlikitkul, S. Trakulsomboon
Bangkok (Thailand)
48.006
Role of Efflux pumps in the development of quinolone-resistance in Peruvian
Escherichia coli isolates
S. Mosquito1, M. J. Pons2, T. J. Ochoa1, R. C. Maves1, J. Ruiz2
1
Lima (Peru), 2Barcelona (Spain)
Session 49
Hyatt Regency Miami
12:30–13:30
ANTIBIOTICS: PHARMACOLOGY AND CLINICAL STUDIES
Various dosages of linezolid in treatment of difficult
multidrug-resistant tuberculosis
W. W. Yew
Hong Kong (China)
49.003
Intravaginal pentamycin for the treatment of bacterial vaginosis
C. Winnips1, J. A. Balmer2
1
Basel (Switzerland), 2Spiez (Switzerland)
49.004
Intravenous colistin therapy for infections caused by multidrug-resistant
gram-negative bacteria in critically ill patients
M. Cusato
Pavia (Italy)
49.005
Pharmacodynamic profiling of intravenous antibiotics against gram-negative
bacteria collected during the Tracking Resistance in the United States Today
(TRUST) surveillance program
P. Koomanachai, D. P. Nicolau, J. L. Kuti, C. C. Bulik
Hartford, CT (USA)
49.006
Oral Cefixime is beneficial in acute uncomplicated Salmonella gastroenteritis in children with mucoid or bloody diarrhea—Do indications of antibiotics therapy
need reassessment?
H.-Y. Lee1, T.-Y. Lin2, C.-T. Wu1, C.-H. Chiu1, Y.-C. Huang1
1
Kweishan, Taoyuan (Taiwan, R.O.C.), 2Linkou (Taiwan, R.O.C.)
49.007
Evaluation of the pharmacodynamics of Daptomycin (DAP)-Rifampin (RIF)
combinations with Staphylococcus aureus using various in vitro methods
S. Zinner1, M. Smirnova2, E. Strukova2, A. Firsov2
1
Boston, MA (USA), 2Moscow (Russian Federation)
49.008
The effectiveness of oral suppression in high risk prosthetic joint infections
after total knee arthroplasty
M. McBroom, D. J. Barbaro
Fort Worth, TX (USA)
49.009
Population pharmacokinetics of meropenem in pediatric patients: a concurrent
analysis of the plasma and urine concentration data
K. Ikawa, N. Morikawa, K. Ikeda, M. Miki, M. Kobayashi
Hiroshima (Japan)
Final Program ~ 115
March 11, 2010
49.002
•
A murine gastritis model to study antibacterial effect of Camellia sinensis
(Green Tea) against H.pylori infection
S. Sherwani, F. Aziz, T. Siddiqui, S. Akhter, W. Ahmed, S. S. U. K. Kazmi
Karachi (Pakistan)
THURSDAY
49.001
Session 50
Hyatt Regency Miami
12:30–13:30
THURSDAY
•
March 11, 2010
ANTIBIOTICS: USAGE AND STEWARDSHIP
116 ~ Final Program
50.001
Appropriate use of fluoroquinolones in a Lebanese tertiary medical center
W. Kabbara, P. Rahbany, S. Al-Natour
Byblos (Lebanon)
50.002
Impact of restriction policy as part of an antimicrobial stewardship program in a
university hospital of a developing country
P. Titanti, V. Berdiñas, J. Ramos, L. Manevich, L. Barcelona, P. Rios, G. Lopardo
50.003
Utilization of activated protein C (Xigris) in a large teaching hospital—
Possible overuse and complications
M. R. Wallace, C. Arinyedokiari, B. Dattani
Orlando, FL (USA)
50.004
Antimicrobial prophylaxis for transrectal ultrasound guided biopsy of prostate:
A comparative study between single dose of Gentamicin vs. Ofloxacin
B. Chazan, G. Zelichenko, Y. Shental, H. Edelstein, R. Raz
Afula (Israel)
50.005
Reducing inappropriate antibiotic usage and costs in an academic
Hematology-Oncology unit via antimicrobial stewardship
C. L. Yeo, T. S. Wu, R. Lim, P. A. Tambyah, L. Y. Hsu
50.006
Tigecycline usage in osteomielitis caused by multidrug-resistent acinetobacter:
A report of 10 cases from a single institution
N. M. Ruiz, E. Gayoso, Y. Vasquez
Caracas, DC (Venezuela)
Session 51
Hyatt Regency Miami
12:30–13:30
EPIDEMIOLOGY OF PATHOGENS
Three-year surveillance of community-acquired and health care-associated
Methicillin-Resistant staphylococcus aureus infections in Uppsala County, Sweden
S. Sylvan, B. Christenson, B. Ardung
Uppsala (Sweden)
51.003
One-year epidemiology of febrile diseases on the Emergency Department of a
Caribbean island: The Curaçao-experience
M. Limper1, I. Gerstenbluth2, A. Duits2, E. Van Gorp1
1
Amsterdam (Netherlands), 2Curacao (Netherlands)
51.004
Transmission risk and predictability of invasive meningococcal disease
V. Racloz1, L. Da Silva2
1
Basel (Switzerland), 2Cambridge, MA (USA)
51.005
Hospitalizations due to pneumonia and case-fatality rates in Brazil
between 2003 and 2007
J. Cássio de Moraes1, E. Berezin1, J. Markowitz2, T. Hong3, P. Seljan3
1
São Paulo SP (Brazil), 2Princeton, NJ (USA), 3Collegeville, PA (USA)
51.006
Meningococcal meningitis epidemic in Arua district North West of Uganda
M. Busuulwa
Kampala (Uganda)
51.007
The study of epidemiological data of the mumps and the effect of MMR vaccine
in the Albanian children
H. Hoxha, A. Simaku, E. Kallfa-Foto, G. Lito, R. Petrela, E. Thartori
Tirana (Albania)
51.008
Pertussis in Brazil: An overview from 1988 to 2009
D. Leite, L. C. V. Melo, T. M. I. Vaz, K. Irino
São Paulo (Brazil)
51.009
Serogroup B epidemiology in the southern cone of South America.
A literature review
L. Da Silva, M. H. Kyaw
Cambridge, MA (USA)
Final Program ~ 117
March 11, 2010
51.002
•
Tetanus immunity among intravenous drug users in Uppsala County, Sweden
S. Sylvan
Uppsala (Sweden)
THURSDAY
51.001
Session 51
Hyatt Regency Miami
12:30–13:30
THURSDAY
•
March 11, 2010
118 ~ Final Program
51.010
Status of bloodborne pathogen education for injection drug users in Indiana
hospital emergency departments
M. Wenger
Indianapolis, IN (USA)
51.011
Neighborhood urban environmental quality conditions probably drive malaria
and diarrhea mortality in Accra, Ghana
J. Fobil1, J. Fobil2, A. Kraemer3, J. May1
1
Hamburg (Germany), 2Legon, Accra (Ghana), 3Bielefeld (Germany)
51.012
Incidence of hospital- and ICU-admitted community-acquired pneumonia: A
population-based study in Uruguay
D. Goleniuk1, H. Albornoz2
1
Rivera (Uruguay), 2Montevideo (Uruguay)
51.013
The Survey of leptospirosis in Mazandaran province, north of Iran by
Microscopic agglutination test, 2006–2007
S. P. Ziapour1, B. Esfandiari1, G. Abdollahpour2, M. Assmar3, M. R. Youssefi4,
G. Amirbozorgi1, B. Amini Navaie1, S. Sattari Tabrizi2, M. Alipour Espeh-kolaie 4
1
Amol (Islamic Republic of Iran), 2Karaj (Islamic Republic of Iran),
3
Tehran (Islamic Republic of Iran), 4Babol (Islamic Republic of Iran)
51.014
Incidence of mycobacteria and fungi in clinically suspected urinary tract
infection of immunocompromised patients—A tertiary care hospital study
S. Jain, V. Nag, R. S. K. Marak, N. Prasad, T. Dhole
Lucknow (India)
51.015
Molecular analysis and risk factors for nasal colonization with
methicillin-resistant Staphylococcus aureus among community individuals
attending a Family Health Care Program in Rio de Janeiro, Brazil
T. Miranda, T. Brust, N. H. T. Miyazaki, H. Kang, L. Isaias, O. Fernandes,
F. Aguiar-Alves
51.016
The prevalence of Staphylococcus aureus nasal colonization among Korean
children attending day care centers
J.-H. Lee1, Y. M. Kim2, E. Y. Cho1, K. B. Hong1, J. Lee1, E. H. Choi1, H. J. Lee1
1
Seoul (Republic of Korea), 2Ulsan (Republic of Korea)
51.017
Leptospirosis: analysis of the notification records and investigation on the year
of 2007, of the municipal district of Salvador-Bahia-Brazil, 2009
S. Cerqueira, J. F. Silva
Salvador, Bahia (Brazil)
Session 51
Hyatt Regency Miami
12:30–13:30
Serological update of the Chikungunya epidemic outbreak in Italy
P. Gaibani, A. Pierro, F. CAVRINI, G. Rossini, M. P. Landini, C. Manisera,
V. Sambri
Bologna (Italy)
51.020
Sero-prevalence of West Nile virus in north-eastern Italy
A. Pierro1, P. Gaibani1, F. CAVRINI2, C. Manisera1, G. Rossini1, M. P. Landini,
V. Sambri
Bologna (Italy)
51.021
A retrospective laboratory analysis of clinically diagnosed Lassa fever cases in a
tertiary hospital in Nigeria
D. Ehichioya1, D. Asogun2, M. Hass3, B. Becker-Ziaja3, S. Gunther3, S. Omilabu1
1
Lagos (Nigeria), 2Irrua, Edo (Nigeria), 3Hamburg (Germany)
51.022
Syphilis among young women: a population based survey in central Brazil
F. L. B. Garcia1, M. Turchi2, E. M. B. Guimaraes2, N. Carvalho2, C. T. Ribeiro2,
M. N. G. Reis2, M. F. C. Alves2
1
Brasilia (Brazil), 2Goiania (Brazil)
51.023
Clinical features of Plasmodium malariae in Venezuela
L. Villegas1, M. E. Guevara2, N. Hernandez2, V. Pacheco2, C. Fuenmayor2,
B. Salazar2, M. Giron2, M. Pacheco2, J. Moreno2
1
Paramaribo (Suriname), 2Tumeremo (Venezuela)
51.024
Severe malaria surveillance and treatment delays in Canada
C. Prematunga, A. McCarthy
Ottawa, ON (Canada)
51.025
Leptospirosis in Mazandaran province, northern Iran, 2008–2009
B. Esfandiari1, S. P. Ziapour1, M. Assmar2, M. R. Youssefi3, G. Amirbozorgi1,
B. Amini Navaie1, Z. Farzaneh-nejad2, M. Alipour Espeh-Kolaie3
1
Amol (Islamic Republic of Iran), 2Tehran (Islamic Republic of Iran),
3
Babol (Islamic Republic of Iran)
51.026
Epidemiologic comparison of Human Brucella suis and
Brucella melitensis infections
D. Stanek1, P. Nicoletti2, D. Harrell2, G. churchwell3, P. Lee3, C. Blackmore1
1
Tallahassee, FL (USA), 2Gainesville, FL (USA), 3Jacksonville, FL (USA)
Final Program ~ 119
March 11, 2010
51.019
•
Lassa fever awareness and practices in a nigerian rural community
D. Asogun1, P. Okokhere1, S. Okogbenin1, G. Akpede1, S. Gunther2, C. Happi3
1
Irrua, Edo (Nigeria), 2Hamburg (Germany), 3Ibadan (Nigeria)
THURSDAY
51.018
Session 52
Hyatt Regency Miami
12:30–13:30
THURSDAY
•
March 11, 2010
GRAM-NEGATIVE BACTERIAL INFECTIONS
120 ~ Final Program
52.001
Shigellosis in Central American countries
R. Achí, K. Barrantes
52.002
Detection and molecular characterization of verotoxin gene in non-O157
diarrheagenic Escherichia coli isolated from Miri hospital, Sarawak, Malaysia
M. N. H. Maziz1, S. ismail2, H. Jamal2, A. Ansary2
1
Shah Alam (Malaysia), 2Kuala Lumpur (Malaysia)
52.003
Isolation and characteristic distribution pattern of cagA+ Helicobacter pylori in
dental plaque of dyspeptic patients
M. Karbalayi, S. Khodadad
52.004
Multiresistant Acinetobacter spp in a burn unit in Argentina
M. T. Rosanova, G. Mudryck, A. Monaco, H. Lopardo, M. Villasboas, G. Berberian
52.005
Investigation of Helicobacter pylori in dyspeptic patients and its relationship
with Iranian life style
L. Shokrzadeh, K. Baghaei, D. Mirsattari, R. Mashayekhi, H. Zojaji, M. R. Zali
52.006
Cytokine profile in patients with severe gram negative sepsis
S. Jain, S. Agrawal, V. Dhawan, N. Sharma, S. Varma
Chandigarh (India)
52.007
Burkholderia pseudomallei musculoskeletal infections (Melioidosis) in India:
Are the orthopaedic surgeons aware?
V. Pandey, S. Rao, K. K. V. Acharya
Manipal (India)
52.008
Spectrum of hepatic dysfunction in enteric fever
S. Bhatia1, M. Prabhu2, K. Saravu1, M. Docherla1, B. Shastry1
1
Karnataka (India), 2Manipal (India)
52.009
Verotoxin gene in non-O157 diarrheagenic Escherichia coli
can be plasmid-mediated
M. N. H. Maziz
Shah Alam (Malaysia)
Session 52
Hyatt Regency Miami
12:30–13:30
Carbapenem-resistant Enterobacteriaceae in a tertiary care cancer hospital
S. Biswas
Mumbai (India)
52.012
Infections due to Haemophilus influenzae encountered in Jamaica:
Analysis of 286 cases at the University Hospital of the West Indies
N. Bodonaik, R. Willis, L. Rainford
Kingston (Jamaica)
52.013
Incidence of human Brucellosis in Gevgelia region, Macedonia
G. Petkov1, Z. MIlenkovic2, M. Toshev3
1
Gevgelia (Macedonia), 2Scopje (Macedonia), 3Negotino (Macedonia)
52.014
Risk factors for death amongst children of five years and younger, with invasive
non-typhoidal Salmonella infection, 2004 – 2008, South Africa
V. Dermaux, A. Sooka, S. Meiring, N. Govender, J. Moyes, C. Cohen, K. Keddy
Sandringham (South Africa)
52.015
Changes in the epidemiology of Haemophilus influenzae invasive disease, in
Portugal, after the introduction of the Hib vaccine
M. P. Bajanca-Lavado, C. Betencourt
Lisbon (Portugal)
52.016
Analysis of clinical outcome in patients with multidrug-resistant
Acinetobacter baumannii bacteremia
M. W. Kang, Y. J. Kim, K.-W. Hong, S. I. Kim, Y. R. Kim, Y.-J. park
52.017
Clinical profile and antimicrobial resistance pattern of Enteroaggregative E.coli
isolated from patients with diarrhoea, using a multiplex PCR assay in a tertiary
care hospital in North India
S. Pahil, N. Taneja, G. Singh, M. Sharma
Chandigarh (India)
Final Program ~ 121
March 11, 2010
52.011
•
Vertebral column damage due to brucellosis
K. Leka
Tirana, (Albania)
THURSDAY
52.010
Session 52
Hyatt Regency Miami
12:30–13:30
THURSDAY
•
March 11, 2010
122 ~ Final Program
52.018
Phenotypic and molecular characterization of Pseudomonas aeruginosa
isolates expressing high-level betalactamic resistance in cystic fibrosis patients
M. D. C. Batlle, J. Ayala
Havana (Cuba)
52.019
Epigenetic regulation of lymphocytes response to LPS
E. Melo, M. Camargo, R. Curi, I. Velasco, F. Soriano
São Paulo (Brazil)
52.020
Clinical and phylogenetic characteristics of Escherichia coli urinary tract infections
S. Y. Lee, J. H. Kim, J. K. Hur, J. H. Kang
52.021
Serogroup W135 meningococcal invasive disease in Argentina
M. R. Agosti1, C. Vescina1, J. C. Morales1, R. S. Oderiz1, M. M. Greco1,
D. M. Cecchini2, S. E. González Ayala1
1
La Plata (Argentina), 2Buenos Aires (Argentina)
52.022
Salmonella prosthetic joint infections: An uncommon entity
R. GUPTA, S. M. Boger, L. R. Leddy, H. D. Schutte, C. E. Marculescu,
H. A. Demos
Charleston, SC (USA)
52.023
Genetic analysis by pulsed-field gel electrophoresis of Enteropathogenic
Escherichia coli (EPEC) strains isolated from Peruvian children
C. A. Contreras1, J. Ruiz2, C. F. Lanata1, T. G. Cleary3, T. J. Ochoa1
1
Lima (Peru), 2Barcelona (Spain), 3Houston, TX (USA)
52.024
Antibody subclasses as a tool for Helicobacter pylori antigen characterization
F. Martine, G. Castillo Rojas2, Y. López
Session 53
Hyatt Regency Miami
12:30–13:30
HEPATITIS
Association of polymorphism of HLA-DRB1 13 and HLA-A 33 alleles with
outcome of hepatitis B virus infection
A. Ramezani, A. Aghakhani, E. Kalantar, A. Eslamifar, M. Banifazl
53.003
Hepatitis A epidemiology in a Brazilian fire department
D. Borghi, R. P. Igreja, M. D. Canetti, R. C. Vasconcellos, C. L. Vitral,
D. R. L. Santos
53.004
Association of exon 9 but not intron 8 VDR polymorphisms with occult
HBV infection in south-eastern Iranian patients
G. Hassanshahiraviz
Rafsanjan (Islamic Republic of Iran)
53.005
IL-12 +1188 and IFN-g +874 polymorphisms is not associated with these
cytokines serum level in occult HBV infected patients
H. Abousaidi
53.006
Occult hepatitis B virus infection in ART-naive HIV-infected Indian patients
S. Singh
New Delhi (India)
53.007
Treatment of chronic hepatitis C: The efficacy and predictors of response
to therapy
M. Bozic
Belgrade (Serbia)
53.008
Occult hepatitis C virus infection among chronic liver disease patients in the
United Arab Emirates
M. Al-Moslih
Sharjah (United Arab Emirates)
53.009
Clinical features of acute viral hepatitis A complicated with acute renal failure
H. Choi, B. S. Chin, S. Y. Shin, S. J. Jin, Y. T. Chae, S. H. Han, J.-H. Baek,
J. Y. Choi, C. O. Kim, J. M. Kim
Final Program ~ 123
March 11, 2010
53.002
•
Age-specific seroprevalence of hepatitis A in SARI (northern part of IRAN)
R. Ghasemian, S. Alian
Sari (Islamic Republic of Iran)
THURSDAY
53.001
Session 53
Hyatt Regency Miami
12:30–13:30
THURSDAY
•
March 11, 2010
HEPATITIS
124 ~ Final Program
53.010
Prevalence of isolated hepatitis B core antibody among injection drug users in
Central Province of Iran
M. Sofian1, A. Rostampour1, N. Izadi1, F. S. Mahdaviani1, A. A. Farazi1,
A. Ramezani2, N. Zarinfar1, H. Sarmadian1, A. Aghakhani2, M. Banifazl2
1
Arak (Islamic Republic of Iran), 2Tehran (Islamic Republic of Iran)
53.011
Persistence of protective antibodies against Hepatitis B virus among vaccinated
health workers, Al-Hussein Hospital, Salt, Jordan, 2008
S. Sheikh Ali, M. Jaghbir
Amman (Jordan)
53.012
Regional and ethnical aspects of viral hepatitis B in pregnant women in the
Slovak Republic
P. Kristian, I. Schreter, Z. Paralicova, P. Jarcuska, L. Siegfried, S. Porubcin
Kosice (Slovak Republic)
53.013
New approaches in in-vitro diagnosis of Hepatitis C infections:
The diagnostic performance of new hepatitis C virus core antigen detection test
B. Kocazeybek, P. Yuksel, S. Saribas, R. Caliskan, S. Ergin, M. Aslan,
A. Yalcıner, M. M. Torun
Istanbul (Turkey)
53.014
No detected hepatitis B virus-DNA in thalassemic patients infected by
hepatitis C virus in Kerman province of Iran
G. Hassanshahiraviz
53.015
Genotypes and reverse transcriptase variability in asymptomatic chronic
hepatitis B virus
M. Basaras, E. Arrese, S. Blanco, P. Ruiz, R. Cisterna
Bilbao (Spain)
53.016
Antiviral treatment with interferon alpha and ribavirin influences serum markers
of liver fibrosis in children with chronic hepatitis C
A. Mania, W. Sluzewski, P. Kemnitz, M. Figlerowicz, A. Kowala-Piaskowska
Poznan (Poland)
53.017
Incidence of HBeAg/anti-HBe and HBs/anti-HBs seroconversion after antiviral
treatment in children with chronic hepatitis B
P. Kemnitz, W. Sluzewski, A. Mania, M. Figlerowicz, A. Kowala-Piaskowska,
M. Michalak
Poznan (Poland)
Session 53
Hyatt Regency Miami
12:30–13:30
HEPATITIS
Prevalence of HBeAg positive cases and abnormal aminotransferase tests in HBV
chronic carriers in Kashan, Iran
M. Momen Heravi
53.020
Positive association of high risk behaviors and Hepatitis B infection
A. Nejatizadeh, F. Abedi, A. Madani
Bandar Abbas (Islamic Republic of Iran)
53.021
Biodynamics of HCV infection in haemodialysis patients in Pahang
M. Mustafa, M. S. Abdul Majid, H. A. Binti Hamzah, M. H. bin Hasmaini
Kuantan (Malaysia)
53.022
Runs test and linear trend test of the time series of primary hepatocellular
carcinoma mortality in Haimen City, 1969–2007
P.-X. Huang, H.-B. Lu, W.-Y. Lin
Haimen (China)
53.023
Predictive factors for sustained virological response in the treatment of patients
with chronic hepatitis C
N. Svirtlih, D. Delic, J. Simonovic, A. Radovanovic, N. Mitrovic, L. Nikitovic,
E. Gvozdenovic, S. Zerjav, I. Boricic
Belgrade (Serbia)
53.024
Is there any association between chronic Hepatitis C virus and celiac disease?
M. Rostami Nejad1, S. R. Mohebbi1, K. Rostami2, K. Cheraghipour3, M. R. Zali1
1
Tehran (Islamic Republic of Iran), 2Birmingham (United Kingdom),
3
Hamedan (Islamic Republic of Iran)
53.025
Prevailing HCV genotypes and subtypes among HIV infected patients in Georgia
M. Karchava, L. Sharvadze, L. Gatserelia, L. Dzigua, N. Dvali, T. Tsertsvadze
Tbilisi (Georgia)
53.026
Hepatitis B Virus (HBV) mutations during long-term therapy in chronic
hepatitis B patients
E. Arrese1, M. Basaras2, S. Blanco2, P. Ruiz2, R. Cisterna2
1
Vitoria-Gasteiz (Spain), 2Bilbao (Spain)
Final Program ~ 125
March 11, 2010
53.019
•
Seroprevalence and associated risk factors of hepatitis B virus among street
children in Isfahan, Iran (2005–2007)
B. Ataei, Z. Nokhodian, A. Babak, P. Shoaei, N. Kassaian, M. Ataie
Isfahan (Islamic Republic of Iran)
THURSDAY
53.018
Session 53
Hyatt Regency Miami
12:30–13:30
THURSDAY
•
March 11, 2010
HEPATITIS
126 ~ Final Program
53.027
Long term virological follow up of Hepatitis C (VHC) monoinfected patients who
achieved end of treatment response (ETR)
C. Vujacich, P. Rodriguez Iantorno, G. Vidiella, E. Poggi, P. Titanti, P. Canda,
E. Sturba, D. Stamboulian
53.028
Seroprevalence of hepatitis A among children and adolescent from south and
southeast region of Brazil
G. Figueiredo1, M. R. Cardoso1, R. Moreira1, L. Pereira2, U. Montarroyos2,
C. Braga2, A. Stein2, G. Coral2, R. Ximenez3
1
São Paulo (Brazil), 2Recife (Brazil), 3Porto Alegre (Brazil)
53.029
Household survey of hepatitis B infection and risk factor assessment in the from
South and Southeast region of Brazil
G. Figueiredo1, R. Moreira1, L. Pereira2, M. R. Cardoso1, G. Coral5, A. Stein5,
U. Montarroyos1, C. Braga2, R. Ximenez2
1
São Paulo (Brazil), 2Recife (Brazil), 3Porto Alegre (Brazil)
53.030
Age-dependent, differentiated prevalence of anti-HAV and anti-HBc antibodies
among patients with chronic hepatits C (CHC): New aspect of future vaccination
perspectives against hepatitis A Virus
J. Bialkowska1, W. Mazur2, J. Slusarczyk3, M. Jablkowski1
1
Lodz (Poland), 2Katowice (Poland), 3Warsaw (Poland)
53.031
Ultrasonography changes of the liver of patients infected with hepatitis C met
in the Foundation of Tropical Medicine of Amazonas
J. R. D. T. Leao1, M. Brock1, R. A. C. Carvalho1, W. S. M. Braga2
1
Manaus, AM (Brazil), 2Amazonas (Brazil)
53.032
Detection of acute HCV infection among different risk groups
L. Gatserelia, L. Sharvadze, M. Karchava, N. Dvali, L. Dzigua, N. Badridze,
T. Tsertsvadze
Tbilisi (Georgia)
53.033
Efficacy of 96 weeks adefovir dipivoxil treatment in HBeAg positive chronic
hepatitis B patients with various baseline biochemical levels
L. Zhuang, J. You, L. Kong, H. Lei, R.-D. Yang, X. Zhang, Q.-Q. Wang
Kunming (China)
Session 53
Hyatt Regency Miami
12:30–13:30
HEPATITIS
Patterns of hepatitis A infection by Brazilian regions:
Results of the national household survey 2004–2009
R. Ximenes1, C.T. Martelli, E. Merchan-Hamman2, U. Montarroyos1, C. Braga1,
R. Moreira3, G. M. Figueiredo6, M. R. Cardoso3, M. Turchi4, G. Coral5, A. Stein5,
M. L. Lima1, M. Costa2, L. C. Arraes-Alencar1, D. Crespo6, A. Santos dos Santos6,
L. Pereira1
1
Recife (Brazil), 2Brasilia (Brazil), 3São Paulo, SP (Brazil), 4Goiania (Brazil),
5
Porto Alegre (Brazil), 6Belem (Brazil)
53.036
Acute liver failure in the Colombian pediatric population: Retrospective and
prospective studies
A. Santamaria1, M. M. Contreras1, L. C. Rubiano2, R. Devivero3,
F. Medina4, J. Mojica5
1
Medellin (Colombia), 2Cali (Colombia), 3Cartagena (Colombia),
4
Bucaramanga (Colombia), 5Bogotá (Colombia)
53.037
Hepatitis B seroprevalence and associated factors in pregnant women and their
couples in 6 Amazonian indigenous populations in Peru 2007–2008
M. Ormaeche, A. Whittembury, L. Suarez-Ognio, M. Pun
Lima (Peru)
53.038
Performance of serologic assays specific to IgM antibodies against
hepatitis E virus: Pan-genotypic evaluation
J. Drobeniuc1, J. Meng1, G. Reuter2, N. Khudyakov1, N.-T. Le1,
T. Greene-Montfort1, Z. Dimitrova1, S. Kamili1, C.-G. Teo1
1
Atlanta, GA (USA), 2Pecs (Hungary)
Final Program ~ 127
March 11, 2010
53.035
•
The relationship between HBV precore region mutation and the variation of
T-lymphocyte subpopulations in chronic HBV-infected individuals with normal
liver function tests
J. You, Y.-H. Chen, H.-Y. Chen, H.-Q. Yang, R.-D. Yang, Y.-F. Zhang, J.-Y. Qu,
L. Zhuang, Q.-Q. Wang, X. Zhang, B.-Z. Tang, J.-H. Huang
Kunming (China)
THURSDAY
53.034
Session 54
Hyatt Regency Miami
12:30–13:30
THURSDAY
•
March 11, 2010
HIV: PATHOGENESIS
128 ~ Final Program
54.001
CC-chemokine Co-receptor R5 genotypes in Ghanaian couples discordant for
human immunodeficiency type 1 infection
Y. Affram
Accra, NA (Ghana)
54.002
Endothelial Progenitors Cells and Microparticles in HIV-infected patients
E. F. R. Silva, F. A. H. Fonseca, C. N. Franca, P. R. Abrao, C. M. C. Monteiro,
L. M. Camargo, R. Salomao, S. B. Tenore, D. S. Lewi
São Paulo (Brazil)
54.003
Analysis of longitudinal nef sequence variation throughout HIV-2 infection
M. Remedios, E. Paixao, H. Feliciano, A. Silva-Graca, E. Pádua
Lisbon (Portugal)
54.004
Prediction of R5, X4 HIV-1 coreceptor usage based on physicochemical
properties of envelope V3-loop using artificial neural network
S. Falahi, M. Ravanshad, A. Kenarkoohi
Session 55
Hyatt Regency Miami
12:30–13:30
HIV: THERAPEUTICS
55.002
Comparison of efavirenz and nevirapine based HAART regimens in 4187
patients with up to 6 years of follow up, a prospective, open label
observational study
C. Cortes, C. Beltran, M. Wolff
Santiago (Chile)
55.003
The economic impact of introducing HIV/AIDS guideline into Colombian
National Drug Formulary. Cost-effectiveness analysis
E. V. Lemos Luengas, B. C. Castañeda, E. Quevedo, C. Castillo, L. R. Lemos
Bogotá (Colombia)
55.004
Prevalence of metabolic abnormalities and metabolic syndrome in a cohort of
hispanic patients on HAART
E. Bissio1, G. Lopardo2
1
55.005
Medication errors in patients receiving antiretroviral therapy at an urban hospital
T. Zangeneh, G. Dickinson
Miami, FL (USA)
55.006
Comparison of the effectiveness of low dose Indinavir/ritonavir (IDV/r) versus
Atazanavir/ritonavir (ATV/r) based antiretroviral therapy in NNRTI experienced
HIV-1 infected patients in India
K. Patel1, A. K. Patel1, J. K. Patel1, E. Naik2, J. Duan2, R. Ranjan1, S. Hamisu 2
1
Ahmedabad (India), 2Tampa, FL (USA)
55.007
NRTI resistance profile of the subtype F HIV-1 strains from children and
adolescents treated with multiple antiretroviral drugs
G. Jugulete, M. L. Luminos, M. Mardarescu, D. Otelea, M. Merisescu
Bucharest (Romania)
55.008
Implementation of HLA-B*5701 genetic screening prior to abacavir
prescription in Georgia
N. Dvali, N. Chkhartishvili, L. Sharvadze, L. Dzigua, M. Karchava,
L. Gatserelia, T. Tsertsvadze
Tbilisi (Georgia)
•
Clinical and immunologic response of HIV patients on different ART regimens at
Gondar University Hospital (GUH)
D. Ergete
THURSDAY
55.001
March 11, 2010
Final Program ~ 129
Session 55
Hyatt Regency Miami
12:30–13:30
THURSDAY
•
March 11, 2010
HIV: THERAPEUTICS
130 ~ Final Program
55.009
Efficacy of multivitamins containing phosphatidyl choline in the mananegment
of hepatotoxicity from antiretroviral and/or antituberculous drugs
N. Ladep1, N. Shehu2, A. Muazu2, P. Ugoagwu2, F. Kakjing2, B. Badung2,
C. Daniyan2, J. Idoko3
1
St George’s (Grenada), 2Jos, Plateau (Nigeria), 3Abuja, FCT (Nigeria)
55.010
Prevalence of minor populations of drug-resistant HIV-1 in newly-diagnosed
treatment-naïve individuals in Singapore
Y.-J. Sun, P. Kaur, Y. S. Leo
55.011
Prevalence of HIV-1 primary resistance among HIV chronically infected patients
in Brazil’s Southeast region
C. M. P. M. Soares1, T. R. C. Vergara1, M. M. Caseiro2, R. Côrtes1, B. Scarpellini1,
M. C. A. Sucupira1, R. S. Diaz1
1
São Paulo (Brazil), 2Santos (Brazil)
55.012
Challenges of antiretroviral therapy among children aged 6 to 15 years in
Kabarole district (Western Uganda)
P. Isabirye, N. Kiwanuka, J. Kiguli
Kampala (Uganda)
55.013
Survival, clinical, immunological and hematological outcomes of antiretroviral therapy among HIV-infected children attending a public clinic in Kinshasa,
Democratic Republic of Congo
M. Yotebieng1, A. Van Rie1, J. Luisiama2, F. Kitetele2, A. Edmonds1, F. Behets1,
G. the SARA team2
1
Chapel Hill, NC (USA), 2Kinshasa (Democratic Republic of Congo)
55.014
Apparent virologic failures and blips in a suburban HIV Clinic caused by
laboratory errors in a commercial HIV-1 RNA PCR assay
P. Cariello, T. Treadwell
Framingham, MA (USA)
55.015
Antiretroviral resistance-associated mutations and genomic diversity in reverse
transcriptase and protease gene among drug-naïve patients
S. Saini, P. Bhalla, U. K. Baveja, S. T. Pasha, R. Dewan
New Delhi (India)
Session 56
Hyatt Regency Miami
12:30–13:30
INFECTION CONTROL, NOSOCOMIAL INFECTIONS AND CRITICAL CARE
Virucidal efficacy of topical antiseptics versus a novel strain of Influenza H1N1
V. Dzyakanava1, K. Burningham1, J. Stahl2
1
Bozeman, MT (USA), 2Saint Paul, MN (USA)
56.003
Risk factors and clinical outcomes of multidrug-resistant
Acinetobacter baumannii bacteremia in a University Hospital, Thailand
S. Anunnatsiri, P. Tonsawan
Khon Kaen (Thailand)
56.004
Assessment of health care workers occupational exposure to HIV and
post-exposure prophylaxis (PEP) in health centers and hospitals of
Addis Ababa, Ethiopia
T. Alemayehu
56.005
Healthcare workers compliance to infection control practices in the
haemodialysis unit in Sungai Buloh Hospital Malaysia
G. Chua1, A. Adnan2, Z. Abdul Wahab1
1
Sungai Buloh (Malaysia), 2Shah Alam (Malaysia)
56.006
Prevalence of nosocomial sinusitis in ICUs admitted patients in
Rasool Hospital, Tehran, Iran
S. Noorbakhsh, M. Barati, J. Mousavi, A. Tabatabaei
56.007
Aspects of needlestick injuries among medical students: Reported or not?
H. J. Salzer1, H. Langmann1, F. Stigler2, M. Sprenger1, M. Hoenigl1
1
Graz (Austria), 2Ferney-Voltaire (France)
56.008
Factors associated with septic shock in patients with hematological malignancies
and Pseudomonas infections
R. Jeddi, H. Ghédira, R. Ben Amor, A. Turki, L. Aissaoui, K. Kacem, W. Bouteraa,
Y. Ben Abdennebi, R. Ben Lakhal, H. Ben Abid, Z. Bel Hadjali, B. Meddeb
Tunis (Tunisia)
Final Program ~ 131
March 11, 2010
56.002
•
Clinical, radiological and microbiological corroboration to assess the role of
endotracheal aspirate in diagnosing ventilator-associated pneumonia in an
intensive care unit of a tertiary care hospital, India
C. Mukhopadhyay, S. Krishna, A. Shenoy, K. Prakashini
Manipal (India)
THURSDAY
56.001
Session 56
Hyatt Regency Miami
12:30–13:30
56.009
Initiatives to decrease the incidence and transmission of Clostridium difficile
(C. difficile)
J. Murillo, V. Heitzer, M. Ruiz, F. Ordieres
Miami, FL (USA)
56.010
Initiatives to decrease the incidence of methicillin-resistant
Staphylococcus aureus (MRSA)
J. Murillo, V. Heitzer, M. Ruiz, F. Ordieres
Miami, FL (USA)
56.011
Failure of dry mist of hydrogen peroxide 5% to kill Mycobacterium tuberculosis
B. M. Andersen, G. Syversen, H. Thoresen, M. Rasch, K. Hochlin, B. Seljordslia,
I. Snevold, J. Berg
Oslo (Norway)
56.012
Outbreak of methicillin-sensitive Staphylococcus aureus joint infections
associated with magnetic resonance arthrograms performed at a single outpatient
radiology center, Los Angeles County, California, USA, 2009
M. Kim, C. Tyson, L. Mascola
Los Angeles, CA (USA)
56.013
Predictors of mortality in neutropenic patients with septic shock
R. Jeddi, H. Ghédira, R. Ben Amor, L. Aissaoui, W. Bouteraa, Y. Ben Abdennebi,
K. Kacem, R. Ben Lakhal, A. Turki, H. Ben Abid, Z. belhadjali, B. Meddeb
Tunis (Tunisia)
56.014
Incidence of nosocomial respiratory tract infection in pediatric intensive care
unit of University Hospital Center (UHC) of Tirana
I. Kasmi, G. Kasmi, S. Sallabanda, E. Kola, F. Zavalani, R. Llukaj, I. Bakalli,
A. Koja, E. Celaj, K. Marku
Tirana, AL (Albania)
56.015
Clinical chracteristics and prognostic factors in patients with
Stenotrophomonas maltophilia bacteremia
Y. Nukui, S. Hatakeyama, Y. Shintani, H. Yotsuyanagi, K. Moriya, K. Koike
Tokyo (Japan)
56.016
Prevalence of mecA, aap genes and slime layer formation and its association
with antibiotic resistance in isolated Staphylococcus epidermidis of TUMS
hospitals health care staffs
M. R. Pourmand, Z. Abdossamadi, M. H. Salari
THURSDAY
•
March 11, 2010
132 ~ Final Program
Session 56
Hyatt Regency Miami
12:30–13:30
Central line associated bloodstream infection rates, extra length of stay, extra
mortality and microbiological profile in a German tertiary intensive care unit:
findings of the International Nosocomial Infection Control Consortium.
A. W. Friedrich1, R. Köck1, C. Goeters1, K. Becker1, K. Pohl1, V. Rosenthal2
1
Munster (Germany), 2Buenos Aires (Argentina)
56.019
Impact of outcome surveillance on ventilator associated pneumonia rates in
3 intensive care units from 2 Mexican cities: findings of the International
Nosocomial Infection Control Consortium (INICC)
M. Sobreyra Oropeza1, V. Rosenthal2, H. Torres Hernández3, A. Chávez Gómez3,
J. Rivera Morales3, J. E. Valero Rodríguez3
1
Mexico City (Mexico), 2Buenos Aires (Argentina), 3Irapuato (Mexico)
56.020
Expectations and perceptions of Nigerian patients regarding infectious diseases
in dentistry
C. Azodo, A. Umoh, H. Oboro
Benin City (Nigeria)
56.021
Nosocomial infections in a pediatric hospital in Santo Domingo,
Dominican Republic
C. S. Mota
56.022
Predominance of diarrhoeagenic E.coli in hospital acquired diarrhoea in a
case-controlled study in a tertiary care hospital in North India
N. Taneja, B. K. Chandra, G. Singh, S. pahil, M. Sharma, S. Singhi
Chandigarh (India)
Final Program ~ 133
March 11, 2010
56.018
•
Central line associated bloodstream infection rates in 166 intensive care units
of 54 cities in 23 developing countries: findings of the International Nosocomial
Infection Control Consortium (INICC)
V. Rosenthal1, C. Álvarez Moreno2, A. Mehta3, H. Leblebicioglu4,
E. A. Medeiros5, L. Raka6, B. Hu7, S. Jamulitrat8, I. A. Khader9,
M. G. Miranda Novales10, Y. Hussain11, R. Fernández Hidalgo12, S. S. Kanj13,
Á. Villacres14, J. A. Navoa-Ng15, T. Mapp16, H. Guanche Garcell17, A. Barkat18,
V. Suljagic19, Z. Mitrev20, L. Dueñas21, L. Cuellar22, A. Hamdi23
1
Buenos Aires (Argentina), 2Bogotá (Colombia), 3Mumbai (India), 4Samsun (Turkey),
5
São Paulo (Brazil), 6Prishtina (Kosovo, Republic of (under UNSCR 1244/1999)),
7
Shanghai (China), 8Songkla (Thailand), 9Amman (Jordan), 10Mexico (Mexico),
11
Lahore (Pakistan), 12San Jose (Costa Rica), 13Beirut (Lebanon), 14Quito (Ecuador),
15
Quezon City (Philippines), 16Panama (Panama), 17La Habana (Cuba),
18
Rabat (Morocco), 19Belgrade (Serbia), 20Skopje (Macedonia), 21San Salvador
(El Salvador), 22Lima (Peru), 23Tunis (Tunisia)
THURSDAY
56.017
Session 56
Hyatt Regency Miami
12:30–13:30
THURSDAY
•
March 11, 2010
134 ~ Final Program
56.023
Nosocomial infections—5 years of prevalence studies in the Czech Republic
B. Cecetkova1, M. Girod Schreinerova2, M. Kolarova3, Z. Kancelova1,
R. Chlibek4, J. Jirous5, J. Kapek1, J. Kohoutova6, J. Kratochvilova3, V. Kurkova7,
E. Mickova4, M. Podzimkova1, V. Ryantova1, I. Sipova8, P. Totusek1
1
Prague (Czech Republic), 2Carlsbad (Czech Republic), 3Brno (Czech Republic),
4
Hradec Kralove (Czech Republic), 5Plzen (Czech Republic), 6Olomouc (Czech
Republic), 7Pisek (Czech Republic), 8Ceske Budejovice (Czech Republic)
56.024
Predicting health care associated infections (HAI) in a high incidence low cost
intensive care unit
G. George, S. Kumar, K. Sivagnanam, P. Srikanth
Chennai (India)
56.025
Gram negative bacillary catheter related blood stream infection in the era of
increased resistance
V. Kapoor, C. Engell, E. Bishburg
Newark, NJ (USA)
56.026
Device-associated infection rates, extra length of stay, extra mortality,
microorganism profile, and bacterial resistance in two ICUs from Cuba:
Findings of the international nosocomial infection control consortium (INICC)
V. Rosenthal1, H. Guanche Garcell2, O. Requejo Pino3, C. Morales Pérez3,
O. Delgado González3, D. Fernández González3
1
Buenos Aires (Argentina), 2La Habana (Cuba), 3Havana (Cuba)
56.027
Characterization of hospital-acquired infections in a University Hospital in
Colombia: January 2005–July 2009
J. G. Jiménez, J. K. Balparda, D. M. Castrillón, S. Y. Díaz, J. A. Echeverri,
C. Estrada, C. Lopera, M. M. Raigosa, L. V. Vásquez
Medellín (Colombia)
56.028
“Non Traditional” Extended Spectrum Beta-lactamase-producing Isolates at a
Community Hospital
R. Nog, K. Singaravelu, P. Dhaubhadel, A. Guddati, S. Upadhyay,
S. Mannheimer, C. Badshah, V. Sivapalan
New York, NY (USA)
56.029
Ventilator-associated pneumonia in HIV-infected ICU patients
L. Gino, H. Bagnulo
Session 56
Hyatt Regency Miami
12:30–13:30
Phenotipic and molecular characteristics of Clostridium difficile infections in a
tertiary-care center
R. Mendoza, A. Camacho, J. O. Herrera, J. E. Diaz, S. D. M. Aldrete,
A. L. Martinez, A. Hernandez, M. Bobadilla, A. Ponce de Leon, J. Sifuentes
56.032
Epidemiology of diarrhea due to Clostridium difficile in a tertiary general
hospital in San José, Costa Rica, from January to October, 2009
E. San-Gil, E. Avendano, N. Mora
56.033
Impact of pretransplant nutritional status and supplement on postoperative sepsis
in living donor liver transplantation
T. Kaido, F. Oike, Y. Ogura, A. Mori, S. Uemoto
Kyoto (Japan)
56.034
Multidrug-resistant Acinetobacter spp. bloodstream infections in a University
Hospital of Buenos Aires, Argentina: frequency and antimicrobial susceptibility
M. Zárate, L. Contardi, D. Cecchini, J. Smayevsky
56.035
Recovery rate of NTM from AFB smear-positive sputum specimens during the
pseudo-outbreak of mycobacterium species at a long-term care facility
Y.-W. Lee, K. A. Jun, S. Y. Shin
Jeju (Republic of Korea)
56.036
Clinical impact of Systemic Inflammatory Response Syndrome (SIRS) in patients
with bloodstream infection
K. A. Jun, S. Y. Shin
Jeju (Republic of Korea)
56.037
Risk factors for central venous catheter-related infections in cardiac unit of
tertiary care hospital in northern India
R. Kumar, B. KAJLA, D. kaur, G. S. wander
Ludhiana (India)
Final Program ~ 135
March 11, 2010
56.031
•
Implementation of a central line bundle to reduce central line associated
bacteremia at the intensive care unit
C. Alvarez, J. Pisapia, C. Rosello, M. Lira, M. Curone, G. Vidiella
THURSDAY
56.030
Session 56
Hyatt Regency Miami
12:30–13:30
THURSDAY
•
March 11, 2010
136 ~ Final Program
56.038
Success in stopping transmission of enterococci in a Brazilian public
teaching hospital
F. Rossini, R. Fagnani, M. Leichsenring, L. Cardoso, M. L. Moretti, P. Trabasso
Campinas (Brazil)
56.039
Pseudooutbreak of Cedecea lapagei bacteremia in emergency room
W. S. Choi, Y. K. Youn, Y. M. Jo, J. Y. Kim, M. J. Kim, W. J. Kim, H. J. Cheong,
J.-W. Sohn, J. Y. Song, D. W. Park
56.040
Development of subsequent bloodstream infections in patients with
positive catheter-drawn blood culture results and negative peripheral
blood culture results
K.-H. Park, S.-H. Kim, O.-H. Cho, Y. P. Chong, S.-O. Lee, S.-H. Choi,
Y. S. Kim, J. H. Woo
56.041
Prevalence and factors associated with hospital acquired infections in Kayunga
district hospital, central Uganda
R. Ankunda1, D. Musisi2, R. Tweheyo1, O. Namusisi1
1
Kampala (Uganda), 2Kayunga (Uganda)
56.042
Vancomycin-resistant enterococci cross-transmission among patients admitted to
public and private hospitals in central Brazil
M. A. Souza, A. O. Guilarde, M. Turchi, M. C. D. P. B. André, J. L. Cardoso,
S. A. S. Paiva, C. A. Kobayashi, C. X. Carvalho, G. S. Leal, A. Kipnis,
J. D. G. Vieira, L. J. A. Batista, A. L. Andrade
Goiania (Brazil)
56.043
Determinants of good adherence to hand hygiene among surgical
health care workers
C. Masuet Aumatell, M. Banque Navarro, I. Roman Romera, D. López Gallego,
A. J. Sanabria Uribe, A. Fité Gallego, J. M. Ramon Torrell
L’Hospitalet de Llobregat (Spain)
56.044
Effectiveness of copper contact surfaces in reducing the microbial burden (MB)
in the intensive care unit (ICU) of hospital del Cobre, Calama, Chile
V. Prado1, C. Durán1, M. Crestto2, A. Gutierrez2, P. Sapiain2, G. Flores2,
H. Fabres2, M. Schmidt3
1
Santiago (Chile), 2Calama (Chile), 3Charlestone, SC (USA)
56.045
An intervention to reduce the rate of Acinetobacter Hospital Acquired Infections
in an urban community teaching hospital
R. B. Hulette
Nashville, TN (USA)
Session 57
Hyatt Regency Miami
12:30–13:30
INFECTIOUS DISEASES SURVEILLANCE
Evaluation of Tanzania National Measles Surveillance System with laboratory
component, for 2006 and 2007
D. M. Kadigi
Dar Es Salaam (Tanzania, United Republic of)
57.003
The first needle and syringe exchange program in Iranian prisons
M. Shahbazi, M. Farnia, M. Keramati
57.004
Prevalence of urinary schistosomiasis in Offinso-South Municipality
in Ashanti Region-Ghana
D. Adu-Gyasi1, K. Kye-Amoah2, E. Sorvor2
1
Kintampo (Ghana), 2Maase-Offinso (Ghana)
57.005
Influenza-like illness among US pilgrims returning from the Hajj in the Kingdom
of Saudi Arabia compared to other US-bound Travelers: Data from the CDC
quarantine activity reporting system (QARS), 2006–2008
E. Yanni, A. Berro, P. Han, C. LAwson, N. Gallagher, K. Liske, P. Houck,
H. Lipman, G. Brunette, N. Marano, C. Brown
Atlanta, GA (USA)
57.006
Assessing burden and depth of hepatitis B infection within Asian Pacific islander
families in San Francisco
T. Vijayan, P. Zheng, C. Nguyen, M. Peters
San Francisco, CA (USA)
57.007
Serological typing improves the epidemiological surveillance of gonorrhoea
among men who have sex with men
S. Sylvan, J. Hedlund
Uppsala (Sweden)
57.008
Surveillance of human infections with Avian influenza in Guangzhou
during 1997–2006
P. Z. Qin, W. Ming, Y. Liu
GuangZhou (China)
Final Program ~ 137
March 11, 2010
57.002
•
Cytomegaloviris antibodies amongst immunocompromised (HIV) patients at
Lagos University Teaching Hospital (LUTH) Idi-Araba, Lagos
A. Akinbami
Lagos (Nigeria)
THURSDAY
57.001
Session 57
Hyatt Regency Miami
12:30–13:30
THURSDAY
•
March 11, 2010
138 ~ Final Program
57.009
Rapid analysis of known and unknown pathogens using a pan-microbial
detection microarray
J. Thissen, S. Gardner, K. McLoughlin, T. Slezak, C. Jaing
Livermore, CA (USA)
57.010
Indexing infectious disease information into a relational database for useful
queries on the World Wide Web
J. Brown
Tacoma, WA (USA)
57.011
Respiratory disease surveillance aboard Peruvian Navy Ships:
Detection of a pandemic influenza A (pH1N1) outbreak
D. Vera1, R. A. Hora1, V. Gonzaga1, J. Quispe1, J. M. Neyra1, M. Ramos1,
C. Loret de Mola1, P. Mote2, M. Fernández1, J. Montgomery1
1
Lima (Peru), 2Athens, GA (USA)
57.012
Population-based seroprevalence of hepatitis C virus infection in the South and
Southeast regions of Brazil
R. Moreira1, G. M. Figueiredo1, R. Ximenez2, U. Montarroyos2, C. Braga2,
M. R. Cardoso1, G. Coral3, F. Carrilho1, A. Stein3, Z. Marion3, A. Spina1,
A. Cardoso4, Y. Moriya5, A. Alves3, E. B. D. Correa4, M. Theme-Filha6,
D. Muzzillo5, A. C. Vidor4, C. V. Nogueira7, M. E. Pinto3, A. A. Barone1,
L. Ferreira5, L. Pereira2
1
São Paulo (Brazil), 2Recife (Brazil), 3Porto Alegre (Brazil), 4Florianópolis (Brazil),
5
Curitiba (Brazil), 6Rio de Janeiro (Brazil)
57.013
The European Centre for Disease Prevention and Control strengthening MedISys
as a tool to accelerate detection of threats to human health from communicable
diseases in the EU
J. Mantero1, A. Cox1, J. Linge2, E. van der Goot2, D. Coulombier1
1
Stockholm (Sweden), 2Ispra, Varese (Italy)
57.014
Changing trend of measles and rubella in Nepal: Is it time to introduce
rubella immunization?
S. P. Dumre1, S. Malla2, G. Shakya2, K. KC2, P. Ghimire2
1
Pathumthani (Thailand), 2Kathmandu (Nepal)
57.015
Influenza A activities in Shanghai, China during 2004 to 2009
L. Jiang, L.-W. Ju, X. Lv, J. Yang, Q. Shi, Y. Tan, H. Shen, Q.-W. Jiang
Shanghai (China)
Session 57
Hyatt Regency Miami
12:30–13:30
57.017
A survey of lymphatic filariasis using ICT test in Attapeu Province, Lao PDR
Y. Knight1, C. Chanthavisouk2, V. Nakhonesid-Fish2, K. Chindavongsa2,
E. Michael1, P. Aratchige 2
1
London (United Kingdom), 2Vientiane (People’s Democratic Republic of Lao)
57.018
Evaluation of bacterial meningitis Sentinel Surveillance Program (BMSSP)
introduced in 2007 in São Paulo state, Brazil
T. R. M. P. Carvalhanas, B. L. Liphaus, A. C. G. Pellini, A. L. F. Yu,
G. D. Freitas, A. F. Ribeiro
São Paulo (Brazil)
57.019
The proportion of influenza infections from severe acute respiratory infection
(SARI) cases in Indonesia 2008–2009
R. Ramadhany1, V. Setiawaty1, H. A. Wibowo1, D. Lokida2
1
Jakarta (Indonesia), 2Tangerang (Indonesia)
57.020
Ranking the burden of infectious diseases in Ontario, Canada
S. Ratnasingham, J. Kwong, N. Daneman, M. Campitelli, N. Crowcroft
Toronto, ON (Canada)
57.021
Burden of new swine-origin H1N1 influenza virus in a subtropical
region of Mexico
G. Ayora-Talavera, M. Betancourt-Cravioto, A. Quijano-Vivas,
M. R. Gonzalez-Losa
Merida (Mexico)
57.022
Measles, neonatal tetanus (NNT), pertussis, cerebrio-spinal meningitis
(CSM) and polio trends in Nigeria, 1994 to 2007
M. O. Akhimien
Abuja (Nigeria)
57.023
A two year surveillance for influenza and RSV using Real-time PCR among
children with acute respiratory infections in Kolkata reveals distinct seasonality
of infection
A. S. Agrawal, S. Chakrabarti, M. Chawla-Sarkar
Kolkata (India)
•
Serological survey on influenza A (H1, H3, H5 and H9) antibodies in human
populations in Shanghai, China in 2008 and 2009
L.-W. Ju, L. Jiang, Q. Shi, X. Lv, J. Yang, H. Shen, Y. Zhou, W. Zhu, Q.-W. Jiang
Shanghai (China)
THURSDAY
57.016
March 11, 2010
Final Program ~ 139
Session 57
Hyatt Regency Miami
12:30–13:30
THURSDAY
•
March 11, 2010
140 ~ Final Program
57.024
Sampling considerations for Flavivirus arthropod vectors in Western Canada—
Making sense at a data collection level
R. Waeckerlin, S. Cork
Calgary, AB (Canada)
57.025
Crossborder infectious disease surveillance in the Netherlands,
Germany and Belgium
C. Kara-Zaïtri1, H. ter Waarbeek2
1
Bradford (United Kingdom), 2Heerlen (Netherlands)
57.026
Realtime intelligence for infectious disease prevention and control
C. Kara-Zaïtri, R. Hamilton
Bradford (United Kingdom)
57.027
The implement of airport fever screening for dengue sentinel
in Taiwan, 2003–2008
M.-M. Kuan
57.028
Comparison of three time series models for predicting campylobacteriosis
risk in Georgia, Minnesota and Oregon
J. Weisent
Knoxville, TN (USA)
57.029
Anticipating the species jump: Surveillance for emerging viral threats
M. Flanagan
State College, PA (USA)
57.030
The making of a world atlas of infectious diseases
H. F. Wertheim1, P. Horby1, T. L. Viet1, T. N. T. Tanh1, J. WOODALL 2
1
Hanoi (Viet Nam), 2Brookline, MA (USA)
57.031
Pertussis in Latin America: Developing the tools to face the challenge ahead
F. Coronado1, M. Griffith1, M. L. Tondella1, M. Bonkosky1, M. Landaverde2,
T. Clark1
1
Atlanta, GA (USA), 2Washington, DC (USA)
57.032
Establishing the tuberculosis monitoring system at Brazil’s, Paraguay’s and
Argentina’s frontier
M. Lise1, J. R. P. D. Santos1, R. G. Abreu1, P. Colombana2, C. Martinez3,
D. Barreira1
1
Brasilia (Brazil), 2Misiones (Argentina), 3Asunción (Paraguay)
Session 57
Hyatt Regency Miami
12:30–13:30
57.034
Elimination of neglected diseases in Latin America and the Caribbean:
A mapping of selected diseases
M. C. Schneider1, X. P. Aguilera1, J. Barbosa da Silva Jr1, S. K. Ault1, P. Najera1,
J. Martinez1, R. Requejo1, R. S. Nicholls1, Z. Yadon1, J. C. Silva2, L. F. Leanes3,
M. Roses Periago1
1
Washington DC, DC (USA), 2Bogotá DC (Colombia), 3Rio de Janeiro (Brazil)
57.035
Warning System in Gaza Strip, post conflict 2009
F. Riccardo1, A. El Jaish2, Y. Shahin1, M. Maqadma2, M. R. Malik3, A. Pinto4,
G. Sabatinelli1
1
Amman (Jordan), 2Gaza City (Palestina), 3Cairo (Egypt), 4Bangkok (Thailand)
57.036
Prevalescent infections post hurricanes Hanna & Ike
S. Font
57.037
Sentinel surveillance of pandemic influenza A H1N1 in Kenya in the period
August–November 2009
R. Achilla, J. Majanja, M. Wadegu, W. Bulimo, D. Schnabel
Nairobi (Kenya)
57.038
Cholerae in the Americas region: An eradicated problem?
P. Ramon-Pardo1, G. de Cosio1, M. Tato2, J. Mckenney1
1
Washington, DC (USA), 2Madrid (Spain)
57.039
Evidence for influenza A virus infection among patients with respiratory tract
infections in Nigeria
D. Ehichioya1, R. Orenolu1, N. Gerloff2, S. De Landtsheer2, A. Nasidi3,
T. Harry3, C. Muller2, S. Omilabu1
1
Lagos (Nigeria), 2Luxembourg (Luxembourg), 3Abuja (Nigeria)
57.040
Relevance of infectious diseases in nephrology patients:
A retrospective single center review of twenty renal biopsies
C. Nguyen
Augusta, GA (USA)
57.041
The impact of socioeconomic factors on risk and frequency of hospitalization
for infectious diseases among teenagers in sub-sahara Africa
O. Udorji, C. Ude
Enugu (Nigeria)
•
Trends in pediatric bacterial meningitis in Sudan 2005–2006
M. H. Mahmoud, M. E. M. Alkarsani
Khartoum (Sudan)
THURSDAY
57.033
March 11, 2010
Final Program ~ 141
Session 58
Hyatt Regency Miami
12:30–13:30
THURSDAY
•
March 11, 2010
PARASITES
142 ~ Final Program
58.001
Seroprevalence of Toxoplasma gondii antibodies amongst pregnant women at
Lagos State University Teaching Hospital
A. Akinbami
Lagos (Nigeria)
58.002
Atypical neuroimaging of neurocystercercosis
L. D. Wilke, J. Farrell
Peoria, IL (USA)
58.003
Detection of Toxoplasma gondii antibody for diagnosis of ocular toxoplasmosis
F. Maleki, S. Sarafpoor
58.004
Two-dimensional gel electrophoresis analysis of T. solium cysticerci lower
molecular mass (10–30 kDa) antigens for the serodiagnosis of neurocysticercosis
in children
V. S. R. Atluri, P. D. Singhi, N. Khandelwal, N. Malla
Chandigarh (India)
58.005
Prevalence of intestinal parasitic infections in the Ministry of Health Hospitals in
Sharjah, UAE: 2-year retrospective study
N. Dash, H. Al-Jesmi, M. AL-Zarouni, D. Panigrahi
Sharjah (United Arab Emirates)
58.006
A study of medically important fish—transmitted parasites in Alexandria
R. M. G. Diab, M. M. El Temsahy, E. D. ElKerdany, M. Gaafar, M. A. Nasr
Alexandria (Egypt)
58.007
Study of the clinical efficiency of covariumtm10 on patients suffering from
intestinal amoebiasis
M. N. Emmanuel
Yaoundé (Cameroon)
58.008
Anisakis simplex from the Adriatic sea
I. Zurak
Zagreb (Croatia)
58.009
Evaluation of OSOM Trichomonas rapid test for diagnosis of Trichomonas
vaginalis infection in females
F. Shujatullah, H. M. Khan, R. Khatoon, T. Rabbani, M. Shahid, A. Raza
Aligarh (India)
Session 58
Hyatt Regency Miami
12:30–13:30
PARASITES
Can cystic Echinococcosis trigger autoimmunity?
M. Aslan, Y. A. Oner, S. Saribas, E. Polat1, H. Cakan, P. Yuksel, K. Zengin,
S. Arikan, M. M. Torun, B. Kocazeybek
Istanbul (Turkey)
58.012
Prevalence of intestinal parasitoses and factors related in the population infant of
the community Santa Bárbara, Municipality Valley Guanape, State Anzoategui,
Bolivarian Republic of Venezuela
R. Martínez
Ciudad Habana (Cuba)
58.013
Efficacy and safety of ivermectin versus high dose albendazole for chronic
strongyloidiasis in immunocompromised patients
Y. Suputtamongkol, K. Bhumimuang, D. Waywa, S. Nilganuwong,
N. Premasathian, A. Karuphong, T. Anekthananon, D. Wanachiwanawin,
S. Silpasakorn
Bangkok (Thailand)
58.014
Biochemical and immunological characterization of the EhCBP30 protein from
Entamoeba histolytica
C. González, A. Carabarin, L. Baylon-Pacheco, J. L. Rosales-Encina
México (Mexico)
58.015
Soil-transmitted helminthiasis in rural South West China:
Prevalence, intensity and risk factor analysis
L. Mofid, Q. Bickle
58.016
Hymenolepiasis in institutionalized Romanian children
T. R. Olariu, G. Darabus, I. Marincu, C. Balutescu, V. Dumitrascu,
C. Petrescu, A. Koreck
Timisoara (Romania)
58.017
Computational characterization of molecular mechanism of surface receptor
binding with alpha-enolase of Trichomonas vaginalis
S. Dwivedi1, S. Mishra2, N. Husain1, N. Malla3
1
Lucknow (India), 2Moradabad, UP (India), 3Chandigarh (India)
Final Program ~ 143
March 11, 2010
58.011
•
Giardia intestinalis: DNA extraction approaches to improve PCR results
Z. Babaei, E. Razmjou, H. Oormazdi, S. Rezaie, M. Rezaeian
THURSDAY
58.010
Session 58
Hyatt Regency Miami
12:30–13:30
THURSDAY
•
March 11, 2010
PARASITES
144 ~ Final Program
58.018
Prevalence of Dientamoeba fragilis among asymptomatic individuals from
North Central Venezuela
S. Jimenez1, J. Cortez1, M. Diaz1, C. Duran2, G. Hidalgo2, W. Aguilera2,
S. Nakal2, C. Albano2, R. N. Incani1, A. Rodriguez-Morales2
1
Valencia (Venezuela), 2Caracas (Venezuela)
58.019
Risk factors in patients with trichinellosis from Western Romania
I. Marincu, L. Negrutiu, A. M. Neghina, I. Iacobiciu, R. Neghina
Timisoara (Romania)
58.020
The prevalence of giardiasis in patients with acute enterocolitis from
Timis County, Romania
I. Marincu, L. Negrutiu, I. Iacobiciu, A. M. Neghina, R. Neghina
Timisoara (Romania)
58.021
Immunological changes in children with giardiasis
T. R. Olariu, V. Dumitrascu, I. Marincu, C. Petrescu, A. Koreck
Timisoara (Romania)
58.022
IgG antibodies relative avidity as a phase-specific diagnosis for toxocariasis in
populations of Venezuela
O. Delgado, J. Ortegoza, V. Coraspe, M. A. Rivas, S. Silvia, C. Duran, Y. Pascual,
A. Rodriguez-Morales
Caracas (Venezuela)
58.023
Characterization of proteins of excretion/secretion (ES) of nematode parasite
Mammomonogamus laryngeus
M. I. Giraldo, J. C. Castaño
Armenia, Quindio (Colombia)
58.024
Fibronectin increases the adherence of Taenia solium oncosphere in CHO–K1
cells in vitro
S. Palma1, N. Chile1, J. Evangelista1, Y. Arana1, M. Verastegui1, R. H. Gilman2
1
Lima (Peru), 2Baltimore, MD (USA)
58.025
Ectopic knee tungiasis and historical aspects in Peru
V. Maco, V. Maco C., E. Gotuzzo
Lima (Peru)
Session 58
Hyatt Regency Miami
12:30–13:30
PARASITES
A Portuguese couple with eosinophilia: From the diagnosis to the treatment
C. Abreu, S. Xerinda, A. Sarmento
Porto (Portugal)
58.028
Role of serology, neuroimaging and stool examination in diagnosis of
neurocysticercosis
K. Sapkota1, K. Sapkota2, S. P. Dumre3, K. Malla4, S. Singh4
1
Myagdi (Nepal), 2Las Cruces, NM (USA), 3Pathumthani (Thailand),
4
Pokhara (Nepal)
58.029
Ixodes persulcatus tick salivary gland extract (SGE) inhibits IL-4 and
IFN-γ secretion and CD69 expression by mitogen-stimulated murine splenocytes
V. Firstova1, S. Biketov1, E. Zyrina1, A. Shtannikov1, I. Vasiljeva2
1
Obolensk (Russian Federation), 2Moscow (Russian Federation)
58.030
Seroprevalence of toxocariasis in hypereosinophilic individuals in Ahwaz city
S. Maraghi
Ahwaz (Islamic Republic of Iran)
58.031
Immunogenicity of the recombinant ASP1r protein of A. caninum in a
murine model
M. I. Giraldo, J. C. Castaño Osorio
Armenia, Quindio (Colombia)
58.032
Prevalence of intestinal parasites in urban, rural and commercial farming
communities in Zimbabwe
S. Mtapuri-Zinyowera
Harare (Zimbabwe)
Final Program ~ 145
March 11, 2010
58.027
•
Blastocystis hominis infection among patients with and without
gastrointestinal disorders
M. Rostami Nejad, E. Nazemalhosseini Mojarad, H. Dabiri, M. R. Zali
THURSDAY
58.026
Session 59
Hyatt Regency Miami
12:30–13:30
THURSDAY
•
March 11, 2010
TUBERCULOSIS: DIAGNOSIS, TREATMENT & DRUG RESISTANCE
146 ~ Final Program
59.001
Beijing genotype and other predominant Mycobacterium tuberculosis
spoligotypes observed in Mashhad City, Iran
M. Rohani1, P. Farnia2, M. Torfeh1
1
Kashan (Islamic Republic of Iran), 2Tehran (Islamic Republic of Iran)
59.002
Integrating TB screening tool improved TB screening in HIV Patients in TASO
S. Okoboi
Tororo (Uganda)
59.003
A case report: Cutaneous tuberculosis presenting as chronic thoracic
chest wall fistula
H. Afsali, M. Momen Heravi
59.004
Use of Imunotest (tuberculin skin test) for early detection of pulmonary
tuberculosis among health workers in a private hospital, 2008, Lima, Peru
S. Manga
Lima (Peru)
59.005
Predictive value and cut off point of PPD in probable patients with
pulmonary tuberculosis
M. Sofian1, L. Moini1, S. Farahani1, A. Rostampour1, H. Khalili1,
A. Aghakhani2, M. Banifazl2, A. Ramezani2
1
Arak (Islamic Republic of Iran), 2Tehran (Islamic Republic of Iran)
59.006
Challenges in the case detection of sputum smear-positive tuberculosis
in Rwanda: A low-resource setting
C. Muvunyi
Butare (Rwanda)
59.007
Predictive factors for the indeterminate result on the QuantiFERON-TB Gold
In-Tube test
S. H. Han, B. S. Chin, H. Choi, S. Y. Shin, Y. T. Chae, S. J. Jin, J.-H. Baek,
C. O. Kim, J. Y. Choi, Y. G. Song, J. M. Kim
59.008
A retrospective study to assess treatment outcomes among TB patients taking
DOTS treatment in South India
P. Narasimhan1, R. Peter2, A. Manoharan2, J. Wood1, R. MacIntyre1,
D. Mathai2, K. John2
1
Sydney (Australia), 2Vellore (India)
59.009
Population-based investigation on molecular characterization of Fluoroquinolones
resistance of Mycobacterium tuberculosis in rural area of eastern China
B. Xu, Y. Hu, W. Jiang, W. Wang
Shanghai (China)
Session 59
Hyatt Regency Miami
12:30–13:30
59.011
Geneticdiversity and population structure of M.tuberculosis strains circulating
in Central Russia
I. Shemyakin, V. N. Stepanshina
Obolensk (Russian Federation)
59.012
Evaluation of IS6110 PCR, BACTEC and conventional methods in rapid
diagnosis of extra pulmonary tuberculosis cases attending two tertiary care
hospitals in North India
A. K. Maurya, V. Nag, S. Kant, R. A. S. Kushwaha, M. K. Rana,
W. Rahman, T. Dhole
Lucknow (India)
59.013
Diagnosis of latent tuberculosis infection by using the QuantiFERON-TB
Gold in-tube test in children whose household contact has contagious
pulmonary tuberculosis disease
T. Lee, N. Kim, J. Kim
Seongnam (Republic of Korea)
59.014
Clinical and epidemiological features of tuberculous meningitis
M. E. Ferreira, N. E. Frassone
Córdoba (Argentina)
59.015
Serum proteins in patients with pulmonary tuberculosis and controls in Nigeria
M. Garbati1, A. Danburam2, H. Yusuph3, D. Mshelia4
1
Riyadh, Riyadh (Saudi Arabia), 2Yola (Nigeria), 3Maiduguri (Peru),
4
Maidugiri (Nigeria)
59.016
High ethionamide resistance in Mycobacterium tuberculosis strains
isolated in Kenya
V. Asiko
Nairobi (Kenya)
59.017
Pulmonary TB among elderly patients: Higher rates, difficulties for diagnosis and
poorer prognosis
L. P. Cruz Hervert, R. A. Baez-Saldaña, L. D. Ferreyra-Reyes,
E. E. Ferreira-Guerrero, B. Cano-Arellano, L. Juarez-Sandino,
M. D. L. García-García
Cuernavaca, Morelos (Mexico)
•
Usefulness of PCR in the differential diagnosis of tuberculosis in paraffin
embedded tissues
S. Montenegro, C. Delgado, S. Pineda, M. Pinilla, D. Guinez, M. Garrido,
C. Cabezas, F. Mucientes
Concepcion (Chile)
THURSDAY
59.010
March 11, 2010
Final Program ~ 147
Session 59
Hyatt Regency Miami
12:30–13:30
THURSDAY
•
March 11, 2010
148 ~ Final Program
59.018
Pleural effusion of patients with tuberculosis is characterized by accumulation
of γδ T lymphocytes that expresses distinct surface markers
L. H. Okamura, D. A. Oliveira, R. F. S. Moreira, F. Figueroa, J. B. Afiune,
L. F. R. Medici, F. A. F. Melo, M. Rivero, D. Rodrigues
São Paulo (Brazil)
59.019
Diagnostics of resistance mycobacterium tuberculosis (MR MT) to isoniazid (H)
and rifampicin (R) by simultaneous identification of mutations in rpoB, katG,
inhA and ahpC genes with use biological microchips (TB-biochip).
V. Zhuravlev
St.Petersburg (Russian Federation)
59.020
Fast identification of Mycobacteria from positive Mb/Bact bottles using a
multiplex PCR
E. P. A. Bensi, C. E. Levy, M. Ramos, P. C. Panunto
Campinas, SP (Brazil)
59.021
Identification and treatment of latent tuberculosis infection in haemodialysis
patients in New Zealand
A. Verrall, M. Leikis, J. Hildreth, N. Raymond, T. Blackmore
Wellington (New Zealand)
59.022
The role of a whole blood interferon-γ releasing assay for the tracing of
tuberculosis infection in bacilli Calmette Guerin vaccinated children
J.-K. Chun, E. Soon, H. M. Kim
Wonju (Republic of Korea)
59.023
An unusual case of esophageal tuberculosis in immunocompetent female patient
H. F. Brito, R. F. Arbex, C. M. S. Messina, M. H. Froes, J. B. Afiune,
C. M. F. Paradela, F. A. F. Melo, D. Rodrigues
São Paulo (Brazil)
59.024
Pott’s Spine in a 3-year-old child
N. Bhumbra, R. Arrouk
Toledo, OH (USA)
59.025
Status of HIV/TB co-infection in Cuba and strategies followed in the
health care of patients with active tuberculosis and AIDS in the Institute of
Tropical Medicine “Pedro Kourí”
M. Diaz Jidy
La Lisa (Cuba)
Meet-the-Expert
Hyatt Regency Miami
07:45–08:45
MEET-THE-EXPERT
Antiviral prophylaxis in transplant recipients
S. Mossad
Cleveland, OH (USA)
Meet-the-Expert
Hyatt Regency Miami
07:45–08:45
MEET-THE-EXPERT
Integration of informal information into disease surveillance
M. Pollack
New York, NY (USA)
FRIDAY
•
March 12, 2010
Final Program ~ 149
Session 60
CME
Hyatt Regency Miami
09:00–09:45
Plenary
FRIDAY
•
March 12, 2010
PLENARY LECTURE VII
150 ~ Final Program
Chair:
Jonathan COHEN, United Kingdom
60.001
Pneumococcal infection and colonization in children and its impact on
pneumococcal disease in adults
K. Klugman
Atlanta, GA (USA)
Session 61
CME
Hyatt Regency Miami
10:15–12:15
Symposium
ANTIMICROBIAL STEWARDSHIP: CHALLENGES AND STRATEGIES FOR THE 21ST CENTURY
Co-Chairs:
Daniel CURCIO, Argentina
Memish ZIAD, Saudi Arabia
61.001
Extreme drug resistance in nosocomial pathogens
F. Pasteran
61.002
Basic principles of implementing an antibiotic optimization program
J. Cortes
Bogotá (Colombia)
61.003
Infection control program as an additional tool to control bacterial resistance
P. Cornejo
61.004
New antibiotics: Which role in a antimicrobial stewardship program?
D. Curcio
Pfizer
FRIDAY
•
March 12, 2010
Final Program ~ 151
Session 62
CME
Hyatt Regency Miami
10:15–12:15
Symposium
FRIDAY
•
March 12, 2010
CURRENT CHALLENGES IN HIV CARE
152 ~ Final Program
Co-Chairs:
Pedro CAHN, Argentina
Maximo BRITO, USA
62.001
State of the art on ARV therapy: How many standards of care?
P. Cahn
62.002
Drug resistance and other laboratory monitoring assays in HIV infection
M. Hirsch
Boston, MA (USA)
62.003
Opportunistic infections and IRIS in the era of HAART
J. Miro
Barcelona (Spain)
62.004
Why are patients dying in the HAART era?
E. Katabira
Kampala (Uganda)
Session 63
CME
Hyatt Regency Miami
10:15–12:15
Symposium
BIOMARKERS IN INFECTIOUS DISEASES
Co-Chairs:
Jonathan COHEN, United Kingdom
Timothy BREWER, Canada
63.001
Clinical use of biomarkers in the diagnosis and management of CAP
P. Ramirez
Valencia (Spain)
63.002
Biomarkers for sepsis
S. LaRosa
Providence, RI (USA)
63.003
Biomarkers for the diagnosis of TB
J. Friedland
63.004
Clinical utility of biomarkers in fungal infection
T. Patterson
San Antonio, TX (USA)
FRIDAY
•
March 12, 2010
Final Program ~ 153
Session 64
CME
Hyatt Regency Miami
10:15–12:15
Symposium
FRIDAY
•
March 12, 2010
BURDEN OF PLASMODIUM VIVAX MALARIA IN LATIN AMERICA
154 ~ Final Program
Co-Chairs:
Jaime TORRES, Venezuela
Keith CARTER, USA
64.001
Epidemiology of P. vivax malaria in the world and Latin America
A. J. Rodriguez-Morales
Caracas (Venezuela)
64.002
Molecular epidemiology of P. vivax: tools for malaria control
A. Escalante
Tempe, AZ (USA)
64.003
Severe and complicated Malaria due to P. vivax
J. Murillo
Miami, FL (USA)
64.004
Treatment, prophylaxis and resistance in P. vivax malaria
J. Torres
Caracas (Venezuela)
Session 65
Hyatt Regency Miami
10:15–12:15
Oral Presentations
INFLUENZA
Mixed infection of influenza A viruses is common
Y. Furuse, A. Suzuki, N. Nukiwa, N. Fuji, H. Oshitani
Sendai (Japan)
65.002
Influenza vaccine delivery to adolescents: Assessment of two
multicomponent interventions
L. M. Gargano1, K. Pazol1, J. E. Painter1, J. M. Sales1, D. Murray2, C. Morfaw2,
L. M. Jones1, P. Weiss1, W. A. Orenstein3, R. J. DiClemente1, J. M. Hughes1
1
Atlanta, GA (USA), 2Augusta, GA (USA), 3Seattle, WA (USA)
65.003
A randomized intervention trial of mask use and hand hygiene to reduce
seasonal influenza-like illness and influenza infections among young adults in a
university setting
A. E. Aiello1, R. M. Coulborn1, V. Perez1, B. M. Davis1, M. Uddin1, G. F. Murray2,
D. K. Shay3, S. H. Waterman3, A. S. Monto1
1
Ann Arbor, MI (USA), 2Mobile, AL (USA), 3Atlanta, GA (USA)
65.004
Population-based surveillance for 2009 pandemic influenza A H1N1 Virus in
Guatemala, 2009
W. Arvelo1, L. Reyes2, A. Estevez2, J. Gray2, S. Lindstrom1, A. Fry1, S. Olsen1,
F. Ardon2, G. Frenkel2, B. Gordillo2, K. Lindblade1
1
Atlanta, GA (USA), 2Guatemala City (Guatemala)
65.005
Adjuvanted influenza vaccines and their potential role for vaccination
of travelers
T. Tsai1, N. Groth2, M. Pellegrini2, D. O’Hagan1, A. Hilbert3
1
Cambridge, MA (USA), 2Siena (Italy), 3Marburg (Germany)
65.006
Seasonal influenza vaccine may be associated with increased risk of
illness due to the 2009 pandemic A/H1N1 virus
D. M. Skowronski1, G. De Serres2, N. Crowcroft3, N. Janjua1, N. Boulianne2,
T. S. Hottes1, L. C. Rosella3, J. A. Dickinson4, G. Rodica2, P. Sethi3,
N. Ouhoummane2, D. J. Willison3, I. Rouleau2, K. Fonseca5, S. J. Drews5,
A. Rebbapragada3, H. Charest6, M.-E. Hamelin6, G. Boivin6, J. Gardy1, Y. Li7,
P. Martin 1
1
Vancouver, BC (Canada), 2Québec, QC (Canada), 3Toronto, ON (Canada),
4
Alberta, AB (Canada), 5Calgary, AB (Canada), 6Quebec, QC (Canada),
7
Winipeg, MB (Canada)
Final Program ~ 155
March 12, 2010
65.001
•
Theodore TSAI, USA
David MORENS, USA
FRIDAY
Co-Chairs:
Session 65
Hyatt Regency Miami
10:15–12:15
Oral Presentations
FRIDAY
•
March 12, 2010
INFLUENZA
156 ~ Final Program
65.007
Monitoring for avian influenza in wild birds on the Far East in 2008
S. Sayfutdinova1, J. Runstadler2, M. Kulak1, M. Sivay1
1
Koltsovo (Russian Federation), 2Fairbanks, AK (USA)
65.008
Influenza surveillance contributions from South and Southeast Asia
R. Jarman, K. S. A. Myint, S. Shrestha, J. Gaywee, J. M. Velasco, I.-K. Yoon,
D. Saunders, A. Timmermans, K. Ungchusak, T. Wongstitwilairoong,
C. J. Mason, R. V. Gibbons, J. A. Pavlin
Bangkok (Thailand)
65.009
H1N1 experience at the Institute for Infectious Diseases Emilio Ribas,
São Paulo, Brazil. The role of a travel clinic as sentinel for emerging diseases
J. Alves, C. E. Guarnieri, T. S. Chaves
São Paulo (Brazil)
65.010
Is a mass immunization program for pandemic (H1N1) 2009 good value for
the money? Early evidence from the Canadian experience
B. Sander1, C. Bauch2, R. A. Fowler1, D. Fisman1, J. Kwong1, A. McGeer1,
M. Zivkovic Gojovic1, M. Krahn1
1
Toronto, ON (Canada), 2Guelph, ON (Canada)
65.011
Rapid real-time surveillance and monitoring of pandemic influenza associated
pneumonia and risk factors using primary care electronic medical records (EMR)
T. Wong, J. G. Mercer, S. Mukhi, S. Totten, K. El Eman, G. Jayaraman, C. Babin,
R. Saginur, R. Kropp, R. Rodin, G. Garber
Ottawa, ON (Canada)
Session 66
CME
Hyatt Regency Miami
10:15–12:15
Symposium
MRSA: THE CLINICAL CHALLENGE
Co-Chairs:
Victor ROSENTHAL, Argentina
AW KARCHMER, USA
66.001
Systemic MRSA infections
E. Rubinstein
Winnipeg (Canada)
66.002
Treatment of severe MRSA infections: Beyond vancomycin
A. Karchmer
Boston, MA (USA)
66.003
The potential for a staphylococcal vaccine
O. Schneewind
Chicago, IL (USA)
66.004
MRSA in Latin America: Special considerations
M. Guzman-Blanco
Caracas (Venezuela)
Pfizer
FRIDAY
•
March 12, 2010
Final Program ~ 157
Cultural Lecture
Hyatt Regency Miami
12:30–14:15
Cultural Lecture
CULTURAL LECTURE
FRIDAY
•
March 12, 2010
158 ~ Final Program
Illness and death of Enrico Caruso, a Neapolitan tenor in the Americas
G. Cornaglia
Siena (Italy)
Session 67
CME
Hyatt Regency Miami
14:30–15:15
Plenary
PLENARY LECTURE VIII
Chair:
Keith KLUGMAN, USA
67.001
Microbial chemical ecology and the future of antibiotics
R. Kolter
Boston, MA (USA)
FRIDAY
•
March 12, 2010
Final Program ~ 159
Session 68
CME
Hyatt Regency Miami
15:45–17:45
Symposium
FRIDAY
•
March 12, 2010
TUBERCULOSIS: TOOLS FOR THE FUTURE
160 ~ Final Program
Co-Chairs:
Timothy BREWER, Canada
Rajesh GHOKALE, India
68.001
Unlocking the mycobacterial cell wall: Insights into virulence, biosynthetic
pathways and systems-based approach to drug discovery
R. Gokhale
Delhi (India)
68.002
Diagnosing drug resistance in low-resource settings: Practical approaches
A. Umubyeyi Nyaruhirira
Corunna (Rwanda)
68.003
Applicable insights from pharmacokinetic and pharmacodynamic modeling of
antituberculosis chemotherapy
E. Nuermberger
Baltimore, MD (USA)
68.004
Addressing latent tuberculosis in areas with high tuberculosis burden:
Implications for control
M. Conde
Session 69
CME
Hyatt Regency Miami
15:45–17:45
Symposium
UPDATE ON INFECTIONS IN TRANSPLANT RECIPIENTS
Co-Chairs:
Sherif MOSSAD, USA
Hans HIRSCH, Switzerland
69.001
Tropical infections in solid organ transplant recipients
J. Cuellar
Bethesda, MD (USA)
69.002
Polyoma virus infection, replication, and disease after kidney transplantation
H. Hirsch
Basel (Switzerland)
69.003
Respiratory viral infections in hematopoietic stem cell transplant recipients
R. Chemaly
Houston, TX (USA)
69.004
Prevention of cytomegalovirus infection after hematopoietic stem cell
transplantation: Preemptive therapy versus universal prophylaxis
S. Mossad
Cleveland, OH (USA)
FRIDAY
•
March 12, 2010
Final Program ~ 161
Session 70
CME
Hyatt Regency Miami
15:45–17:45
Symposium
FRIDAY
•
March 12, 2010
INTERNATIONAL PERSPECTIVES ON INFECTION CONTROL
162 ~ Final Program
Co-Chairs:
Richard WENZEL, USA
Sergio WEY, Brazil
70.001
Engaging nations in a commitment to infection control
D. Pittet
70.002
International controversies: Bare below the elbow and the incremental value
of MRSA screening
M. Edmond
Richmond, VA (USA)
70.003
With limited resources: How to begin and how to sustain an
infection control program
S. Wey
São Paulo (Brazil)
70.004
The future hospital epidemiologist’s portfolio for success
R. Wenzel
Richmond, VA (USA)
Session 71
CME
Hyatt Regency Miami
15:45–17:45
Symposium
BACTERIAL MENINGITIS: PREVENTION AND CURE
Co-Chairs:
Heikki PELTOLA, Finland
Andre LOMAR, Brazil
71.001
The global impact of bacterial meningitis
P. Heath
71.002
Pathophysiology of bacterial meningitis
R. Nau
Göttingen (Germany)
71.003
Vaccination against bacterial meningitis
H. Peltola
Helsinki (Finland)
71.004
Effective adjuvant therapies for meningitis
S. Singhi
Chandigarh (India)
FRIDAY
•
March 12, 2010
Final Program ~ 163
Session 72
Hyatt Regency Miami
15:45–17:45
Oral Presentations
FRIDAY
•
March 12, 2010
PARASITOLOGY
164 ~ Final Program
Co-Chairs:
Eskild PETERSEN, Denmark
Ruben Santiago NICHOLLS, USA
72.001
One year impact of a single dose of Praziquantel in five schistosomiasis endemic
districts in Rwanda
D. Mupfasoni1, E. Ruberanziza1, S. Jackson1, K. Blaise1, O. Mukabayire1,
M. Kabera1, M. Kramer1, J. Ruxin2
1
Kigali (Rwanda), 2New York, NY (USA)
72.002
A comparative study of Arco and Coartem in the treatment of uncomplicated
malaria in patients aged 4 months to 16 years attending Mulago hospital,
Kampala, Uganda
J. Rujumba, E. A. Mworozi, A. K. Maganda, R. Kiguba, B. Rwakimali, S. Nsobya
Kampala (Uganda)
72.003
The effect of malaria on the outcome of Lassa Fever
P. Okokhere, D. Asogun, S. A. Okogbenin
Irrua (Nigeria)
72.004
Clinical analysis and eco-epidemiology data of pediatric visceral leishmaniasis
(VL) in Argentina
S. Ruvinsky1, O. Salomon1, L. Arce2, D. Jozami3, J. Altcheh1, R. Cappellini1,
S. Lopez Papucci4, A. Riarte1, S. Gomez3, L. Borchichi2, R. Bologna1, P. Paulin1,
R. Pividori3, G. Moscatelli1, H. Freilij1, R. Chiabrando1, A. Gentile1, A. Aletti4,
A. Gajo Gane5, T. Orduna1
1
Buenos Aires (Argentina), 2Posadas (Argentina), 3Santiago del Estero (Argentina),
4
Rosario (Argentina), 5Corrientes (Argentina)
72.005
Novel molecular detection of drug resistance markers in Plasmodium falciparum
from Papua New Guinean children with uncomplicated malaria
R. Wong1, H. Karunajeewa1, I. Mueller2, P. Siba2, E. P. Carnevale3,
P. Zimmerman3, T. M. E. Davis1
1
Perth, WA (Australia), 2Madang (Papua New Guinea), 3Cleveland, OH (USA)
72.006
Identification of intestinal parasites from naturally contaminated hands of people
living in low socio-economic areas of Dhaka, Bangladesh
M. K. Ijaz1, J. R. Rubino1, K. A. Talukder2, A. Nur-E-Kamal3
1
Montvale, NJ (USA), 2Mohakhali (Bangladesh), 3Brooklyn, NY (USA)
72.007
Training in fever case management and use of malaria rapid diagnostic testing
kits improved fever case management in Uganda
U. Ssekabira
Kampala (Uganda)
Session 73
Hyatt Regency Miami
12:30–13:30
ANIMAL MODELS, PATHOGENESIS & HOST DEFENSES
Antibacterial effects of Humulus lupulus L. extract on topical staphylococcal
infection in BALB/c Mice cornea
M. Hadipour Jahromy, S. Khakpour, M. Hadipour Jahromy, A. Najafi
73.002
Up regulation of IRF-2 in West Nile Virus infection: Implications for
establishment of viremia in the brain leading to encephalitis
K. L. Yeo, M. L. Ng
73.003
Crimean-Congo hemorrhagic fever virus infects human hepatocytes and
induces IL-8 secretion
R. Rodrigues, G. Paranhos-Baccala, C. Peyrefitte
Lyons (France)
73.004
The course of infection in respiratory infected chickens caused by avian
influenza virus A/H5N1
A. Sergeev, O. V. P’yankov, O. K. Demina, L. N. Shishkina, A. S. Safatov,
A. N. Sergeev,
I. G. Drozdov
73.005
Role of leukotrienes in resistance and susceptibility to infection by
Histoplasma capsulatum
A. Secatto1, E. M. Soares1, A. I. Medeiros2, L. H. Faccioli1
1
Ribeirão Preto, SP (Brazil), 2Araraquara (Brazil)
73.006
Different clinical isolates of Mycobacterium tuberculosis induced distinctive
pulmonary inflammation in mice
E. Soares1, C. M. Peres2, A. Secatto3, C. L. Silva4, L. H. Faccioli5
1
Ribeirao Preto, SP (Brazil), 2Bauru, SP (Brazil), 3Ribeirão Preto, SP (Brazil),
4
Ribeirao Preto (Brazil), 5Ribeirão Preto (Brazil)
73.007
Evaluation of the ferret as a model for influenza A/Brisbane/10/07 H3N2
J. Garver, K. Van Zandt, J. Rhone, G. Stark, J. Bigger
Columbus, OH (USA)
FRIDAY
73.008
Natural history study of a low dose HPAI (A/Vietnam/1203/04) infection in ferrets
J. Long, J. Edwards, A. Wasko, M. Gainey, P. Herr-Calomeni, G. Stark, J. Bigger
Columbus, OH (USA)
March 12, 2010
Final Program ~ 165
•
73.001
Session 73
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
ANIMAL MODELS, PATHOGENESIS & HOST DEFENSES
166 ~ Final Program
73.009
FcγR IIA polymorphism -131H/R and malaria severity in Ghanaian children
D. Amoako-Sakyi
Cape Coast (Ghana)
73.010
An animal model to study antimicrobial effects on community-acquired
methicillin-resistant Staphylococcus aureus infection
M. Ip, E. T. Y. Leung, C. Wong, K. To
Hong Kong (China)
73.011
Increased killing of liver NK cells by Fas/FasL and NKG2D/NKG2DL contributes
to hepatocyte necrosis in virus-induced liver failure
T. Chen, Y. Zou, M. Han, H. Wang, W. Yan, G. Song, Z. Wu, X. Wang,
C. Zhu, X. Luo, Q. Ning
Wuhan, Hubei (China)
73.012
CMV infection causing Adult Onset Still’s Disease: A clinical case
D. Bento, R. Leite, R. Tavares, A. MIranda, F. Ventura, C. Araújo, K. Mansinho
Lisbon (Portugal)
73.013
Telbivudine preserves Th1 cytokine response and down regulates PD-L1 in
MHV-3–induced viral hepatitis model
Z. Wu, W. Yan, W. Guo, Y. Zou, H. Wang, X. Wang, X. Yang, Y. Lu,
X. Luo, Q. Ning
Wuhan, Hubei (China)
73.014
Transcriptome profile of the human endothelial cell response to high- and
low-density infections of Candida albicans
P. P. Chong1, C. S. Y. Lim1, Y.-H. Tan1, H. F. Seow2, R. Rosli1
1
Selangor (Malaysia), 2Melbourne, Victoria (Australia)
73.015
Levels of pro-inflammatory cytokines and soluble cell adhesion molecules serves
as early markers for recognition of diseases severity in patients with dengue fever
and dengue hemorrhagic fever
M. Odreman, S. Vielma, C. Torres, L. Tellez, J. Mendoza, S. Perez, N. Mosqueda,
M. Muñoz, J. Muñoz, J. Goyo
Merida (Venezuela)
73.016
Cavia porcellus as a model for experimental infection by Trypanosoma cruzi
Y. Castro Sesquen1, R. H. Gilman2, M. Verastegui1, V. Yauri1, N. Angulo1,
D. E. Velasquez Portocarrero1, C. Bern3
1
Lima (Peru), 2Baltimore, MD (USA), 3Atlanta, AT (USA)
Session 74
Hyatt Regency Miami
12:30–13:30
ANTIBIOTIC RESISTANCE: GRAM-POSITIVE
A worldwide surveillance program studying the In Vitro Activity of Tigecycline
and 10 common therapeutic agents against methicillin-resistant Staphylococcus
aureus and Vancomycin-resistant Enterococcus species from 2004–2009
B. Johnson1, M. Renteria1, J. Johnson1, R. Badal1, S. Bouchillon1,
D. Hoban1, M. Dowzicky2
1
Schaumburg, IL (USA), 2Collegeville, PA (USA)
74.003
The survey of risk factors of multi drug resistant of E. faecalis isolated from
clinical samples
R. Moniri
74.004
The relationship between macrolide resistance in Streptococcus pneumoniae
and consumption of oral macrolides in Republic of Croatia and City of Zagreb
J. Vranes, J. Knezevic, B. Bedenic, D. Stimac, N. Jarza-Davila, M. Anusic
Zagreb (Croatia)
74.005
Blood culture isolates in a tertiary care hospital of Eastern Nepal:
Trends in antimicrobial resistance
B. Khanal, S. Shrestha, N. Gyawali
Dharan (Nepal)
74.006
Multicenter evaluation of tigecycline activity in Latin America:
Report from the SENTRY antimicrobial surveillance program (2009)
D. J. Farrell, H. Sader, S. D. Putnam, R. N. jones
North Liberty, IA (USA)
74.007
Genetic diversity of enterococci harboring high-level gentamicin resistance
genes aac(6’)-Ie-aph(2”)-Ia or aph(2”)-Ie in a Japanese hospital
N. Kobayashi1, S. Watanabe1, S. Nagashima1, D. Quinones2, N. Urushibara1
1
Sapporo, Hokkaido (Japan), 2Ciudad de La Habana (Cuba)
74.008
The expansion of ST80-SCCmec-IV clone of community-acquired
methicillin-resistant Staphylococcus aureus in Kuwait hospitals
E. Udo, E. Sarkhoo
Safat (Kuwait)
Final Program ~ 167
March 12, 2010
74.002
•
Prevalence of Vancomycin Intermediate Staphyloccus aureus (VISA) in a
tertiary care hospital in Eastern Nepal
B. Khanal, R. Baral, A. Acharya
Dharan (Nepal)
FRIDAY
74.001
Session 74
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
168 ~ Final Program
74.009
A novel multiplex real-time PCR assay for CA-MRSA: Rapid typing of SCCmec
type assignment with detection of the pathogenicity
K. Yanagihara, M. Motoshima, Y. Yamada, S. Kamihira, S. Kohno
Nagasaki (Japan)
74.010
Trend of vancomycin MIC values among MRSA clinical isolates and
association with patient outcome
K. A. Kincaid, J. M. Koo, S. M. Borchardt, T. S. Lo
Fargo, ND (USA)
74.011
Prevalence of Methicillin Resistant Staphylococcus aureus (MRSA) in tertiary
referral hospital in Nepal
K. Sapkota1, S. R. Basnyat1, C. D. Shrestha1, J. Shrestha1, S. P. Dumre2,
N. Adhikari1
1
Kathmandu (Nepal), 2Pathumthani (Thailand)
74.012
Emergence of linezolid-resistant coagulase-negative staphylococci in an
Intensive Care Unit
O. Zarkotou, G. Chrysos, E. Magira, G. Altouvas, A. Prekates, K. Digalaki,
A. Tsakris
Athens (Greece)
74.013
Inducible clindamycin-resistance in clinical staphylococcal isolates with
reduced vancomycin susceptibility in a University Teaching Hospital
B. Olayinka1, A. Olayinka2, A. Obajuluwa1, J. Onaolapo1, P. Olurinola1
1
Zaria (Nigeria), 2Shika-Zaria (Nigeria)
74.014
Different antibiotic treatments in patients suffering from MRSA-mediastinitis
after cardiac surgery
P. Dohmen, J. Schaefer, W. Konertz
Berlin (Germany)
74.015
Trends in Methicillin resistant staphylococcus aureus (MRSA) minimal
inhibitory concentration (MIC) to Vancomycin over a 2 year period in a
community-based hospital
J. Murillo, C. Garcia, F. Ordieres
Miami, FL (USA)
Session 74
Hyatt Regency Miami
12:30–13:30
74.016
Antimicrobial susceptibilities, and SCCmec and multi-locus VNTR analyses of
polymorphism and genetic relationships of clinical isolates of MRSA
P. Brown, S.-L. Peart, J.-A. Dookie
Kingston (Jamaica)
74.017
Resistance to antibiotics of acinetbacter strains isolated from
hospital-associated infections
L. M. Junie1, E. Papadomanolaki2, G. Aleuraki2, P. Karagianni2, A. Tsafaraki2,
A. Tsouri2, D. Labousaki2, E. Volanis2, S. Kastanakis2
1
Cluj Napoca (Romania), 2Chania (Greece)
74.018
Real time PCR resolution of community acquired MRSA reservoirs:
A strategy for the reduction of time to detection of hospital acquired MRSA
S. Connolly, S. N. Connolly, Y. Pasari
Middlesbrough (United Kingdom)
74.019
Study of Vancomycin (VA) and Trimethoprim/sulfamethoxazole (TMP-SMX)
activity on community-associated Methicillin-Resistant Staphylococcus aureus
(CA-MRSA) biofilms (Bf) in vitro
A. Farinati1, M. V. Campana1, S. C. Lopez1, R. Notario2, J. M. Casellas2,
G. Vazquez1
1
Buenos Aires (Argentina), 2Rosario, Santa Fe (Argentina)
74.020
Disc diffusion methods versus PCR for mecA gene in detection of
Methicillin-Resistant Staphylococcus aureus
Z. Mohammadtaheri, M. Pourpaki, F. Mohammadi, S. Raeissi,
M. A. Khodadoust, M. Masjedi
FRIDAY
•
March 12, 2010
Final Program ~ 169
Session 75
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
DIAGNOSTICS
170 ~ Final Program
75.001
Molecular diagnosis of Helicobacter pylori infection and risk factor of the
presence of cagA and vacA genes
A. Hassan
Alexandria (Egypt)
75.002
Competitive ELISA for Toxoplasma gondii Zoonoses
A. A. Entrena García
La Habana (Cuba)
75.003
Sensivity and specifity of ELISA test for diagnosis of brucellosis
Z. Vakili, M. Momen Heravi, A. Sharif
Kashan, Isfahan (Islamic Republic of Iran)
75.004
Molecular epidemiology of selected sexually transmitted bacterial infections
H. Jalal
Cambridge (United Kingdom)
75.005
Burden of infection with C. trachomatis, N. gonorrhoeae, T. vaginalis and
HR-HPV in homeless youth determined by APTIMA testing
M. Chernesky1, D. Jang1, M. Smieja1, E. Portillo1, J. Kapala2, J. Sumner2
1
Hamilton, ON (Canada),3Brampton, ON (Canada)
75.006
Evaluation of PCR versus EIA for diagnosis of Clostridium difficile infection
M. T. Busowski, C. DeRyke, D. bohmer, J. D. Busowski, R. Franklin, A. F. Walsh,
M. R. Wallace
Orlando, FL (USA)
75.007
Serodiagnosis of tuberculosis using nine in silico predicted B-cell epitopes
peptides derived from Mycobacterium tuberculosis proteins
L. BaassIi1, K. Sadki1, F. Seghrouchni1, S. Contini2, W. Cherki1, N. Nagelkerke3,
A. Benjouad1, C. Saltini2, V. Colizzi2, R. El aouad1, M. Amicosante2
1
Rabat (Morocco), 2Rome (Italy), 3Al Ain (United Arab Emirates)
75.008
Cerebrospinal and blood nitric oxide in tubercular meningitis
S. Jain, R. Srinivas, N. Sharma, M. Khullar
Chandigarh (India)
75.009
Combinatorial use of IgG antibodies to secreted mycobacterial proteins to create
a screening test for childhood tuberculosis
Z. Araujo1, F. Giampietro1, M. A. Patarroyo2, C. Fernandez de Larrea3
1
Caracas (Venezuela), 2Bogotá (Colombia), 3Barcelona (Spain)
Session 75
Hyatt Regency Miami
12:30–13:30
DIAGNOSTICS
Reverse transcritpase multiplex PCR for detection of viral agents in
central nervous system infections
V. Gopalakrishnan, H. Amar Singh, T. Sadanandan, G. Perkash Singh
Ipoh (Malaysia)
75.012
An improve dot enzyme immunoassay for serodiagnosis of melioidosis
S. A. K. Zainoodin1, I. Asma2
1
Kepala Batas (Malaysia), 2Georgetown (Malaysia)
75.013
Diagnostic value of Elisa serological test using synthetic peptides of
Mycobacteriun tuberculosis antigens in childhood tuberculosis
D. Lopez1, F. Giamprieto1, J. DE Waard1, M. A. Patarroyo2,
C. Fernandez de Larrea3, Z. Araujo1
1
Caracas (Venezuela), 2Bogotá (Colombia), 3Barcelona (Spain)
75.014
Can the nucleic acid amplification test (NAT) be an alternative to the
serologic tests? A prospective study results of 18,200 blood donors from
Turkish Red Crescent
B. Kocazeybek1, P. Yuksel2, H. Altunay1, E. Kosan1, M. Aymelek1, E. Alan1,
S. Saribas1, M. Aslan1, O. S. Yenen1, I. Birinci1, K. Kirali1, A. Aksoy2
1
Istanbul (Turkey), 2Ankara (Turkey)
75.015
Comparison of Bactec MGIT 960 and new culture system VersaTREK for
isolation rate, time of detection and and contamination rate
S. Saribas, P. Yuksel, Y. Bagdatli
Istanbul (Turkey)
75.016
Development of genetic typing method to assign staphylocoagulase (SC)
serotype I-X and two SC genotypes for Staphylococcus aureus
N. Kobayashi1, S. Ghosh1, M. Hirose2, S. K. Paul3, N. Urushibara1,
M. Kawaguchiya1
1
Sapporo, Hokkaido (Japan), 2Tobetsu (Japan), 3Mymensingh (Bangladesh)
75.017
Serological diagnosis of lyme disease in Valencia (Spain)
M. T. Fraile Fariñas, J. L. Ramos Marti, N. Tormo Palop, C. Gimeno Cardona
Valencia (Spain)
Final Program ~ 171
March 12, 2010
75.011
•
Specificities of the APTIMA Combo 2 and ProbeTec for Chlamydia trachomatis
and Neisseria gonorrhoeae in oropharyngeal and rectal specimens from MSM
J. Schachter, J. Moncada, A. Roger, L. Rauch, S. Liska, C. Shayevich,
J. D. Klausner
San Francisco, CA (USA)
FRIDAY
75.010
Session 75
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
DIAGNOSTICS
172 ~ Final Program
75.018
Multicenter evaluation of Ziehl-Neelsen bleach sedimentation method for
diagnosis of smear-negative tuberculosis in Kenya
S. Matu, L. Muita, E. Juma
Nairobi (Kenya)
75.019
Multilocus PCR in real time for detection of highly dangerous and dangerous
viral infections
A. O. Sementsova, A. N. Shikov, V. A. Ternovoy, A. P. Agafonov, V. B. Loctev,
I. G. Drozdov
75.020
Expression of matrix metalloproteinases and tissue inhibitors in the serum and
cerebrospinal fluid of patients with meningitis
H.-C. Tsai, M.-H. Shi, S. S.-J. Lee, Y.-S. Chen
Kaohsiung (Taiwan, R.O.C.)
75.021
Combination of PCR and electrical microarray allows rapid and sensitive
multiplex detection of mosquito-transmitted pathogens
M. Kaiser1, M. Ulrich1, A. Löwa1, G. Piechotta2, R. Wörl2, H. Ellerbrok1
1
Berlin (Germany), 2Itzehoe (Germany)
75.022
Detection and differentiation of Dengue infections with highly sensitive
real-time PCRs
M. Kaiser1, D. Bray2, K. Benlhassan-Chahour2, F. Bissuel3, P. Huc Anais3,
W. Rozenbaum4, H. Ellerbrok1
1
Berlin (Germany), 2Buckinghamshire (United Kingdom),
3
Saint-Martin (France), 4Paris (France)
75.023
An automated workflow for high throughput MLVA using the BioNumerics®
software, able to deal with varying experimental settings
L. Del Rosario1, B. Pot2, J. Goris2, K. Janssens2, P. Vauterin2, L. Vauterin2
1
Austin, TX (USA), 2Sint-Martens-Latem (Belgium)
75.024
Navigating Dante’s inferno: Creation of signatures for the rapid detection of
heamorraghic fever agents
K. Pitz, A. C. Carrillo, J. Thissen, J. Olivas, B. Harrel, S. Hall, M. El Sheikh,
R. Lenhoff, P. Naraghi-Arani
Livermore, CA (USA)
Session 75
Hyatt Regency Miami
12:30–13:30
DIAGNOSTICS
Study of the efficient treatment of the influenza (S-OIV, A/H1N1)
H. Iwamura, W. Nakanishi, C. Yamada, M. Shinogami
Tokyo (Japan)
75.027
Design of improved polymerase chain reaction (PCR) method containing internal
positive control (IPC) for molecular detection of Yersinia pestis
F. Eini, M. Fallah Raoufi, M. Soleimani, F. Azarifard, E. Jamshidiyan,
K. Majidzadeh
75.028
Development of a multiplex PCR system with application of IPC (internal
positive control) for detecting Bacillus anthracis from environmental samples
M. Fallah Raoufi, F. Eini, F. Azarifard, M. Soleimani, E. Jamshidiyan,
K. Majidzadeh2
75.029
TB test-kit for rapid drug susceptibility testing of M.tuberculosis
L. Domotenko, M. Khramov
Obolensk (Russian Federation)
75.030
Production and standardization of Brucella national standard antiserum
equivalent to OIEISS in Sudan
M. F. E. M. Alawad, M. T. Musa
Khartoum (Sudan)
75.031
Identification of novel microRNA biomarkers of viral infection
P. Naraghi-Arani1, S. Bavari2, S. Gardner1, C. Jaing1, J. Thissen1
1
Livermore, CA (USA), 2Fredrick, MD (USA)
75.032
Procalcitonin as a diagnostic marker in differentiating bacterial from
abacterial meningitis
H. El-Shamy, A. Abbass, Y. Omran, A. Amine
Alexandria (Egypt)
Final Program ~ 173
March 12, 2010
75.026
•
Usefulness of Montenegro skin test for the diagnosis of Mucosal Leishmaniasis
B. Valencia, P. Diaz, O. Ponce, A. Ramos, A. Llanos-Cuentas
Lima (Peru)
FRIDAY
75.025
Session 75
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
DIAGNOSTICS
174 ~ Final Program
75.033
Western blotting studies of IgG antibodies, IgG avidity and IgG subclasses during
the follow up of patients with pulmonary tuberculosis, under treatment
A. C. Felix, O. H. M. Leite, R. Arruda, A. W. Ferreira
75.034
A multiplex real-time PCR method for presumptive identification of NAP1 clone
of Clostridium difficile from stools
P. Jayaratne, C. Lee, C. Rutherford
Hamilton, ON (Canada)
75.035
Accuracy of an ‘in-house’ sputum polymerase chain reaction assay for rapid
diagnosis of sputum smear negative pulmonary tuberculosis at Mulago
Hospital, Uganda
L. Nakiyingi, P. Ocama, B. Asiimwe, F. Katabazi, A. Katamba, M. Joloba,
H. Mayanja-Kizza
Kampala (Uganda)
75.036
Amplification of pre-membrane and non-structural region 5 for detection and
typification of Dengue virus by real-time PCR using SYBR green I assay
S. Vielma, M. Odreman, D. Atchley, J. McAvin, G. Comach, C. Torres,
G. Aguilera, A. Chiarello, L. Tellez, M. Muñoz
Merida (Venezuela)
75.037
Cytokine response in severe sepsis—Predicting and modelling the
course of illness
J. Malaska, M. Kratochvil, M. Kyr, P. Jabandziev, F. Otevrel, K. Muriova,
M. Fedora, V. Sramek, J. Michalek, P. Sevcik
Brno (Czech Republic)
75.038
Circulating antigens of Mycobacterium tuberculosis: Standardization of
immunoenzymatic assay to detect circulating antigens related in the pathology
of tuberculosis
A. C. Felix, C. B. Tanganelli, K. Kanunfre, O. H. M. Leite, R. Arruda,
A. W. Ferreira
Session 75
Hyatt Regency Miami
12:30–13:30
DIAGNOSTICS
75.039
Variation in liver histopathology in chronic HBV-infected individuals with
normal liver function tests correlates with HBV replication
J. You, L. Zhuang, H.-Y. Chen, J.-H. Huang, B.-Z. Tang, M.-L. Huang
Kunming (China)
75.040
Short primers for amplification of diverse virus strains
C. Hara1, A. Hiddessen2, S. Gardner1, C. Bailey2
1
Livermore, CA (USA), 2Pleasanton, CA (USA)
75.041
Evaluation of the C. difficile toxin A/B iitm, C. difficile check-60TM, and
premier toxin A&BTM with the cytotoxin assay for the detection of
Clostridium difficile GDH antigen and toxins A and B in feces
W. Greene
Hershey, PA (USA)
75.042
A highly sensitive reverse transcription polymerase chain reaction method for
yellow fever virus detection
J. Méndez1, C. Mendez1, C. Domingo2, G. Rey1, A. Tenorio3
1
Bogotá (Colombia), 3Berlin (Germany), 4Madrid (Spain)
75.043
Molecular diagnosis of American tegumentary leishmaniasis with minimally
invasive samples
B. Valencia1, N. Veland1, J. Arevalo1, A. Llanos-Cuentas1, J.-C. Dujardin2
1
Lima (Peru), 2Antwerp (Belgium)
75.044
Multiprobes real-time PCR direct detection of MDR-TB related genes in
pulmonary samples
W. Watcharasamphankul, S. Foongladda
Bangkok (Thailand)
FRIDAY
•
March 12, 2010
Final Program ~ 175
Session 76
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
EMERGING INFECTIOUS DISEASES
176 ~ Final Program
76.001
Successful containment of an avian influenza outbreak through public health
intervention in district Howrah, West Bengal, India, January ‘08
G. Roy
Kolkata, West Bengal (India)
76.002
How different is Chikungunya from Dengue?
A. Chow, D. C. Lye, V. Lee, M. K. win, A. Tan, Y. S. Leo
76.003
Community-acquired Staphylococcus aureus infection in previously
healthy neonates
G. Berberian, G. Castro, H. Lopardo, C. Hernandez, A. Mónaco, M. T. Rosanova
76.004
Etiologic aspects of 341 cases of acute undifferentiated febrile syndrome (AUFS)
in southeast Brazil
P. S. Gonçalves da Costa, L. M. Carvalho Valle, M. E. Brigatte
Juiz de Fora (Brazil)
76.005
Tick-borne encephalitis virus in Mongolia
M. Khasnatinov1, D. Tserennorov2, P. Nymadavaa2, E. A. Tchaporgina1,
T. Glushenkova1, E. Arbatskaya1, J. Bataa2, D. Abmed2, G. A. Danchinova1,
D. Otgonbaatar2
1
Irkutsk (Russian Federation), 2Ulaanbaatar (Mongolia)
76.006
Bartonella spp infections diagnosed between 2005 and 2009 by the National
Rickettsial Reference Laboratory in Rio de Janeiro, Brazil
C. Lamas, K. Koppe, T. Azevedo, M. A. Mares-Guia, D. Almeida, A. Guterres,
T. Rozental, A. Favacho, E. R. Lemos
76.007
Multiplexed diagnostic assays for detection of high consequence foreign and
emerging animal disease
A. C. Carrillo1, J. Thissen1, J. Olivas1, K. Pitz1, M. El Sheikh1, B. Harrel1, S. Hall1,
M. Rasmussen2, L. Bentley Tammero1, R. Lenhoff1, P. Naraghi arani1
1
Livermore, CA (USA), 2Green Port, NY (USA)
76.008
Transmission of chikungunya in Singapore, 2008
P. L. Ooi
Session 76
Hyatt Regency Miami
12:30–13:30
What is the current situation with plague in North Africa?
E. Bertherat1, K. England2
1
Geneva (Switzerland), 2Bethesda, MD (USA)
76.011
Analysis and characterization of mouse monoclonal antibodies reactive to
Chikungunya virus (CHIKV)
G. Rossini, A. Pierro, P. Gaibani, F. Cavrini2, M. P. Landini2, V. Sambri1
Bologna (Italy)
76.012
Study of Hanta-viral hemorrhagic fever with renal syndrome (HFRS) in an
endemic region of Bulgaria
I. Baltadzhiev
Plovdiv (Bulgaria)
76.013
The complete genome sequence and analysis of the betaproteobacterium
Laribacter hongkongensis
K. L. Tsang, P. C. Y. Woo, S. K. P. Lau
Hong Kong (China)
76.014
The 2008 dengue epidemic on Curaçao: Correlation with climatological factors
M. Limper1, C. Van de Weg2, P. Koraka2, Y. Halabi3, I. Gerstenbluth3,
J. Boekhoudt3, A. Martis3, B. Martina2, A. Duits3, A. Osterhaus2, E. Van Gorp1
1
Amsterdam (Netherlands), 2Rotterdam (Netherlands), 3Curacao (Netherlands)
76.015
Cross-reactive neutralizing antibody response to enterovirus 71 infection in
Taiwanese young children
M.-S. Lee1, P.-S. Chiang1, M.-L. Huang1, S.-C. Chen1, S.-T. Luo1, K.-C. Tsao2,
G.-Y. Liou1, T.-Y. Lin2
1
Zhunan (Taiwan, R.O.C.), 2Linkou (Taiwan, R.O.C.)
76.016
‘One World One Health’ in practice: Integrating public health and veterinary
curricula on emerging infectious diseases in Africa
G. Mullins1, J. Jagne1, L. Stone2, E. Konings2, L. Howard-Grabman3,
F. Hartman2, M. Fulton4
1
Bethesda, MD (USA), 2Cambridge, MA (USA), 3Arlington, VA (USA),
4
Lansing, MI (USA)
Final Program ~ 177
March 12, 2010
76.010
•
Escalation of Japanese encephalitis in India: Evidence from 2005 viral
encephalitis outbreak and appraisal of niceties
S. K. Saxena1, R. Saxena1, A. Mathur2
1
Hyderabad (AP) (India), 2Lucknow (India)
FRIDAY
76.009
Session 76
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
178 ~ Final Program
76.017
Vector-based metagenomics for animal virus surveillance
T. F. F. Ng1, D. Willner2, C. Nilsson3, Y. W. Lim2, R. Schmieder2, B. Chau2,
Y. Ruan3, F. Rohwer2, M. Breitbart1
1
Saint Petersburg, FL (USA), 2San Diego, CA (USA), 3Singapore (Singapore)
76.018
Epidemiological, clinical and zoonotic evidences for the existence of Lyme
disease in Central of Mexico
G. Gordillo1, F. Solorzano Santos2, J. Torres3, E. Velazquez2, G. Ramon2,
R. Garcia2, M. Vargas4
76.019
Population incidence estimates for hepatitis C virus infection in Egypt
F. D. Miller
Honolulu, HI (USA)
76.020
Prioritizing US Dengue fever interventions utilizing remote sensing and
predictive modeling
F. Grant
Atlanta, GA (USA)
76.021
Prevalence and presentation of Lassa fever in Nigerian children
G. Akpede1, A. Odike1, P. Okokhere1, S. C. Olomu1, D. Asogun1, C. Happi2,
S. Gunther3
1
Irrua, Edo (Nigeria), 2Ibadan (Nigeria), 3Hamburg (Germany)
76.022
New lessons from a case series review of Lassa fever in pregnancy
S. A. Okogbenin1, D. Asogun1, G. Akpede1, P. Okokhere1, S. Gunther2, C. Happi3
1
Irrua, Edo (Nigeria), 2Hamburg (Germany), 3Ibadan (Nigeria)
76.023
Neuroimmunological findings from the first report of Angiostrongylus
cantonensis outbreak in Ecuador
A. J. Dorta-Contreras1, B. Padilla-Docal1, J. M. Moreira2, L. Martini Robles3,
J. Muzzio Aroca3, F. Alarcon2, R. Bu Coifiu Fanego1
1
Ciudad de la Habana (Cuba), 2Quito (Ecuador), 3Guayaquil (Ecuador)
76.024
Pericarditis caused by spatype t011 MRSA in a butcher; an occupational hazard
M. Schouten
Tiel (Netherlands)
Session 76
Hyatt Regency Miami
12:30–13:30
Skin and soft-tissue infections caused by community-associated
methicillin-resistant Staphylococccus aureus
W. Cornistein, M. I. Lespada, C. Rodriguez
76.026
The emergence of Clostridium difficile NAP1 hypervirulent strain in Latin America
C. Quesada-Gómez1, T. Du2, M. D. M. Gamboa-Coronado1, C. Rodríguez1,
M. R. Mulvey2, E. Rodríguez-Cavallini1
1
San José (Costa Rica), 2Winnipeg, MB (Canada)
76.027
Differential patterns of tuberculosis disease between immigrant and native
Spanish patients
P. Merino, A. Vanegas, R. Cias, I. Gestoso, J. Picazo
Madrid (Spain)
76.028
Imported cases of Chikungunya and Dengue fever in Emilia Romagna region, Italy
F. Cavrini, P. Gaibani, C. Manisera, A. Pierro, G. Rossini, M. P. Landini, V. Sambri
Bologna (Italy)
76.029
Importance of the animal/human interface in events of international concern for
the Americas
M. C. Schneider1, X. P. Aguilera2, R. M. Smith3, M. Moynihan4,
J. Barbosa da Silva Jr2
1
Washington, DC (USA), 2Washington DC, DC (USA), 3Pomona, CA (USA),
4
Charlottesville, VA (USA)
76.030
Dengue fever in a Southeastern region of Brazil. Ten years period (1997–2007)
clinical and epidemiological retrospective study.
V. Ribeiro1, R. Angerami1, M. Resende1, M. H. Pavan1, E. Hoehne1, V. Souza2,
C. Souza2, M. Souza2, M. Wonhrathi2, S. Cadogan2, F. Aoki1
1
Campinas, SP (Brazil), 2Sumaré, SP (Brazil)
76.031
The potential of social networks for early warning nad outbreak detection
systems: The swine flu Twitter study
P. Kostkova, E. de Quincey, G. Jawaheer
FRIDAY
76.032
The meanings of resistance in a Brazilian dengue fever epidemic
C. Alley
Brooklyn, NY (USA)
March 12, 2010
Final Program ~ 179
•
76.025
Session 77
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
GRAM-POSITIVES & MISCELLANEOUS PATHOGENS
180 ~ Final Program
77.001
Assessment of prognosis of tetanus and its related factors among Albanian adults
A. Pilaca, A. Ndreu, G. Byrazeri, K. Shytaj
Tirana (Albania)
77.002
Thrombocytopenia in murine typhus: A study of 161 cases
S. Doukakis, M. Papadakis, M. Daoukakis, P. Stavroulakis, K. Bambili,
G. Polymili, D. Triantafillidou, M. Junie, S. Kastanakis
Chania (Greece)
77.003
Prevalence of neonatal conjunctivitis due to Chlamydia trachomatis in two
hospitals in Iran
S. Rafiei Tabatabaei, S. A. Afjeiee, A. Karimi, F. Fallah, A. Tavakkoly Fard,
N. Tahami Zanjani, R. Radmanesh Ahsani, A. R. Shamshiri
77.004
Invasive Streptococcus pneumoniae serotypes associated with in-patient and
out-patient isolates from the United States
M. Hackel1, C. Lascols1, S. Bouchillon1, D. Hoban1, J. Johnson1, M. Dowzicky2
1
Schaumburg, IL (USA), 2Collegeville, PA (USA)
77.005
Clinical and laboratory test follow up of patients with severe leptospirosis, after
hospital discharge
A. Spichler1, D. Athanazio2, A. C. Seguro1
1
São Paulo (Brazil), 2Salvador, BA (Brazil)
77.006
The detection of antibodies directed against specific antigens of
Borrelia burgdorferi sensu lato (B. burgdorferi s.s., B. afzelii, B. garinii,
B. spielmanii) in patients with borreliosis in Eastern Poland
M. Tokarska-Rodak1, H. Fota-Markowska1, M. Kozioł-Montewka1,
F. Śmiechowicz1, B. Gajownik2, M. Prokop1, R. Modrzewska1
1
Lublin (Poland), 2Łuków (Poland)
77.007
Enterococcal bone and joint infections: A working group experience
along 17 years
C. A. Pensotti, F. Nacinovich, C. Di Stéfano, J. Thierer, A. Ferraris,
D. Stamboulian
77.008
Bacillus cereus bacteremia in hospital setting
G. Ohji, Y. Oba, K. Takimoto, H. Kagawa, D. Uchida, R. Suganaga, H. Oka,
S. Kinoshita, M. Nakamura, H. Yoshida, K. Iwata
Kobe (Japan)
Session 77
Hyatt Regency Miami
12:30–13:30
Prognostic markers and out comes in severe leptospirosis in a tertiary care
hospital from south India
M. Prabhu, R. Valsalan, N. KS, B. Ramachandran
Manipal, Karnataka (India)
77.010
Multilocus sequence typing of Enterococcus faecalis clinical isolates in Cuba
D. Quinones1, N. Kobayashi2, S. Nagashima2, S. Watanabe2
1
Ciudad de La Habana (Cuba), 2Sapporo, Hokkaido (Japan)
77.011
Analysis and correlates of atypical lymphocytosis in leptospirosis in the cohort of
patients at an infectious diseases unit, University Hospital, from 1996 to 2009,
in Rio de Janeiro, Brazil
A. Barbosa, P. V. Damasco, C. A. L. Ávila, M. Ribeiro-Carvalho,
E. R. S. Lemos, M. N. Bóia, M. M. Pereira
77.012
Knowledge of Leptospirosis among community-based rural residents in Kandy,
Sri Lanka: Implications for intervention
C. Nwafor-Okoli1, S. Kularatne2, C. Gamage1, R. Rajapaske2, Y. Obayashi1,
H. Tamashiro1
1
Sapporo, Hokkaido (Japan), 2Kandy (Sri Lanka)
77.013
Bacillus cereus as a pathogen and retention of medical devices are risk factors
for Bacillus bacteremia
M. Kamimura, T. Kitazawa, Y. Yoshino, K. Tatsuno, K. Koike
Tokyo (Japan)
77.014
Concordance between Vir and protein M gene (emm) types of
Streptococcus pyogenes strains isolated from patients with invasive and
non-invasive infections of Mexico
M. Carranza1, M. Quiñonez-Alvarado1, E. Martìnez-Lopez1, L. Perea-Mejia2,
A. Inzunza-Montiel2, A. Villaseñor-Sierra1
1
Guadalajara (Mexico), 2Mexico (Mexico)
77.015
Clinical aspects of neuroborreliosis in Bydgoszcz, Poland
A. Olczak, E. Grabczewska
Bydgoszcz (Poland)
77.016
Diagnosis and treatment challenges in patients with chronic tick Associated
Poly-organic Syndrome (TAPOS)—Case series
A. Radulescu, M. Flonta, D. Tatulescu
Cluj (Romania)
FRIDAY
77.009
•
March 12, 2010
Final Program ~ 181
Session 77
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
182 ~ Final Program
77.017
Corynebacterium striatum: an under recognised cause of
diabetic foot osteomyelitis.
G. J. Boyd, N. Weightman, J. Martin
Harrogate (United Kingdom)
77.018
The rising concern of community-acquired methicillin-resistant
Staphylococcus aureus central nervous system infections: 2 case reports
R. Nog, H. Anyimadu, T. Schliep, O. Alao, V. Sivapalan, C. Badshah
New York, NY (USA)
77.019
A scoring system for severity of disease associated with mortality for
Clostridium difficile associated disease
P. Ko, R. Jayasingam, C. Modi, R. Hallit, N. Nguyen, S. Daniel, T. Soleymani,
J. Fallon, L. Booth, G. Perez, J. Slim, J. Sensakovic, J. Boghossian
Newark, NJ (USA)
77.020
Disseminated nocardiosis
A. R. Bastidas, M. Pérez, A. Piotrostanalzki, P. Reyes, M. Gonzáles, R. Rada
Bogotá (Colombia)
77.021
Effectiveness of linezolid versus vancomycin treatment for MRSA skin and
soft tissue infections
M. Yim, J. Steingisser, R. Kan, A. Nshala, R. Larson
Hanover, NH (USA)
77.022
Follow-up of Gambian 9-valent pneumococcal conjugate vaccine trial
participants who experienced acute lower respiratory infection aged less
than 2.5 years
G. Mackenzie1, B. Okoko1, A. Akinsola1, O. T. Idoko1, T. Corrah1, S. Howie1,
E. K. Mulholland2, B. Greenwood2, R. A. Adegbola3
1
Fajara (Gambia), 2London (United Kingdom), 3Seattle, WA (USA)
77.023
Tetanus: Clinical and epidemiological characteristics. Review of 11 years
R. Ilardo1, N. E. Frassone2
1
Cordoba (Argentina), 2Córdoba (Argentina)
Session 77
Hyatt Regency Miami
12:30–13:30
Characterization of community-acquired Staphylococcus aureus
methicillin-resistant (CA-MRSA) vs methicillin-susceptible
Staphylococcus aureus (CA-MSSA) infection (Inf) in Argentinean children
G. A. Yerino, M. S. Vazquez, C. Magneres, G. Abalos, C. I. Cazes, M. L. Vozza,
C. I. Echave, V. Valle, M. Langard, A. Procopio, M. M. Contrini, E. L. Lopez
77.025
Diphtheria tox gene polymorphism in C. diphtheriae strains isolated in Russia
during 2002–2009
S. Kombarova, I. Mazurova, O. Borisova, N. Gadua, T. Kornienko
Moscow (Russian Federation)
77.026
Staphylococcus lentus: The troublemaker
C. Mazal1, B. Sieger2
1
Sanford, FL (USA), 2Orlando, FL (USA)
77.027
Staphylococcus lugdunensis—A wolf in sheep’s clothing
A. Klotchko, M. Wallace, A. F. Walsh, B. Sieger, C. M. Licitra
Orlando, FL (USA)
77.028
Association of breast milk Lactobacilli and Staphylococcus aureus in women
with mastitis using quantitative PCR
U. srinivasan, N. Shrivastwa, S. Ponnaluri, J. Debusscher, C. Barbossa-Cesnik,
C. F. Marrs, B. Foxman
Ann Arbor, MI (USA)
77.029
Streptococcus pneumoniae treatment with catecholamines affects growth based
on strain isolation site with a lack of effect on biofilm formation
X. F. Gonzales, F. Quinones Falconi, G. Castillo Rojas, Y. Lopez Vidal
77.030
Chronic pain: Crucial symptom in a case of neuroborreliosis analysis of
three cases
E. Marcinkowska, A. Horban, M. Malec-Milewska
Warsaw (Poland)
FRIDAY
77.024
•
March 12, 2010
Final Program ~ 183
Session 78
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
HIV: OPPORTUNISTIC INFECTIONS & MALIGNANCIES
184 ~ Final Program
78.001
The emerging of non-AIDS related neoplasms in the era of combined
antiretroviral therapy
R. Manfredi
Bologna (Italy)
78.002
The role of the tuberculosis in outcome and treatment failure in HIV-infected
Cambodian children
V. Krčméry, B. Irad, J. Vujcikova, E. Mitterpachova, A. Kalavska, P. Kisac
78.003
AIDS-Associated mycobacterial infections in a large urban hospital during the
HAART era (2003–2006)
A. Sanche, M. Nguyen
Los Angeles, CA (USA)
78.004
A prospective cohort study of immunologic and virologic outcomes in patients
with HIV/AIDS and hepatitis virus co-infection in Jos, Nigeria
S. Isa1, L. N. Gwamzhi2, C. Akolo3, C. Ukoli4
1
Abuja (Nigeria), 2St Georges (Grenada), 3Rockville, MD (USA), 4Jos (Nigeria)
78.005
Pulmonary microbiology of HIV positive subjects with community-acquired
pneumonia (CAP) with special emphasis on Mycoplasma pneumoniae
U. Rao, E. Shankar, N. Kumarasamy, P. Balakrishnan, S. Solomon
Chennai (India)
78.006
Kaposi’s sarcoma (KS) and AIDS. Survival study
D. B. Lima, A. Barbosa, E. F. Cunha, R. G. Cunha, J. P. Almeida, V. R. Gomes
78.007
Opportunistic infections in central nervous system and associated neurologic
disorders in HIV-infected patients in a Western Hospital of Venezuela,
2007–2009
A. Herrera-Martínez, Y. Herrera, A. M. Pineda
Barquisimeto (Venezuela)
78.008
HIV and opportunistic infections in a western hospital of Venezuela, 2007–2009
A. Herrera-Martínez, Y. Herrera, A. M. Pineda
Barquisimeto, Lara (Venezuela)
Session 78
Hyatt Regency Miami
12:30–13:30
Prevalence of occult hepatitis B infection among HIV infected patients at an
inner city clinic
R. Nog, K. Singaravelu, A. Haider, V. Sivapalan, S. Mannheimer
New York, NY (USA)
78.010
Predictors for hepatic carcinoma surveillance screening in a cohort of hepatitis B
and HIV co-infected patients in a large urban HIV clinic
A. Adejumo, Z. Oshikanlu, V. Sivapalan
New York, NY (USA)
78.011
Virological and biochemical evolution of HIV-HBV co-infected patients treated
with tenofovir
G. Vidiella, P. Rios, C. Biscayart, S. Castillo, A. Botas, M. Christin,
D. Stamboulian, P. Rodriguez Iantorno, C. Vujacich
78.012
An assessment of the seroprevalence of hepatitis A antibody and vaccination
among HIV patients in an inner city HIV clinic
A. Adejumo, V. Sivapalan, S. Mannheimer
New York, NY (USA)
78.013
Central nervous system opportunistic infections (CNS-OI) in HIV-infected
children from Buenos Aires, Argentina
A. Fallo, A. de Mena, L. Torrado, N. Sordelli, G. Manonelles, E. L. Lopez
78.014
Parvovirus B 19 infection in immunodeficient patient
A. V. Lombar, M. Segovia, C. M. Carranza, M. L. Chessari, A. I. Sanchez,
A. M. Assetta
78.015
Strategies to enhance Hepatitis B disease surveillance in Human
Immunodeficiency Virus / Hepatitis B Virus co-infected patients
C. Bannan, D. Gallagher, G. Farrell, S. Akin, C. Bergin
Dublin (Ireland)
FRIDAY
78.009
•
March 12, 2010
Final Program ~ 185
Session 78
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
186 ~ Final Program
78.016
Risk of an outbreak of Kaposi’s sarcoma associated with HIV/AIDS
in Mozambique
A. Caterino-de-Araujo1, R. C. R. Manuel2, R. Del Bianco1, E. Santos-Fortuna1,
M. C. Magri1, J. M. K. Silva1, R. Bastos2
1
São Paulo (Brazil), 2Maputo (Mozambique)
78.017
Severe febrile neutropenia (SFN) in HIV / AIDS
D. Villalon, N. E. Frassone, L. Marianelli
Cordoba (Argentina)
78.018
Abnormal vaginal cytology and colpocytology in a group of HIV infected women
at Fundação de Medicina Tropical do Amazonas
M. Brock, J. R. D. T. Leao, C. M. O. Soeiro, L. C. D. L. Ferreira
Manaus, AM (Brazil)
78.019
Coinfection of tuberculososis and histoplasmosis in HIV patients from
Medellin, Colombia
A. Tobon, C. Agudelo, D. Molina, J. Marin, C. Restrepo, A. Restrepo
Medellin, Antioquia (Colombia)
78.020
Human Papillomavirus (HPV) detection in urine of HIV-infected women
I. Rosa-Cunha, J. Prewitt, T. Guettouche, T. Hooton
Miami, FL (USA)
Session 79
Hyatt Regency Miami
12:30–13:30
OBSTETRICAL-GYNECOLOGICAL, SURGICAL AND SEXUALLY TRANSMITTED INFECTIONS
Syphilis and HIV co-infection in Thai Medical School Hospital
N. Hiransuthikul
Bangkok (Thailand)
79.003
Genotyping of Chlamydia trachomatis and human papillomavirus in clinical
specimens from North-Eastern Croatia
Z. Bosnjak, M. Peric, D. Pavlinic, S. Dzijan, I. Roksandic-Krizan, D. Vukovic,
N. Ruzman, J. Burazin, G. Lauc, A. Antolovic-Pozgain
Osijek (Croatia)
79.004
Frequent infections in Mexican women experiencing spontaneous
pregnancy loss
L. Conde-Ferráez, R. Suarez-Allen, L. Manzano-Cabrera, M. R. Gonzalez-Losa,
G. Koh-Tec, M. Perez-Tuyub, J. Camara-Mejia, J. Carrillo-Martinez,
M. Puerto-Solis
Merida, Yucatan (Mexico)
79.005
Maternal group B Streptococcus colonization: Prevalence, risk factors,
phenotypical and genotypical characteristics in a Brazilian population
T. S. Pires, M. Turchi, M. C. D. P. B. André, J. L. Cardoso, L. E. P. R. Schmaltz,
O. M. Peres, A. L. Andrade
Goiania (Brazil)
79.006
Puerperal group A streptococci (GAS) infection:
Re-emergence of a dreaded disease—A case series
M. T. Busowski, M. Lee, J. D. Busowski, K. Akhter, M. R. Wallace
Orlando, FL (USA)
79.007
Potential impact of spouse’s circumcision on herpes simplex virus type 2
prevalence among antenatal women in five northeastern states of India
B. Borkakoty1, D. Biswas1, K. Walia2, J. Mahanta1
Dibrugarh, Assam (India), 2Delhi (India)
79.008
The “PREVEN” urban community randomised trial of a combined intervention
for sexually transmitted disease prevention in Nepal
R. P. Bhandari1, S. D. Joshi2
1
Kathmandu (Nepal), 2Kail (Nepal)
Final Program ~ 187
March 12, 2010
79.002
•
Prevalence of bacterial vaginosis amongst women of child bearing age
E. O. Chima-Oduko, C.J. Uneke
Abuja (Nigeria)
FRIDAY
79.001
Session 79
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
OBSTETRICAL-GYNECOLOGICAL, SURGICAL AND SEXUALLY TRANSMITTED INFECTIONS
188 ~ Final Program
79.009
HIV and syphilis seroprevalence and associated factors in pregnant
women and their couples in 6 Amazonian indigenous populations
in Peru 2007–2008
M. Omaeche, A. Whittembury, M. Pun, L. Suarez-Ognio
Lima (Peru)
79.010
Superoxide anion in lesions of cervix associated or not papillomavirus-infection
Y. Carrero, D. Callejas, R. Mindiola, L. Porto, F. Alana, M. E. castellanos,
C. Silva, L. Costa
Maracaibo, Zulia (Venezuela)
79.011
Detection of human Papilloma virus DNA in cervical samples in
Maracaibo-Venezuela
D. Callejas, M. E. castellanos, R. Mindiola, Y. Carrero, F. Monsalve,
L. Porto, R. Atencio
Maracaibo, Zulia (Venezuela)
79.012
Sexually transmitted disease recurrence in the department of defense
A. McCabe, G. Nowak
Portsmouth, VA (USA)
Session 80
Hyatt Regency Miami
12:30–13:30
PEDIATRIC AND PERINATAL INFECTIONS
Neonatal tetanus cases in a region in Ghana: Contributory factors and
consequential outcomes
E. Koomson
Cape Coast (Ghana)
80.003
Role of adjuvant zinc in the treatment of severe pneumonia in young children:
A meta-analysis of benefits and risks
R. Das, M. Singh, N. Gupta, N. Shafiq
Chandigarh (India)
80.004
DNA amplification and sequence analysis of P1 adhesin gene fragments in
M.pneumoniae from pediatric respiratory infections
S. Kumar, S. R. Saigal, G. R. Sethi, R. Chaudhry
New Delhi (India)
80.005
Incidence and characterization of neonatal sepsis cases in a Colombian hospital
during 2007–2008
M. L. Raciny Aleman, A. M. Castro Cordero, L. R. Ramos Hernandez,
A. B. Muñoz Delgado
Monteria (Colombia)
80.006
Epidemiological data of infectious disease for 10 years in PICU
F. Zavalani, I. Bujari, A. Koja, I. Bakalli, E. Kola, E. Kallfa, S. Sallabanda,
R. Petrela, R. Lluka, E. Celaj
Tirana (Albania)
80.007
The feasibility of rectal artesunate as pre-referral treatment for severe malaria in
under fives at community level in rural Uganda
J. Rujumba, E. A. Mworozi, B. A. Mpeka, T. Lutalo, R. Azairwe
Kampala (Uganda)
80.008
Clinical features predicting mortality (M) in high risk febrile neutropenic
cancer children (HR-NTPCH) at Hospital de Niños Ricardo Gutiérrez
(HNRG), Argentina
N. Rivas, A. Viña, G. Yerino, C. Ceccoli, F. Plat, C. Hascalovici, E. L. Lopez
Final Program ~ 189
March 12, 2010
80.002
•
Effect of zinc supplementation on clinical course of acute diarrhea in patients
admitted in Ali Asghar Children Hospital Medical Center Iran University of
Medical SciencesTehran Iran
K. Mahlouji
FRIDAY
80.001
Session 80
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
190 ~ Final Program
80.009
Non-typeable Haemophilus influenzae and Streptococcus pneumoniae:
Primary causes of acute otitis media in Colombian children
P. Lopez1, A. Sierra1, M. A. Zapata1, B. Vanegas1, R. De Antonio2,
M. M. Castrejon2, W. Hausdorff3, R. Colindres4
1
Cali (Colombia), 2Panama City (Panama), 3Wavre (Belgium),
4
80.010
Risk factors (RF) for necrotizing enterocolitis (NE) in Pediatric oncologic patients
(POP) with neutropenia (NTP)
N. Rivas, A. Viña, G. Yerino, M. L. Praino, C. Ceccoli, F. Plat, C. Hascalovici,
A. Cane, E. L. Lopez
80.011
Temporal variation of human rotavirus types circulating in Caracas
during 2007–2008
E. Vizzi, O. Piñeros, A. C. Alcala, M. D. Oropeza, L. Naranjo, J. A. Suarez,
J. L. Zambrano, F. Liprandi
Caracas (Venezuela)
80.012
Kawasaki disease in a children hospital at Dominican Republic, period
January 2006–October 2009
C. S. Mota
80.013
Epidemiology, clinical and microbiology characteristic of multiresistant
Acinetobacter spp. bacteremia in a pediatric hospital in Argentina
S. Ruvinsky, G. Fiorilli, G. Perez, B. Juzielewski, L. Mannino, L. Casimir,
M. T. Rosanova, H. Lopardo, R. Bologna
80.014
Spectrum of infections in children with nephrotic syndrome
D. Chopra, P. Kini, N. Bhaskaranand, S. Aroor
Manipal (India)
80.015
Multicenter study of meningococcal disease in children in pediatric hospitals
in Argentina
H. Paganini, E. L. Lopez, A. Mónaco, M. L. Praino, C. Sarkis, L. Vozza,
M. C. Ceinos, C. Echave, L. Inda, V. Vazquez, S. Neyro, A. Procopio,
M. M. Contrini
Session 80
Hyatt Regency Miami
12:30–13:30
The association between vitamin D deficiency, folate deficiency and
seropositivity to persistent pathogens among U.S. children
A. Simanek1, J. Dowd2, A. Aiello1
1
Ann Arbor, MI (USA), 2New York, NY (USA)
80.017
Pilot study to determine feasibility of development of an influenza clinical
diagnostic tool
R. Nipp, T. Bell, D. Ruhl, C. Lee, J. Kirkland
Amarillo, TX (USA)
80.018
Data management, design and analysis challenges in the prevention of perinatal
sepsis (PoPS) randomized control trial, Soweto, South Africa
L. Kuwanda, C. Cutland, S. Madhi
80.019
RCT Methodology, population profile and pneumonia rates in socioeconomically deprived infants of Kabul: Data from a RCT investigating the
effects of vitamin D supplementation on the incidence of infant pneumonia
Z. Zabihullah1, S. Manaseki-Holland2, D. Chandramohan1, Z. Bhutta3,
Z. Mughal4
1
London (United Kingdom), 2Birmingham (United Kingdom), 3Karachi (Pakistan),
4
Manchester (United Kingdom)
80.020
Morbility and mortality for neonatal sepsis in a Hospital in
Havana City, 1998–2008
M. Cristia Pacheco
Ciudad de la Habana (Cuba)
80.021
Age and sex specific pattern of urban malaria and diarrhea mortalities in Accra
J. Fobil1 2, A. Kraemer3, J. May1
1
Hamburg (Germany), 2Legon, Accra (Ghana), 3Bielefeld (Germany)
80.022
Paediatric rotavirus disease in The Gambia: A hospital based sentinel study
R. C. Ideh1, O. Rodrigues2, G. E. Armah3, A. S. Batchilly1
1
Banjul (Gambia), 2Accra (Ghana), 3Legon (Ghana)
FRIDAY
80.016
•
March 12, 2010
Final Program ~ 191
Session 80
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
192 ~ Final Program
80.023
The role of viruses in the aetiology of IRA in Peruvian children
J. del Valle1, A. Cornejo1, L. del Valle2, T. Pumarola2, E. Verne1, V. Helasvuo1,
R. Nazario1, D. Champin1
1
Lima (Peru), 2Barcelona (Spain)
80.024
Clinical and epidemiology characterization of children hospitalized with
influenza A H1N1 (FLU AH1N1) during the first wave of 2009 outbreak,
Santiago, Chile
C. Sandoval, C. Vizcaya, C. Perret, M. Ferrés, C. Martinez, P. Godoy,
P. Ferrer, M. Monge, K. Abarca, A. Castillo, M. Potin, J. C. Lopez
Santiago (Chile)
80.025
Rapid diagnostic tests for neonatal malaria: How reliable?
A. A. Orogade1, S. Aminu2
1
Kaduna (Nigeria), 2Zaria (Nigeria)
80.026
Detection of rotavirus antigen in stools samples collected from children
in parts of Nigeria
D. Ehichioya1, C. Bode1, C. J. Elikwu1, I. Ossai2, R. Orenolu1, S. Omilabu1
1
Lagos (Nigeria), 2Benin (Nigeria)
Session 81
Hyatt Regency Miami
12:30–13:30
PUBLIC HEALTH INTERVENTIONS, MODELING & TRAINING
Quantitatively estimated the global burden of disease of chronic
and infectious diseases interface in 2002
Y. Yan1, B. Choi2, H. Morrison2, T. Wong2, J. Wu2
1
Xi’an (China), 2Ottawa, ON (Canada)
81.003
Application of international health regulations in the Singapore pandemic
influenza experience
P. L. Ooi
81.004
Models and data for determining transmission routes
J. Koopman
Ann Arbor, MI (USA)
81.005
Epidemiological transition in Venezuela: Relationships between infectious
diarrheas, ischemic heart diseases and transportation accidents mortalities and
the human development index (HDI) in Venezuela, 2005–2007
A. Rísquez Parra, L. Echezuria, A. Rodriguez-Morales
Caracas (Venezuela)
81.006
Medical needs assessment and infectious diseases concerns in rural Honduras—
Implications for medical relief planning
M. P. Stevens, K. Elam, L. F. Stevens, S. Shodhan, D. Markley, R. Hemrajani,
K. Sanogo, G. Bearman
Richmond, VA (USA)
81.007
Redevelopment and evaluation of EpiData: A practical software tool for use in
the public health field
A. Arthur1, J. Garay2, B. Guarda3, L. Sieswerda4, A. Stevens5
1
Toronto, ON (Canada), 2Newmarket, ON (Canada), 3Ottawa, ON (Canada),
4
Thunder Bay, ON (Canada), 5Brantford, ON (Canada)
81.008
Similarities and differences between persons of higher and lower income in
Argentina, concerning their knowledge on vertically transmitted diseases
M. Mayer Wolf, A. V. Sanchez, C. Ezcurra, V. Rodríguez, C. Freuler
Final Program ~ 193
March 12, 2010
81.002
•
Bed net coverage, usage and condition in fishing villages of Suba district,
Western Kenya
D. Gabriel
Kisumu (Kenya)
FRIDAY
81.001
Session 81
Hyatt Regency Miami
12:30–13:30
81.009
Socioeconomical aspects of malaria morbidity and mortality in Venezuela:
An analysis of their correlations with the Human Development Index
and its components
A. Rodriguez-Morales1, J. Benitez2, R. Harter-Griep3, M. A. Lopez-Zambrano4
1
Trujillo (Venezuela), 2Maracay (Venezuela), 3Rio de Janeiro (Brazil),
4
Caracas (Venezuela)
81.010
FluZone: A national decision support system for the H1N1 flu pandemic
in England
C. Kara-Zaïtri1, M. Schweiger2, R. Hamilton1
1
Bradford (United Kingdom), 2Leeds (United Kingdom)
81.011
Economic burden of health care at household level: Examination of
out-of-pocket expenditure on sexual and reproductive health care
T. Akalu
81.012
Testing the effectiveness of dengue vector control interventions
L. Sanchez1, J. Maringwa2, Z. Shkedy3, M. Castro1, N. Carbonell4,
P. Van der Stuyft5
1
Havana City (Cuba), 2Brussels (Belgium), 3Hasselt (Belgium),
4
Sancti Spiritus (Cuba), 5Antwerp (Belgium)
81.013
Age at sexual initiation and its determinants among youths in NE Ethiopia
F. Mazengia
Gondar (Ethiopia)
81.014
World Rabies Day Campaign: Evaluating a global initiative
P. Costa1, P. Orlosky2, J. Blanton2, D. Briggs1, C. Williams1, A. Tumpey2
1
Manhattan, KS (USA), 2Atlanta, GA (USA)
81.015
From strategy to action: The vital roles of trained field epidemiologists and
laboratory management professionals in epidemic control and prevention
in Tanzania
O. Oleribe1, F. Mosha1, M. Mohammed1, J. Mghamba1, P. Mmbuji1,
P. Nsubuga2, D. Mukanga3
1
Dar Es Salaam (Tanzania, United Republic of), 2Atlanta, GA (USA),
3
Kampala (Uganda)
81.016
Continuous medical education: Teaching infectology using the internet
T. Zitto, A. Melamud, M. L. Arcidiacono, H. Lopez
FRIDAY
•
March 12, 2010
194 ~ Final Program
Session 81
Hyatt Regency Miami
12:30–13:30
GLaDMap: Global Laboratory Directory Map
S. Mukhi1, L.-K. Ng1, M. Chu2, B. Swaminathan3
1
Winnipeg, MN (Canada), 2Geneva (Switzerland), 3Atlanta, GA (USA)
81.019
Comprehensive community hygiene promotion in peri-urban Cape Town:
gastrointestinal and respiratory disease reduction in families
E. Cole1, M. Hawkley1, J. R. Rubino2, K. McCue2, B. Crookston3, J. Dixon1,
T. Maqelana4, J. Cwayi4, C. Adams4
1
Provo, UT (USA), 2Montvale, NJ (USA), 3Salt Lake City, UT (USA),
4
Cape Town (South Africa)
81.020
An alternative standard for radiological pneumonia in children
G. Mackenzie, U. Uchendu, D. Ameh, O. Adeyemi, D. Saha
Basse (Gambia)
81.021
Field evaluation of ZeroVector™ Durable Lining as an alternative to indoor
residual spraying (IRS) for the control Anopheles vectors of malaria in rural
villages of Obuasi, Ghana
J. Stiles-Ocran1, S. Knowles1, D. A. Boakye2
1
Obuasi (Ghana), 2Accra (Ghana)
81.022
Mass screening and treatment for malaria among gold miners in Suriname
L. Villegas, H. Cairo, A. Huur, H. Vinisi, H. Pereira, N. Jozuazoon, F. Refos,
S. Summerville, L. Hardjopawiro, M. Jordaan, S. Mitro, H. Hiwat, C. Alensi,
P. Malaria Technical Committee
Paramaribo (Suriname)
81.023
Almost 10.000 second opinion consultations in infectious diseases.
A telemedicine program in Argentina
C. Sarkis, C. Vujacich, F. García, L. Carniglia, S. Enrique, R. Debbag,
D. Stamboulian
81.024
7 Years’ experience in a telemedicine program in infectious diseases in Argentina
R. Debbag, S. Enrique, F. García, C. Sarkis, C. Vujacich, E. Andión, L. Carniglia,
D. Stamboulian
81.025
Sustained malaria control in Suriname after 3 years of effective interventions
L. Villegas, H. Hiwat, H. Cairo, L. Hardjopawiro, S. National Malaria Board
Paramaribo (Suriname)
Final Program ~ 195
March 12, 2010
81.018
•
Measles epidemy with complications in Bosnian children during 2008—
Prevention strategy
A. Bajraktarevic
Sarajevo (Bosnia and Herzegovina)
FRIDAY
81.017
Session 82
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
TRYPANOSOMIASIS, LEISHMANIASIS & SCHISTOSOMIASIS
196 ~ Final Program
82.001
Inhibition of entry and survival of Leishmania donovani by down regulation of
TACO gene on human macrophages using Vitamin D3 & Retinoic Acid
V. Reddy
Chandigarh (India)
82.002
A diagnostic approach to detect murine Shistosoma mansoni infection using a
polymerase chain reaction
A. Hassan
Gizan (Saudi Arabia)
82.003
Leishmania aethiopica: The unusual etiologic agent of cutaneous leishmaniasis
in Ho District of the Volta region of Ghana
G. Kwakye-Nuako
Accra (Ghana)
82.004
The role of colonoscapy and squash preparations in diagnosis and follow-up of
stool negative enteric schistosomiasis: A case report of double infection with
S. mansoni and S. intercalatum
M. Astriti, K. Tzanetou, K. Sarri, K. Ntinos, G. Adamis, V. Delis, G. Moustakas,
M. Choreftaki, P. Gargalianos
Athens (Greece)
82.005
Trypanocidal activity of novel alkanediamide-linked bisbenzamidines and
bisbenzamidoximes
T. Huang1, N. Kode1, C. Bacchi2, D. Rattendi2, J. J. Vanden Eynde1, A. Mayence1,
N. Yarlett2, I. Londono2
1
New Orleans, LA (USA), 2New York, NY (USA)
82.006
A critical role of CD2 as an immunoprophylactic agent to combat
visceral leishmaniasis
S. Sinha1, S. Bimal2, S. Sundaram1
1
Allahabad (India), 2Patna (India)
82.007
Patients with suspected visceral leishmaniasis in Istanbul
H. Cakan, S. Saribas, V. Oz, E. Polat, M. Aslan, B. Kocazeybek
Istanbul (Turkey)
Session 82
Hyatt Regency Miami
12:30–13:30
TRYPANOSOMIASIS, LEISHMANIASIS & SCHISTOSOMIASIS
Immunological profile of CD18-deficient mice during
Schistosoma mansoni infection
M. S. Espíndola, F. G. Frantz, L. H. Faccioli
Ribeirão Preto, SP (Brazil)
82.009
Control of Chagas disease patients whith chronic form of its treatment after
Benznidazole treatment
M. T. Fraile Fariñas, C. Parada Barba, J. L. Ramos Marti, M. Chanza Avino,
M. Garcia Rodriguez, C. Gimeno Cardona
Valencia (Spain)
82.010
Population structure of Leishmania infantum from Morocco
H. Salsabil1, A. Amro2, G. Schönian3, L. Meryem1
1
Casablanca (Morocco), 2Jerusalem (Palestina), 3Berlin (Germany)
82.011
Propolis and derivatives of megazol: In vitro and in vivo activity on
Trypanosoma cruzi, mechanism of action and selectivity
K. Salomão1, E. M. De Souza2, H. S. Barbosa1, S. L. de Castro2
1
Rio de Janeiro, Rio de Janeiro (Brazil), 2Rio de Janeiro (Brazil)
82.012
Alanine 163 in loop C of Leishmania major aquaglyceroporin LmAQP1
resides near the pore mouth of the channel
Y. Zhou1, G. Mandal1, V. S. R. Atluri1, E. Beitz2, R. Mukhopadhyay1
1
Miami, FL (USA), 2Kiel (Germany)
82.013
Chagas disease: Mother to child transmission (MTCT).
A single experience in a public hospital from Buenos Aires
M. T. Rodriguez Brieschke, M. Seoane, C. Nieto, V. Loggia, E. Bottaro,
M. Giacco, J. C. Gonzalez, P. G. Scapellato
82.014
Trypanosoma cruzi expressing luciferase for drug screening using a
Bolivian strain
S. Nunez1, H. Mayta1, M. Verastegui1, C. Lafuente2, C. Bern3, R. Gilman4
1
Lima (Peru), 3Santa Cruz (Bolivia), 3Atlanta, GA (USA), 4Baltimore, MD (USA)
FRIDAY
82.008
•
March 12, 2010
Final Program ~ 197
Session 83
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
VACCINES AND VACCINE DEVELOPMENT
198 ~ Final Program
83.001
The effectiveness of one dose of varicella vaccine
Z. Kurugol
Izmir (Turkey)
83.002
Production and characterization of a chimeric recombinant protein from
synthetic genes consisting antigenic domain of EspA, Intimin and Tir of
Escherichia coli O157 and evaluation as a candidate vaccine antigen
in animal model
J. Amani, S. L. Mousavi, S. Rafati, A. H. Salmanian
83.003
Variability of PspC (Pneumococcal surface protein C) in strains isolated in the
University Hospital of the University of São Paulo (Brazil)
A. T. Moreno1, D. M. Ferreira1, F. C. Pimenta2, S. R. Santos1,
M. B. Martinez1, E. Miyaji1
1
São Paulo (Brazil), 2Atlanta, GA (USA)
83.004
Combination of whole cell pertussis vaccine and the pneumococcal surface
protein A (PspA) antigen: proposal of a combined vaccine against pertussis and
pneumococcal diseases
M. L. Sarno de Oliveira, D. M. Ferreira, A. T. Moreno, P. C. D. Ferreira,
E. Miyaji, P. Ho
São Paulo (Brazil)
83.005
Protection against pneumococcal nasopharyngeal colonization in mice
immunized with PspC (“Pneumococcal Surface Protein C”)-based vaccines
formulated with whole bacteria as carriers or adjuvants
M. De Lúcia Hernani, D. M. Ferreira, P. C. D. Ferreira, A. T. Moreno, E. Miyaji,
P. Ho, M. L. Sarno de Oliveira
São Paulo (Brazil)
83.006
Immunogenicity of interleukin 12 and DNA vaccine prime-BCG boost against
Mycobacterium tuberculosis
L. Bao, L. Gao, Y. Bao
Chengdu (China)
83.007
The role of inactivated polio vaccine (IPV) in achieving polio eradication in India
A. Bhatti
Delhi (India)
Session 83
Hyatt Regency Miami
12:30–13:30
Know essentials—A novel algorithm for informed vaccine-related
decision-making in developing countries.
J. L. Mathew
Chandigarh (India)
83.010
vax-SPIRAL®: Cuban antileptospirosis vaccines for humans: Clinical and field
assays and impact of the vaccine on the disease after 11 years of application
in Cuba
R. Martínez
Ciudad Habana (Cuba)
83.011
Immunization with surface protein 2 (TcSP2) protects mice from acute
experimental Trypanosoma cruzi infection: A potential candidate for
vaccine development
A. Carabarin, C. González, L. Baylon-Pacheco, J. L. Rosales-Encina
México (Mexico)
83.012
Long term immunogenicity following a booster dose of the inactivated Japanese
encephalitis vaccine IXIARO®, IC51
K. L. Dubischar-Kastner1, S. Eder1, T. Jelinek2, B. Jilma1, A. Kaltenboeck1,
H. Kollaritsch1, E. Schuller1, C. Klade1
1
Vienna (Austria), 2Berlin (Germany)
83.013
Cost effectiveness of Pneumovax® 23 stockpile to prevent secondary
pneumococcal infections among a high-risk population in the United States
during an influenza pandemic
P. Dhankhar1, J. Grabenstein2, M. O’Brien2, E. J. Dasbach1
1
North Wales, PA (USA), 2West Point, PA (USA)
83.014
Cost-effectiveness of the use 23-valent pneumococcal polysaccharide vaccine to
prevent secondary bacterial infections related to pandemic influenza in Brazil
M. O’Brien1, P. Dhankhar2, J. Grabenstein1, E. J. Dasbach2
1
West Point, PA (USA), 2North Wales, PA (USA)
Final Program ~ 199
March 12, 2010
83.009
•
Antibody persistence 22 months after vaccination of adolescents with the
Novartis investigational meningococcal ACWY-CRM197 conjugate vaccine
or Menactra®
C. Gill1, A. Anemoma2, G. Ciavarro1, A. Kleinschmidt3, P. Dull1
1
Cambridge, MA (USA), 2Siena (Italy), 3Marburg (Germany)
FRIDAY
83.008
Session 83
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
200 ~ Final Program
83.015
Impact study of hepatitis B vaccination in Sikkim—A north eastern state of India
A. Verma, V. Gupta
Gangtok (India)
83.016
A vaccine derived poliovirus case in an immunocompromised argentinian child
M. E. Burgos, S. Elkik, P. Barbosa, M. Oleastro, C. Freire, A. Parra, M. Caparelli,
C. Sarkis
83.017
Influenza vaccine: Immunization rates, knowledge, attitudes and practice of
health care workers in Iran in 2008/09
Z. Khazaeipour, N. Ranjbar Novin, N. Hoseini
83.018
Variable serological response to PPV in HIV-positive patients—A need to review
pneumococcal boost-prime strategies?
A. Brown, C. Rock, C. Ní Bhuachalla, T. Coulter, C. Dowling, C. Bergin
Dublin (Ireland)
83.019
The generation of immortalized human B-lymphocytes secreting neutralizing
monoclonal antibodies against Dengue virus
E. Teoh
83.020
Factors Contributing to Uptake of the Publicly-funded HPV vaccine in Toronto
H. Meghani, V. Dubey, O. Kadri, A. Mathur, J. Cameron, K. Beckermann
Toronto, ON (Canada)
83.021
Effectiveness of influenza vaccine in elderly people with chronic pulmonary and
cardiovasculardiseases in Argentina
F. Nacinovich, P. Bonvehi, R. Ruttimann, D. Stamboulian
83.022
Development and immunogenicity of a novel polyetherimine (PETIM)
endrimer-based nanoformulated DNA rabies vaccine
M. Shampur, U. Padinjarenmattathil, A. Desai, J. Narayanaswamy
Bangalore (India)
Session 83
Hyatt Regency Miami
12:30–13:30
83.023
Factors associated with DPT 1–3 vaccine dropout in Kabarole district,
western Uganda
M.-S. Opollo, F. Makumbi, D. Mukanga, O. Namusisi, N. Ayebazibwe,
R. Tweheyo
Kampala (Uganda)
83.024
Antibody persistence 10 years after 1st and 2nd doses of 23-valent
pneumococcal polysaccharide vaccine (PN23), and immunogenicity and safety
of 2nd and 3rd doses in older adults
S. Manoff1, R. McFetridge1, C. Liss1, R. Marchese1, J. Rabb2, A. Rueda3,
D. Musher3
1
North Wales, PA (USA), 2Wayne, PA (USA), 3Houston, TX (USA)
83.025
Public health approach after detection of an iVDPV case in Argentina
M. C. Freire, M. Caparelli, S. Garcia Jimenez, D. Cisterna, C. Vizzotti,
C. Lema, A. Gentile
83.026
Yellow fever vaccine (YFV) and events supposedly attributable to
vaccination or immunization (ESAVIs): Argentina’s experience
C. Vizzotti, C.Biscayart, D. Stecher, E. Perez Carrega, M. A. Morales, C. Digiglio,
D. Enria, T. Orduña, S. Garcia Jimenez, A. Gentile, S. Betancourt, M. Diosque
83.027
Genetic characterization of Mycobacterium bovis BCG Mexico 1931
P. Orduña1, Y. López1, M. A. Cevallos2, S. Ponce de León1
1
Mexico City (Mexico), 2Cuernavaca (Mexico)
83.028
Pneumococcal vaccination—Is hyporesponsiveness a problem?
H. Lode
Berlin (Germany)
FRIDAY
•
March 12, 2010
Final Program ~ 201
Session 84
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
VIROLOGY AND VIRAL INFECTIONS (NON-HIV)
202 ~ Final Program
84.001
Intravenous immunoglobulin manufactured from selected Chinese donors
protects mice from lethal Enterovirus 71 infection
R. Cao, J. Han, E. Qin, C. Qin
Beijing (China)
84.002
Polio controling Nigeria and other developing countries: A systematic review/
meta-analysis of literature on the use of combined OPV & IPV measure as
against OPV only
S. I. Ezikeanyi
Abuja (Nigeria)
84.003
Factors associated with outbreaks of measles in the highly immunized hilly areas
of district Kangra, Himachal Pradesh, India, 2007
S. N. Gupta1, V. ramachandran2, N. N. Gupta1, M. D. Gupte2
1
Kangra (India), 2Chennai (India)
84.004
Outbreak investigations of double measles in a two highly immunized hilly areas
of district Kangra, Himachal Pradesh, India, 2007
S. N. Gupta1, V. ramachandran2, N. N. Gupta1, M. D. Gupte2
1
Kangra (India), 2Chennai (India)
84.005
Higher prevalence of norovirus than rotavirus as cause of acute gastroenteritis in
hospitalized infants of Concepcion, Chile
S. Montenegro, S. Pineda, I. Enriquez, N. Enriquez, M. Pinilla,
N. Rivera, C. Delgado
Concepcion (Chile)
84.006
Lessons that human virology can acquire from studies on avian circoand tumor viruses
I. Davidson
Bet Dagan (Israel)
84.007
Optimization of IgG-ELISA and molecular analysis of Reston-ebolavirus among
swine in Northern Luzon, the Philippines
S. Yusuke1, F. Shuetsu2, S. Mariko1, C. Demetria3, I. Itoe2, M. Tetsuya2,
S. Masayuki2, O. Momoko2, S. Akira1, S. Lupisan3, K. Ichiro2, R. Olveda3,
O. Hitoshi1, M. Shigeru2
1
Sendai (Japan), 2Tokyo (Japan), 3Manila (Philippines)
84.008
A newly discovered viral enzyme capable of alteration of nucleic acid structure
via phospho-triester and phosphodiester bonding complex: An event leading to a
new frontier of research and development for viral diseases
D. Pan
Madison, WI (USA)
Session 84
Hyatt Regency Miami
12:30–13:30
Symptomatic, long-term Parvovirus B19 infection in otherwise healthy adults
R. Manfredi
Bologna (Italy)
84.011
Detection of Sudan ebolavirus (strain Gulu) epitopes that are targets of the
humoral immune response in survivors
A. Sobarzo1, A. Groseth2, O. Dolnik2, S. Becker2, J. J. Lutwama3, V. Yavelsky1,
R. S. Marks1, L. Lobel1
1
Beer Sheva (Israel), 2Marburg (Germany), 3Entebbe (Uganda)
84.012
Full genome sequence analysis of Group B human rotaviruses
D. Yamamoto1, N. Kobayashi1, S. Ghosh1, S. Nagashima2, T. Krishnan3,
M. Chawla-Sarkar3, S. K. Paul4, T. S. Aung5
1
Sapporo (Japan), 2Tochigi (Japan), 3Kolkata (India), 4Mymensingh (Bangladesh),
5
Yangon (Myanmar)
84.013
Diagnostic criteria for Herpes simplex encephalitis: 5 year analysis in
Mofid Children’s Hospital
A. Karimi, M. Hadipour Jahromy, S. Tabatabaei
84.014
Problems Associated with Community-Based Parenteral Anti-Infective Therapy
with Intravenous Ganciclovir for Cytomegalovirus Prophylaxis in Allogeneic
Hematopoietic Stem Cell Transplant Recipients
S. Mossad, N. Shrestha, S. Rehm, R. Avery, B. Bolwell
Cleveland, OH (USA)
84.015
A description of the pathogenesis associated with pirital virus (an arenavirus)
infection in the Syrian golden hamster
R. Stammen, J. Garver, S. Sarrazine, E. Vela
Columbus, OH (USA)
84.016
Modification of the type I interferon and proinflammatory cytokine responses
by enterovirus 71
Y.-P. Lee, S.-W. Huang, Y.-F. Wang, C.-K. Yu
Tainan City (Taiwan, R.O.C.)
84.017
The study of epidemiological data of varicella and its complications in
Albanian children
H. Hoxha, E. Kallfa-Foto, G. Lito, R. Petrela, A. Simaku
Tirana (Albania)
Final Program ~ 203
March 12, 2010
84.010
•
Infectious mononucleosis in Albanian children
R. Petrela, E. Kallfa, G. Lito, H. Hoxha, G. Mullalli, N. Como
Tirana (Albania)
FRIDAY
84.009
Session 84
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
204 ~ Final Program
84.018
Latent manifestations in the US Congenital Rubella Syndrome (CRS) Population
N. Armstrong
Rockville Centre, ny (USA)
84.019
Inhibition of high risk HPV-31 in human cervical epithelial cells in vitro by the
PC-PLC inhibitor LMV-601
E. Amtmann1, F. Mayer2, H. Pink1, W. Baader1
1
Heidelberg (Germany), 2Basel (Switzerland)
84.020
The pain topography caused by misdiagnosed zoster
K. Duraku, N. Como, E. Meta, D. Kraja, A. Kica
Tirane (Albania)
84.021
Study on the prevalence of human bocavirus among children with acute
respiratory tract infection in Guangdong, China
X. Lu
ShenZhen (China)
84.022
Deciphering the infectious entry process of human entrovirus 71
K. Mohamed Hussain, K. L. J. Leong, M. L. Ng, J. J. H. Chu
84.023
The clinical severity of Puumala hantavirus-induced nephropathia epidemica
and partial complement protein C4 deficiencies
J. Sane1, S. Mäkelä2, S. Meri1, A. Vaheri1, O. Vapalahti1, J. Mustonen2
1
Helsinki (Finland), 2Tampere (Finland)
84.024
Diagnosis of congenital cytomegalovirus infection by detection of viral DNA in
urine of neonates in Honduras—Advances
A. Ferrera Boza, M. Rivera, A. Mena, J. Ortiz
Tegucigalpa (Honduras)
84.025
Epidemiology of human rhinovirus C (HRV-C) in Hong Kong reveals a potential
HRV-C subgroup
C. Y. Yip, S. K. P. Lau, K. H. Chan, P. C. Y. Woo, K. Y. Yuen
Hong Kong (China)
84.026
The role of human papillomavirus Infection in prostate carcinoma
A. Aghakhani, R. Hamkar, M. Parvin, M. Banifazl, A. Eslamifar, A. Ramezani
Session 84
Hyatt Regency Miami
12:30–13:30
Rotavirus diarrhea in Kashmir: Detection of genotype G12P[6] strains
I. Ahmad
Kashmir (India)
84.028
Surveillance of rotavirus strains reveals evidence of emerging G12 and unusual
human-animal reassortant strains in Manipur, North-eastern India
A. Mukherjee, M. Chawla-Sarkar
Kolkata (India)
84.029
The nucleocapsid protein of measles virus and other morbillivirus blocks host
interferon signaling pathway
I. Takayama, H. Sato, C. Kai
Tokyo (Japan)
84.030
Analysis of phosphorylation residues on Nipah virus nucleoprotein and role
of the phosphorylation
M. Huang, H. Sato, K. Hagiwara, A. Watanabe, F. Ikeda, M. Oyama,
M. Yoneda, C. Kai
Tokyo (Japan)
84.031
Regulation of poly(A) binding protein during herpes simplex virus infection
O. G. Larralde-Diaz1, R. W. P. Smith1, P. Malik1, S. V. Graham2, N. K. Gray1
1
Edinburgh (United Kingdom), 2Glasgow (United Kingdom)
84.032
Complications of varicella in healthy children in Izmir, Turkey
Z. Kurugol, O. Halicioglu, I. Devrim, G. Koturoglu, F. Vardar, C. Dizdarer,
M. Helvacı
Izmir (Turkey)
84.033
Para influenza type 3 epidemic in intermediate care nursery
K. AlTawil, S. Al Saif, I. Ali, H. Tawakol, A. Shafei
Riyadh (Saudi Arabia)
84.034
Introduction of a new lineage VP7 of rotavirus G1 in the Venezuelan population
E. Vizzi, O. Piñeros, A. C. Alcala, L. Naranjo, J. A. Suarez, F. Liprandi
Caracas (Venezuela)
FRIDAY
84.035
The nucleocapsid protein of SARS CoV interacts with PIAS1 and affects
the NFkappaB pathway
N. Satija, R. Ahmed, S. Lal
Delhi (India)
March 12, 2010
Final Program ~ 205
•
84.027
Session 84
Hyatt Regency Miami
12:30–13:30
FRIDAY
•
March 12, 2010
206 ~ Final Program
84.036
Molecular epidemiology of rhinoviruses among children diagnosed as
severe pneumonia in the Philippines
N. Fuji1, A. Suzuki1, S. Lupisan2, R. Tamaki2, M. Saito2, A. De Leon3,
R. Olveda2, H. Oshitani1
1
Sendai (Japan), 2Manila (Philippines), 3Tacloban (Philippines)
84.037
Ferrovir in treatment of viral infectious diseases
E. Kaplina1, E. Nazarova2, V. Ignatiev3, I. Evstaphieva1, N. Nosik1, D. Nosik1
1
Moscow (Russian Federation), 2Kirov (Russian Federation),
3
Saransk (Russian Federation)
84.038
Initial poor prognostic factors of echovirus 6 and 9 infections in children
H.-Y. Lee1, Y.-C. Huang1, C.-T. Wu1, C.-H. Chiu1, T.-Y. Lin2
1
Taoyuan (China), 2Linkou (Taiwan, R.O.C.)
84.039
Detection and clinical characterization of WU polyomavirus with acute
respiratory tract infection in children, Guangdong of China
X. Lu1, Q. Wang1, W. L. Zhuang2, G. Y. Lin2
1
ShenZhen (China), 2ShanTou (China)
84.040
Amplification of early genes of Human Papilloma Virus targeting nine virus
genotypes. Z Mérida, Venezuela
E. Michelli1, L. Tellez1, J. Mendoza1, C. Jurgensen1, W. Botello1, M. Correnti2,
M. Cavazza2, S. Vielma1
1
Merida (Venezuela), 2Caracas (Venezuela)
84.041
Development of a new genotyping system for predicting TTV genotype using
evolutionary restriction map and artificial neural network
A. Kenarkoohi1, M. Ravanshad1, S. Falahi1, M. Rasouli2
1
Tehran (Islamic Republic of Iran),2Shiraz (Islamic Republic of Iran)
84.042
Seroprevalence of human cytomegalovirus infection in Singapore
H. N. Leong, B. H. Tan, S. H. Lim, K. P. Chan
Session 84
Hyatt Regency Miami
12:30–13:30
84.043
Viral load and genome integration detection: Two molecular markers for
HPV persistent infection
C. Jurgensen1, S. Vielma1, E. Michelli1, L. Tellez1, J. Mendoza1, M. Muñoz1,
M. Correnti2, M. Cavazza2
1
Merida (Venezuela), 2Caracas (Venezuela)
84.044
Rabies cases in dog markets in Kaduna state, northern Nigeria
A. Ehimiyein1, M. Niezgoda1, L. Orciari1, I. Kuzmin1, M. Osinubi1, |
I. O. Ehimiyein2, D. Adawa2, S. Abdullahi2, A. Ogunkoya2, C. E. Rupprecht1
1
Atlanta, GA (USA), 2Zaria (Nigeria)
84.045
Clinical and epidemiological aspects of mumps virus infection
L. Maninska, M. Arapova
Strumica (Macedonia)
84.046
Spatial and temporal trends of the Lassa fever epidemic in Nigeria 2001–2009,
with particular reference to the Edo State experience
G. Akpede1, D. Asogun1, P. Okokhere1, S. Okogbenin1, H. Akpan H.2,
J. Ehiemuan1, C. Happi3, S. Gunther4
1
Irrua (Nigeria), 2Abuja (Nigeria), 3Ibadan (Nigeria), 4Hamburg (Germany)
84.047
Immunocompromised patients with shingles—Therapeutic approach
L. Zabaznoska, L. Ilieva, V. Markovski, V. Semenakova-Cvetkovska
Skopje (Macedonia)
84.048
Peculiar case of herpetic viral encephalitis
S.-M. Draghici, N. Negrut, A. Csep, I. Zaporojan, M. Petric
Oradea (Romania)
FRIDAY
•
March 12, 2010
Final Program ~ 207
Faculty Disclosures
In order to assure the highest quality programming, individuals in a position to control conference content are
required to disclose relevant financial relationships with any commercial or proprietary entity producing health care
goods or services relevant to the content being presented. The following speakers have no disclosures.
SPEAKER NAME
SPEAKER NAME
ACUNA Guillermo (Chile)
LLOVERAS Susan (Argentina)*
ALTER Galit (USA)
LOPARDO Gustavo (Argentina)*
AMBROSIONI Juan (Argentina)
LOUTAN Louis (Switzerland)*
ANSDELL Vernon (USA)*
MACCHI Alejandra (Argentina)*
ARGUIN Paul (USA)*
MADOFF Larry (USA)
AULT Steven (USA)
MAGILL Alan (USA)*
BARBOSA Jarbas (Brazil)*
MALAQUE Ceila (Brazil)
BARACCO Gio (USA)*
MASCHERETTI Melissa (Brasil)
BARRE-SINOUSSI Francoise (France)
McCULLERS Jonathan (USA)
BHUTTA Zulfiqar (Pakistan)
METZGER Dennis (USA)
BISCAYART Cristian (Argentina)*
MOORE Penny (USA)
BOCKARIE Moses (UK)
MORENS David (USA)
BOULOS Marcos (Brazil)*
MOROSINI Maria Isabel (Spain)
BRITO Maximo (USA)
MOSSAD Sherif (USA)
CABADA Miguel (PERU)*
MOUNTS Anthony (Switzerland)
CARROLL Dale (USA)*
MULHOLLAND E.K. (United Kingdom)
CARTER Keith (USA)
NDASE Patrick (Uganda)
CETRON Martin (USA)*
NORDMANN Patrice (France)
CHAVES Tania (Brazil)*
NYARUHIRIRA Alaine (Rwanda)
CHRISTIANSEN Keryn (Australia)
ODIO Carla (Costa Rica)
CONDE Marcus (Brazil)
PASTERAN Fernando (Argentina)
CORTES Jorge (Colombia)
PATTERSON, Thomas (USA)
COYLE Christina (USA)
PERRET Cecilia (Chile)*
CUELLAR-RODRIGUEZ Jennifer (El Salvador)
PITTET Didier (Switzerland)
DABANCH Jeanette (Chile) *
RAMIREZ Paula (Spain)
De la MORENA, Maite (USA)
RESTREPO Angela (Colombia)
ESCALANTE Ananias (USA)
RODRIGUEZ-MORALES Alfonso (Venezuela)
FRANCA Francisco (Brazil)*
SANCHEZ Pablo (USA)
FRANCO-PAREDES Carlos (USA)
ROSENTHAL Victor (Argentina)
FREEDMAN David (USA)*
SAEZ-LLORENS Xavier (Panama)
FRIEDLAND Jonathan (United Kingdom)
SAVIO Eduardo (Uruguay)*
GOKHALE Rajesh (India)
SCHWABER Mitchell (Israel)
GOONETILLRKE Nilu (United Kingdom)
SHIBL Atef (Saudi Arabia)
GOOSSENS Herman (Belgium)
SINGHI Sunit (India)
HIRSCH Martin (USA)
SOSA-ESTANI, Sergio (Argentina)
HUSSELL Tracy (United Kingdom)
SOTELO Julio (Mexico)*
JENTES Emily (USA)*
TELLEZ Ildedonso (USA)
KOLTER Roberto (USA)
TORRES Jaime (Venezuela)
LaROSA Steven (USA)
VILA Jordi (Spain)
LEFRANCOIS Thierry (Guadeloupe)
WARRELL David (United Kingdom)*
LEMOS HINRICHSEN Sylvia (Brazil)*
WENZEL Richard (USA)
LEPETIC Alejandro (Argentina)*
WEY Sergio (Brazil)
YADON Zaida (Brazil)
208 ~ Final Program
Faculty Disclosures
In order to assure the highest quality programming, individuals in a position to control conference content are
required to disclose relevant financial relationships with any commercial or proprietary entity producing health care
goods or services relevant to the content being presented. The following disclosures are provided:
SPEAKER NAME
COMPANY NAME
RELATIONSHIP
BEARMAN Gonzalo (USA) Cardinal Health
Pfizer
Vestagen
BioVigil LLC
Investigator Initiated Research Grant
CAHN Pedro (Argentina)
Boehringer-Ingelheim
BMS
Abbott
Pharmasset Merck
Pfizer
Glaxo
Avexa
Tibotec
Schering-Plough
Investigator
Investigator, Speaker’s Bureau
Investigator
Investigator
Investigator, Scientific Advisor
Scientific Advisor
Investigator, Scientific Advisor, Speaker’s Bureau
Investigator, Scientific Advisor, Consultant
CHEMALY Roy (USA) ADMABiologies
Valeant Pharmaceuticals
Roche
GSK
Grant Support
Grant Support
Grant Support
Grant Support
COHEN Myron (USA)
Merck
Consultant
CONRAD Corrie (USA) Google
Employee
CORNEJO Patricia (Mexico) Astra-Zeneca
Merck Sharp & Dohme
Wyeth Janssen
Scientific Advisor
Scientific Advisor & Research Grant
Research Grant
Research Grant
CURCIO Daniel (Argentina) Pfizer
Consultant
DABANCH Jeanette (Chile) *
DAGAN Ron (Israel)
Berna/CRucell
GSK
MSD
Novartis
Protea
Pfizer (Wyeth)
Research Grant, Scientific Consultant, Speaker
Scientific Consultant, Speaker
Research Grant, Scientific Consultant
Scientific Consultant
Scientific Consultant, Shareholder
Research Grant, Scientific Consultant, Speaker
DAIKOS George (Greece)
Novartis
Bayer
Research Grant
Travel Grant
DIAMENT Decio (Brazil) Tibotec/Janssen
Pharmasset
Schering-Plough
Research Grant
Research Grant
Research Grant
EDMOND Michael (USA)
Bio Vigil
Cardinal Health
Research Grant
Research Grant
GISKE Christian (Sweden)
Calixa
Conference Support
GOTUZZO Eduardo (Peru)* Pfizer
MSD
Tibotec
Advisory Board
Grant for
Grant for
GOULD Ian (Scotland) Amoeba
Astellas
Becton Dickinson
Biomerieux
Cubist
GSK
Johnson & Johnson
Lab 901
Lilly
MSD
Novartis
Pfizer
Phico
Wyeth
Zeneca
Consultancy
Consultancy / Sponsorship for meetings
Consultancy
Sponsorship for meetings
Consultancy / Lecture fees / Sponsorship for meetings
Shares / Consultancy
Consultancy
Consultancy
Shares
Consultancy / Lecture fees
Consultancy / Sponsorship for meetings / Lecture fees
Research funding / Consultancy
Research funding / Sponsorship for meetings / Lecture fee
Final Program ~ 209
Faculty Disclosures
SPEAKER NAME
COMPANY NAME
RELATIONSHIP
GRAYBILL Richard (USA) Merck
Pfizer
Speaker with honorarium
Speaker with honorarium, Advisory Board
GUZMAN-BLANCO Manuel (Venezuela)
Pfizer
Advisory Board Member
HAY Roy (United Kingdom) Celtic Pharma
Bayer Consumer Health
International Advisory Board
Consultant
HEATH Paul (United Kingdom) Novartis Sanofi Pasteur
Wyeth
Research Grant
Research Grant
Research Grant
HIRSCH Hans (Switzerland) Biogen Idec
Chimerix Inc
Novartis Pharma
Wyeth
Consultant
Research Grant
Research Grant
Consultant
ISTURIZ Raul (Venezuela)* Pfizer
Sanofi Pasteur
Advisory Board Committee
IDMC Membership
JACOBS Michael (USA)
Abbott Pharmaceuticals
ARPIDA Pharmaceuticals
Aventis Pharmaceuticals
Basilea Pharmaceuticals
Bayer Pharmaceuticals
BMS Pharmaceuticals
Cerexa Pharmaceuticals
Daiichi Pharmaceuticals
Dr. Reddy’s Laboratory
Eli Lilly & Co
GeneSoft Pharmaceuticals
GSK Pharmaceuticals
Lupin Pharmaceuticals
Meiji Pharmaceuticals
Ortho-McNeil Pharmaceuticals
Pfizer, Inc.
Rambaxy Laboratories
Roche Pharmaceuticals
Sanofi-Pasteur Pharmaceuticals
TAP Pharmaceuticals
Warner-Lambert Pharmaceuticals
Wockhardt Pharmaceuticals
Wyeth Ayerst/
Lederle Pharamaceuticals
Research Grants, Consultant
Research Grants
Research Grants
Research Grants, Consultant, Speakers Bureau
Research Grants
Research Grants
Research Grants
Research Grants
Consultant
Consultant
Research Grants
Research Grants
Research Grants
Research Grants
Consultant
Research Grants
JONG Elaine (USA) Berna-Crucell
GlaxoSmithKline
Novartis
Speakers Bureau
Medical Advisory Board
Medical Advisory Board
KLUGMAN Keith (USA)
Pfizer Vaccines
Merck Vaccines
GSK Vaccines
Sanofi Vaccines
Novartis Vaccines
Research Support & Consultancy
Consultancy
Consultancy
Consultancy
Consultancy
KRCMERY Vladimir (Slovakia)
Targanta
Pfizer
GSK
Pfizer
Pliva
Advisory Board 2008
Research Grants 2000–2009
Speaker 2001
Speaker 2009
Speaker 2007
MACCHI Alejandra (Argentina)* McCARTHY Anne (Canada)* Shorelands, Inc,
Consultant
MIRO Jose (Spain)
Abbot
Boehringer-Ingelheim
Bristol-Myers Squibb
Cubist
Gilead Sciences
Glaxo Smith Kline
Merck
Novartis
Pfizer
Theravance
Consultant, Speakers honoraria
Research Grant
Consultant, Research Grant, Speakers honoraria
Research Grant, Speakers honoraria
Consultant, Research Grant, Speakers honoraria
Research Grant
Research Grant, Speakers honoraria
210 ~ Final Program
Faculty Disclosures
SPEAKER NAME
COMPANY NAME
RELATIONSHIP
MONTO Arnold (USA) CSL
GSK
Novartis
Roche
Sanofi Pasteur
DSmB
Consultant
DSmB member
Consultant
Grant
MURILLO, Jorge (USA) Cubist
Ortho-McNeil
Pfizer
Speaker
Speaker
Speaker
NAU Roland (Germany)
Vasopharm
Research Grant
NUCCI Marcio (Brazil) Astellas
Merck
Pfizer
Consultant
Research Grant, Speaker, Consultant
Research Grant, Speaker, Consultant
NUERMBERGER Eric (USA) Pfizer
Otsuka
Research Grant, Patent
Research Grant
ORDUNA Tomas (Argentina)*
Novartis Argentina
Advisor
PATTERSON, Thomas (USA) PELTOLA Heikki (Finland)
Serum Institute of India
Novartis Vaccines Consultant
Monitor
PONCE de LEON Samuel (Mexico)
Laboratoris de Biologicos y
Reactivos de Mexico, (BIRMEX)
a state owned company
General Director
RAMIREZ Paula (Spain) RISQUEZ PARRA Alejandro (Venezuela)*
Sanofi Aventis Vaccine Venezuela
Wyeth/Pfizer Venezuela
GSK Venezuela
Speaker, Research Grant
Speaker, Research Grant, Consultant
Speaker
RUBINSTEIN Ethan (Canada) Astellas
Bayer
Cubist
Pfizer
Theravance
Consultant
Consultant
Consultant
Consultant
Consultant
SARMENTO e CASTRO Rui (Portugal)
Janssen Cilag
Roche
Schering Plough
Boehringer
Participation in Advisory Board
STEFFEN Robert (Switzerland)*
Dr Falk Pharma
Intercell
Janssen-Cilag
Johnson & Johnson
Optimer
Salix
Santarus
Principal Investigator
Consultant
Sponsored Lectures
Consultant
Principal Investigator, Sponsored Poster Presentation
Research Grant, Sponsored Lecture
Consultant
THOMSON, Kenneth (USA) Merck
Becton Dickinson
Biomerieux
Ortho-McNeil
Speaker, Research Grants
Speaker, Patent Holder, Research Grant
Research Grants
Research Grant
Final Program ~ 211
Authors Index
Abalos G. 77.024
Abarca K. 80.024
Abati P. 29.018
Abbasi F. 23.011
Abbass A. 75.032
Abd Elfadeel A. S. 28.047
Abd-Elmagid E. 23.018
Abdallah F. 21.007
Abdollahpour G. 51.013
Abdool Karim S. 17.003
Abdossamadi Z. 56.016
Abdul Majid M. S. 53.021
Abdul Wahab Z. 56.005
Abdullahi S. 84.044
Abdul Rahman H. 27.031,
27.018
Abedi F. 53.020
Abel P. 30.003, 30.002
Abousaidi H. 53.005
Abrahams M.-R. 17.003
Abrao P. R. 54.002
Abreu C. 58.027, 32.031
Abreu R. G. 57.032
Abubakar I. 32.010
AbuSamah B. 27.018, 27.031
Acharya A. 74.001
Acharya K. K. V. 52.007
Achí R. 52.001
Achilla R. 57.037
Ackerman A. 33.001
Acuña G. 02.002
Adamis G. 82.004
Adams C. 81.019
Adamu Kida M. 26.007
Adawa D. 84.044
Adegbola R. A. 21.006, 77.022
Adejumo A. 78.012, 78.010
Adeyemi O. 81.020
Adhikari N. 74.011
Adnan A. 56.005
Adu-Gyasi D. 57.004
Adu-Sarkodie Y. 23.003
Affram Y. 27.008, 54.001
Afifi R. 34.004
Afiune J. B. 59.023, 59.018
Afjeiee S. A. 77.003
Afsali H. 59.003
Afzal Aghee M. 30.008
Agafonov A. P. 75.019
Agarwal J. 40.001
Aghakhani A. 27.004, 53.002,
59.005, 84.026, 53.010
Agosti M. R. 52.021
Agrawal A. S. 57.023
Agrawal C. S. 25.005
Agrawal S. 52.006
Agudelo C. 78.019
Agudelo P. 47.001
Aguiar-Alves F. 51.015
Aguilar J. 27.015
Aguilera G. 75.036
Aguilera K. 32.016
Aguilera W. 58.018
212 ~ Final Program
Aguilera X. P. 76.029, 57.034
Ahmad I. 84.027
Ahmad Mahayiddin A. 33.009
Ahmed A. 33.002
Ahmed R. 84.035
Ahmed W. 49.001
Ahmetagic S. 34.016
Aiello A. 80.016
Aiello A. E. 65.003, 28.036
Aissaoui L. 56.013, 56.008
Ait Belghiti F. 28.037
Ajogi I. 26.001
Akalu T. 81.011
Akhavan Sepahi A. 33.010
Akhimien M. O. 26.009, 57.022
Akhter K. 79.006
Akhter S. 49.001
Akin S. 78.015
Akinbami A. 58.001, 57.001
Akinsola A. 77.022
Akinwande O. A. 27.005
Akira S. 84.007
Akolo C. 78.004
Akpaka P. E. 33.005
Akpan H. H. 84.046, 26.009
Akpede G. 51.018
Akpede G. 76.021, 76.022,
84.046
Aksoy A. 75.014
Al Saif S. 84.033
Al-Jesmi H. 58.005
Al-Moslih M. 53.008
Al-Natour S. 50.001
Al-Zarouni M. 58.005
Alabi O. 25.010
Alan E. 75.014
Alana F. 79.010
Alao O. 77.018
Alarcon F. 76.023
Alawad M. F. E. M. 75.030
Albano C. 58.018
Albernaz R. 24.017
Albornoz H. 51.012, 25.015
Alcala A. C. 80.011, 84.034
Alcala W. 28.004
Alcid D. 23.008
Aldaba J. 33.014
Aldrete S. D. M. 56.031
Alemayehu T. 56.004
Alensi C. 81.022
Aletti A. 72.004
Aleuraki G. 23.002, 74.017
Alexopoulos A. 26.008
Ali H. 21.007
Ali I. 84.033
Alian S. 53.001
Alipour Espeh-kolaie M. 51.025,
51.013
Alkan M. L. 27.005
Alkarsani M. E. M. 57.033
Alley C. 76.032
Almasi Nokiani F. 27.020
Almeida D. 76.006
Almeida G. D. 30.020, 23.025,
30.023
Almeida J. 23.025, 30.023,
23.024
Almeida J. P. 78.006
Almeida L. G. 33.013
Almeida JR J. N. 30.020
Alomar Y. 34.022
Alsisto S. 32.021
AlTawil K. 84.033
Altcheh J. 72.004
Alter G. 17.001
Altouvas G. 74.012
Altunay H. 75.014
Alvarez C. 28.053
Alvarez C. 56.030
Alvarez S. 32.004
Álvarez Moreno C. 56.017
Alves A. 57.012
Alves J. 07.003, 65.009
Alves J. V. 30.015, 30.014
Alves M. F. C. 51.022
AlYasino Y. 34.022
Amador E. 31.004
Amani J. 83.002
Amar Singh H. 75.011
Ambrosioni J. 30.013, 14.001
Ambu L. 32.021
Ameh D. 81.020, 21.006
Amicosante M. 75.007
Amine A. 75.032
Amini Navaie B. 51.013, 51.025
Aminu S. 80.025
Amirbozorgi G. 51.013, 51.025
Amoako-Sakyi D. 73.009
Amro A. 82.010
Amtmann E. 84.019
Amuasi J. 29.016
Anand K. 33.006
Ancona Lopez F. 27.012, 27.013
Andersen B. M. 56.011
Anderson L. J. 40.002
Andión E. 81.024
Andrade A. L. 79.005, 56.042
Andrade C. D. M. 34.025
Andrawa M. 26.010
André M. C. D. P. B. 56.042,
79.005
Anekthananon T. 58.013
Anemoma A. 83.008
Angerami R. 76.030, 28.050,
28.045
Anguaku A. 26.010
Angulo N. 73.016
Anguzu P. 26.010
Angwafo III F. 27.030
Ankunda R. 56.041
Ansari J. 27.017
Ansary A. 52.002
Ansdell V. 32.004, 12.004
Antolovic-Pozgain A. 79.003
Anunnatsiri S. 56.003
Anusic M. 74.004
Anwan E. E. 29.007
Anyimadu H. 77.018
Aoki F. 76.030
Arabshahi M. 34.015
Aragão S. G. A. 31.003
Arakaki N. 32.024
Arana Y. 58.024
Arapova M. 84.045
Aratchige P. 57.017
Araújo C. 73.012
Araujo J. 23.028
Araujo Z. 75.013, 75.009
Arbatskaya E. 76.005
Arbex R. F. 59.023
Arboleda M. 47.001
Arce L. 72.004
Arcidiacono M. L. 81.016
Ardon F. 65.004
Ardung B. 51.002
Arechavala A. 30.018
Arevalo J. 75.043
Arguin P. 19.002
Arikan S. 58.011
Arinyedokiari C. 50.003
Aristizabal G. 28.053
Armah G. E. 80.022
Armero J. 27.019
Armstrong G. 40.002
Armstrong N. 84.018
Arnold F. 29.008
Aroor S. 80.014
Arraes-Alencar L. C. 53.035
Arrese E. 53.026
Arrese E. 53.015
Arrestia M. 32.027
Arrouk R. 59.024
Arruda R. 75.033, 75.038
Arthur A. 81.007
Arvelo W. 40.004, 65.004
Asghar R. J. 27.017
Asiimwe B. 75.035
Asiko V. 59.016
Aslan M. 30.005, 58.011,
53.013, 82.007, 30.006,
75.014
Asma I. 75.012
Asogun D. 51.021, 51.018,
84.046, 76.021, 76.022,
72.003
Assetta A. M. 78.014
Assmar M. 51.025, 51.013
Astriti M. 82.004
Ataei B. 53.018
Ataie M. 53.018
Atchley D. 75.036
Atencio R. 79.011
Athanazio D. 77.005, 47.008
Atluri V. S. R. 82.012
Atluri V. S. R. 58.004
Atmar R. L. 11.003
Augusto K. 28.045, 28.050
Ault S. 39.002
Ault S. K. 57.034
Authors Index
Aung T. S. 84.012
Avendano E. 56.032
Avery R. 84.014
Ávila C. A. L. 77.011
Awad L. A. 33.002
Awaisu A. 27.018, 27.031,
33.009
Ayala J. 52.018
Ayebazibwe N. 83.023
Aymelek M. 75.014
Ayora-Talavera G. 57.021
Azairwe R. 80.007
Azarifard F. 75.027, 75.028
Azevedo T. 76.006
Azimi Rad M. 34.015
Aziz F. 49.001
Azocar T. 28.039
Azodo C. 56.020, 27.016
Baader W. 84.019
Baassli L. 75.007
Babaei Z. 58.010
Babak A. 53.018
Babapoor S. 28.013
Babin C. 65.011
Baboolal S. 33.005
Bacchi C. 82.005
Badal R. 74.002, 23.009
Baddour L. M. 25.017, 25.011,
25.013
Badescu A. 23.019
Badhu B. 25.005
Badji H. 21.006
Badri A. A. 28.047
Badridze N. 30.021, 53.032
Badshah C. 56.028, 77.018
Badung B. 55.009
Baek J.-H. 53.009, 59.007
Baez-Saldaña R. A. 59.017
Bagdatli Y. 75.015
Baghaei K. 52.005
Bagnulo H. 56.029, 28.007
Bai X. L. 24.003
Bailey C. 75.040
Bailey J. 29.010
Bajanca-Lavado M. P. 52.015
Bajic J. 34.016
Bajraktarevic A. 81.017
Bakalli I. 80.006, 56.014
Bakamutumaho B. 28.027
Bakhiet M. 47.003
Balaban V. 32.012
Balajee A. 30.009
Balakrishnan P. 78.005
Ballantyne J. 40.002
Ballester E. 28.019
Balmer J. A. 49.003
Balparda J. K. 56.027
Balqui J. 21.004
Baltadzhiev I. 76.012
Balutescu C. 58.016
Bam O. J. 29.007
Bambili K. 77.002
Bandawe G. 17.003
Banifazl M. 59.005, 53.002,
53.010, 27.004, 84.026
Bannan C. 78.015
Banque Navarro M. 56.043
Banura C. 40.008
Bao L. 83.006
Bao Y. 83.006
Baracco G. 07.004
Baral R. 74.001
Barati M. 56.006
Barbaro D. J. 49.008
Barberis F. 28.004
Barbosa A. 78.006, 77.011
Barbosa H. S. 82.011
Barbosa P. 83.016
Barbosa da Silva Jr J. 05.001,
57.034, 76.029
Barbossa-Cesnik C. 77.028
Barbouche M. R. 31.002
Barboza P. 28.037
Barcelona L. 50.002
Barkat A. 56.017
Barlic - Maganja D. 28.016
Barnett E. D. 21.008, 32.029
Barone A. A. 57.012
Barradas I. 27.024
Barrantes K. 52.001
Barre-Sinoussi F. 09.001
Barreira D. 57.032
Barrios P. R. 34.030
Barry A. 32.005
Bartlett D. 40.003
Basaras M. 53.026
Basaras M. 53.015
Basnyat S. R. 74.011
Bastidas A. R. 77.020
Bastos R. 78.016
Basuno E. 34.026
Bataa J. 76.005
Batchilly A. S. 80.022
Batista L. J. A. 56.042
Batista R. B. 32.033
Batlle M. D. C. 52.018
Bauch C. 28.048, 65.010
Bauer F. 25.002
Bavari S. 75.031
Baveja U. K. 55.015
Baxa D. 27.015
Baylon-Pacheco L. 58.014,
83.011
Bean D. 23.010
Bearman G. 26.011, 81.006,
10.001
Becker K. 56.018
Becker S. 84.011
Becker-Ziaja B. 51.021
Beckermann K. 83.020
Bedenic B. 74.004, 23.005
Behets F. 55.013
Beikert F. 30.011
Beitz E. 82.012
Bel Hadjali Z. 56.008
Bélec L. 27.030
Belhadjali Z. 56.013
Bell T. 80.017
Bellesi V. 25.016
Beltran C. 55.002
Ben Abdennebi Y. 56.008,
56.013
Ben Abid H. 56.008, 56.013
Ben Amor R. 56.008, 56.013
Ben Lakhal R. 56.013, 56.008
Benetucci J. 30.018
Benitez J. 81.009
Benjouad A. 75.007
Benlhassan-Chahour K. 75.022
Benoit C. 21.008, 32.029
Bensenor I. M. 27.022
Bensi E. P. A. 59.020
Bentley Tammero L. 76.007
Bento D. 73.012
Berbari E. F. 25.017
Berberian G. 76.003
Berberian G. 52.004
Berdiñas V. 50.002
Berenji F. 30.008
Berezin E. 51.005, 37.001
Berg D. E. 21.004
Berg J. 56.011
Bergin C. 27.025, 83.018,
78.015
Bergman S. 23.014
Bermudez G. V. M. 34.032
Bern C. 73.016, 82.014
Berro A. 57.005
Bertherat E. 76.010
Betancourt S. 83.026
Betancourt-Cravioto M. 57.021
Betencourt C. 52.015
Bezirtzoglou E. 26.008
Bhalla P. 55.015
Bhandari R. P. 79.008
Bhaskaranand N. 80.014
Bhatia S. 52.008
Bhatti A. 83.007
Bhumbra N. 59.024
Bhumimuang K. 58.013
Bhutta Z. 22.003, 80.019
Bialkowska J. 53.030
Bianchi I. 34.025
Bickle Q. 58.015
Bidaisee S. 34.028
Biedenbach D. J. 48.002
Biedenkopf R. 30.004
Bigger J. 73.008, 73.007
Biketov S. 58.029
Bimal S. 82.006
Bin Abdulhak A. 25.013, 25.011
bin Hasmaini M. H. 53.021
Bino S. 28.017
Bino S. 34.029
Binti Hamzah H. A. 53.021
Birinci I. 75.014
Biscayart C. 78.011, 32.015,
32.034, 32.027, 83.026,
32.020, 06.004
Bishburg E. 56.025
Bissio E. 55.004
Bissuel F. 75.022
Biswas D. 79.007
Biswas S. 52.011
Biya O. 25.010
Blackmore C. 51.026
Blackmore T. 59.021
Blaise K. 72.001
Blanco C. 29.015
Blanco S. 53.015
Blanco S. 53.026
Blanton J. 81.014
Blay S. 29.016
Boakye D. A. 81.021
Boakye I. 29.016
Bobadilla M. 56.031
Boboş C. 23.002
Boccardo E. 27.021
Bochkova N. G. 24.004
Bockarie M. J. 39.004
Bocoli Rossi M. 27.021
Bode C. 80.026
Bodonaik N. 52.012
Boehringer C. 28.023
Boekhoudt J. 76.014
Boffa J. 33.011
Bofill L. 27.027
Boger S. M. 52.022
Boghossian J. 77.019
Bohmer D. 75.006
Bóia M. N. 77.011
Boisson E. 28.046
Boivin G. 65.006
Bojanic J. 34.016
Bok K. 47.006
Bologna R. 80.013, 72.004
Boloorian A. 30.008
Bolstorff B. 23.017
Bolwell B. 84.014
Bonkosky M. 57.031
Bononi do Carmo F. 27.010
Bonvehi P. 83.021, 28.004
Booth L. 77.019
Borchardt S. M. 74.010
Borchichi L. 72.004
Borges A. D. F. 28.015
Borges M. C. L. 25.004
Borghi D. 53.003, 24.002
Boricic I. 53.023
Borisova O. 77.025
Borkakoty B. 79.007
Borrow P. 17.002
Bosnjak Z. 79.003
Bosnjak Z. 23.005
Botas A. 78.011
Botas M. A. 32.015
Botello W. 84.040
Bottaro E. 82.013
Bouchillon S. 77.004, 74.002,
23.009
Boulianne N. 65.006
Boulos M. 19.003, 29.018
Final Program ~ 213
Authors Index
Bourne V. 17.002
Bouteraa W. 56.008, 56.013
Bouzas M. B. 30.018
Boyd G. J. 77.017
Boze P. F. A. 28.022
Bozic M. 53.007
Bradley S. E. 29.008
Braga C. 53.029, 53.035, 53.028
Braga C. 57.012
Braga W. S. M. 53.031
Brandtner E. M. 24.010
Brar I. 27.015
Brasil R. 24.017
Bray D. 75.022
Braz M. I. P. S. 33.007
Braz W. 24.002
Breitbart M. 76.017
Brewer T. 21.002
Bricks L. F. 28.022
Brigatte M. E. 76.004
Briggs D. 81.014, 34.011
Brito H. F. 59.023
Brito M. 13.004
Brock M. 29.017, 53.031,
78.018
Brown A. 27.025, 83.018
Brown C. 32.001, 57.005
Brown J. 57.010
Brown P. 74.016
Brownstein J. 46.001
Brugues J. 32.022
Brum E. 34.030
Brunette G. 32.005, 32.004,
57.005
Brust T. 51.015
Bu Coifiu Fanego R. 76.023
Budimir A. 23.005
Bueno Sánchez J. G. 48.001
Bujari I. 80.006
Bulik C. C. 49.005
Bulimo W. 57.037
Burattini M. N. 23.025, 30.020
Burazin J. 79.003
Burger E. 30.015, 30.014
Burgert C. 29.008
Burgos M. E. 83.016
Burmaa A. 28.006
Burningham K. 56.002
Buroni M. 28.007
Burt F. J. 24.007, 24.009, 24.008
Busowski J. D. 75.006, 79.006
Busowski M. T. 75.006, 79.006
Busuulwa M. 27.014, 51.006
Buzina W. 30.007
Buzon R. 33.014
Byaruhanga R. 40.008
Byrazeri G. 77.001
Cabada M. 45.001
Cabezas C. 59.010
Cabrera B. 33.014
Cabrera L. 21.004
Caceres H. A. 30.016
Cadogan S. 76.030
214 ~ Final Program
Cahill J. 32.004
Cahn P. 62.001
Caiaffa H. 23.024, 23.025
Cairo H. 81.022, 81.025
Cakan H. 82.007, 58.011
Calanni L. 32.019
Caldas C. 32.031
Caliskan R. 53.013
Callejas D. 79.011
Callejas D. 79.010
Calva J. J. 26.003, 21.003
Calzada L. J. E. 34.008
Camacho A. 56.031
Camara-Mejia J. 79.004
Camargo L. M. 54.002
Camargo M. 52.019
Cameron J. 83.020
Campana M. V. 74.019
Campitelli M. 57.020
Campos F. D. 21.003, 26.003
Canava S. 26.012
Canda P. 53.027
Cane A. 80.010
Canetti M. D. 24.002, 53.003
Cañizal A. M. 30.018
Cannella V. 26.006
Cannon S. 29.014
Cano-Arellano B. 59.017
Cantoni G. 32.019
Cao R. 84.001
Caparelli M. 83.016
Caparelli M. 83.025
Cappellini R. 72.004
Carabarin A. 83.011, 58.014
Carballal G. 28.004
Carbonell N. 81.012
Cardoso A. 57.012
Cardoso J. L. 79.005, 56.042
Cardoso L. 56.038
Cardoso M. R. 57.012, 53.028,
53.035, 53.029
Cariello P. 55.014
Carli M. S. 24.017
Carnevale E. P. 72.005
Carniglia L. 81.024, 81.023
Carranza C. M. 78.014
Carranza M. 77.014
Carrero Y. 79.010, 79.011
Carrilho F. 57.012
Carrillo A. C. 75.024, 76.007
Carrillo-Martinez J. 79.004
Carroll D. 45.004
Carter K. 19.001
Carvalhanas T. R. M. P. 28.030,
28.026, 28.028, 57.018
Carvalho C. X. 56.042
Carvalho J. 28.050
Carvalho N. 51.022
Carvalho R. A. C. 53.031
Carvalho Siqueira E. 28.015
Carvalho valle L. M. 76.004,
28.015
Caseiro M. M. 55.011
Casellas J. M. 74.019
Casimir L. 80.013
Cássio de Moraes J. 51.005
Castañeda B. C. 55.003
Castaño J. C. 58.023
Castaño Osorio J. C. 58.031
Castellanos M. E. 79.011,
79.010
Castillo A. 80.024
Castillo A. I. 31.005, 31.004
Castillo C. 55.003
Castillo R. 34.020
Castillo S. 78.011
Castillo Rojas G. 52.024, 77.029
Castrejon M. M. 80.009
Castrillón D. M. 56.027
Castro G. 76.003
Castro J. G. 27.024
Castro M. 81.012
Castro C. N. 34.003
Castro Cordero A. M. 80.005
Castro del C. N. 34.017
Castro del Campo N. 34.031
Castro Sesquen Y. 73.016
Caterino-de-Araujo A. 78.016
Cavazza M. 84.043, 84.040
Cavrini F. 76.011, 51.019,
24.016, 76.028, 51.020
Cazes C. I. 77.024
Cecchini D. 30.018, 56.034
Cecchini D. M. 52.021
Ceccoli C. 80.010, 80.008
Cecetkova B. 56.023
Ceinos M. C. 80.015
Celaj E. 80.006, 56.014
Celentano A. 25.016
Celik A. 30.005, 30.006
Celum C. 17.004
Cepeda D. 34.020
Cera D. 25.016
Ceragioli Oliveira F. L. 27.013,
27.010, 27.011, 27.012
Cerqueira S. 33.013, 51.017
Cespedes-Zambrano M. J.
34.020
Cetron M. 16.001
Cevallos M. A. 83.027
Chadha M. 28.009
Chae Y. T. 53.009, 59.007
Chagas-Junior A. 47.008
Chakrabarti S. 57.023
Chalandon Y. 30.013
Champin D. 80.023
Chan K. P. 24.003, 84.042
Chan K. H. 28.043, 84.025
Chandra B. K. 56.022
Chandra C. 40.006
Chandra P. 34.010
Chandramohan D. 80.019
Chang H.-L. 40.005
Chanthavisouk C. 57.017
Chanza avino M. 82.009
Chao L.-L. 34.009
Charest H. 65.006
Chatterjee S. 23.001
Chau B. 76.017
Chaudhry R. 80.004
Chaves T. S. 65.009, 06.003
Chávez Gómez A. 56.019
Chavez RIos A. 33.016
Chawla-Sarkar M. 84.012,
84.028, 57.023
Chazan B. 50.004
Cheema A. 30.024
Chemaly R. 69.003
Chen C.-M. 28.032
Chen D. 47.005
Chen H.-Y. 53.034, 75.039
Chen L. H. 21.008, 32.029
Chen S.-C. 76.015
Chen T. 73.011
Chen Y.-S. 75.020
Chen Y.-H. 53.034
Cheong H. J. 56.039
Cheraghipour K. 53.024
Cherki W. 75.007
Chernesky M. 75.005
Chessari M. L. 78.014
Chiabrando R. 72.004
Chiang P.-S. 76.015
Chiarello A. 75.036
Chile N. 58.024
Chima-Oduko E. O. 79.001
Chin B. S. 53.009, 59.007
Chindavongsa K. 57.017
Chitnis D. 23.021
Chitnis S. 23.021
Chitnis V. 23.021
Chiu C.-H. 49.006, 84.038
Chkhartishvili N. 55.008
Chlibek R. 56.023
Cho B. 28.035
Cho E. Y. 51.016
Cho O.-H. 56.040
Choi B. 81.002
Choi E. H. 51.016
Choi H. 53.009, 59.007
Choi H. 21.002
Choi J. Y. 59.007, 53.009
Choi S.-H. 56.040
Choi W. S. 56.039
Chong M. K. 24.013
Chong P. P. 47.007, 73.014
Chong Y. P. 56.040
Chopra D. 80.014
Choreftaki M. 82.004
Chou Y.-P. 28.032
Chow A. 76.002
Christ T. 25.012
Christenson B. 51.002
Christiansen K. 10.002
Christin M. 78.011
Chrysos G. 74.012
Chu J. J. H. 84.022
Chu M. 81.018
Chu V. 25.013, 25.011
Authors Index
Chua A. J. S. 24.010, 24.013
Chua G. 56.005
Chuang J.-H. 40.005
Chudk F. 24.017
Chui L. 33.011
Chun J.-K. 59.022
Churchill Smith M. 32.006
Churchwell G. 51.026
Ciampi A. 21.002
Cias R. 76.027
Ciavarro G. 83.008
Cibuku S. 28.017
Cisneros G. A. 40.007
Cisterna D. 83.025
Cisterna R. 53.015
Cisterna R. 53.026
Clad A. 30.011
Clark T. 57.031
Cleary T. G. 52.023
Cleaveland S. 34.011
Cockayne A. 47.004
Coelho H. 32.028
Coelho R. 32.031
Cohen C. 52.014
Cohen M. 35.001, 17.002
Cohen N. 32.001
Cole E. 81.019
Colindres R. 80.009
Colizzi V. 75.007
Collado L. 28.005
Collado M. 28.005
Colombana P. 57.032
Comach G. 75.036
Como N. 84.020, 84.009,
30.010, 28.017
Conde M. 68.004
Conde-Ferráez L. 79.004
Conley G. B. 29.014
Connolly S. 74.018
Connolly S. N. 74.018
Conrad C. 46.002
Contardi L. 56.034
Contini S. 75.007
Contreras A. M. 28.039
Contreras C. A. 52.023
Contreras M. M. 53.036
Contrini M. M. 80.015, 28.011
Contrini M. M. 77.024
Coral G. 53.028, 57.012,
53.035, 53.029
Coraspe V. 58.022
Cork S. 57.024
Cornaglia G. 20.003
Cornejo A. 80.023
Cornejo P. 61.003
Cornet A. 47.002
Cornistein W. 76.025
Coronado F. 57.031
Corrah T. 21.006, 77.022
Correa E. B. D. 57.012
Correa M. 32.016
Correnti M. 84.043, 84.040
Corso A. 23.020
Cortes C. 28.005
Cortes C. 55.002
Cortes J. 40.003, 40.004
Cortes J. A. 30.016, 28.053
Cortes J. 30.026, 61.002
Cortes L. 24.002
Côrtes R. 55.011
Cortese M. 40.003
Cortez J. 58.018
Costa L. 79.010
Costa M. 53.035
Costa P. 81.014
Costa Jr. V. H. 28.022
Couceiro J. N. S. S. 34.025
Coulborn R. M. 65.003
Coulombier D. 57.013
Coulter T. 83.018
Cowan E. 29.014
Cowling B. J. 28.043
Cox A. 57.013
Coyle C. 12.003
Crespo D. 53.035
Crestto M. 56.044
Criollo-Mora E. 23.028
Cristia Pacheco M. 80.020
Cromeans T. 40.002
Crookston B. 81.019
Crowcroft N. 65.006, 57.020
Cruz Hervert L. P. 59.017
Cruzat V. 28.040
Csep A. 84.048
Cuellar J. 69.001
Cuellar L. 56.017
Cuervo S. I. 30.026
Culebras E. 23.026
Cunha E. F. 78.006
Cunha R. G. 78.006
Curcio D. 61.004
Curi R. 52.019
Curic I. 34.016
Curns A. 40.002, 40.003
Curone M. 56.030, 28.040
Cury A. P. 23.024, 23.025
Cusato M. 49.004
Cutland C. 80.018
Cwayi J. 81.019
Da Silva L. 51.009, 28.010,
51.004, 32.023
Dabanch Pena J. 04.001, 07.002
Dabiri H. 58.026
Dagan R. 22.004
Dai J. 24.006
Daikos G. 41.004
Dakhave M. 28.009
Dakum P. S. 27.005
Damasco P. V. 77.011
Damdinjav B. 34.024
Danburam A. 59.015
Danchinova G. A. 76.005
Daneman N. 57.020
Dangerfield J. A. 24.010
Daniel S. 77.019
Danina F. 32.031
Daniyan C. 55.009
Daoukakis M. 77.002
Dapaah E. 32.013
Dar L. 33.006
Darabus G. 58.016
Darmaa B. 28.006
Darwich N. 32.031
Das R. 80.003
Das S. 24.015
Dasbach E. J. 83.014, 83.013
Dash N. 58.005
Dastugue M. 28.011
Dattani B. 50.003
Davidson I. 84.006
Davis B. M. 65.003
Davis T. M. E. 72.005
Davis X. 32.002, 32.003
Ddamulira J. 27.033
De Andrade-Lima J. R. P. 32.033
De Antonio R. 80.009
de Castro S. L. 82.011
de Cosio G. 57.038
de Gascun C. 27.025
de la Morena M. 43.001
de la Parra G. 32.016
De la Torre A. 33.016
De Landtsheer S. 57.039
De Leon A. 21.005, 84.036
De Lúcia Hernani M. 83.005
de Mena A. 78.013
de Menezes Succi R. C. 27.011,
27.010, 27.013, 27.012
De Paz Garcia R. 33.016
de Quincey E. 76.031, 28.049
De Serres G. 65.006
De Souza E. M. 82.011
De Tora L. 32.023
De Waard J. 75.013
De Wouters L. 32.019
Debbag R. 81.023, 81.024
Debusscher J. 77.028
Deckert M. 31.002
Declich S. 28.037
Dedmon R. 34.011
Del Bianco R. 78.016
Del Castillo M. 32.024
Del Rosario L. 75.023
del Valle J. 80.023
del Valle L. 80.023
Delamain J. 28.045
Delgado C. 59.010, 84.005
Delgado O. 58.022
Delgado González O. 56.026
Delic D. 53.023
Delis V. 82.004
Della Latta M. P. 32.027,
32.034, 32.020
DeMaria A. 23.017
Demetria C. 84.007
Demina O. K. 73.004, 28.012
Demitrovicova A. 25.002
Demos H. A. 52.022
Deng Y. 24.006
Dente M.-G. 28.037
Derakhshan A. 30.008
Dermaux V. 52.014
Derviskadic N. 34.016
DeRyke C. 75.006
Desai A. 24.015
Desai A. 83.022
Desmecht D. 47.002
Devivero R. 53.036
Devrim I. 84.032
Dewan R. 55.015
Dhankhar P. 83.014, 83.013
Dhaubhadel P. 56.028
Dhawan V. 52.006
Dhole T. 51.014, 59.012
Di Marco P. 26.006
Di Stéfano C. 25.008, 77.007,
25.009
Diab R. M. G. 58.006
Diament D. 13.001
Diap G. 29.016
Díaz F. 47.001
Diaz J. E. 56.031
Diaz M. 58.018
Diaz P. 75.025
Diaz R. S. 55.011
Díaz S. Y. 56.027
Diaz Colodrero G. 28.040
Diaz Jidy M. 59.025
Diaz-Mitoma F. 40.009
Dickinson G. 55.005,
Dickinson J. A. 65.006
DiClemente R. J. 65.002
Digalaki K. 74.012
Digiglio C. 83.026
Dimitrova Z. 53.038
Ding Y. 23.022
Diosque M. 83.026
Dixon J. 81.019
Dizdarer C. 84.032
Docherla M. 52.008
Dohmen P. 74.014, 25.012
Dolnik O. 84.011
Domingo C. 75.042
Domotenko L. 75.029
Dookie J.-A. 74.016
Dorea E. L. 27.022
Dorneanu O. 23.019
Dorobat C. 23.019
Dorta-Contreras A. J. 76.023
Doukakis S. 77.002
Dowd J. 80.016
Dowling C. 83.018
Dowzicky M. 74.002, 23.009,
77.004
Draghici S.-M. 26.013, 84.048
Drake C. 23.014
Drews S. J. 65.006
Drgona L. 30.022
Drobeniuc J. 53.038
Drozdov I. G. 75.019, 28.012,
73.004
Du T. 76.026
Final Program ~ 215
Authors Index
Duan J. 55.006
Duarte J. A. 23.024
Dubey V. 83.020
Dubischar-Kastner K. L. 83.012
Dueñas L. 56.017
Duijkeren E. V. 34.027
Duits A. 76.014, 51.003
Dujardin J.-C. 75.043
Dull P. 83.008
Dumitrascu V. 58.021, 58.016
Dumre S. P. 57.014, 74.011,
58.028
Dunkel N. 30.013
Dupont B. 30.007
Duraku K. 30.010, 84.020
Durán C. 56.044
Duran C. 58.022, 58.018
Durlach R. 28.024
Durrant L. G. 47.004
Dvali N. 55.008, 53.025,
30.021, 53.032
Dwivedi S. 58.017
Dzigua L. 53.025, 30.021,
53.032, 55.008
Dzijan S. 79.003
Dzyakanava V. 56.002
Echavarria E. 28.007
Echavarria M. 28.004
Echave C. I. 30.019, 77.024
Echave C. 80.015
Echazarreta S. E. 32.025,
32.030, 32.026, 32.032
Echeverri J. A. 56.027
Echezuria L. 32.017, 81.005
Eckert E. 29.008
Edelstein H. 50.004
Eder S. 83.012
Edmond M. 70.002, 10.001
Edmonds A. 55.013
Edwards J. 73.008
Ehichioya D. 80.026, 51.021,
57.039
Ehiemuan J. 84.046
Ehimiyein A. 84.044
Ehimiyein I. O. 84.044
Ehrlich H. 37.004
Eini F. 75.027, 75.028
Eira M. 27.021
El aouad R. 75.007
El Eman K. 65.011
El Jaish A. 57.035
El Omeiri N. 28.037
El Sheikh M. 75.024, 76.007
El-Naggar W. 23.018
El-Shamy H. 75.032
Elagib R. 28.047
Elam K. 81.006, 10.001, 26.011
Eleckova E. 24.004
Elikwu C. J. 80.026
ElKerdany E. D. 58.006
Elkik S. 83.016
Ellerbrok H. 75.022, 75.021
216 ~ Final Program
Elmassian P. 32.027, 32.015,
32.020, 32.034
ElTemsahy M. M. 58.006
Emikpe B. O. 34.002
Emmanuel M. N. 58.007
Enfedaque C. 30.019
Engell C. 56.025
England K. 76.010
Enria D. 83.026
Enrico A. 28.042
Enrique S. 81.024, 81.023
Enriquez I. 84.005
Enriquez N. 84.005
Entrena García A. A. 75.002
Erdman D. D. 40.002
Ergete 55.001
Ergin S. 53.013
Erima B. 28.027
Erindi E. 28.017
Erzin Y. 30.006, 30.005
Escalante A. 64.002
Esfandiari B. 51.025, 51.013
Eshun-Wilson I. 30.012
Eslamifar A. 27.004, 84.026,
53.002
Espíndola M. S. 82.008
Espinosa F. E. M. 29.017
Esposito D. 40.003, 40.002
Esposto A. 32.016
Essafi M. 31.002
Estevez A. 65.004
Estrada C. 56.027
Estrada-Garcia T. 21.003
Estrada-Garcia T. 26.003
Eugene R. 72.001
Evangelista J. 58.024
Evstaphieva I. 84.037
Ezcurra C. 81.008, 28.024
Ezikeanyi S. I. 84.002
Ezzati M. 25.011, 25.013
Fabres H. 56.044
Fabri I. 34.023
Fabri M. 34.023
Faccioli L. H. 73.005, 82.008,
73.006
Fagnani R. 56.038
Falahi S. 54.004, 84.041
Falcone C. C. 32.026, 32.032,
32.025
Fallah F. 77.003
Fallah Raoufi M. 75.027, 75.028
Fallo A. 28.011, 78.013
Fallon J. 77.019
Fang V. J. 28.043
Farahani S. 59.005
Farazi A. A. 53.010
Farias E. 32.006
Farinati A. 74.019
Farnia M. 57.003
Farnia P. 59.001
Farrell D. 23.027
Farrell D. J. 74.006
Farrell G. 78.015
Farrell J. 58.002, 30.024
Farzaneh-nejad Z. 51.025
Fata A. 30.008
Fata S. 30.008
Favacho A. 76.006
Fe Marques A. 28.019
Fedora M. 75.037
Feitosa T. S. 31.003
Feliciano H. 54.003
Felix A. C. 75.033, 75.038
Feltrin A. 28.050, 28.045
Fenn E. 43.002
Fernandes O. 51.015
Fernandez A. 33.014
Fernández M. 57.011
Fernandez de Larrea C. 75.009,
75.013
Fernández González D. 56.026
Fernández Hidalgo R. 56.017
Fernandez Oses P. 25.020,
25.009, 25.008
Ferraiuoli G. I. D. 25.018
Ferrari A. 26.006
Ferraris A. 77.007, 25.009,
25.008
Ferrauioli G. D. 21.010
Ferreira A. W. 75.038, 75.033
Ferreira D. M. 83.005, 83.004,
83.003
Ferreira L. 57.012
Ferreira L. C. D. L. 78.018
Ferreira M. E. 59.014
Ferreira P. C. D. 83.005, 83.004
Ferreira-Guerrero E. E. 59.017
Ferrer P. 28.039, 80.024
Ferrera Boza A. 84.024
Ferrés M. 28.039, 80.024
Ferreyra-Reyes L. D. 59.017
Ferriani V. P. L. 25.004
Figlerowicz M. 53.016, 53.017
Figueiredo G. 53.029
Figueiredo G. M. 57.012
Figueiredo G. 53.028
Figueiredo G. M. 53.035
Figueras L. 28.004
Figueroa F. 59.018
Finger S. A. 21.004
Fiore A. E. 11.001
Fiorilli G. 80.013
Firpo A. S. 28.042
Firsov A. 49.007
Firstova V. 58.029
Fischer G. E. 40.002
Fishbein D. 40.006, 32.001
Fisman D. 28.048, 65.010
Fité Gallego A. 56.043
Flanagan M. 57.029
Flonta M. 77.016
Flores G. 56.044
Fobil J. 51.011
Fobil J. 80.021, 51.011
Fobil J. 80.021
Foley D. H. 29.012
Fonseca F. A. H. 54.002
Fonseca K. 65.006
Font S. 57.036
Foongladda S. 75.044
Fornells Arentz L. A. 34.025
Fortaleza C. 24.017
Fota-Markowska H. 77.006
Fournier P.-E. 21.010
Fowler R. A. 65.010
Foxman B. 77.028
Fraile Fariñas M. T. 75.017,
82.009
Franca C. N. 54.002
Franca F. 08.003
Franco-Paredes C. 32.004
Franklin R. 75.006
Frantz F. G. 82.008
Fraser C. 27.029
Frasinejad B. 23.011
Frassone N. E. 78.017, 59.014,
77.023
Fratnik Steyer A. 28.016
Fredeking T. 24.001
Fredriksson-Ahomaa M. 34.018
Freedman D. 46.004
Freilij H. 72.004
Freire C. 83.016
Freire M. C. 83.025
Freitas A. R. R. 28.045, 28.050
Freitas G. D. 28.028, 28.026,
28.030, 57.018
Frenkel G. 65.004
Freuler C. 81.008, 28.024
Friedland J. 63.003
Friedrich A. W. 56.018
Froes M. H. 59.023
Frolova T. V. 24.004
Fry A. 65.004
Fuenmayor C. 51.023
Fuji N. 21.005
Fuji N. 84.036
Fuji N. 65.001
Fujitani S. 25.003
Fulton M. 76.016
Furuse Y. 21.005, 65.001
Gaafar M. 58.006
Gabriel O D. 81.001
Gade L. 30.009
Gadua N. 77.025
Gaibani P. 24.016
Gaibani P. 51.019
Gaibani P. 76.028
Gaibani P. 76.011, 51.020
Gainey M. 73.008
Gajo Gane A. 72.004
Gajownik B. 77.006
Galea S. 28.036
Galesi V. M. N. 33.007
Gallagher D. 78.015
Gallagher N. 57.005, 32.004,
32.005
Gallego P. 28.040
Authors Index
Gallo J. C. 28.040
Gamage C. 77.012
Gamboa-Coronado M. D. M.
76.026, 25.019
Gantsooj B. 28.006
Ganusov V. 17.002
Gao F. 17.002
Gao L. 83.006
Gao S. 28.002, 28.003
Garay J. 81.007
Garbati M. 59.015
Garber G. 65.011
Garbino J. 30.013
Garcia A. 48.001
Garcia C. 74.015
Garcia D. O. 23.025
García F. 81.024, 81.023
Garcia F. L. B. 51.022
Garcia R. 76.018
Garcia Jimenez S. 83.025,
83.026
Garcia Rodriguez M. 82.009
García-García M. D. L. 59.017
Garcia-Vara P. 34.020
Gardner S. 57.009, 75.040,
75.031
Gardner T. J. 40.002
Gardy J. 65.006
Gargalianos P. 82.004
Gargano L. M. 65.002
Garigliany M.-M. 47.002
Garrido M. 59.010
Garro S. L. 32.025, 32.032,
32.026
Garver J. 73.007, 84.015,
24.005
Gastellu-Etchegorry M. 28.037
Gatserelia L. 53.032, 55.008,
53.025, 30.021
Gatzima M. 23.002
Gaxiola C. S. M. 34.003
Gaxiola Camacho S. M. 34.031,
34.017
Gaxiola M. J. 34.017
Gayoso E. 50.006
Gaywee J. 65.008
Gebi U. I. 27.005
Gelaglie A. K. 29.003
Gentile A. 83.025
Gentile A. 72.004
Gentile A. 83.026
Gentsch J. 40.003
George G. 56.024
George M. 25.013, 25.011
Gerloff N. 57.039
Gerorge S. 23.018
Gerstenbluth I. 51.003, 76.014
Geskus R. B. 21.001
Gestoso I. 76.027
Ghasemian R. 53.001
Ghédira H. 56.008, 56.013
Ghimire M. 25.006
Ghimire P. 57.014
Gholamin S. 23.011
Ghosh S. 34.006, 75.016,
84.012
Giacco M. 82.013
Giamberardino H. 28.022
Giampietro F. 75.009
Giamprieto F. 75.013
Gibbons R. V. 65.008
Giezendanner N. 34.018
Gilani Z. 27.009
Gill C. 83.008
Gilman R. 82.014
Gilman R. H. 34.020, 21.004,
58.024, 73.016
Gimeno X. 32.022
Gimeno Cardona C. 82.009,
75.017
Gino L. 56.029
Giorgi E. 17.002
Giraldo M. I. 58.023, 58.031
Giri R. 34.012
Girod Schreinerova M. 56.023
Giron M. 51.023
Giske C. 41.001
Gjermeni N. 28.017, 30.010
Gloeckner A. 30.002, 30.003
Glushenkova T. 76.005
Goad J. 32.004
Godino M. 28.007
Godoy P. 80.024, 28.039
Goeters C. 56.018
Gokhale R. 68.001
Golebiovski W. 21.010
Golembieski A. 27.015
Goleniuk D. 51.012, 25.015
Gomes V. R. 78.006
Gomez C. H. 30.026
Gomez M. 23.026
Gomez S. 72.004
Gonçalves da Costa P. S. 76.004,
28.015
Gongora V. 46.003
Gonzaga V. 57.011
Gonzáles M. 77.020
Gonzales X. F. 77.029
González C. 58.014, 83.011
Gonzalez F. 23.026
Gonzalez G. D. 32.026, 32.025,
32.032
Gonzalez J. C. 82.013
Gonzalez M. C. 34.032
Gonzalez N. 28.011
González Ayala S. E. 52.021
González Nuñez I. 27.001
Gonzalez-Losa M. R. 79.004,
57.021
Goonetilleke N. 17.002
Goossens H. 22.002
Gopalakrishnan V. 75.011
Gorbacheva O. 32.009, 33.008
Gordillo B. 65.004, 40.004
Gordillo G. 76.018
Goris J. 75.023
Gottdenker N. L. 34.008
Gotuzzo E. 21.002, 14.003,
58.025, 03.002
Gotz H. M. 34.027
Gould E. A. 24.004
Gould I. 10.003
Govender N. 52.014
Goyal A. 68.001
Goyo J. 73.015
Grabczewska E. 77.015
Grabenstein J. 83.014, 83.013
Graham S. V. 84.031
Grant F. 76.020
Gray E. 17.003
Gray J. 65.004
Gray N. K. 84.031
Graybill R. 15.001
Greco M. M. 52.021
Green K. Y. 47.006
Greene D. G. 25.017
Greene M. 34.019
Greene W. 75.041
Greene-Montfort T. 53.038
Greenwood B. 21.006, 77.022
Greet V. 68.002
Gregis C. 32.008
Grichener J. 28.011
Griffith M. 57.031
Gritsun T. S. 24.004
Groseth A. 84.011
Groth N. 65.005
Guanche Garcell H. 56.026,
56.017
Guarda B. 81.007
Guarnieri C. E. 65.009
Gubernot D. 29.014
Guddati A. 56.028
Guedes M. 28.022
Gueguen J. 28.037
Guercio A. 26.006
Guettouche T. 78.020
Guevara M. E. 51.023
Guiadem R. 27.030
Guilarde A. O. 56.042
Guimaraes E. M. B. 51.022
Guinez D. 59.010
Gunawan C. 29.002, 27.007
Gunther S. 51.021, 76.022,
51.018, 76.021, 84.046
Gunzburg W. H. 24.010
Guo W. 73.013
Guo Y. 24.006
Guo Y. 27.026
Gupta N. N. 84.003, 84.004
Gupta N. 80.003
Gupta R. 52.022
Gupta S. 33.015
Gupta S. N. 84.003, 84.004
Gupta V. 83.015
Gupte M. D. 84.004, 84.003
Guterres A. 76.006
Gutierrez A. 56.044
Gutierrez F. 26.003, 21.003
Guzman-Blanco M. 66.004
Gvozdenovic E. 53.023
Gwamzhi L. N. 78.004
Gyawali N. 74.005
Habib E. 23.018
Habyarimana A. 47.002
Hackel M. 23.009, 77.004
Hadipour Jahromy M. 73.001
Hadipour jahromy M. 84.013,
73.001
Hadzic E. 34.016
Hadzovic Cengic M. 34.016
Hagan R. 27.025
Hagiwara K. 84.030
Hagmann S. 32.004
Hahn B. 17.002
Hahne C. 28.033
Haider A. 78.009
Halabi Y. 76.014
Halicioglu O. 84.032
Hall S. 75.024, 76.007
Hallit R. 77.019
Halperin S. 40.009
Hamdi A. 56.017
Hamdi K. 33.010
Hamelin M.-E. 65.006
Hamer D. H. 32.029, 21.008
Hamilton R. 57.026, 81.010
Hamisu S. 55.006
Hamkar R. 84.026
Han J. 84.001
Han M. 47.005, 73.011
Han P. 32.003, 57.005, 32.002
Han S. H. 59.007, 53.009
Hanage W. P. 27.029
Hanlon C. 34.014
Hanssen A. D. 25.017
Happi C. 76.021, 84.046,
76.022, 51.018
Hara C. 75.040
Hardjopawiro L. 81.022, 81.025
Hariastuti N. I. 28.013
Harish B. 23.015
Harmon K. 34.033
Harmsen W. S. 25.017
Haro Osnaya A. 33.016
Harrel B. 76.007, 75.024
Harrell D. 51.026
Harris J. 32.011
Harry T. 57.039
Harter-Griep R. 81.009
Hartman F. 76.016
Hasan M. M. T. 32.009
Hascalovici C. 80.010, 80.008
Hass M. 51.021
Hassan A. 82.002, 75.001
Hassanshahiraviz G. 53.014,
53.004
Hasseltvedt V. 28.031
Hatakeyama S. 56.015
Hatemi G. 30.005, 30.006
Hatemi I. 30.006, 30.005
Hausdorff W. 80.009
Final Program ~ 217
Authors Index
Hawkley M. 81.019
Hawser S. 23.009
Hay R. 15.003
Hays J. 23.015
Head J. 23.026
Heath P. 71.001
Hedlund J. 57.007
Heitzer V. 56.009, 56.010
Helasvuo V. 80.023
Helvacı M. 84.032
Hemrajani R. 26.011, 81.006
Hentrich M. 30.004
Herbert-Hackshaw K. 46.003
Hernandez A. 56.031
Hernandez C. 76.003
Hernandez N. 51.023
Herr-Calomeni P. 73.008
Herrera F. 28.004
Herrera F. 34.032
Herrera J. O. 56.031
Herrera Y. 78.007, 78.008
Herrera Aldana P. 21.004
Herrera-Martínez A. 78.008,
78.007
Herrero E. 32.019
Hidalgo G. 58.018
Hiddessen A. 75.040
Higgins P. 23.009
Hilbert A. 65.005
Hildreth J. 59.021
Hill P. 21.006
Hillier S. 17.004
Hiransuthikul N. 79.002
Hirose M. 75.016
Hirotsu N. 28.008
Hirsch H. 69.002
Hirsch M. 62.002
Hitoshi O. 84.007
Hiwat H. 81.025, 81.022
Ho L.-L. 28.032
Ho P. 83.005, 83.004
Hoban D. 74.002, 23.009,
77.004
Hochberg N. S. 21.008, 32.029
Hochlin K. 56.011
Hoehne E. 76.030
Hoen B. 25.013, 25.011
Hoenigl M. 30.001, 56.007
Hoffman R. 32.004
Hollingsworth T. D. 27.029
Holness L. G. 29.014
Hong K. B. 51.016
Hong K.-W. 52.016, 25.014
Hong T. 51.005
Hooton T. 78.020
Hora R. A. 57.011
Horban A. 77.030
Horby P. 57.030
Hoseini N. 83.017
Hosokawa N. 25.001
Hottes T. S. 65.006
Houck P. 57.005
Howard-Grabman L. 76.016
218 ~ Final Program
Howie S. 77.022, 21.006
Houas M. 31.002
Hoxha H.
Hoxha H. 84.009 84.017,
51.007
Hrabovsky V. 30.025
Hsu L. Y. 23.022, 50.005
Hu B. 56.017
Hu Y. 33.004, 59.009
Huaman M. 27.015
Huang C.-C. 40.005
Huang H.-P. 28.032
Huang J.-H. 53.034, 75.039
Huang M.-L. 76.015
Huang M.-L. 75.039
Huang M. 84.030
Huang P.-X. 53.022
Huang S.-W. 84.016
Huang T. 82.005
Huang W. 28.003, 28.002
Huang Y. 28.013
Huang Y.-C. 49.006, 84.038
Huc Anais P. 75.022
Huertas Jimenez M. 33.016
Hughes J. M. 65.002
Hulette R. B. 56.045
Humphries C. 40.002
Hunter P. R. 32.010
Hupkova H. 30.022
Hur J. K. 52.020
Hurst S. 30.009
Husain N. 58.017
Hussain Y. 56.017
Hussell T. 44.003
Huur A. 81.022
Iacobiciu I. 58.019
Iacobiciu I. 58.020
Iacono M. 32.019
Ibrahim A. Y. 27.018, 27.031
Ibrahim R. 23.018
Ibrahimpasic N. 34.016
Ichiro K. 84.007
Ideh R. C. 80.022
Idoko J. 55.009
Idoko O. T. 77.022
Idris S. A. 26.007
Ignatiev V. 84.037
Igreja R. P. 53.003
Ijaz M. K. 72.006
Ikawa K. 49.009
Ikeda F. 84.030
Ikeda K. 49.009
Ikram N. 27.017
Ikumapayi N. 21.006
Ilardo R. 77.023
Ilham N. 34.026
Ilieva L. 84.047
Imagawa T. 26.005
Imnadze P. 26.012, 28.018
Incani R. N. 58.018
Inda L. 80.015
Insuasty B. 48.001
Inzunza-Montiel A. 77.014
Ip M. 73.010
Irad B. 78.002
Irino K. 51.008
Irons B. 28.046
Isa S. 78.004
Isabirye P. 55.012
Isaias L. 51.015
Ishida T. 28.008
Ishino M. 34.006
Ismail S. 52.002
Isper V. 28.045
Isturiz R. 38.003
Itoe I. 84.007
Iwamura H. 75.026
Iwamura H. 25.007
Iwata K. 28.025
Iwata K. 77.008
Izadi N. 53.010
Jabandziev P. 75.037
Jablkowski M. 53.030
Jackson S. 72.001
Jacobs M. 22.001
Jafari F. 34.015
Jaghbir M. 53.011
Jagne J. 76.016
Jain A. 40.001
Jain K. 29.001
Jain S. 52.006, 75.008
Jain S. 51.014
Jaing C. 57.009, 75.031
Jalal H. 75.004
Jamal H. 52.002
Jambai A. 29.016
James R. 47.004
Jamshidiyan E. 75.027, 75.028
Jamulitrat S. 56.017
Jamuna V. 23.013
Jang D. 75.005
Janjua N. 65.006
Janssens K. 75.023
Jarca A. 26.013
Jarcuska P. 53.012
Jarman R. 65.008
Jarza-Davila N. 74.004
Jasseh M. 21.006
Jawaheer G. 28.049, 76.031
Jayaraman G. 65.011
Jayaratne P. 75.034
Jayasingam R. 77.019
Jeddi R. 56.008, 56.013
Jedlicka A. E. 29.010
Jelinek T. 83.012
Jenkerson S. A. 40.002
Jensen R. O. 47.004
Jentes E. 32.002, 32.003
Jergens A. 34.033
Jhao W.-S. 28.032
Ji G. 24.006
Jiang C.-Y. 28.001
Jiang C.-H. 40.005
Jiang L. 57.015, 57.016
Jiang Q.-W. 57.016, 34.005,
57.015, 28.001
Jiang T. 24.006
Jiang W. 28.003
Jiang W. 28.002
Jiang W. 33.004, 59.009
Jilma B. 83.012
Jiménez J. G. 56.027
Jimenez S. 58.018
Jin J. 23.022
Jin S. J. 59.007, 53.009
Jirous J. 56.023
Jo Y. M. 56.039
Job F. 27.019
John K. 59.008
Johnson B. 23.009, 74.002
Johnson J. 23.009, 77.004,
74.002
Joloba M. 75.035
Jones D. 27.024
Jones L. M. 65.002
Jones R. N. 74.006, 48.002
Jong E. 45.003
Joodan J. S. 34.001
Jordaan M. 81.022
Josh R. 72.001
Joshi S. D. 79.008
Jozami D. 72.004
Jozuazoon N. 81.022
Ju L.-W. 57.016, 57.015, 28.001
Juarez-Sandino L. 59.017
Juganariu G. 23.019
Jugulete G. 55.007
Juma E. 75.018
Jun K. A. 56.035, 56.036
Junie L. M. 74.017, 23.002
Junie M. 77.002
Jureen R. 26.004
Jurgensen C. 84.043, 84.040
Juzielewski B. 80.013
Kaasila M. 40.008
Kabanov A. 28.014, 28.012
Kabbara W. 50.001
Kabir B. 23.006
Kacem K. 56.008, 56.013
Kadigi D. M. 57.002
Kadota J. 28.008
Kadri O. 83.020
Kagawa H. 77.008
Kai C. 84.030, 84.029
Kaido T. 56.033
Kaiser M. 75.021, 75.022
Kajla B. 56.037
Kakjing F. 55.009
Kalantar E. 53.002
Kalavska A. 78.002
Kalavsky E. 25.002
Kalbfleisch J. 28.036
Kalenic S. 23.005
Kalimuddin S. 24.003
Kalla G. C. M. 27.030
Kallfa E. 80.006, 84.009
Kallfa-Foto E. 84.017, 51.007
Kalloo M. 46.003
Kaltenboeck A. 83.012
Authors Index
Kamigaki T. 28.006
Kamihira S. 74.009
Kamili S. 53.038
Kamimura M. 77.013
Kan R. 77.021
Kancelova Z. 56.023
Kang H. 51.015
Kang H. M. 34.024
Kang J. H. 52.020
Kang M. W. 52.016, 25.014
Kang Y. 24.006
Kang Y. A. 28.035, 28.034
Kanj S. S. 56.017
Kant S. 59.012
Kant S. 33.006
Kanunfre K. 75.038
Kapala J. 75.005
Kapek J. 56.023
Kapikian A. Z. 47.006
Kaplina E. 84.037
Kapoor G. 40.001
Kapoor V. 56.025
Kara-Zaïtri C. 57.025, 81.010,
57.026
Karagianni P. 74.017, 23.002
Karbalayi M. 52.003
Karchava M. 53.032, 53.025,
55.008, 30.021
Karchmer A. W. 32.029, 21.008
Karchmer A. 66.002
Karikari Y. 29.016
Karimi A. 77.003, 84.013
Karsani M. S. 28.047
Karthaus M. 30.004
Karunajeewa H. 72.005
Karunakaran R. 23.023
Karuphong A. 58.013
Karvaj M. 25.002
Kasmi G. 56.014
Kasmi I. 56.014
Kassaian N. 53.018
Kastanakis S. 77.002, 23.002,
74.017
Katabazi F. 75.035
Katabira E. 62.004
Katamba A. 75.035
Kaur D. 56.037
Kaur P. 55.010, 27.032
Kawaguchiya M. 75.016
Kawana A. 28.021
Kawooya V. 27.034
Kazeem H. M. 26.001
Kazi B. M. 27.017
Kazimirova M. 24.004
Kazmi S. S. U. K. 49.001
KC K. 57.014
Keddy K. 52.014
Keele B. 17.002
Keenan A. 32.011
Kemnitz P. 53.017, 53.016
Kemp B. 28.045, 28.050
Kenarkoohi A. 54.004, 84.041
Keramati M. 57.003
Kesavachandran U. 30.009
Keuter M. 21.001
Khader I. A. 56.017
Khakpour S. 73.001
Khakshoor H. 30.008
Khalili H. 59.005
Khan H. M. 58.009
Khan M. I. 28.013
Khan M. 23.015
Khanal B. 25.005
Khanal B. 74.005, 74.001
Khanal B. 29.004
Khandelwal N. 58.004
Khasnatinov M. 76.005, 24.004
Khatoon R. 58.009
Khazaeipour Z. 83.017
Kheltabadi Farahani R. 23.007
Khishgee B. 34.024
Khodadad S. 52.003
Khodadoust M. A. 74.020
Khosravi Y. 23.013
Khramov M. 75.029
Khudyakov N. 53.038
Khullar M. 75.008
Kica A. 28.017, 84.020, 30.010
Kida H. 34.024, 28.008
Kiguba R. 72.002
Kiguli J. 55.012
Kim C. O. 53.009, 59.007
Kim H.-C. 29.012
Kim H. M. 59.022
Kim H. S. 28.034, 28.035
Kim J. Y. 56.039
Kim J. 59.013
Kim J. S. 28.034, 28.035
Kim J. H. 52.020
Kim J. H. 28.034, 28.035
Kim J. M. 59.007, 53.009
Kim M. J. 56.039
Kim M. 56.012
Kim N. 59.013
Kim S. I. 25.014, 52.016
Kim S.-H. 56.040
Kim W. J. 56.039
Kim W. K. 28.034
Kim Y. R. 52.016, 25.014
Kim Y. S. 56.040
Kim Y. J. 25.014, 52.016
Kim Y. M. 51.016
Kincaid K. A. 74.010
Kini P. 80.014
Kinoshita S. 77.008
Kipnis A. 56.042
Kirali K. 75.014
Kirchner J. 17.002
Kirkland J. 80.017
Kirnbauer R. 40.008
Kirunda B. T. 27.034
Kisac P. 78.002 , 25.002
Kitazawa T. 77.013
Kitetele F. 55.013
Kittitrakul C. 32.007
Kiwanuka N. 55.012
Klade C. 83.012
Klausner J. D. 75.010
Klein T. 29.012
Kleinschmidt A. 83.008
Klempa B. 24.004
Klotchko A. 77.027
Klugman K. 60.001, 44.004
Knezevic J. 74.004
Knight Y. 57.017, 32.013
Knouse M. 32.004
Knowles S. 81.021
Ko P. 77.019
Kobayashi C. A. 56.042
Kobayashi M. 49.009
Kobayashi N. 77.010, 34.006,
75.016, 74.007, 84.012
Kocazeybek B. 75.014, 53.013,
30.005, 30.006, 58.011,
82.007
Köck R. 56.018
Kodama T. 25.003
Kode N. 82.005
Kogelman L. 32.029, 21.008
Koh L. P. 23.022
Koh-Tec G. 79.004
Kohan G. 28.040
Kohno S. 74.009, 28.008
Kohoutova J. 56.023
Koike K. 56.015
Koike K. 77.013
Koirala J. 23.014, 23.029
Koja A. 56.014, 80.006
Kola E. 80.006, 56.014
Kolarova M. 56.023
Kollaritsch H. 83.012
Kolter R. 67.001
Kombarova S. 77.025
Konertz W. 25.012, 74.014
Kong L. 53.033
König M. 34.018
Konings E. 76.016
Koo J. M. 74.010
Koomanachai P. 49.005
Koomson E. 80.002
Koopman J. 81.004
Koppe K. 76.006
Koraka P. 76.014
Korber B. T. 17.002
Koreck A. 58.021, 58.016
Kornienko T. 77.025
Kosan E. 75.014
Koskela P. 40.008
Kostkova P. 28.049, 76.031,
23.027
Koturoglu G. 84.032
Kovac R. 25.002
Kowala-Piaskowska A. 53.017,
53.016
Kozarsky P. 32.004
Kozioł-Montewka M. 77.006
Kraemer A. 80.021, 51.011
Krahn M. 28.048, 65.010
Kraja D. 84.020, 30.010, 28.017
Krapp F. 21.002
Kratochvil M. 75.037
Kratochvilova J. 56.023
Krause P. R. 47.006
Krause R. 30.001
Krčméry V. 14.004, 25.002,
78.002
Krishna S. 56.001
Krishnan T. 84.012
Kristian P. 53.012
Krkic Dautovic S. 34.016
Kropp R. 65.011
Ks N. 77.009
Kuan M.-M. 57.027
Kudriavcev A. S. 28.012
Kulak M. 34.021, 65.007
Kularatne S. 77.012
Kumar A. 23.001
Kumar R. 56.037
Kumar R. 40.001
Kumar R. 33.006
Kumar S. 56.024
Kumar S. 80.004
Kumarasamy N. 78.005
Kunimoto D. 33.011
Kurkova V. 56.023
Kurtzman C. 30.024
Kurugol Z. 83.001, 84.032
Kushwaha R. A. S. 59.012
Kusolsuk T. 32.007
Kuti J. L. 49.005
Kuwanda L. 80.018
Kuzmin I. 84.044
Kwakye-Nuako G. 82.003
Kwong J. 57.020, 65.010
Kyaw M. H. 51.009, 28.010
Kye-Amoah K. 57.004
Kyr M. 75.037
La M.-V. 26.004
Laabidi N. 31.002
Labousaki D. 74.017
Labuda M. 24.004
Ladep N. 55.009
Lafuente C. 82.014
Lai S.-K. 40.005
Lal S. 84.035
Lamas C. 25.018, 21.010,
76.006
Lambrecht B. 47.002
Lambson B. 17.003
Lanata C. F. 52.023
Landaverde M. 57.031
Landini M. P. 76.028, 51.020,
24.016, 51.019, 76.011
Lang H.-J. 29.013
Langard M. 77.024
Langlois-Klassen D. 33.011
Langmann H. 56.007
Lara A. 29.018
Lares M. 32.016
LaRocque R. 32.005, 32.004
LaRosa S. 63.002
Larralde-Diaz O. G. 84.031
Final Program ~ 219
Authors Index
Larson R. 77.021
Lascols C. 77.004
Lashkarashvili M. 26.012
Laslau C. 26.013
Lau L. 28.043
Lau S. K. P. 76.013, 84.025
Lau Y. 23.016
Lauc G. 79.003
Lawhorn J. 23.014
Lawson C. 57.005
Lawton T. 32.005
Lazaro M. E. 32.019
Lazzarini D. 28.011
Le M. T. 30.011
Le N.-T. 53.038
Leal G. S. 56.042
Leal Moran P. 33.016
Leanes L. F. 57.034
Leao J. R. D. T. 53.031, 29.017,
78.018
Leblebicioglu H. 56.017
Leca D. 23.019
Lecky D. 23.027
Leddy L. R. 52.022
Lee C. 80.017
Lee C. 75.034
Lee H. G. 28.034, 28.035
Lee H.-Y. 84.038, 49.006
Lee H. J. 51.016
Lee J. 32.004
Lee J. 51.016
Lee J.-H. 51.016
Lee K. C. 29.014
Lee M. 79.006
Lee M.-S. 76.015
Lee P. 51.026
Lee S.-O. 56.040
Lee S. Y. 52.020
Lee S. S.-J. 75.020
Lee T. 59.013
Lee V. 76.002
Lee Y.-P. 84.016
Lee Y. J. 34.024
Lee Y.-W. 56.035
Lefrancois T. 46.003
Leguen F. 28.051
Lehtinen M. 40.008
Lei H. 53.033
Leichsenring M. 56.038
Leikis M. 59.021
Leite D. 51.008
Leite O. H. M. 75.038, 75.033
Leite R. 73.012
Leka K. 52.010
Lema C. 83.025
Lembo T. 34.011
Lemke A. 32.021
Lemos E. R. 76.006, 77.011
Lemos L. R. 55.003
Lemos Hinrichsen S. 02.004
Lemos Luengas E. V. 55.003,
30.016
220 ~ Final Program
Lenhoff R. 75.024, 76.007
Leo Y. S. 55.010, 27.032, 76.002
Leon M. 21.003, 26.003
Leong H. N. 24.003, 84.042
Leong K. L. J. 84.022
Lepetic A. 02.001, 32.027
Lepidi H. 21.010
Lespada M. I. 76.025
Leung E. T. Y. 73.010
Leung G. M. 28.043
Leung W. H. A. 28.038
Levina L. S. 24.004
Levy C. E. 59.020
Lew D. 14.001
Lewi D. S. 54.002
Leyna G. H. 21.007
Li C. 29.012
Li H. 17.002
Li L. 27.026
Li W. 47.005
Li Y. 65.006
Li Y.-T. 34.005
Li Y. 47.005
Liberal M. H. T. 34.025
Licitra C. M. 77.027
Liew Y. X. 23.022
Ligthelm R. J. 21.001
Lim C. S. Y. 73.014
Lim R. 50.005
Lim S. H. 24.003, 84.042
Lim Y. W. 76.017
Lima D. B. 78.006
Lima M. L. 53.035
Limongi G. 28.007
Limper M. 51.003, 76.014
Lin G. Y. 84.039
Lin M.-Y. 23.017
Lin R. 26.004
Lin T.-Y. 49.006, 76.015, 84.038
Lin W.-Y. 53.022
Lindblade K. 40.004, 65.004
Lindstrom S. 65.004
Linge J. 57.013
Linneweber J. 25.012
Liou G.-Y. 76.015
Liphaus B. D. L. 28.030
Liphaus B. L. 28.026
Liphaus B. D. L. 28.028
Liphaus B. L. 57.018
Lipman H. 40.006, 32.001,
57.005
Liprandi F. 84.034, 80.011
Lira M. 56.030
Lise M. 57.032
Liska S. 75.010
Liske K. 57.005
Liss C. 83.024
Lito G. 84.009
Lito G. 51.007, 84.017
Liu M. K. 17.002
Liu Y. 48.003
Liu Y. 57.008
Lizaso D. 32.016
Llanos-Cuentas A. 75.043,
75.025
LLau A. 28.051
Lloret L. 31.004
Lloret-Sanchez L. 31.005
Lloveras S. 32.032, 32.025,
32.030, 04.003, 32.026
Lluka R. 80.006
Llukaj R. 56.014
Lo T. S. 74.010
Loayza M. 40.007
Lobel L. 84.011
Lockhart C. 34.030
Loctev V. B. 75.019
Lode H. 83.028
Lodigiani M. 25.016
Loggia V. 82.013
Loh L. T. T. 28.038
Lokida D. 57.019
Lombar A. V. 78.014
Londoño A. 47.001
Londono I. 82.005
Long J. 73.008
Long R. 33.011
Lopardo G. 50.002, 55.004,
38.004
Lopardo H. 76.003, 80.013,
52.004
Lopera C. 56.027
Lopes G. Q. 25.018, 21.010
Lopez B. 40.004
Lopez D. 75.013
Lopez E. L. 28.011, 78.013,
80.010, 80.008, 30.019,
80.015, 77.024
Lopez H. 81.016
Lopez J. C. 80.024
Lopez L. 28.042
Lopez M. 27.024
Lopez P. 80.009
Lopez S. C. 74.019
López Y. 31.004, 83.027, 52.024
López Gallego D. 56.043
Lopez Papucci S. 72.004
Lopez Vidal Y. 77.029
López-Vidal Y. 31.005
Lopez-Zambrano M. A. 81.009
Loret de Mola C. 57.011
Loro L. 40.007
Lotufo P. A. 27.022
Loutan L. 01.001
Low N. 27.009
Löwa A. 75.021
Lu H.-B. 53.022
Lu X. 40.002
Lu X. 84.039, 84.021
Lu Y.-H. 28.001, 34.005
Lu Y. 73.013
Lubogo D. 27.033
Lucchetti G. 32.022
Lucero C. 23.020
Luchetti P. 25.008
Luisiama J. 55.013
Lukwago L. 28.027
Luminos M. L. 55.007
Luo S.-T. 76.015
Luo X. 47.005, 73.013, 73.011
Lupisan S. 26.005, 84.007,
84.036, 21.005
Lutalo T. 80.007
Lutwama J. J. 84.011, 28.027
Lv X. 57.016, 57.015
Lye D. C. 76.002
M. D. C. 29.001
Ma E. 28.043
Macchi A. 06.001, 32.027,
32.034, 32.020
Macedo J. 47.008
Machado D. M. 27.013, 27.012,
27.011
Macías Hernandez A. 23.028,
33.016
MacIntyre R. 59.008
Mackenzie G. 81.020, 21.006,
77.022
Macleod W. B. 21.008, 32.029
Maco V. 58.025
Maco C. V. 58.025
Madani A. 53.020
Madhi S. 80.018
Madiga M. 17.003
Madoff L. 46.001
Madrid C. 32.018
Maffucci M. 23.024
Maganda A. K. 72.002
Magdaleni A. R. 29.002
Magill A. 19.004
Magira E. 74.012
Magneres C. 77.024
Magri M. C. 78.016
Mahanta J. 79.007
Mahdaviani F. S. 53.010
Mahlouji K. 80.001
Mahmood T. 27.017
Mahmoud M. H. 57.033
Maina W. G. 27.034
Maitland K. 29.013
Majanja J. 57.037
Majidzadeh K. 75.027, 75.028
Mäkelä S. 84.023
Makumbi F. 83.023
Makundi V. 28.044
Malaque C. 08.002
Malaria Technical Committee P.
81.022
Malas T. 32.006
Malaska J. 75.037
Maldonado M. H. 32.018
Malec-Milewska M. 77.030
Maleki F. 58.003
Malik M. R. 57.035
Malik P. 84.031
Malla K. 58.028
Authors Index
Malla N. 58.017, 58.004
Malla S. 57.014
Mallavialle A. 31.002
Manandhar D. 29.004
Manaseki-Holland S. 80.019
Mandal G. 82.012
Mandrekar J. N. 25.017
Manevich L. 50.002
Manfredi R. 23.004, 31.001,
84.010, 78.001
Manga S. 59.004
Mangory M. 28.047
Mania A. 53.017, 53.016
Maninska L. 84.045
Manisera C. 51.019
Manisera C. 76.028
Manisera C. 51.020
Mannheimer S. 78.009, 56.028,
78.012
Mannino L. 80.013
Manoff S. 83.024
Manoharan A. 59.008, 23.001
Manonelles G. 28.011, 78.013
Mansinho K. 73.012
Manso C. 30.019
Mantero J. 57.013
Manuel R. C. R. 78.016
Manzano-Cabrera L. 79.004
Mapp T. 56.017
Maqadma M. 57.035
Maqelana T. 81.019
Maraghi S. 58.030
Marak R. S. K. 51.014
Marano C. 32.003, 32.004,
32.005, 32.012, 32.002
Marano N. 32.004, 32.005,
57.005
Marchese R. 83.024
Marcinkowska E. 77.030
Marculescu C. E. 52.022
Mardani M. 23.011
Mardarescu M. 55.007
Mares-Guia M. A. 76.006
Margareth E. 27.022
Marianelli L. 78.017
Mariko S. 84.007
Marin J. 78.019
Marin M. 25.020, 25.008
Marincu I. 58.021, 58.016,
58.020, 58.019
Maringwa J. 81.012
Marion Z. 57.012
Markley D. 26.011, 81.006
Markovski V. 84.047
Markowitz J. 51.005
Markowitz N. 27.015
Marks R. S. 84.011
Marku K. 56.014
Marrs C. F. 77.028
Martelli C. T. 53.035
Martin J. 40.009
Martin J. 77.017
Martin P. 65.006
Martina B. 76.014
Martine T. 68.002
Martinez A. L. 56.031
Martinez C. 57.032
Martinez C. 80.024, 28.039
Martinez F. 21.003, 26.003
Martinez F. 52.024
Martinez J. 57.034
Martinez L. A. 32.021
Martinez M. B. 83.003
Martínez R. 83.010, 58.012
Martinez Burkett A. 30.019
Martìnez-Lopez E. 77.014
Martini Robles L. 76.023
Martis A. 76.014
Masago Y. 26.005
Masauni S. 21.007
Masayuki S. 84.007
Mascaro O. 32.022
Mascheretti M. 29.018, 24.017,
03.003
Mascola L. 56.012
Mashayekhi R. 52.005
Masjedi M. 74.020
Mason C. J. 65.008
Masuet Aumatell C. 56.043
Mathai D. 59.008, 23.001
Mathengtheng L. 24.009
Mathew J. L. 83.009
Mathur A. 83.020
Mathur A. 76.009
Matu S. 75.018
Maurya A. K. 59.012
Maves R. C. 48.006, 34.020
May J. 51.011, 80.021
Mayanja-Kizza H. 75.035
Mayence A. 82.005
Mayer F. 84.019
Mayer Wolf M. 81.008
Mayer-Wolf M. 28.024
Mayo-Montero E. 28.019
Mayta H. 82.014
Mazal C. 77.026
Mazari-Hiriart M. 31.005
Mazengia F. 81.013
Maziz M. N. H. 52.002, 52.009
Mazur W. 53.030
Mazurova I. 77.025
Mbele R. 27.030
Mbelle N. 23.012
Mbidde E. K. 40.008
Mbopi-Keou F.-X. 27.030
McAvin J. 75.036
McBride A. 47.008
McBride F. 47.008
McBroom M. 49.008
McCabe A. 79.012
McCarthy A. 12.001, 51.024
McClenahan S. D. 47.006
McCue K. 81.019
McCullers J. 44.001
McFetridge R. 83.024
McGeer A. 65.010
Mckenney J. 57.038
McLaughlin J. B. 40.002
McLoughlin K. 57.009
McMichael A. J. 17.002
McNulty C. 23.027
Meddeb B. 56.013, 56.008
Medeiros A. I. 73.005
Medeiros E. A. 56.017
Medici L. F. R. 59.018
Medina F. 53.036
Meghani H. 83.020
Megrelishvili T. 26.012
Mehanic S. 34.016
Mehta A. 56.017
Meiring S. 52.014
Melamud A. 81.016
Melo E. 52.019
Melo F. A. F. 59.023, 59.018
Melo L. C. V. 51.008
Mena A. 84.024
Mendez C. 75.042
Méndez J. 75.042
Mendez M. 21.004
Mendez-Galvan J. 36.001
Mendoza J. 84.040, 73.015,
84.043
Mendoza R. 56.031
Menezes G. 23.015
Menezes M. 47.008
Meng J. 53.038
Mengel M. 27.019
Mercer J. G. 65.011
Merchan-Hamman E. 53.035
Meri S. 84.023
Merino P. 76.027
Merisescu M. 55.007
Meryem L. 82.010
Meshkat M. 30.008
Messina C. M. S. 59.023
Meta E. 84.020, 28.017
Metzger D. 44.002
Mghamba J. 28.044, 21.007,
81.015
Michael E. 57.017
Michael K. 72.001
Michalak M. 53.017
Michalek J. 75.037
Michee K. 72.001
Michelli E. 84.043, 84.040
Mickova E. 56.023
Miftode E. 23.019
Migliazzo A. 26.006
Miki M. 49.009
MIlenkovic Z. 52.013
Miller F. D. 76.019
Milone J. 28.042
Mindiola R. 79.010, 79.011
Ming W. 57.008
Mlranda A. 73.012
Miranda T. 51.015
Miranda Novales M. G. 56.017
Miro J. 62.003
Mirsattari D. 52.005
Mishra A. 28.009
Mishra A. K. 32.009, 33.008
Mishra B. 47.010, 24.011
Mishra S. 58.017
Mistchenko A. 28.011
Mitrev Z. 56.017
Mitro S. 81.022
Mitrovic N. 53.023
Mitterpachova E. 78.002
Miyaji E. 83.004, 83.003,
83.005
Miyazaki N. H. T. 51.015
Mizuguchi M. 28.008
Mlisana K. 17.003
Mlkvy P. 25.002
Mmbuji P. 21.007, 28.044,
81.015
Modi C. 77.019
Modi M. 47.010, 24.011
Modrzewska R. 77.006
Mofid L. 58.015
Mohamad Noordin N. 33.009
Mohamed M. A. 28.044
Mohamed Hussain K. 84.022
Mohammadi F. 74.020
Mohammadtaheri Z. 74.020
Mohammed M. 21.007, 81.015
Mohd Nawi S. F. A. 23.023
Mohebbi S. R. 53.024
Mohraz M. 27.004
Moine I. 28.040
Moini L. 59.005
Mojica J. 53.036
Molina D. 78.019
Molina F. J. 30.016
Molina R. F. S. 30.015, 30.014
Molise C. 28.011
Momen Heravi M. 59.003,
75.003, 53.019
Momoko O. 84.007
Monaco A. 52.004
Mónaco A. 80.015, 76.003
Moncada J. 75.010
Mondoy M. 21.005
Monfante I. 34.008
Monge M. 80.024
Moniri R. 23.007, 74.003
Monsalve F. 79.011
Montarroyos U. 57.012, 53.035,
53.029, 53.028
Monteiro C. M. C. 54.002
Montenegro S. 59.010, 84.005
Montgomery J. 57.011
Monto A. S. 28.036, 11.002,
65.003, 18.004
Moore P. 17.003
Moore S. 17.002
Moore S. 34.014
Mora C. A. 32.024
Mora N. 56.032
Morabito S. 34.015
Morales G. 23.026
Morales J. C. 52.021
Final Program ~ 221
Authors Index
Morales M. A. 83.026
Morales Pérez C. 56.026
Morehouse B. 26.011
Moreira I. 27.021
Moreira J. M. 76.023
Moreira R. 53.028, 53.029,
53.035, 57.012
Moreira R. F. S. 59.018
Morelli J. 28.050
Moreno A. T. 83.005, 83.004,
83.003
Moreno A. 28.040
Moreno J. 51.023
Morens D. 18.001
Moretti M. L. 56.038
Morfaw C. 65.002
Mori A. 56.033
Morikawa N. 49.009
Moriya K. 56.015
Moriya Y. 57.012
Morosini M.-I. 20.001
Morris L. 17.003
Morrison H. 81.002
Morrison M. 23.017
Moscatelli G. 72.004
Mosha F. 81.015, 21.007
Mosqueda N. 73.015
Mosquito S. 48.006
Moss W. J. 27.009
Mossad S. 84.014, 69.004
Mota C. S. 56.021, 80.012
Mote P. 57.011
Motoshima M. 74.009
Motta A. 30.020, 30.023
Motta F. A. 28.022
Mounts A. W. 18.003
Mousavi J. 56.006
Mousavi S. L. 83.002
Moustakas G. 82.004
Moyes J. 52.014
Moynihan M. 76.029
Mpeka B. A. 80.007
Mshelia D. 59.015
Mtapuri-Zinyowera S. 58.032
Muazu A. 55.009
Mucientes F. 59.010
Muco E. 28.017
Mudryck G. 52.004
Muehlenbein M. 32.021
Mueller I. 72.005
Mughal Z. 80.019
Muhammadu Gobir S. 33.009
Muita L. 75.018
Mukanga D. 81.015, 83.023
Mukherjee A. 84.028
Mukhi S. 65.011, 81.018
Mukhopadhyay C. 56.001
Mukhopadhyay R. 82.012
Mulholland E. K. 43.002, 77.022
Mullaguri N. 29.009
Mullalli G. 84.009
Muller C. 57.039
Mullins G. 76.016
222 ~ Final Program
Mulvey M. R. 76.026
Muñoz J. 73.015
Muñoz M. 73.015, 84.043,
75.036
Muñoz Delgado A. B. 80.005
Mupfasoni D. 72.001
Murillo J. 56.009, 74.015,
56.010, 08.004, 04.004,
64.003
Muriova K. 75.037
Murray D. 65.002
Murray G. F. 65.003
Musa M. T. 75.030
Musher D. 83.024
Musisi D. 56.041
Mustafa M. 53.021
Mustafa S. 28.047
Mustonen J. 84.023
Mutonga D. 21.009
Muttalif A. R. 33.009
Mutton K. 32.011
Muvunyi C. 59.006
Muwanga M. 40.008
Muzzillo D. 57.012
Muzzio Aroca J. 76.023
Mwakapeje E. 28.044
Mworozi E. A. 80.007, 72.002
Myint K. S. A. 65.008
Myint K. A. 27.003
Nabukenya I. 28.027
Nacinovich F. 25.008, 25.020,
83.021, 77.007, 25.009
Nag V. 59.012, 51.014
Nagashima S. 84.012
Nagashima S. 74.007, 77.010
Nagatomo H. 34.013
Nagelkerke N. 75.007
Naik E. 55.006
Naik T. 34.006
Najafi A. 73.001
Najafzadeh M. J. 30.008
Najera P. 57.034
Nakaggwa S. M. 33.012
Nakal S. 58.018
Nakamura M. 77.008
Nakanishi W. 75.026, 25.007
Nakhasi H. 29.014
Nakhonesid-Fish V. 57.017
Nakiyingi L. 75.035
Nalwadda C. 26.010
Namujju P. B. 40.008
Namusisi O. 56.041, 26.010,
83.023
Nand Garg D. 34.010
Napal J. J. 28.042
Nara P. 34.033
Naraghi arani P. 76.007
Naraghi-Arani P. 75.031, 75.024
Naranjo L. 84.034, 80.011
Naranzul T. 28.006
Narasimhan P. 59.008
Narayanaswamy J. 83.022
Narov U. E. 28.012
Nasidi A. 57.039
Nasr M. A. 58.006
Nasution P. D. 29.002
Nataraj K. 29.005
Nathan S. 32.021
National Malaria Board S.
81.025
Nau R. 71.002
Navia D. 25.020
Navoa-Ng J. A. 56.017
Nazario R. 80.023
Nazarova E. 84.037
Nazemalhosseini Mojarad E.
58.026
Ndase P. 17.004
Ndreu A. 77.001
Ndumbe P. 27.030
Neghina A. M. 58.020, 58.019
Neghina R. 58.020, 58.019
Negroni R. 30.018
Negrut N. 84.048
Negrutiu L. 58.020
Negrutiu L. 58.019
Nejatizadeh A. 53.020
Neyra J. M. 57.011
Neyro S. 28.011, 80.015
Ng E. 23.022
Ng L.-K. 81.018
Ng M. L. 73.002, 24.010,
84.022, 24.012
Ng M. L. M. 24.013
Ng T. F. F. 76.017
Ngui Ngamini A. 27.006
Nguyen A. 32.001
Nguyen C. 57.040
Nguyen C. 57.006
Nguyen M. 78.003
Nguyen N. 77.019
Ní Bhuachalla C. 83.018,
27.025
Nicholls R. S. 57.034
Nichols G. 32.011
Nicolau D. P. 49.005
Nicoletti P. 51.026
Nieto C. 82.013
Niezgoda M. 84.044
Nik Mohamed M. H. 33.009
Nikitovic L. 53.023
Nilganuwong S. 58.013
Nilsson C. 76.017
Ning Q. 73.011, 73.013, 47.005
Nipp R. 80.017
Nishikaku A. S. 30.014, 30.015
Nishiura H. 28.021
Njuguna C. 21.009
Nkada C. 27.030
Nog R. 56.028, 78.009, 77.018
Nogueira C. V. 57.012
Nogueira R. D. 25.004
Nokhodian Z. 53.018
Noorbakhsh S. 56.006
Nordmann P. 20.002
Norizuki M. 25.001
Nosik D. 84.037
Nosik N. 84.037
Notario R. 74.019
Noveri S. 28.007
Nowak G. 79.012
Nsabiyumva L. 29.016
Nseir B. 30.017
Nsekpong D. 21.006
Nsengiyumva E. 25.021
Nshala A. 77.021
Nsobya S. 72.002
Nsubuga P. 81.015
Ntinos K. 82.004
Nuak J. 32.031
Nucci M. 15.004
Nuchprayoon S. 29.010
Nuermberger E. 68.003
Nukiwa N. 65.001, 28.006
Nukui Y. 56.015
Numsuwan W. 23.008
Nunez S. 82.014
Nur-E-Kamal A. 72.006
Nwafor-Okoli C. 77.012
Nyale E. 28.044
Nyaruhirira I. 25.021
Nydam D. V. 34.020
Nymadavaa P. 76.005
Nymadawa P. 28.006
Nzioka C. M. 21.009
O’Brien M. 83.014, 83.013
O’Callaghan S. 29.014
O’Connell E. 28.051
O’Hagan D. 65.005
Oba Y. 77.008
Obajuluwa A. 74.013
Obayashi Y. 77.012
Oboro H. 56.020
Ocama P. 75.035
Ochoa T. J. 52.023, 48.006
Oderiz R. S. 52.021
Odette M. 72.001
Odikamnoro O. 29.006
Odike A. 76.021
Odio C. 43.003
Odreman M. 75.036, 73.015
Ogunkoya A. 84.044
Ogura Y. 56.033
Ohji G. 77.008
Ohno A. 21.005
Ohuma E. 29.013
Oike F. 56.033
Oka H. 77.008
Okamura L. H. 59.018
Okoboi S. 59.002
Okogbenin S. 51.018
Okogbenin S. A. 72.003
Okogbenin S. 84.046
Okogbenin S. A. 76.022
Okokhere P. 51.018
Okokhere P. 76.021, 76.022
Okokhere P. 84.046
Okokhere P. 72.003
Okoko B. 77.022
Authors Index
Okonkwoh C. 27.002
Okot C. 28.027
Okumura C. 26.005
Olariu T. R. 58.021, 58.016
Olayinka A. 74.013
Olayinka B. 74.013
Olczak A. 77.015
Oleastro M. 83.016
Oleribe O. 21.007, 28.044,
81.015
Olivas J. 75.024
Olivas J. 76.007
Oliveira A. P. P. 28.022
Oliveira D. A. 59.018
Oliveira I. R. S. 27.022
Olodo-Atitebi S. T. 34.007
Olomu S. C. 76.021
Olsen S. 65.004
Olurinola P. 74.013
Olveda R. 21.005, 26.005,
84.007, 84.036
Omaeche M. 79.009
Omar K. 21.007
Omilabu S. 51.021, 80.026,
57.039
Omran Y. 75.032
Omura T. 26.005
Onaolapo J. 74.013
Ondobo Andze G. 27.030
Oner Y. A. 58.011
Onofrey S. 23.017
Onorio S. 30.023
Onsongo J. K. 21.009
Ooi P. L. 76.008, 81.003
Ooi W. W. 21.008, 32.029
Oormazdi H. 58.010
Opollo M.-S. 83.023
Opromolla P. 24.017
Orciari L. 84.044
Ordieres F. 56.010, 74.015,
56.009
Ordouzadeh N. 48.004
Orduña P. 83.027
Orduna T. 04.002, 32.026,
72.004, 32.030, 83.026,
32.032, 32.025
Orellana N. 32.024
Orenolu R. 57.039, 80.026
Orenstein W. A. 65.002
Oreste H. 21.005
Orlosky P. 81.014
Ormaeche M. 53.037
Orogade A. A. 80.025
Oropeza M. D. 80.011
Ortegoza J. 58.022
Ortiz J. 84.024
Oshikanlu Z. 78.010
Oshitani H. 28.006, 84.036,
65.001, 21.005, 26.005
Osinubi M. 84.044
Osmon D. R. 25.017
Ossai I. 80.026
Osterhaus A. 76.014
Ostreni V. 28.017
Otelea D. 55.007
Otevrel F. 75.037
Otgonbaatar D. 76.005
Ottone C. 25.016
Ouhoummane N. 65.006
Owolabi R. 27.005
Oyama M. 84.030
Oz V. 82.007
P’yankov O. V. 73.004
Pacheco M. 51.023
Pacheco V. 51.023
Pachkoria E. 26.012
Pacola M. 28.050, 28.045
Padilla-Docal B. 76.023
Padinjarenmattathil U. 83.022
Pádua E. 54.003
Paganini H. 80.015
Pahil S. 52.017, 56.022
Painter J. E. 65.002
Paiva S. A. S. 56.042
Paiva T. 28.020
Paiva W. 25.018
Paixao E. 54.003
Pal’cev A. V. 28.012
Palma S. 58.024
Pan D. 84.008
Pandey V. 34.001
Pandey V. 52.007
Panigrahi D. 58.005
Panozzo C. A. 40.002
Panunto P. C. 59.020
Papadakis M. 77.002
Papadomanolaki E. 23.002,
74.017
Parada Barba C. 82.009
Paradela C. M. F. 59.023
Paralicova Z. 53.012
Paranhos-Baccala G. 73.003
Parashar U. 40.003, 40.004
Parino E. 28.040
Park D. W. 56.039
Park K.-H. 56.040
Park Y.-J. 52.016
Parra A. 83.016
Parra L. 32.017
Parshin P. 34.012
Parvin M. 84.026
Pasari Y. 74.018
Pascalicchio F. V. 32.008
Pascual Y. 58.022
Pasha S. T. 55.015
Passweg J. 30.013
Pasteran F. 23.020, 61.001
Patarroyo M. A. 75.013, 75.009
Patel A. K. 55.006
Patel J. K. 55.006
Patel K. 55.006
Patel M. 40.003
Patricia E. 25.011, 25.013
Patterson T. 63.004
Patzi-Vargas S. 21.003
Paul S. K. 84.012, 75.016
Paulin P. 72.004
Paulino E. R. 27.011
Pavan M. H. 76.030
Pavlin J. A. 65.008
Pavlinic D. 79.003
Pawar M. 28.052, 28.029
Payne D. 40.003
Pazol K. 65.002
Pearce T. 34.033
Peart S.-L. 74.016
Pedragosa A. 32.022
Peiris M. 28.043
Pellegrini M. 65.005
Pellegrino D. 27.021
Pellini A. C. G. 28.028, 28.026,
57.018, 28.030
Peltola H. 71.003
Peña J. 32.017
Peng H. 28.002
Peng M.-C. 28.032
Pensotti C. A. 77.007, 25.009,
25.008
Perea-Mejia L. 77.014
Pereira H. 81.022
Pereira L. 53.029, 57.012,
53.035, 53.028
Pereira L. A. 25.018
Pereira M. M. 77.011
Perelson A. 17.002
Peres C. M. 73.006
Peres O. M. 79.005
Perez C. 28.041
Perez G. 77.019, 27.028
Perez G. 80.013
Pérez M. 77.020
Perez S. 73.015
Perez V. 28.036, 65.003
Perez Carrega E. 83.026, 25.020
Perez-Tuyub M. 79.004
Peric M. 79.003
Perkash Singh G. 75.011
Perret C. 80.024, 28.039,
02.003, 38.002
Pessoa S. 27.013
Peter R. 59.008
Peters M. 57.006
Petit-Sinturel M. 46.003
Petkov G. 52.013
Petrascu M. 23.002
Petrela R. 28.017, 84.009,
80.006
Petrela R. 51.007, 84.017
Petrescu C. 58.021, 58.016
Petric M. 84.048
Petrie H. 32.006
Peyrefitte C. 73.003
Pfaff M. 21.008, 32.029
Philippe M. 14.004
Picazo J. 76.027, 23.026
Piccinini F. 25.020
Piechotta G. 75.021
Pierro A. 51.020, 24.016,
76.028, 51.019, 76.011
Pilaca A. 77.001
Pimenta F. C. 83.003
Pimentel R. 28.041
Pineda A. M. 78.007, 78.008
Pineda S. 84.005, 59.010
Pineda Segundo V. J. 34.008
Piñeros O. 80.011, 84.034
Pinilla M. 84.005, 59.010
Pink H. 84.019
Pinto A. 57.035
Pinto G. A. 27.022
Pinto M. E. 57.012
Pinto M. I. 30.023, 30.020
Pinto V. 24.014
Piotrostanalzki A. 77.020
Pipero P. 28.017
Pires T. S. 79.005
Pisapia J. 56.030
Pittet D. 70.001
Pitz K. 75.024, 76.007
Pividori R. 72.004
Piyaphanee W. 32.007
Pizzo C. R. P. 30.014, 30.015
Plat F. 80.008, 80.010
Plessas S. 26.008
Plotkin S. 37.003
Plowe C. V. 42.001
Podzimkova M. 56.023
Poggi E. 53.027
Pogodina V. V. 24.004
Pohl K. 56.018
Polanco A. 26.003, 21.003
Polat E. 82.007, 58.011
Pöllabauer E. M. 37.002
Pollard W. 32.002, 32.003
Polymili G. 77.002
Ponam T. 32.007
Ponce O. 75.025
Ponce de Leon A. 56.031
Ponce de León S. 83.027
Ponce de Leon S. 18.002
Ponce de León Rosales S. 33.016
Ponce-de-Leon A. 23.028
Ponnaluri S. 77.028
Pons M. J. 48.006
Portaels F. 68.002
Portillo E. 75.005
Porto L. 79.011, 79.010
Porubcin S. 53.012
Pot B. 75.023
Potdar V. 28.009
Potin M. 80.024
Pourmand M. R. 56.016
Pourpaki M. 74.020
Prabhakar S. 24.011, 47.010
Prabhu M. 29.005, 52.008,
77.009
Prado V. 56.044
Praino M. L. 80.010, 30.019,
80.015
Prakashini K. 56.001
Prasad K. N. 23.001
Prasad N. 51.014
Final Program ~ 223
Authors Index
Prates M. V. 28.042
Prekates A. 74.012
Premasathian N. 58.013
Prematunga C. 51.024
Prewitt J. 78.020
Prior C. 34.033
Procopio A. 80.015, 77.024
Procopio A. 30.019
Profapi 2009/160 34.031
Prokop M. 77.006
Pucci F. 31.003
Puello J. M. 29.015
Puerto-Solis M. 79.004
Puga S. 34.008
Pujhari S. K. 24.011, 47.010
Pumarola T. 80.023
Pun M. 79.009, 53.037
Purevsuren B. 34.024
Purpari G. 26.006
Putnam S. D. 74.006
Qaqa A. 27.028
Qato M. 30.010
Qin C. 84.001, 24.006
Qin E. 84.001, 24.006
Qin P. Z. 57.008
Qu J.-Y. 53.034
Querci M. 28.004
Quesada-Gómez C. 76.026,
25.019
Quevedo E. 55.003
Quigley C. 32.011
Quijano-Vivas A. 57.021
Quinones D. 74.007, 77.010
Quinones Falconi F. 77.029
Quiñonez-Alvarado M. 77.014
Quintas E. 32.031
Quintero Vélez J. C. 47.001
Quinteros H. 28.040
Quiroga J. 48.001
Quiroga M. 29.018
Quiroz V. 47.001
Quispe J. 57.011
Rabb J. 83.024
Rabbani T. 58.009
Rachas A. 28.037
Raciny Aleman M. L. 80.005
Racloz V. 51.004
Rada R. 77.020
Radmanesh ahsani R. 77.003
Radovanovic A. 53.023
Radulescu A. 77.016
Raeissi S. 74.020
Rafati S. 83.002
Rafiei tabatabaei S. 77.003
Raggam R. B. 30.001
Raghavan B. 24.012
Raghavendra K. 29.011
Rahbany P. 50.001
Rahman W. 59.012
Rai S. 33.006
Raigosa M. M. 56.027
Rainford L. 52.012
Rajapaske R. 77.012
224 ~ Final Program
Raka L. 56.017
Ramachandran B. 29.005,
77.009
Ramachandran V. 84.004,
84.003
Ramadhany R. 57.019
Ramamoorthy S. 34.033
Ramezani A. 53.010, 84.026,
59.005, 27.004, 53.002
Ramirez P. 63.001
Ramirez Borga S. J. 28.042
Ramon G. 76.018
Ramon Torrell J. M. 56.043
Ramon-Pardo P. 57.038
Ramos A. 75.025
Ramos J. 50.002
Ramos M. 59.020
Ramos M. 57.011
Ramos R. G. 21.010
Ramos Hernandez L. R. 80.005
Ramos Marti J. L. 75.017, 82.009
Ramos-Hinojosa A. 23.028
Ramoutar D. 33.005
Rampal L. 27.018, 27.031
Rana M. K. 59.012
Ranchobe N. 17.003
Ranjan R. 55.006
Ranjbar novin N. 83.017
Rao S. 32.004, 32.005
Rao S. 52.007
Rao S. 23.006, 52.007
Rao U. 78.005
Raoult D. 21.010
Rasch M. 56.011
Rasmussen M. 76.007
Rasouli M. 84.041
Ratho R. K. 47.010
Ratho R. K. 24.011
Ratnasingham S. 57.020
Rattendi D. 82.005
Rauch L. 75.010
Ravanshad M. 54.004, 84.041
Rawat M. 29.011
Raymond N. 59.021
Raz R. 50.004
Raza A. 58.009
Razmjou E. 58.010
Rebbapragada A. 65.006
Reddy V. 82.001
Refos F. 81.022
Rehm S. 84.014
Reid J. 32.011
Reis M. 28.050
Reis M. 47.008
Reis M. N. G. 51.022
Remedios M. 54.003
Ren H. 34.005
Renteria M. 74.002
Requejo R. 57.034
Requejo Pino O. 56.026
Resa A. J. 32.019
Resende M. 76.030
Restrepo A. 15.002, 78.019
Restrepo C. 78.019
Reuter G. 53.038
Rey G. 75.042
Reyes J. R. 29.015
Reyes L. 40.004, 65.004
Reyes P. 30.026, 77.020
Reyes-Garay H. A. 34.020
Reynaga E. 32.022
Rezaeian M. 58.010
Rezaie S. 58.010
Rhone J. 73.007
Riarte A. 72.004
Ribeiro A. F. 28.026
Ribeiro A. 24.017
Ribeiro A. 28.028
Ribeiro A. F. 57.018
Ribeiro A. 28.030
Ribeiro C. T. 51.022
Ribeiro V. 76.030
Ribeiro-Carvalho M. 77.011
Riccardo F. 57.035
Richardus J. H. 34.027
Rijal S. 29.004
Rimal N. 32.009
Rios P. 78.011, 50.002
Ripoll S. 25.016
Rísquez Parra A. 81.005, 32.018,
06.002, 32.017, 45.002
Rivas M. A. 58.022
Rivas N. 80.010, 80.008, 30.019
Rivas P. 30.026
Rivera M. 84.024
Rivera N. 84.005
Rivera Morales J. 56.019
Rivero J. 34.032
Rivero M. 59.018
Robbins C. L. 40.002
Roberti L. R. 25.004
Rock C. 83.018
Rodas J. 47.001
Rodica G. 65.006
Rodin R. 65.011
Rodrguez-Osorio C. 23.028
Rodrigues D. 59.018, 59.023
Rodrigues O. 80.022
Rodrigues R. 73.003
Rodriguez C. 28.053
Rodriguez C. 21.004
Rodríguez C. 76.026
Rodriguez C. 76.025
Rodríguez V. 81.008, 28.024
Rodriguez Brieschke M. T.
82.013
Rodriguez Iantorno P. 53.027,
78.011
Rodríguez-Cavallini E. 25.019,
76.026
Rodriguez-Morales A. 58.018,
81.009, 32.018, 32.017,
81.005, 58.022
Rodriguez-Morales A. J. 64.001
Rodriguez-Taveras C. 29.015
Roger A. 75.010
Rohani M. 59.001
Rohwer F. 76.017
Rojas H. 30.018
Rojas S. 25.016
Roksandic-Krizan I. 79.003
Roman Romera I. 56.043
Romero C. 33.016
Rosa-Cunha I. 78.020
Rosales-Encina J. L. 58.014,
83.011
Rosanova M. T. 76.003, 80.013,
52.004
Rosato A. 10.001
Rosella L. C. 65.006
Rosello C. 56.030
Rosenthal V. 56.018, 10.004,
56.017, 56.026, 56.019
Roses Periago M. 57.034
Rosli R. 47.007, 73.014
Rossi F. 23.025, 23.024, 30.020,
30.023
Rossini F. 56.038
Rossini G. 76.028
Rossini G. 24.016, 51.020
Rossini G. 51.019
Rossini G. 76.011
Rostami K. 53.024
Rostami Nejad M. 53.024,
58.026
Rostampour A. 59.005, 53.010
Rouleau I. 65.006
Roy G. 26.002, 76.001
Rozenbaum W. 75.022
Rozental T. 76.006
Rozos G. 26.008
Ruan Y. 76.017
Rubiano L. C. 53.036
Rubino J. R. 81.019, 72.006
Rubinstein E. 66.001
Rubio Robles M. C. 34.003,
34.031, 34.017
Rudd R. J. 34.014
Rueda A. 83.024
Rueda L. M. 29.012
Rufino A. M. 27.010
Ruhl D. 80.017
Ruiz J. 52.023, 48.006
Ruíz J. M. 34.032
Ruiz M. 56.010, 56.009
Ruiz N. M. 50.006
Ruiz P. 53.015
Ruiz P. 53.026
Rujumba J. 80.007, 72.002
Runstadler J. 65.007
Rupprecht C. E. 84.044
Russman M. 30.019
Rutherford C. 75.034
Ruttimann R. 83.021
Ruuragchaa S. 34.024
Ruvinsky S. 80.013, 72.004
Ruzman N. 79.003
Rwakimali B. 72.002
Ryan E. 32.004, 32.005
Authors Index
Ryantova V. 56.023
Saad A. 27.031, 27.018, 33.009
Sabatinelli G. 57.035
Sabitu K. 27.018, 27.031
Sablan B. J. 33.014
Sabol M. 30.025
Sadanandan T. 75.011
Sader H. 48.002, 74.006
Sadki K. 75.007
Safatov A. S. 73.004
Safdar R. M. 27.017
Saginur R. 65.011
Saha D. 21.006, 81.020
Saigal S. R. 80.004
Saini S. 55.015
Saito M. 84.036, 26.005, 21.005
Saito M. 34.020
Sakoda Y. 34.024
Sakong R. 32.021
Salari M. H. 56.016
Salazar B. 51.023
Salazar J. 17.002
Saldaña A. 34.008
Saldanha G. 32.014
Sales J. M. 65.002
Sallabanda S. 56.014, 80.006
Salman M. 27.017
Salmanian A. H. 83.002
Salmons B. 24.010
Salomão K. 82.011
Salomao R. 54.002
Salomon O. 72.004
Salsabil H. 82.010
Saltini C. 75.007
Salzer H. J. 56.007, 30.001
Sambri V. 24.016, 51.019,
76.028, 76.011, 51.020
Samoukovic G. 32.006
samra T. 28.052, 28.029
Samudzi R. 24.007
San-Gil E. 56.032
Sanabria Uribe A. J. 56.043
Sanche A. 78.003
Sanchez A. I. 78.014
Sanchez A. V. 81.008
Sanchez L. 81.012
Sanchez P. 43.004
Sanchez R. 30.026
Sander B. 28.048, 65.010
Sandoval C. 80.024
Sane J. 84.023
Sangar M. 29.005
Sankaranarayanan R. 68.001
Sanogo K. 81.006
Santa Olalla P. 28.019
Santamaria A. 53.036
Santamaria A. M. 34.008
Santivañez L. 21.004
Santos B. A. 33.013
Santos D. R. L. 53.003
Santos J. R. P. D. 57.032
Santos M. D. S. 25.018, 21.010
Santos S. R. 83.003
Santos dos Santos A. 53.035
Santos-Fortuna E. 78.016
Sapiain P. 56.044
Sapkota K. 58.028
Sapkota K. 58.028, 74.011
Sarafpoor S. 58.003
Saravu K. 52.008
Saribas S. 75.015
Saribas S. 75.014, 58.011,
53.013, 82.007
Sarkhoo E. 74.008
Sarkis C. 83.016, 80.015,
81.024, 81.023
Sarmadian H. 53.010
Sarmento A. 58.027, 32.031
Sarmento e Castro R. 32.028,
13.003
Sarno de Oliveira M. L. 83.005,
83.004
Sarrazine S. 84.015, 24.005
Sarri K. 82.004
Sassaki A. L. 27.022
Satija N. 84.035
Sato H. K. 24.017
Sato H. 84.030, 84.029
Sattari Tabrizi S. 51.013
Saunders D. 65.008
Saunders D. 33.011
Saville M. 36.002
Savio E. 13.002
Savioli L. 39.001
Saxena R. 76.009
Saxena S. K. 76.009
Sayfutdinova S. 34.021, 65.007
Scapellato P. G. 82.013
Scarpellini B. 55.011
Schachter J. 75.010
Schaefer J. 74.014
Schiel X. 30.004
Schliep T. 77.018
Schmaltz L. E. P. R. 79.005
Schmidt M. 56.044
Schmieder R. 76.017
Schmittmann M. 28.033
Schnabel D. 57.037
Schneewind O. 66.003
Schneider E. 40.002
Schneider M. C. 76.029
Schneider M. C. 57.034
Schoenfeld D. 32.004, 32.005
Schönian G. 82.010
Schop W. 34.027
Schouten M. 76.024
Schreter I. 53.012
Schteinschnaider A. 32.024
Schuller E. 83.012
Schuth I. 30.004
Schutte H. D. 52.022
Schwaber M. 41.003
Schwartz B. S. 32.004
Schwarzkopf-Steinhauser G.
30.004
Schweiger M. 81.010
Scott A. L. 29.010
Scott P. 27.009
Seas C. 21.002
Secatto A. 73.006, 73.005
Sedaghat M. 30.008
Seghrouchni F. 75.007
Segovia M. 78.014
Seguro A. C. 77.005
Seifert H. 23.009
Seljan P. 51.005
Seljordslia B. 56.011
Semenakova-Cvetkovska V.
84.047
Sementsova A. O. 28.014,
75.019
Sengee S. 34.024
Sensakovic J. 77.019
Seoane M. 82.013
Seow H. F. 47.007, 73.014
Sergeev A. N. 73.004, 28.014
Sergeev A. 73.004, 28.012
Sesso M. L. T. 25.004
Sethi G. R. 80.004
Sethi P. 65.006
Setiawaty V. 57.019
Sevcik P. 75.037
Shaaban H. 27.028
Shafei A. 84.033
Shafiq N. 80.003
Shah L. 21.002
Shahbazi M. 57.003
Shahid M. 58.009
Shahin Y. 57.035
Shahzad A. 30.017
Shakya G. 57.014
Shampur M. 83.022
Shamshiri A. R. 77.003
Shankar E. 78.005
Shanker R. 47.009
Shapovalov D. 33.008
Sharif A. 75.003
Sharkhuu T. 34.024
Sharma A. 29.011
Sharma M. 56.022, 52.017
Sharma M. 24.011, 47.010
Sharma N. 75.008, 52.006
Sharma N. 34.001
Sharma S. K. 25.005, 29.004
Sharvadze L. 55.008
Sharvadze L. 30.021
Sharvadze L. 53.032, 53.025
Shastry B. 52.008
Shaw G. 17.002
Shaw J. 46.003
Shay D. K. 65.003
Shayevich C. 75.010
Shebbe M. 29.013
Shehu N. 55.009
Sheikh Ali S. 53.011
Shemyakin I. 59.011
Shen H. 57.015, 57.016
Shenoy A. 56.001
Shental Y. 50.004
Sherman J. 21.004
Sherwani S. 49.001
Sheward D. 17.003
Shi M.-H. 75.020
Shi Q. 57.016, 57.015
Shibl A. 14.002
Shigeru M. 84.007
Shih C.-M. 34.009
Shikov A. N. 75.019
Shimada J. 28.008
Shin S. Y. 56.035, 56.036
Shin S. Y. 59.007, 53.009
Shin S. Y. 28.035
Shinogami M. 75.026
Shinogami M. 25.007
Shintani Y. 56.015
Shirai C. 28.025
Shirreff G. 27.029
Shishkina L. N. 28.012,
73.004, 28.014
Shkedy Z. 81.012
Shoae Hassani A. 33.010,
48.004
Shoaei P. 53.018
Shodhan S. 81.006
Shokrzadeh L. 52.005
Shrestha C. D. 74.011
Shrestha J. 74.011
Shrestha N. 84.014
Shrestha S. 65.008
Shrestha S. 25.005
Shrestha S. 74.005
Shrivastwa N. 77.028
Shtannikov A. 58.029
Shuetsu F. 84.007
Shujatullah F. 58.009
Shwartz J. I. 33.001
Shytaj K. 77.001
Siba P. 72.005
Siddiqui T. 49.001
Sieger B. 77.027 , 77.026
Siegfried L. 53.012
Siegfried L. 30.025
Sierra A. 80.009
Sierra-Moros M. J. 28.019
Sieswerda L. 81.007
Sifuentes J. 56.031
Sifuentes-Osornio J. 23.028
Silpasakorn S. 58.013
Silva A. 28.050
Silva A. R. 32.028
Silva A. 32.028
Silva C. L. 73.006
Silva C. 79.010
Silva C. 28.050
Silva E. F. R. 54.002
Silva J. M. K. 78.016
Silva J. C. 57.034
Silva J. F. 51.017
Silva R. 27.021
Silva-Graca A. 54.003
Silvério Amâncio O. M. 27.013,
27.012
Final Program ~ 225
Authors Index
Silvia S. 58.022
Simaku A. 84.017, 51.007
Simanek A. 80.016
Simões L. C. 25.018
Simonovic J. 53.023
Singaravelu K. 56.028, 78.009
Singh G. 52.017, 56.022
Singh G. 47.009
Singh K. P. 40.001
Singh M. 80.003
Singh S. 58.028
Singh S. 53.006
Singh U. 33.006
Singh Y. 34.010
Singhi P. D. 58.004
Singhi S. 71.004, 56.022
Sinha S. 82.006
Sipova I. 56.023
Sivagnanam K. 56.024
Sivapalan V. 77.018, 78.012,
78.009, 78.010, 56.028
Sivay M. 65.007, 34.021
Skarnovich M. O. 28.014
Skowronski D. M. 65.006
Slezak T. 57.009
Slim J. 77.019, 27.028
Sloan T. 47.004
Slovak M. 24.004
Slusarczyk J. 53.030
Sluzewski W. 53.017, 53.016
Smayevsky J. 56.034
Śmiechowicz F. 77.006
Smieja M. 75.005
Smirnova M. 49.007
Smith R. W. P. 84.031
Smith R. M. 76.029
Smouse S. 24.008
Snevold I. 56.011
Soares C. M. P. M. 55.011
Soares E. 73.006
Soares E. M. 73.005
Sobarzo A. 84.011
Sobreyra Oropeza M. 56.019
Soca A. 28.007
Socias L. C. 29.015
Socolich C. 32.022
Soeiro C. M. O. 78.018
Soentjens P. 30.012
Sofian M. 59.005, 53.010
Sohn J.-W. 56.039
Solano M. 34.020
Soleimani M. 75.027, 75.028
Soleymani T. 77.019
Soliman S. 33.002
Soloaga R. 23.020
Solomon S. 78.005
Solorzano Santos F. 76.018
Sombrero L. 21.005
Sonder G. J. B. 21.001
Song G. 73.011
Song J. Y. 56.039
Song L. 28.003, 28.002
Song Y. G. 59.007
226 ~ Final Program
Soo Youn S. 28.034
Sooka A. 52.014
Soon E. 59.022
Sopwith W. 32.011
Sordelli N. 78.013
Soriano F. 52.019
Sorvor E. 57.004
Sosa M. M. 21.008, 32.029
Sosa Estani S. 03.004
Sosnovtsev S. 47.006
Sossa M. 28.053
Sotelo Morales J. 07.001
Soto R. 30.016
Souza C. 76.030
Souza M. 76.030
Souza M. A. 56.042
Souza R. 24.017
Souza V. 76.030
Souza Pinto V. 33.007
Speil C. 23.014
Spichler A. 77.005
Spina A. 57.012
Sponseller B. 34.033
Sprenger M. 56.007
Sramek V. 75.037
Srikanth P. 56.024
Srinivas R. 75.008
Srinivasan U. 77.028
Srivastava S. 40.001
Ssekabira U. 72.007
Stahl J. 56.002
Stamboulian D. 81.023, 77.007,
32.020, 83.021, 25.020,
25.009, 81.024, 53.027,
32.027, 32.015, 32.034,
25.008, 78.011
Stammen R. 24.005, 84.015
Stanek D. 51.026
Stark G. 73.007, 73.008
Stavroulakis P. 77.002
Stecher D. 83.026
Steckelberg J. M. 25.017
Steffen R. 12.002
Stein A. 53.029, 57.012, 53.035,
53.028
Steingisser J. 77.021
Stepanshina V. N. 59.011
Stephan R. 34.018
Stevens A. 81.007
Stevens L. F. 81.006, 26.011
Stevens M. P. 26.011, 81.006
Stigler F. 56.007
Stiles-Ocran J. 81.021
Stimac D. 74.004
Stockman L. J. 40.002
Stone L. 76.016
Strait E. 34.033
Strukova E. 49.007
Stryjewski M. 28.004
Study Group N. 28.011
Sturba E. 53.027, 32.027
Suarez J. A. 80.011, 84.034
Suarez-Allen R. 79.004
Suarez-Ognio L. 53.037, 79.009
Sucari A. 25.020, 25.008
Sucupira M. C. A. 55.011
Sudtasay S. 33.008
Sueyoshi M. 34.013
Suganaga R. 77.008
Suljagic V. 56.017
Summerville S. 81.022
Sumner J. 75.005
Sun Y.-J. 27.032, 55.010
Sundaram S. 82.006
Sundareshan V. 23.014
Sungpradit S. 29.010
Suputtamongkol Y. 58.013
Surcel H.-M. 40.008
Suttithum W. 32.007
Suzuki A. 24.017
Suzuki A. 21.005, 84.036,
26.005, 65.001
Svirtlih N. 53.023
Swaminathan B. 81.018
Syed Q. 32.011
Sylvan S. 57.007, 51.002,
51.001
Syversen G. 56.011
Szejnfeld V. L. 27.010, 27.011
Szymanowski P. 40.006
Tabatabaei A. 56.006
Tabatabaei S. 84.013
Taha S. 47.003
Tahami Zanjani N. 77.003
Tajbakhsh M. 34.015
Takayama I. 84.029
Takimoto K. 77.008
Takoungang I. 27.030
Taljaard J. 30.012
Talukder K. A. 72.006
Tamaki R. 21.005, 84.036
Tamashiro H. 77.012
Tambyah P. A. 50.005
Tan A. 76.002
Tan B. H. 84.042
Tan T. 36.004
Tan Y.-H. 73.014
Tan Y. 57.015
Taneja N. 52.017, 56.022
Tang B.-Z. 75.039, 53.034
Tanganelli C. B. 75.038
Tanh T. N. T. 57.030
Tarkhan-Mouravi O. 28.018
Tate J. 40.002, 40.003
Tato M. 57.038
Tatsuno K. 77.013
Tatulescu D. 77.016
Tavakkoly Fard A. 77.003
Tavares R. 73.012
Távora L. F. 31.003
Tawakol H. 84.033
Tay S. T. 23.013
Tchaporgina E. A. 76.005
Tchouamani H. 27.030
Teixeira T. 32.028
Tellez I. 38.001
Tellez L. 84.040
Tellez L. 75.036
Tellez L. 84.043, 73.015
Temporiti E. 28.004
Tengan C. 24.017
Tenore S. B. 54.002
Tenorio A. 75.042
Teo C.-G. 53.038
Teodor A. 23.019
Teófilo C. R. 31.003
Teoh E. 83.019
Teper A. 28.011
Teplyakova T. V. 28.014
ter Waarbeek H. 57.025
Ternovoy V. A. 75.019
Tetsuya M. 84.007
Tevzadze L. 26.012
Thamlikitkul V. 48.005
Thartori E. 51.007
The SARA team G. 55.013
Thebus R. 17.003
Theme-Filha M. 57.012
Then C. 28.041
Thierer J. 77.007, 25.020,
25.009, 25.008
Thissen J. 75.024, 75.031,
57.009, 76.007
Thomas L. 40.002
Thomé Barbosa Gouvea A. D. F.
27.012, 27.010
Thompson G. 28.033
Thomson K. 41.002
Thong K.-L. 23.023
Thoresen H. 56.011
Thormann M. 28.041
Timenetsky M. D. C. S. T.
28.028, 28.030
Timmermans A. 65.008
Titanti P. 53.027, 28.040
Titanti P. 50.002
Tjon-A-Tsien A. M. 34.027
Tleyjeh I. M. 25.013, 25.011
To K. 73.010
Tobon A. 78.019
Tokarska-Rodak M. 77.006
Tolough G. 25.010
Tondella M. L. 57.031
Toniatti F. 28.050
Tonsawan P. 56.003
Toplak N. 28.016
Torabi P. 34.015
Torfeh M. 59.001
Tormo Palop N. 75.017
Torrado L. 78.013
Torres C. 73.015, 75.036
Torres J. 03.001, 64.004
Torres J. 76.018
Torres Hernández H. 56.019
Torrico F. 34.020
Torroija C. 32.034, 32.027
Torun M. M. 53.013, 58.011
Toshev M. 52.013
Totten S. 65.011
Authors Index
Totusek P. 56.023
Trabasso P. 56.038
Trakulsomboon S. 48.005
Travancas P. R. 25.018
Travassos C. E. P. F. 34.025
Treadwell T. 55.014
Triantafillidou D. 77.002
Trivedi J. B. 32.029, 21.008
Trivi M. 25.020
Trotman M. 46.003
Trujillo J. 34.033
Trupl J. 30.022
Tsafaraki A. 74.017
Tsai H.-C. 75.020
Tsai T. 65.005
Tsai Y. T. 40.005
Tsakris A. 74.012
Tsang K. L. 76.013
Tsao K.-C. 76.015
Tsaras G. 25.017
Tseren-Ochir E.-O. 34.024
Tserennorov D. 76.005
Tsertsvadze T. 53.032, 30.021,
53.025, 55.008
Tsibris A. 32.005
Tsouri A. 23.002, 74.017
Tulloh R. 29.013
Tumpey A. 81.014
Turchi M. 51.022, 53.035,
79.005, 56.042
Turki A. 56.008, 56.013
Turnbull E. 17.002
Tweheyo R. 56.041, 27.033,
27.034, 83.023, 26.010
Twimba M. 29.013
Tyagi I. 23.014, 23.029
Tyson C. 56.012
Tzanetou K. 82.004
Uchejuru I. O. 29.007
Uchendu U. 21.006, 81.020
Uchida D. 77.008
Uçkay I. 14.001
Uddin M. 65.003
Ude C. 57.041
Udo E. 74.008
Udorji O. 57.041
Uemoto S. 56.033
Uemura R. 34.013
Ugoagwu P. 55.009
Uhlenhaut C. 47.006
Ukoli C. 78.004
Ulrich M. 75.021
Umoh A. 56.020
Umoh J. U. 26.001
Umubyeyi Nyaruhirira A. 68.002
Uneke C. J. 79.001
Ungchusak K. 65.008
Upadhyay S. 56.028
Urushibara N. 75.016, 74.007
Usoro N. 29.007
Ustanikova K. 24.004
Usuf E. 21.006
Vadivelu J. 23.023
Vaheri A. 84.023
Vajpayee P. 47.009
Vakili Z. 75.003
Valcheva V. 33.003
Valdes F. 33.014
Valencia B. 75.043, 75.025
Valentin T. 30.001
Valero Rodríguez J. E. 56.019
Valle V. 77.024
Valsalan R. 77.009
Van de Paar E. 47.002
Van de Weg C. 76.014
Van den Berg T. 47.002
Van Den Hoek J. A. R. 21.00
van der Goot E. 57.013
Van der Stuyft P. 81.012
Van Genderen P. J. J. 21.001
Van Gorp E. 76.014, 51.003
Van Rie A. 55.013
Van Rijckevorsel G. 21.001
Van Zandt K. 73.007
Vanden Eynde J. J. 82.005
Vanegas A. 76.027
Vanegas B. 80.009
Vapalahti O. 84.023
Vardar F. 84.032
Vargas M. 76.018, 31.005
Varma S. 52.006
Varthalitis I. 23.002
Vasanthapuram R. 24.015
Vasconcellos R. C. 24.002,
53.003
Vasconcelos Beltrão S. 27.011
Vashakidze E. 26.012
Vasiljeva I. 58.029
Vasques M. R. G. 25.018
Vásquez L. V. 56.027
Vasquez Y. 50.006
Vassos D. 26.008
Vatopoulos A. 26.008
Vauterin L. 75.023
Vauterin P. 75.023
Vaz T. M. I. 51.008
Vazquez G. 74.019
Vazquez M. S. 77.024
Vazquez V. 80.015
Vdovichenko G. 28.012
Vega Patin R. 27.011, 27.012,
27.010, 27.013
Vela E. 84.015, 24.005
Veland N. 75.043
Velapatiño B. 21.004
Velasco I. 52.019
Velasco J. M. 65.008
Velasquez Portocarrero D. E.
73.016
Velazquez E. 76.018
Ventura F. 73.012
Vera D. 57.011
Verastegui M. 82.014, 73.016,
58.024
Verdaguer V. 32.034, 32.020,
32.027
Vergara T. R. C. 55.011
Verma A. 83.015
Verma P. 68.001
Verne E. 80.023
Verrall A. 59.021
Vescina C. 52.021
Vidiella G. 56.030, 28.040,
78.011, 53.027
Vidor A. C. 57.012
Vieira J. D. G. 56.042
Vielma S. 84.043
Vielma S. 75.036
Vielma S. 84.040
Vielma S. 73.015
Viet T. L. 57.030
Vijay S. 29.011
Vijayan T. 57.006
Vila J. 20.004
Villacres Á. 56.017
Villalon D. 78.017
Villasboas M. 52.004
Villaseñor-Sierra A. 77.014
Villegas L. 81.022, 51.023,
81.025
Viña A. 80.008, 80.010
Vinetz J. 32.004
Vinisi H. 81.022
Visser L. G. 21.001
Vita A. 23.019
Vitone J. 28.050
Vitral C. L. 53.003
Vivancos R. 32.010, 32.011
Vizcaya C. 28.039, 80.024
Vizzi E. 84.034, 80.011
Vizzotti C. 83.025
Vizzotti C. 25.009, 25.008
Vizzotti C. 83.026
Voidarou X. 26.008
Volanis E. 74.017
Vos M. C. 34.027
Voundi E. 27.030
Vozza L. 80.015
Vozza M. L. 77.024, 30.019
Vranes J. 74.004, 23.005
Vujacich C. 81.023, 81.024
Vujacich C. 78.011
Vujacich C. 53.027
Vujcikova J. 78.002
Vukovic D. 79.003
Wacheck S. 34.018
Wada K. 28.021
Wadegu M. 57.037
Waeckerlin R. 57.024
Wakatake H. 25.003
Walia K. 79.007
Walke H. 27.017
Wallace M. 77.027
Wallace M. R. 79.006, 50.003,
75.006
Walsh A. F. 75.006, 77.027
Walsh B. 32.013
Wamala J. 28.027
Wamani H. 27.033
Wanachiwanawin D. 58.013
Wander G. S. 56.037
Wang X. 73.011, 73.013
Wang F.-D. 34.005
Wang H. 73.013, 73.011
Wang Q.-Q. 53.034, 53.033
Wang Q. 28.003
Wang Q. 84.039
Wang T.-H. 28.032
Wang W. 59.009, 33.004
Wang X. 47.005
Wang Y.-F. 84.016
Wannet W. J. 34.027
Wareham D. 23.010
Warrell D. 08.001
Wasko A. 73.008
Watanabe A. 84.030
Watanabe J. 21.004
Watanabe S. 77.010, 74.007
Watcharasamphankul W. 75.044
Waterman S. H. 65.003
Watson C. M. 40.002
Waywa D. 58.013
Waziri N. E. 26.001
Weightman N. 77.017
Weinberg J. 23.027
Weisent J. 57.028
Weiss P. 65.002
Weiss S. 27.024
Weksler C. 21.010
Wenger M. 51.010
Wenzel R. 70.004
Wertheim H. F. 57.030
West A. 34.033
Westcott M. 40.002
Wetsteyn J. C. F. M. 21.001
Wey S. 70.003
Whalen C. 33.001
Whittembury A. 79.009, 53.037
Wibowo H. A. 57.019
Wilairatana P. 32.007
Wilke L. D. 58.002
Wilkerson R. C. 29.012
Williams C. 81.014
Williams P. 47.004
Williamson C. 17.003
Willis R. 52.012
Willison D. J. 65.006
Willner D. 76.017
Wilson M. E. 32.029, 21.008
Wilson W. R. 25.017
Win M. K. 76.002
Winnips C. 30.007, 49.003
Wirsing von König C. H. 36.003
Wise R. P. 29.014
Wiseman S. 28.049
Wolff M. 55.002
Wong C. 73.010
Wong R. 72.005
Wong S. J. 34.014
Wong T. 81.002, 65.011
Wongstitwilairoong T. 65.008
Wonhrathi M. 76.030
Final Program ~ 227
Authors Index
Woo J. H. 56.040
Woo P. C. Y. 76.013, 84.025
Wood J. 59.008
Woodall J. 57.030
Wörl R. 75.021
Wu C.-T. 84.038, 49.006
Wu J. 81.002
Wu T. S. 50.005
Wu Z. 73.011
Wu Z. 73.013
Wuryaninggsih E. 34.030
Xerinda S. 58.027
Xia Y.-G. 34.005
Ximenes R. 53.035
Ximenez R. 53.028, 53.029,
57.012
Xu B. 33.004, 59.009
Yacoub S. 29.013
Yadav A. 28.052, 28.029
Yadegarynia D. 23.011
Yadon Z. 57.034, 39.003
Yaghubi T. 23.011
Yalcıner A. 53.013
Yale G. 40.007
Yamada C. 25.007
Yamada C. 75.026
Yamada Y. 74.009
Yamamoto D. 84.012
Yamamomto S. 25.001
Yan W. 73.013, 73.011, 47.005
Yan Y. 81.002
Yanagihara K. 74.009
Yanai M. 25.003
Yang H.-Q. 53.034
228 ~ Final Program
Yang H. 17.002
Yang J. 57.016, 57.015
Yang R.-D. 53.034, 53.033
Yang X. 73.013
Yanni E. 32.003, 32.005,
57.005, 32.004
Yantorno M. L. 32.016
Yantorno S. 28.042
Yao J.-H. 34.005
Yarlett N. 82.005
Yauri V. 73.016
Yavelsky V. 84.011
Yazici H. 30.006, 30.005
Ye Q. H. 23.016
Yegneswaran B. 23.008
Yenen O. S. 75.014
Yeo C. L. 50.005
Yeo K. L. 24.012, 73.002
Yerino G. A. 77.024
Yerino G. 80.008, 80.010
Yew W. W. 49.002
Yim M. 77.021
Yip C. Y. 84.025
Yoneda M. 84.030
Yong V.-C. P. 47.007
Yoon I.-K. 65.008
Yoshida H. 77.008
Yoshino Y. 77.013
Yotebieng M. 55.013
Yotsuyanagi H. 56.015
You J. 53.033, 75.039, 53.034
Youn Y. K. 56.039
Youssefi M. R. 51.013, 51.025
Yu A. L. F. 28.030, 57.018,
28.026
Yu A. L. F. L. F. 28.028
Yu C.-K. 84.016
Yuen K. Y. 84.025
Yuksel P. 58.011, 75.014,
75.015, 53.013
Yusdja Y. 34.026
Yusof M. Y. 23.023
Yusuke S. 84.007
Yusuph H. 59.015
Zabaznoska L. 84.047
Zabihullah Z. 80.019
Zaheer H. A. 27.017
Zaidi A. 43.002
Zaidi M. B. 21.003, 26.003
Zainoodin S. A. K. 75.012
Zakhashvili K. 28.018
Zali M. R. 53.024, 34.015,
58.026
Zali M. R. 52.005
Zalwango S. 33.001
Zambrano J. L. 80.011
Zambriski J. A. 34.020
Zamudio C. 21.002
Zangeneh T. 55.005
Zanin Palchetti C. 27.012,
27.011, 27.010, 27.013
Zapata M. A. 80.009
Zaporojan I. 84.048
Zárate M. 56.034
Zarinfar N. 53.010
Zarkotou O. 74.012
Zavala Castro J. 24.001
Zavalani F. 56.014
Zavalani F. 80.006
Zelichenko G. 50.004
Zengin K. 58.011
Zerjav S. 53.023
Zewde T. 27.023
Zhang G. 28.051
Zhang S. 48.003
Zhang X. 53.033, 53.034
Zhang Y.-F. 53.034
Zheng P. 57.006
Zheng Y.-J. 34.005, 28.001
Zhou Y. 57.016
Zhou Y. 82.012
Zhu C. 73.011
Zhu W. 57.016
Zhuang L. 53.033, 53.034,
75.039
Zhuang W. L. 84.039
Zhuravlev V. 59.019
Ziapour S. P. 51.013, 51.025
Zimic M. 21.004
Zimmerman P. 72.005
Zimmermann K. 30.003
Zinner S. 49.007
Zitto T. 81.016
Zivkovic Gojovic M. 65.010,
28.048
Zojaji H. 52.005
Zollner-Schwetz I. 30.001
Zorman Rojs O. 28.016
Zou Y. 73.011, 73.013
Zrimec A. 28.016
Zulaina S. 26.004
Zurak I. 58.008
Zyrina E. 58.029
A Decade of Experience
With PCV7:
Helping to Prevent Pneumococcal
Disease Then and Now
12:30 - 14:15 • South Hall
James L. Knight International Center & Hyatt Regency Miami
Miami, Florida, United States
Introduction and Opening Remarks
Gail L. Rodgers, MD (Chair)
Pneumococcal Disease: Global Epidemiology and Antibiotic Resistance
Keith P. Klugman, MD, PhD
Pneumococcal Disease Prevention:
Efficacy and Effectiveness of PCV7 Worldwide
Sarah S. Long, MD
Assessing Challenges in Pneumococcal Disease Prevention
Gail L. Rodgers, MD
Question and Answer Session
Faculty Panel
Indication for Prevnar®, Pneumococcal 7-valent Conjugate
Vaccine (Diphtheria CRM197 Protein)
• Prevnar is indicated for active immunization of infants and toddlers
against invasive disease caused by S. pneumoniae due to capsular
serotypes included in the vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F).
The routine schedule is 2, 4, 6, and 12 to 15 months of age.
®
• The decision to administer Prevnar® should be based primarily on
its efficacy in preventing invasive pneumococcal disease. As with
any vaccine, Prevnar® may not protect all individuals receiving the
vaccine from invasive pneumococcal disease.
• Prevnar® is also indicated for active immunization of infants and
toddlers against otitis media caused by serotypes included in the
vaccine. However, for vaccine serotypes, protection against otitis
media is expected to be substantially lower than protection against
invasive disease. Additionally, because otitis media is caused by
many organisms other than serotypes of S. pneumoniae
represented in the vaccine, protection against all causes of otitis
media is expected to be low.
Important Safety Information for Prevnar®
• In clinical trials (n=18,168), the most frequently reported adverse
events included injection site reactions, fever (≥38ºC/100.4ºF),
irritability, drowsiness, restless sleep, decreased appetite, vomiting,
diarrhea, and rash.
• Risks are associated with all vaccines, including Prevnar®.
Hypersensitivity to any vaccine component, including diphtheria
toxoid, is a contraindication to its use. Prevnar® does not provide
100% protection against vaccine serotypes or protect against
nonvaccine serotypes.
Please see accompanying Prescribing Information
for Prevnar®.
This program is a satellite symposium sponsored
by Pfizer.
• This vaccine is not intended to be used for treatment of active infection.
Manufactured by Wyeth Pharmaceuticals Inc.
263801-01
© 2010 Pfizer Inc.
Marketed by Pfizer Inc.
All rights reserved.
Printed in USA/February 2010
Creating vaccines,
protecting life
WORLDWIDE, OUR VACCINES PROTECT AGAINST:
CHICKENPOX • CHOLERA • DIPHTHERIA • HAEMOPHILUS INFLUENZAE type b
INFECTIONS • HEPATITIS A • HEPATITIS B • INFLUENZA • JAPANESE ENCEPHALITIS •
MEASLES • MENINGOCOCCAL MENINGITIS (serogroups A, C, Y and W-135) • MUMPS •
PERTUSSIS • PNEUMOCOCCAL INFECTIONS • POLIOMYELITIS • RABIES • RUBELLA •
TETANUS • TUBERCULOSIS • TYPHOID FEVER • YELLOW FEVER

final program - International Society for Infectious Diseases

Transcription

Similar documents

TC İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi